Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024

Therapeutic Goods (Poisons Standard— June 2024) Instrument 2024 I, Sarah Syme, as delegate of the Secretary of the Department of Health and Aged Care, make the following instrument. Dated 28 May 2024 Sarah Syme Assistant Secretary Regulatory Engagement Branch Health Products Regulation Group Department of Health and Aged Care Authorised Version F2024L00589 registered 30/05/2024 Authorised Version F2024L00589 registered 30/05/2024 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 i Contents Reader’s guide i Introduction i Classification iii Principles of scheduling iv Reading the schedules v Availability of poisons vii Appendices viii Appendix A (General exemptions) viii Appendix B (Substances considered not to require control by scheduling) ix Appendix C (blank) ix Appendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8) ix Appendix E (First aid instructions for poisons) ix Appendix F (Warning statements and general safety directions for poisons) x Appendix G (Dilute preparations) x Appendix H (Schedule 3 medicines permitted to be advertised) x Appendix I (blank) x Appendix J (Conditions for availability and use of certain poisons included in Schedule 7) x Appendix K (Human medicines required to be labelled with a sedation warning) x Appendix L (Requirements for dispensing labels for medicines) x Appendix M (blank) x Poisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons xi Part 1—Preliminary and interpretation 1 1 Name .......................................................................................................................................1 2 Commencement........................................................................................................................1 3 Authority ..................................................................................................................................1 4 Repeal and transitional provisions ...........................................................................................1 5 Reader’s guide and Index .........................................................................................................2 6 Definitions ................................................................................................................................2 7 References to substances ........................................................................................................10 8 References to concentration, strength or quantity of substances............................................11 9 References to boiling or distillation temperatures..................................................................11 10 References to standards ........................................................................................................11 Part 2—Controls on substances 12 Division 1—Preliminary 12 11 Application of Part 2 ............................................................................................................12 12 Preparations containing poisons included in different schedules.........................................12 Division 2—Labels 13 Subdivision A—General 13 13 General requirements ...........................................................................................................13 Authorised Version F2024L00589 registered 30/05/2024 ii Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 14 Immediate wrapper...............................................................................................................13 Subdivision B—Primary packs and immediate containers 13 15 Primary packs and immediate containers.............................................................................13 16 Signal words .........................................................................................................................14 17 Cautionary statement—possession without authority illegal ...............................................14 18 Cautionary statement—keep out of reach of children..........................................................15 19 Cautionary statement—fire and explosion hazard ...............................................................15 20 Cautionary statement—burns skin and throat ......................................................................15 21 Cautionary statements for aqueous solution of paraquat......................................................16 22 Cautionary statement—read safety directions......................................................................16 23 Cautionary statement—flammable.......................................................................................17 24 Cautionary statement—for animal treatment only ...............................................................17 25 Cautionary statement—do not swallow ...............................................................................17 26 Approved name and quantity, proportion or strength ..........................................................17 27 Statement—an anticholinesterase compound.......................................................................18 28 Directions for use .................................................................................................................18 29 Safety directions ...................................................................................................................19 30 Warning statements ..............................................................................................................19 31 First aid.................................................................................................................................20 32 Name and address of manufacturer or distributor ................................................................20 33 Warning statements and sedation warnings for certain medicines for human use...............21 Subdivision C—Statements of quantity, proportion or strength 21 34 Statements of quantity, proportion or strength.....................................................................21 Subdivision D—Exemptions from labelling requirements 22 35 Selected containers and measure packs................................................................................22 36 Ampoules, pre-filled syringes and injection vials ................................................................23 37 Transport containers and wrappings.....................................................................................23 38 Dispensary, industrial, laboratory and manufacturing poisons ............................................23 39 Exemptions from label requirements in certain circumstances............................................24 40 Dispensed medicines ............................................................................................................24 41 Gas cylinders ........................................................................................................................24 42 Paints ....................................................................................................................................24 43 Camphor and naphthalene ....................................................................................................25 Subdivision E—Prohibitions 25 44 Prohibitions ..........................................................................................................................25 Division 3—Containers 27 45 General requirements ...........................................................................................................27 46 Containers for poisons other than poisons included in Schedule 5......................................27 47 Containers for poisons included in Schedule 5 ....................................................................27 48 Approved containers.............................................................................................................28 49 Child-resistant closures ........................................................................................................28 50 Poisons included in Schedule 8 ............................................................................................30 51 Exemptions...........................................................................................................................30 52 Camphor and naphthalene ....................................................................................................31 53 Prohibitions—use of containers for poisons ........................................................................31 Division 4—Storage 32 54 General storage requirements...............................................................................................32 Division 5—Disposal 33 55 General disposal requirements .............................................................................................33 Authorised Version F2024L00589 registered 30/05/2024 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 iii Division 6—Record keeping 34 56 General record-keeping requirements ..................................................................................34 Division 7—Advertising 35 57 General advertising requirements.........................................................................................35 Division 8—Supply, prescribing, possession or use 36 58 Poisons included in Schedule 2 ............................................................................................36 59 Poisons included in Schedule 3 ............................................................................................36 60 Poisons included in Schedule 4 ............................................................................................37 61 Poisons included in Schedules 5 and 6.................................................................................37 62 Poisons included in Schedule 7 ............................................................................................37 63 Poisons included in Schedule 10 ..........................................................................................38 64 Poisons included in Schedule 4 or 8 and Appendix D .........................................................38 65 Hawking ...............................................................................................................................39 Division 9—Paints and tinters 40 66 General requirements ...........................................................................................................40 67 Definition of first group paint ..............................................................................................40 68 Definition of second group paint .........................................................................................41 Schedule 1—Blank 42 Schedule 2—Pharmacy medicines 43 Schedule 3—Pharmacist only medicines 61 Schedule 4—Prescription only medicines and prescription animal remedies 70 Schedule 5—Caution 174 Schedule 6—Poisons 208 Schedule 7—Dangerous poisons 262 Schedule 8—Controlled drugs 275 Schedule 9—Prohibited substances 280 Schedule 10—Substances of such danger to health as to warrant prohibition of supply and use 288 Appendix A—General exemptions 294 1 Exempt preparations and products .......................................................................................294 Appendix B—Substances considered not to require control by scheduling 297 1 Reasons for including substances in the table in clause 3....................................................297 2 Areas of use in relation to substances included in the table in clause 3...............................297 3 Substances exempt in certain uses........................................................................................299 Authorised Version F2024L00589 registered 30/05/2024 iv Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix C—Blank 307 Appendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8 308 1 Poisons available for human use only from or on the prescription or order of an authorised medical practitioner .................................................................................308 2 Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist......................................................................308 3 Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act..................................................309 4 Poisons available only from or on the order of a specialist physician .................................309 5 Poisons for which possession without authority is illegal....................................................309 6 Poisons available for human use only from or on the prescription or order of a specialist physician....................................................................................................311 7 Poisons available for human use only from or on the prescription or order of a dermatologist.............................................................................................................311 8 Poisons available for initial treatment of a patient only if authorised by certain health practitioners...............................................................................................................311 9 Poisons which must be stored in a locked container to prevent unauthorised access ..........312 10 Poisons available only when prescribed or authorised in certain circumstances ...............312 Appendix E—First aid instructions for poisons 313 1 Standard statements for first aid instructions .......................................................................313 2 Poisons information centre contact information in statements ............................................314 3 First aid instructions for poisons ..........................................................................................314 Appendix F—Warning statements and general safety directions for poisons 325 1 Warning statements ..............................................................................................................325 2 Safety directions—general ...................................................................................................329 3 Poisons information centre contact information in statements ............................................331 4 Poisons that must be labelled with warning statements and safety directions .....................331 Appendix G—Dilute preparations 346 1 Substances exempt at or below certain concentrations ........................................................346 Appendix H—Schedule 3 medicines permitted to be advertised 348 1 Schedule 3 medicines permitted to be advertised ................................................................348 Appendix I—Blank 350 Appendix J—Conditions for availability and use of certain poisons included in Schedule 7 351 1 Conditions for supply of certain poisons included in Schedule 7 ........................................351 Appendix K—Human medicines required to be labelled with a sedation warning 354 1 Human medicines required to be labelled with a sedation warning.....................................354 Appendix L—Requirements for dispensing labels for medicines 359 1 General .................................................................................................................................359 2 Additional warning statements for certain human medicines ..............................................359 Authorised Version F2024L00589 registered 30/05/2024 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 v Appendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist 362 Index 363 Authorised Version F2024L00589 registered 30/05/2024 Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 i Reader’s guide Introduction This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989 (the Act), and is a compilation of decisions made under section 52D of the Act. This instrument should be read in conjunction with the Scheduling Policy Framework (the SPF) of the Australian Health Ministers’ Advisory Council. Further information on the scheduling amendments and the SPF can be viewed on the Therapeutic Goods Administration’s website (www.tga.gov.au). Refer to section 6 for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine). This instrument serves 2 key purposes. Firstly, this instrument contains the decisions of the Secretary of the Department of Health and Aged Care or the Secretary’s delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes. Secondly, this instrument includes provisions for labelling, containers, storage, disposal, record-keeping, supply and possession of poisons in general which are intended to be adopted for use in each jurisdiction of Australia. Other government agencies may also impose controls on certain products. The requirements for labelling and containers in this instrument are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation. Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in this instrument as they are covered by labelling requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time. Note, however that this exemption does not extend to controls on supply of these poisons. This instrument is presented with a view to promoting uniform: • scheduling of poisons throughout Australia; and • signal headings on labels for poisons throughout Australia; and • labelling and packaging requirements for poisons throughout Australia; and • additional controls on the availability and use of poisons in Australia. The various Commonwealth Acts, legislative instruments and other documents, which integrate with this instrument include the following: • the Act; • the Agricultural and Veterinary Chemicals Code Act 1994; • the Agricultural and Veterinary Chemicals Code Regulations 1995; Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide ii Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 • the Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines; • the Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines; • the Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017; • the Therapeutic Goods Order No. 95 - Child-resistant packaging requirements for medicines 2017 (TGO 95); • the Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021; • the Therapeutic Goods (Medicines Advisory Statements) Specification 2021 – Schedule 1 Required Advisory Statements for Medicine Labels No. 6 (RASML). Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 iii Classification Poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with each relevant State or Territory authority. Schedule Title Description Schedule 1 Blank This Schedule is intentionally blank. Schedule 2 Pharmacy medicines Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person. Schedule 3 Pharmacist only medicines Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription. Schedule 4 Prescription only medicines and prescription animal remedies Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription. Schedule 5 Caution Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label. Schedule 6 Poisons Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label. Schedule 7 Dangerous poisons Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply. Schedule 8 Controlled drugs Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence. Schedule 9 Prohibited substances Substances which may be abused or misused, the manufacture, possession, supply or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. Schedule 10 (previously Appendix C) Substances of such danger to health as to warrant prohibition of supply and use Substances which are prohibited for the purpose or purposes listed for each poison. Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide iv Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Principles of scheduling Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance. This instrument lists poisons in 10 Schedules according to the degree of control recommended to be exercised over their availability to the public. Poisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls. For some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7. Products for domestic use must not include poisons listed in Schedule 7. Schedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this instrument, the method by which it is implemented in the States and Territories may vary. Schedule 10 (previously Appendix C) contains a list of substances or preparations, the supply or use of which should be prohibited because of their known dangerous properties. Substances in products which have been considered for scheduling, but have been exempted from this instrument, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling). Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 v Reading the schedules Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result, they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries. Firstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned below. Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled. Secondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the 2 different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies. Where exceptions are included in an entry, these have been emphasised by printing the word “except” in bold type. Where the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this instrument do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply. Where a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (“reverse scheduling”), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed. Where a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved. It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise (see section 7). It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, and toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison. However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply. Finally, when using this instrument to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A, B and the Index. In this process, if the poison is not found under its “approved name” it may be shown under a group term such as: Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide vi Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Group Example the parent acid of salts “oxalic acid” to find sodium oxalate the radical of a salt “chromates” to find potassium chromate the element “arsenic” to find arsenic trioxide a chemical group with similar toxicological or pharmacological activity “hydrocarbons, liquid” to find kerosene a pharmacological group “anabolic steroidal agents” to find “androsterone” Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 vii Availability of poisons The purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability. These Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons. Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country. Inclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It does not: • indicate that the poison is available; or • indicate that it is has been approved or is efficacious for any use that may be specified in a Schedule; or • negate any obligation for registration of therapeutic goods, or agricultural or veterinary chemical product containing that poison. Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide viii Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendices Some substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this instrument. The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them. Appendix Title Purpose/controls imposed Appendix A General exemptions List of preparations and products exempted from this instrument. Appendix B Substances considered not to require control by scheduling List of poisons exempted from scheduling. Appendix C Appendix is intentionally left blank See Schedule 10. Appendix D Additional controls on possession or supply of poisons included in Schedule 4 or 8 List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply. Appendix E First aid instructions for poisons First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). Appendix F Warning statements and general safety directions for poisons Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). Appendix G Dilute preparations Concentration cut-offs for specified poisons, below which the requirements of this instrument do not apply Appendix H Schedule 3 medicines permitted to be advertised List of medicines included in Schedule 3 that are permitted to be advertised to the public. Appendix I Appendix is intentionally left blank Appendix J Conditions for availability and use of Schedule 7 poisons List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use. Appendix K Human medicines required to be labelled with a sedation warning List of poisons in medicines for human use required to be labelled with a warning regarding their sedation potential. Appendix L Requirements for dispensing labels for medicines Requirements applying to labels attached to medicines at the time of dispensing. Appendix M Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist Appendix is intentionally left blank and is reserved for future use. Appendix A (General exemptions) Appendix A lists preparations and products that are exempted from this instrument. Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ix Appendix B (Substances considered not to require control by scheduling) Substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times. Inclusion in Appendix B indicates that a decision has been taken not to include substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list (that is, there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non-hazardous, but have not been considered in relation to the need for scheduling). Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include: • the toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules; • the use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or • the public access was limited such that scheduling was inappropriate or unnecessary. The list of substances included in Appendix B was developed from scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”. Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance. Applications are considered for scheduling. Applications for inclusion in Appendix B will not be accepted. Appendix C (blank) Appendix C is intentionally blank. Appendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8) Appendix D lists poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply. Appendix E (First aid instructions for poisons) Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. Standard statements have been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in Appendix E may be varied provided that the intent is not changed. The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non-toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood. The First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide x Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate. Appendix F (Warning statements and general safety directions for poisons) It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely. Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. Warning statements and safety directions have been prepared as a guide for this purpose. The wording of warning statements and safety directions specified in Appendix F may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects. Appendix G (Dilute preparations) Appendix G lists concentration cut-offs for specified substances, below which the requirements of this instrument do not apply. Appendix H (Schedule 3 medicines permitted to be advertised) Appendix H lists medicines included in Schedule 3 that are permitted to be advertised to the public. Appendix I (blank) Appendix I is intentionally blank. Appendix J (Conditions for availability and use of certain poisons included in Schedule 7) All poisons included in Appendix J are not to be available except to authorised or licensed persons. The use of a poison may be restricted for a particular purpose. Controls recommended for the Schedule 7 poisons included in Appendix J may be implemented through poisons controls or other State or Territory legislation. Appendix K (Human medicines required to be labelled with a sedation warning) Medicines for human use that contain a poison included in Appendix K are required to be labelled with a warning regarding their sedation potential. Appendix L (Requirements for dispensing labels for medicines) Appendix L sets out the requirements for labels attached to medicines at the time of dispensing. Appendix M (blank) Appendix M is intentionally blank and is reserved for future use. Authorised Version F2024L00589 registered 30/05/2024 Reader’s guide Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 xi Poisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product. Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria: 1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and 2. calls must be logged and submitted for incorporation into the official collection of poisoning data. Authorised Version F2024L00589 registered 30/05/2024 Authorised Version F2024L00589 registered 30/05/2024 Preliminary and interpretation Part 1 Section 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 1 Part 1—Preliminary and interpretation 1 Name (1) This instrument is the Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024. (2) This instrument may also be cited as the Standard for the Uniform Scheduling of Medicines and Poisons No. 44. Note: This instrument is the current Poisons Standard for the purposes of the Act until a document is prepared in substitution for it (see sections 52A and 52D of the Act). 2 Commencement (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms. Commencement information Column 1 Column 2 Column 3 Provisions Commencement Date/Details 1. The whole of this instrument 1 June 2024. 1 June 2024 Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument. (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument. 3 Authority This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989. 4 Repeal and transitional provisions Repeal (1) The Therapeutic Goods (Poisons Standard—February 2024) Instrument 2024 is repealed. Saving—things done under the repealed instrument (2) If: (a) a thing was done for a particular purpose under the Therapeutic Goods (Poisons Standard—February 2024) Instrument 2024 as in force immediately before that instrument was repealed; and Authorised Version F2024L00589 registered 30/05/2024 Part 1 Preliminary and interpretation Section 5 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) the thing could be done for that purpose under this instrument; the thing has effect for the purposes of this instrument as if it had been done for that purpose under this instrument. (3) Without limiting subsection (2), a reference in that subsection to a thing being done includes a reference to an approval, authorisation, certificate, exemption, requirement or other instrument being given, made, granted or issued. 5 Reader’s guide and Index (1) The Reader’s guide is not part of this instrument. (2) The Index is not part of this instrument. 6 Definitions Note 1: The following expressions used in this instrument are defined in the Act: (a) current Poisons Standard; (b) poison; (c) Register; (d) Secretary; (e) supply; (f) therapeutic goods. Note 2: The definition of poison in the Act is as follows: poison means an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury and includes any ingredient, compound, material or preparation referred to in a schedule to the current Poisons Standard. In this instrument: Act means the Therapeutic Goods Act 1989. agricultural chemical means: (a) a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly: (i) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing; or (ii) destroying a plant; or (iii) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity; or (iv) modifying an effect of another agricultural chemical; or (v) attracting a pest for the purpose of destroying it; or (b) an active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be an agricultural chemical product; but does not include a veterinary chemical. agricultural chemical product has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994. Authorised Version F2024L00589 registered 30/05/2024 Preliminary and interpretation Part 1 Section 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 3 animal means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs. animal feed premix means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food. appropriate authority: each of the following is an appropriate authority: (a) each person who is the head of the body (however described) in a State or Territory that is responsible for the administration of matters relating to health in that State or Territory; (b) the Deputy Secretary of the Department with responsibility for the part of the Department known as the Therapeutic Goods Administration, or their delegate; (c) the Chief Executive Officer of the Australian Pesticides and Veterinary Medicines Authority, or their delegate. approved name means: (a) for a poison that is for human therapeutic use—the name for the poison in the Australian Approved Names List within the meaning of the Therapeutic Goods Regulations 1990; or (b) for a poison that is for animal or agricultural use—the name approved for use by the Australian Pesticides and Veterinary Medicines Authority under the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994; or (c) for any other poison—the name for the poison mentioned in the first-occurring of the following paragraphs that applies to the poison: (i) the name used for the poison in this instrument; (ii) the name recommended by Standards Australia as the common name for the poison; (iii) the English name given to the poison by the International Organization for Standardization; (iv) the name given to the poison by the British Standards Institution; (v) the English name given to the poison by the European Committee for Standardization (CEN); (vi) the international non-proprietary name recommended for the poison by the World Health Organization; (vii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the International Cosmetic Ingredient Dictionary & Handbook published by the Personal Care Products Council of America; (viii) the accepted scientific name or the name descriptive of the true nature and origin of the poison. Australian Dangerous Goods Code means the Australian Code for the Transport of Dangerous Goods by Road & Rail, published by the National Transport Commission, as existing from time to time. Authorised Version F2024L00589 registered 30/05/2024 Part 1 Preliminary and interpretation Section 6 4 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Note: The Australian Dangerous Goods Code could in 2022 be viewed on the Commission’s website (www.ntc.gov.au). authorised prescriber means any of the following: (a) a dental practitioner; (b) a medical practitioner; (c) a veterinarian; (d) a person for whom an authorisation, given for the purposes of this paragraph by an appropriate authority, is in effect. blood means whole blood extracted from human donors. blood components means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma. child-resistant closure means: (a) a closure that complies with the requirements for a child-resistant closure in Australian Standard AS 1928-2007, Child-resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD); or (b) a closure that complies with the requirements for child-resistant closures specified in Therapeutic Goods Order No. 95 - Child-resistant packaging requirements for medicines 2017 (TGO 95); or (c) a closure that is taken to comply with the requirements mentioned in paragraph (b) under Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021; or (d) in the case of a can fitted with a press-on lid, a lid of the design known as “double tight” or “triple tight”. Note: See also the definition of non-access packaging. child-resistant packaging means packaging that: (a) complies with the requirements of Australian Standard AS 1928-2007, Child resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD); or (b) is reclosable and complies with the requirements of at least one of the following: (i) the International Organization for Standardization Standard ISO 8317:2015, Child-resistant packaging—Requirements and testing procedures for reclosable packages; (ii) the British Standards Institution Standard BS EN ISO 8317:2004, Child-resistant packaging—Requirements and testing procedures for reclosable packages; (iii) the Canadian Standards Association Standard CSA Z76.1-06, Reclosable Child-Resistant Packages; (iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, Poison prevention packaging standards and Section 1700.20, Testing procedure for special packaging, as in force from time to time; or Authorised Version F2024L00589 registered 30/05/2024 Preliminary and interpretation Part 1 Section 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 5 (c) a closure that complies with the requirements for child-resistant packaging specified in Therapeutic Goods Order No. 95 - Child-resistant packaging requirements for medicines 2017 (TGO 95); or (d) a closure that is taken to comply with the requirements mentioned in paragraph (c) under Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021; or (e) is in the form of blister or strip packaging: (i) in which a unit of use is individually protected until the time of release; and (ii) that complies with section 3 (Requirements for non-reclosable packages) of Australian Standard AS 1928-2001, Child-resistant packages. Note: See also the definition of non-access packaging. compounded in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means. cosmetic means a substance or preparation intended for placement in contact with any external part of the human body, including: (a) the mucous membranes of the oral cavity; and (b) the teeth; with a view to: (c) altering the odours of the body; or (d) changing its appearance; or (e) cleansing it; or (f) maintaining it in good condition; or (g) perfuming it; or (h) protecting it. debitterised neem seed oil means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids. dental practitioner means a person who is registered, in a State or internal Territory, as a dental practitioner (other than a dental therapist, dental hygienist, dental prosthetist or oral health therapist). dermal use means application to the skin primarily for localised effect. designated solvent means the following: (a) acetone; (b) dimethylformamide; (c) N-(N-dodecyl)-2-pyrrolidone; (d) hydrocarbons, liquid; (e) methanol when included in Schedule 5; (f) methyl ethyl ketone; (g) methyl isoamyl ketone; (h) methyl isobutyl ketone; (i) N-methyl-2-pyrrolidone; Authorised Version F2024L00589 registered 30/05/2024 Part 1 Preliminary and interpretation Section 6 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (j) N-(N-octyl)-2-pyrrolidone; (k) phenyl methyl ketone; (l) styrene; (m) tetrachloroethylene; (n) 1,1,1-trichloroethane. dispensing label, for a substance for therapeutic use, means the label attached to the immediate container of the substance at the time of dispensing. Note: See section 40 and Appendix L. distributor means a person who imports or supplies a poison. divided preparation means a preparation manufactured and packed as discrete pre-measured dosage units prior to supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules. dosage unit means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules. drug means a poison intended for human or animal therapeutic use. essential oils means: (a) products obtained from natural raw materials by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation; or (b) oils of equivalent composition to products mentioned in paragraph (a) that are derived through synthetic means; or (c) prepared mixtures of oils of equivalent composition to products mentioned in paragraph (a) that comprise a mixture of synthetic and natural components. external in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice. first group paint: see section 67. free formaldehyde includes all hydrated and non-hydrated formaldehyde present in aqueous solution, including methylene glycol and formaldehyde released from formaldehyde donors. graphic material means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks. hand sanitiser preparation means an antimicrobial skin care product that: (a) consists of, contains or generates one or more antimicrobial active substances; and (b) is represented in any way to be, or is likely to be taken to be (whether because of the way in which it is presented or for any other reason): (i) for use on hands when soap and water are not available; and Authorised Version F2024L00589 registered 30/05/2024 Preliminary and interpretation Part 1 Section 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 7 (ii) applied to the hands without rinsing off; and (iii) intended to destroy, deter, render harmless, prevent the action of, or otherwise exert a controlling effect on any microbes on the skin. hawking means to supply (including peddle or distribute or cause to be distributed) in a public place. height in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender. hemp seed oil means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa. immediate container includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper. immediate wrapper means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing. internal use means administration: (a) orally, except for topical effect in the mouth; or (b) for absorption and the production of a systemic effect: (i) by way of a body orifice other than the mouth; or (ii) parenterally, other than by application to unbroken skin. label: (a) means a written statement on a container of a poison; and (b) in relation to therapeutic goods, includes a display of printed information about the product: (i) on, or attached to, the goods; or (ii) on, or attached to, a container or primary pack in which the goods are supplied; or (iii) supplied with such a container or pack. main label, for a container of poison, means: (a) the part of the label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and (b) if there are 2 or more labels: (i) the label or the part of the label where the product name is more or most conspicuously shown; or (ii) if the product name is equally more or most conspicuously displayed on more than one of those labels—each of the labels on which the product name is equally more or most conspicuously displayed. manufacturer of a poison means a person who manufactures, produces, or packs a poison. marker dyes or pigments means any product that is added to a liquid used in agricultural or veterinary chemicals to identify or distinguish treated from Authorised Version F2024L00589 registered 30/05/2024 Part 1 Preliminary and interpretation Section 6 8 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 untreated objects, land or organisms by temporarily imparting colour on the relevant object, land or organism through, for example, spot- or boom-spraying. measure pack means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack. medical practitioner means a person who is registered, in a State or internal Territory, as a medical practitioner. medicine means any poison for therapeutic use. midwife means a person who is registered, in a State or internal Territory, as a midwife. non-access packaging, for a product that is not intended for human therapeutic use, means packaging that complies with the requirements of AS 4710-2001, Packages for chemicals not intended for access or contact with their contents by humans. Note: See also the definitions of child-resistant closure and child-resistant packaging. non-volatile content in relation to a paint or tinter means that portion of a paint or tinter determined to be the non-volatile content by Method 301.1 of Australian Standard AS 1580-301.1-2005, Paints and related materials – Methods of test – Non-volatile content by mass. nurse means a person who is registered, in a State or internal Territory, as a nurse. oromucosal use means administration to the oral mucosa, specifically the oral cavity and/or the pharynx. paint includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use. pesticide means any substance or mixture of substances used or intended to be used: (a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or (b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non-agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers. pharmacist means a person who is registered, in a State or internal Territory, as a pharmacist. primary pack, in relation to a poison, means the pack in which the poison and its immediate container or immediate wrapper or measure pack are presented for supply. Authorised Version F2024L00589 registered 30/05/2024 Preliminary and interpretation Part 1 Section 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 9 product sample means a packed poison supplied directly to a consumer: (a) free of charge or for a nominal charge; and (b) as a mechanism to promote the supply of the product; and (c) in the form of: (i) a small pack produced specifically for the purposes of promotion; or (ii) a normal commercial pack that in other circumstances could be purchased by the consumer. public place means any place where members of the public are lawfully entitled, invited or permitted to be present in their capacity as members of the public. Note: Examples of a public place include a street, road, footway, court, alley or thoroughfare that the public may use in any residential premises or to get from door to door, place to place or house to house. required advisory statements for medicine labels means the Therapeutic Goods (Medicines Advisory Statements) Specification 2021. restricted flow insert means a restriction: (a) that is fitted or moulded in the neck of a container; and (b) that cannot readily be removed from the container by manual force; and (c) that limits the delivery of the contents of the container to drops each of which is not more than 200 microlitres. second group paint: see section 68. selected container means: (a) an injection vial having a nominal capacity of 10 ml or less; or (b) a single use syringe; or (c) any other container for substances for therapeutic use having a nominal capacity of 10 ml or less. solid includes powder. substance has the same meaning as in Part 6-3 of the Act. Note 1: In general terms, that definition covers an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury to persons or animals. Note 2: See also section 7. therapeutic use means use in or in connection with: (a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals; or (b) influencing, inhibiting or modifying a physiological process in human beings or animals; or (c) testing the susceptibility of human beings or animals to a disease or ailment; or (d) influencing, controlling or preventing conception in human beings or animals; or (e) testing for pregnancy in human beings or animals; or (f) the replacement or modification of parts of the anatomy in human beings or animals. Authorised Version F2024L00589 registered 30/05/2024 Part 1 Preliminary and interpretation Section 7 10 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 tinter means any pigment or admixture of pigment with other substances, in powder, semi-solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint. topical use means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied. toy means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of 14 years. transdermal use means application to the skin primarily for systemic effect. veterinarian means a person who is registered under the law of a State or Territory as a veterinarian, a veterinary practitioner or a veterinary surgeon. veterinary chemical means: (a) a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly: (i) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest; or (ii) curing or alleviating an injury suffered by the animal; or (iii) modifying the physiology of the animal: (A) so as to alter its natural development, productivity, quality or reproductive capacity; or (B) so as to make it more manageable; or (iv) modifying the effect of another veterinary chemical; or (b) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a); or (c) any active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be a veterinary chemical product; but does not include an agricultural chemical. veterinary chemical product has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994. 7 References to substances In this instrument, unless the contrary intention appears, a reference to a substance includes the following: (a) that substance prepared from natural sources or artificially; (b) if the substance is a plant (other than a plant included in Schedule 8 or 9)— that plant or any part of that plant when packed or prepared for therapeutic use; (c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative; (d) every alkaloid of the substance and every salt of such an alkaloid; (e) every stereoisomer of the substance and every salt of such a stereoisomer; Authorised Version F2024L00589 registered 30/05/2024 Preliminary and interpretation Part 1 Section 8 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 11 (f) every recombinant form of the substance; (g) a preparation or admixture containing any proportion of the substance. Note: Part 2 (controls on substances) does not apply in relation to certain substances (see section 11). 8 References to concentration, strength or quantity of substances In this instrument, for a reference to a concentration, strength or quantity of a substance: (a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance; and (b) the expression “1%” means: (i) in the case of a liquid preparation, 1 g of the substance per 100 mL of the preparation; or (ii) in the case of a solid, semi-solid or pressurised spray aerosol preparation, 1 g of the substance per 100 g of the preparation; and (iii) any expression of greater or lesser percentages shall have a corresponding meaning; and (c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine. 9 References to boiling or distillation temperatures In this instrument, a reference to a boiling or distillation temperature means that temperature at an atmospheric pressure of 101.325 kPa (760 mm of mercury). 10 References to standards A reference in this instrument to an Australian standard, an international standard or a standard of a foreign country is a reference to that standard as it exists from time to time. Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 1 Preliminary Section 11 12 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Part 2—Controls on substances Division 1—Preliminary 11 Application of Part 2 This Part applies to a substance or preparation included in a schedule to this instrument, other than the following: (a) a preparation or product included in the table in clause 1 of Appendix A; (b) a substance included in the table in clause 3 of Appendix B when used in an area, sub-area or sub-sub-area of use specified in the table in relation to that substance; (c) a substance included in the table in clause 1 of Appendix G at a concentration not exceeding the concentration specified in that table in relation to that substance; (d) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8; (e) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022, published by the Australian Pesticides and Veterinary Medicines Authority, as existing from time to time. Note: For paragraph (e), the Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022 is a legislative instrument that could in 2023 be accessed at www.legislation.gov.au. 12 Preparations containing poisons included in different schedules (1) If a preparation contains 2 or more poisons, the provisions relating to each of the schedules in which those poisons are included apply to the preparation. (2) However, if it is not possible to comply both with a provision relating to one of those schedules and with a provision relating to another of those schedules, the provision relating to the more restrictive schedule applies, unless a contrary intention is indicated in the schedules or relevant State or Territory legislation. (3) The Schedules listed in order of greatest to least restrictiveness are 9, 10, 8, 4, 7, 3, 2, 6, 5. Note: Schedule 1 is not currently in use. Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Labels Division 2 Section 13 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 13 Division 2—Labels Subdivision A—General 13 General requirements (1) A poison must not be supplied unless it is labelled in accordance with this Division. (2) Any word, expression or statement required by this instrument to be written on a label or container must be written: (a) on the outside face of the label or container; and (b) in English; and (c) in durable characters; and (d) in a colour or colours to provide a distinct contrast to the background colour; and (e) in letters at least 1.5 mm in height. (3) Paragraph (2)(e) does not apply to a word, expression or statement on a container which has a capacity of 20 ml or less, or on the label of such a container if: (a) an appropriate authority approves the use of smaller letters; and (b) the letters are at least 1 mm in height. (4) The label must be printed on, or securely attached to: (a) the outside of the immediate container; and (b) if the immediate container is enclosed in a primary pack—the outside of that primary pack. 14 Immediate wrapper If a poison is enclosed in an immediate wrapper: (a) the poison must be contained in a primary pack labelled in accordance with section 15; and (b) the immediate wrapper must be conspicuously labelled with: (i) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and (ii) the approved name of the poison; and (iii) a statement of the quantity, proportion or strength of the poison in accordance with section 34. Subdivision B—Primary packs and immediate containers 15 Primary packs and immediate containers This Subdivision sets out how the primary pack and immediate container of a poison must be labelled. Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 2 Labels Section 16 14 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 16 Signal words (1) The signal word or words for the poison, as shown in the following table, must be written: (a) on the first line or lines of the main label; and (b) in bold-face sans serif capital letters of uniform thickness; and (c) subject to subsection (3), in letters at least half the height of the largest letter or numeral on the label; and (d) with nothing else other than the following written on the same line or lines: (i) if the poison is included in Schedule 5—a class label as specified in the Australian Dangerous Goods Code or a statement of the principal hazard of the poison; (ii) if the poison is not included in Schedule 5—a class label as specified in the Australian Dangerous Goods Code. Signal word or words for poisons Item For a poison included in the following schedule … that is to be used for the following purpose … the signal word or words are … 1 Schedule 2 for any purpose PHARMACY MEDICINE 2 Schedule 3 for any purpose PHARMACIST ONLY MEDICINE 3 Schedule 4 for human use PRESCRIPTION ONLY MEDICINE 4 Schedule 4 for animal use PRESCRIPTION ANIMAL REMEDY 5 Schedule 5 for any purpose CAUTION 6 Schedule 6 for any purpose POISON 7 Schedule 7 for any purpose DANGEROUS POISON 8 Schedule 8 for any purpose CONTROLLED DRUG (2) For the purposes of paragraph (1)(c), the largest letter or numeral does not include: (a) a single letter or numeral which is larger than other lettering on the label; or (b) an affix forming part of the trade name for the poison; or (c) in the case of a poison for therapeutic use—numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison. (3) For the purposes of paragraph (1)(c), the letters need not be larger than: (a) 6 mm on labels for packages having a nominal capacity of 2 L or less; or (b) 15 mm on labels for packages having a nominal capacity of more than 2 L. 17 Cautionary statement—possession without authority illegal If the poison is included in Schedule 8, the cautionary statement: POSSESSION WITHOUT AUTHORITY ILLEGAL must be written: Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Labels Division 2 Section 18 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 15 (a) on a separate line or lines immediately below the signal words required by section 16; and (b) in bold-face sans serif capital letters of uniform thickness; and (c) in letters at least four-tenths the height of the letters used for the signal words; and (d) with no other statement written on the same line or lines. 18 Cautionary statement—keep out of reach of children The cautionary statement: KEEP OUT OF REACH OF CHILDREN must be written: (a) on a separate line or lines: (i) immediately below the signal word or words required by section 16; or (ii) if the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by section 17—immediately below that statement; and (b) in bold-face sans serif capital letters of uniform thickness; and (c) in letters at least four-tenths the height of the letters used for the signal word or words; and (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines. 19 Cautionary statement—fire and explosion hazard (1) If the poison is a dry chlorinating compound containing more than 10% of available chlorine, the cautionary statement: FIRE AND EXPLOSION HAZARD must be written: (a) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and (b) in bold-face sans serif capital letters of uniform thickness; and (c) in letters at least four-tenths the height of the letters used for the signal word or words; and (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines. (2) This section does not apply to a preparation certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code. 20 Cautionary statement—burns skin and throat If the poison is an alkaline salt in a dishwashing machine product, the cautionary statement: BURNS SKIN AND THROAT Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 2 Labels Section 21 16 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 must be written: (a) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and (b) in bold-face sans serif capital letters of uniform thickness; and (c) in letters at least four-tenths the height of the letters used for the signal word; and (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines of the main label. 21 Cautionary statements for aqueous solution of paraquat If the poison is an aqueous solution of paraquat, the cautionary statements: CAN KILL IF SWALLOWED DO NOT PUT IN DRINK BOTTLES KEEP LOCKED UP must be written: (a) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and (b) in bold-face sans serif capital letters of uniform thickness; and (c) in letters at least four-tenths the height of the letters used for the signal words; and (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same lines of the main label. 22 Cautionary statement—read safety directions (1) If safety directions are required on the label by section 29, the following cautionary statement: READ SAFETY DIRECTIONS BEFORE OPENING OR USING or the following cautionary statement: READ SAFETY DIRECTIONS must be written: (a) on a separate line or lines: (i) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; or (ii) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and (b) in bold-face sans serif capital letters of uniform thickness; and (c) in letters at least four-tenths the height of the letters used for the signal word or words; and (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines. (2) This section does not apply to a medicine for human use that is labelled in accordance with the required advisory statements for medicine labels. Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Labels Division 2 Section 23 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 17 23 Cautionary statement—flammable If the poison meets the criteria for a “flammable liquid” in the Australian Dangerous Goods Code, the cautionary statement: FLAMMABLE must be written on the main label in bold-face sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the Australian Dangerous Goods Code. 24 Cautionary statement—for animal treatment only If the poison is only for the treatment of animals, the cautionary statement: FOR ANIMAL TREATMENT ONLY must be written on the main label in bold-face sans serif capital letters of uniform thickness. 25 Cautionary statement—do not swallow If the poison is included in Schedule 5 and is intended for any purpose other than internal or pesticidal use, the cautionary statement: DO NOT SWALLOW must be written in sans serif capital letters on the main label or as part of the directions for use. 26 Approved name and quantity, proportion or strength (1) The approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with section 34 must be: (a) if the poison is for human therapeutic use—written on the main label in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or (b) if the poison is not for human therapeutic use—written in bold-face sans serif capital letters on the main label, unless: (i) a list of approved names is required; and (ii) it is impractical to include the list on the main label; and (iii) it is included on another part of the label in accordance with an authorisation given by an appropriate authority. (2) If the poison is included in Schedule 5 and is referred to in column 1 of an item of the following table, the appropriate name in column 2 of that item may be used as the approved name. Appropriate names for poisons Item Column 1 Poison Column 2 Appropriate name 1 Alkaline salts Alkaline salts Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 2 Labels Section 27 18 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appropriate names for poisons Item Column 1 Poison Column 2 Appropriate name 2 Amines for use as curing agents for epoxy resins (unless separately specified in the Schedules) Aliphatic amines or aromatic amines 3 Epoxy resins, liquid Liquid epoxy resins 4 Hydrocarbons, liquid Liquid hydrocarbons 5 Quaternary ammonium compounds Quaternary ammonium compound(s) (3) If a poison contains a mixture of designated solvents in excess of 25% of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25%, the approved names of those solvents may be expressed as follows: (a) where the designated solvent is a liquid hydrocarbon—as “liquid hydrocarbons”; (b) where the designated solvent is a ketone—as “ketones”; (c) in any other case—as “solvents” or “other solvents”. 27 Statement—an anticholinesterase compound (1) If the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, the following expression: AN ANTICHOLINESTERASE COMPOUND must be written immediately below the approved name or the list of declared contents on the label. (2) This section does not apply to: (a) dazomet, mancozeb, metiram, propineb, thiram, tri-allate, zineb or ziram; or (b) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or (c) an organophosphorus compound or carbamate contained in a pressurised spray pack for household use. 28 Directions for use If the poison is prepared, packed or sold for a specific purpose, it must be labelled with clear and adequate directions for use, unless: (a) it is a medicine for human use that is labelled in accordance with: (i) Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines; or (ii) Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines; or (b) it is in an agricultural or veterinary chemical product labelled in compliance with the Agricultural and Veterinary Chemicals Code Act 1994; or (c) it is included in Schedule 4 or 8; or (d) all of the following apply: Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Labels Division 2 Section 29 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 19 (i) it is impractical to include such directions on the label; (ii) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”; (iii) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label; (iv) the insert is enclosed in the primary pack. 29 Safety directions (1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each safety direction required for the poison by that clause, grouped together as a distinct section of the label and prefaced by the words: SAFETY DIRECTIONS written in bold-face capital letters. (2) This section does not apply to the following: (a) a poison that: (i) is a medicine for human use; and (ii) is labelled in accordance with the required advisory statements for medicine labels; (b) a poison that: (i) is an agricultural chemical or a veterinary chemical; and (ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994. 30 Warning statements (1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each warning statement required for the poison by that clause, grouped together: (a) if safety directions are included on the label—immediately after the words “SAFETY DIRECTIONS”; or (b) if there are no safety directions—immediately preceding the directions for use. (2) This section does not apply to the following: (a) a poison that: (i) is a medicine for human use; and (ii) is labelled in accordance with the required advisory statements for medicine labels; (b) a poison that: (i) is an agricultural chemical or a veterinary chemical; and (ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994. Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 2 Labels Section 31 20 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 31 First aid (1) If the poison is included in the table in clause 3 of Appendix E, it must be labelled with each statement required for the poison by clause 3 of Appendix E: (a) grouped together and prefaced by the following words: FIRST AID written in bold-face capital letters; or (b) if a primary pack contains 2 or more immediate containers of poisons each requiring different first aid instructions: (i) written on each immediate container as specified in paragraph (a); and (ii) replaced on the primary pack with the statement: FIRST AID: See inner packs. (2) This section does not apply to the following: (a) a poison that: (i) is for human internal use; and (ii) is included in Schedule 3, 4 or 8; (b) a poison that: (i) is a medicine for human use; and (ii) is labelled in accordance with the required advisory statements for medicine labels; (c) a poison that: (i) is an agricultural chemical or a veterinary chemical; and (ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994. 32 Name and address of manufacturer or distributor (1) The poison must be labelled with the name and address of its manufacturer or distributor. The address: (a) must be a physical address in Australia; and (b) must not be a post office, cable, telegraphic or code address. (2) However, if the manufacturer or distributor is a company incorporated under the law of a State or Territory, or a firm registered under a law of a State or Territory dealing with business names, the name and address may be: (a) the registered name of the corporation or firm, or its branch or division; and (b) the city or town in which a registered office of the company or firm is situated. Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Labels Division 2 Section 33 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 21 33 Warning statements and sedation warnings for certain medicines for human use Warning statements for certain medicines (1) A dispensed medicine for human use containing a poison included in column 1 of the table in clause 2 of Appendix L must be clearly labelled with each warning statement required for the poison by that clause. Sedation warning for certain medicines (2) A dispensed medicine for human use containing a poison included in Appendix K must be clearly labelled with a warning statement set out in item 39, 40 or 90 of the table in clause 1 of Appendix F. Subdivision C—Statements of quantity, proportion or strength 34 Statements of quantity, proportion or strength (1) The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms: (a) if the poison is for human therapeutic use—the manner required by the standards for the goods specified in orders made under subsection 10(1) of the Act; (b) if the poison is for a purpose or purposes other than human therapeutic use—as follows: (i) if the poison is in a pressurised spray aerosol preparation—as the mass of the poison per stated mass of the preparation; (ii) if the poison is a liquid in a liquid preparation—as the mass or volume of the poison per stated volume of the preparation; (iii) if the poison is a liquid in a solid or semi-solid preparation—as the mass or volume of the poison per stated mass of the preparation; (iv) if the poison is a solid or semi-solid in a liquid preparation—as the mass of the poison per stated volume of the preparation; (v) if the poison is a solid or semi-solid in a solid or semi-solid preparation—as the mass of the poison per stated mass of the preparation; (vi) if the poison is a gas in a liquid preparation—as the mass of the poison per stated volume of the preparation; (vii) if the poison is a gas in a solid or semi-solid preparation—as the mass of the poison per stated mass of the preparation; (viii) if the poison is a gas in a gaseous preparation—as the mass of the poison per stated mass of the preparation; (c) if the poison is a solution of a mineral acid, the proportion of the acid (un-neutralised by any bases present in the preparation) in a preparation may be expressed as the un-neutralised mass of the acid per stated mass of the preparation; (d) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate: Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 2 Labels Section 35 22 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (i) “contains not more than 10 per cent of (insert name of the metal)”; (ii) “contains not more than 30 per cent of (insert name of the metal)”; (iii) “contains more than 30 per cent of (insert name of the metal)”; (e) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5% of the product; (f) if the poison is a lead-based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non-volatile content of the paint; (g) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative. (2) In paragraph (1)(g): derivative includes alkaloid. Note: For requirements to state the quantity, proportion or strength of a poison, see subparagraph 14(b)(iii), section 26 and sub-subparagraphs 35(b)(ii)(B) and 36(1)(b)(ii)(A) and (2)(b)(iii)(B). Subdivision D—Exemptions from labelling requirements 35 Selected containers and measure packs The requirements of Subdivision B do not apply to an immediate container of poison that is a measure pack or a selected container (other than an ampoule, a pre-filled syringe or an injection vial to which subsections 36(1) or (2) applies) if: (a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or (b) the immediate container is: (i) packed in a primary pack labelled in accordance with Subdivision B; and (ii) labelled with: (A) the signal word or words for the poison as shown in the table in subsection 16(1); and (B) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and (C) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and (D) if the poison is only for the treatment of animals—the cautionary statement: FOR ANIMAL TREATMENT ONLY written in sans serif capital letters. Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Labels Division 2 Section 36 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 23 36 Ampoules, pre-filled syringes and injection vials (1) The requirements of Subdivision B do not apply to a selected container of poison or an ampoule of poison (other than an ampoule to which subsection (2) applies) when: (a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or (b) the selected container or ampoule is: (i) packed in a primary pack labelled in accordance with Subdivision B; and (ii) labelled with: (A) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and (B) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and (C) if the poison is only for the treatment of animals—the cautionary statement: FOR ANIMAL TREATMENT ONLY written in sans serif capital letters. (2) The requirements of Subdivision B do not apply to a selected container of poison that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when: (a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or (b) the poison is not therapeutic goods and all of the following apply: (i) the ampoule is packed in a primary pack labelled in accordance with Subdivision B; (ii) the strip is labelled in accordance with this section; (iii) the ampoule is labelled with: (A) the approved name of the poison or the trade name of the poison; and (B) the quantity, proportion or strength of the poison in accordance with section 34. 37 Transport containers and wrappings The labelling requirements of this instrument do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery. 38 Dispensary, industrial, laboratory and manufacturing poisons The labelling requirements of this instrument do not apply to a poison that: (a) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 2 Labels Section 39 24 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) is labelled in accordance with requirements under applicable jurisdictional work health and safety laws, as in force from time to time. 39 Exemptions from label requirements in certain circumstances (1) A requirement specified in Subdivision B or section 35 or 37 does not apply to a poison if an appropriate authority has granted a labelling exemption under this subsection in relation to that requirement for the poison. (2) A labelling exemption granted by an appropriate authority under subsection (1) remains in force: (a) if the exemption relates to a product that is indicated for the treatment or prevention of the coronavirus known as COVID-19: (i) for the period specified in the exemption; or (ii) if no period is specified—until revoked by the appropriate authority; or (b) in any other case: (i) for the period, specified in the exemption, that is 12 months or less from the date of commencement of the exemption; or (ii) if no period is specified—12 months from the date of commencement of the exemption. (3) For the avoidance of doubt, this section does not apply to an authorisation given under subparagraph 28(d)(iii). 40 Dispensed medicines Unless otherwise specified in relevant State or Territory legislation and subject to section 33, the labelling requirements of this instrument do not apply to a medicine that: (a) is: (i) supplied by an authorised prescriber; or (ii) supplied on and in accordance with a prescription written by an authorised prescriber; or (iii) prepared and supplied by a pharmacist for an individual patient; and (b) is labelled in accordance with the requirements of clause 1 of Appendix L. 41 Gas cylinders The requirements of paragraph 16(1)(d) and paragraphs 18(d) and 22(1)(d) do not apply to a cylinder containing a poison that is a compressed gas. 42 Paints The requirements of Subdivision B do not apply to: (a) a paint (other than a paint for therapeutic or cosmetic use) that contains only poisons included in Schedule 5; or (b) a first group paint or second group paint that is labelled with: Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Labels Division 2 Section 43 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 25 (i) the word “WARNING”, written in bold-face sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and (ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-face sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and (iii) the appropriate warnings required for the paint by clause 4 of Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and (iv) the name and proportion of the first group or second group poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non-volatile content” or “in the dried film” of the paint; or (c) a tinter which contains only poisons included in Schedule 5; or (d) a tinter that contains a poison mentioned in a table in section 67 or 68, if: (i) the tinter is labelled with the name and proportion of the poison; and (ii) if the poison is a metal or metal salt—the proportion is expressed as the metallic element present as “calculated on the non-volatile content” or “in the dried film”. 43 Camphor and naphthalene The labelling requirements of paragraph 13(2)(d) and Subdivision B do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device: (a) complies with section 52; and (b) is sold or supplied in a primary pack labelled in accordance with section 13 and Subdivision B. Subdivision E—Prohibitions 44 Prohibitions (1) A label used in connection with a poison must not include: (a) any reference to this instrument, or any comment on, reference to, or explanation of any expression required by this instrument that directly or by implication contradicts, qualifies or modifies such expression; or (b) any expression or device suggesting or implying that the poison is safe, harmless, non-toxic, non-poisonous, or is recommended or approved by a government or government authority unless required by legislation; or (c) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or (d) any trade name or description that: (i) represents any single constituent of a compound preparation; or (ii) misrepresents the composition or any property or quality of the poison; or (iii) gives any false or misleading indication of origin or place of manufacture of the poison. Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 2 Labels Section 44 26 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (2) A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure any of the ribs or any expression required by this instrument to be written or embossed on the container or pack. Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Containers Division 3 Section 45 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 27 Division 3—Containers 45 General requirements A poison must not be supplied unless the requirements of this Division for the immediate container for the poison are met. 46 Containers for poisons other than poisons included in Schedule 5 (1) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of 2 L or less, the container must comply with Australian Standard AS 2216-1997, Packaging for poisonous substances. (2) Despite subsection (1), a poison included in Schedule 6 that is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216-1997, Packaging for poisonous substances, if: (a) other safety factors are not diminished; and (b) the container has a restricted flow insert and a child-resistant closure. (3) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of more than 2 L: (a) the container must comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997, Packaging for poisonous substances; and (b) the word “POISON” must be embossed, or indelibly written in a colour in distinct contrast to the background colour, on the side or shoulder of the container, in sans serif capital letters the height of which is at least one thirty-second part of the length, height or width of the container, whichever is the greatest. 47 Containers for poisons included in Schedule 5 (1) The container in which a poison included in Schedule 5 is supplied must: (a) comply with the container requirements of subsection 46(1) or (3); or (b) comply with subsection (2). (2) A container complies with this subsection if: (a) it is readily distinguishable from a container in which food (including a condiment) or drink is sold; and (b) it complies with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997, Packaging for poisonous substances, excluding paragraph 1.4.3; and (c) it is securely closed and, except when containing a preparation for use on one occasion only, is capable of being re-closed to prevent spillage of its contents; and (d) the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” is: (i) embossed or indelibly written on the container; or Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 3 Containers Section 48 28 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (ii) printed on a label that complies with subsection (3) that is attached to the container. (3) For the purposes of subparagraph (2)(d)(ii), the label must be a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate. (4) Despite subsection (1), the following poisons included in Schedule 5: (a) methylated spirit(s); (b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid; (c) petrol; (d) toluene; (e) xylene; must not be supplied in a bottle or jar having a nominal capacity of 2 L or less, unless the immediate container complies with the container requirements of subsection 46(1). 48 Approved containers Despite subsections 46(1) and (3) and section 47, a poison may be packed in a container that does not comply with the tactile identification requirements of AS2216-1997 (Packaging for poisonous substances) or the requirements of paragraph 46(3)(b) or 47(2)(d) if: (a) other safety factors are not diminished; and (b) the container is for a specific purpose; and (c) an appropriate authority has approved the use of the container for that purpose. 49 Child-resistant closures (1) If a poison specified in column 1 of an item of the following table is supplied in a container having a nominal capacity specified in column 2 of the item, it must be closed with a child-resistant closure that: (a) is appropriate for the container and the poison; and (b) will retain its child-resistant properties for the expected life of the poison. Poisons that must be closed with a child-resistant closure Item Column 1 Poison Column 2 Nominal capacity of container 1 Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine tablets All sizes 2 Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine liquids, solids or gels 5 L/kg or less 3 Alkaline salts included in Schedule 5, when packed and labelled as a food additive 2.5 L or less 4 Anise oil when included in Schedule 5 200 mL or less 5 Basil oil when included in Schedule 5 200 mL or less Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Containers Division 3 Section 49 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 29 Poisons that must be closed with a child-resistant closure Item Column 1 Poison Column 2 Nominal capacity of container 6 Bay oil when included in Schedule 6 200 mL or less 7 Cajuput oil when included in Schedule 6 200 mL or less 8 Cassia oil when included in Schedule 5 200 mL or less 9 Cineole when included in Schedule 6 2 L or less 10 Cinnamon bark oil when included in Schedule 5 200 mL or less 11 Cinnamon leaf oil when included in Schedule 6 200 mL or less 12 Clove oil when included in Schedule 6 200 mL or less 13 CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) when included in Schedule 6, when presented in a wipe All sizes 14 Essential oils when included in Schedule 6 because of their natural camphor component 200 mL or less 15 Ethylene glycol when included in Schedule 6 5 L or less 16 Ethylene glycol when included in Schedule 5 in preparations containing more than 50% of ethylene glycol 5 L or less 17 Eucalyptus oil when included in Schedule 6 2 L or less 18 Eugenol when included in Schedule 6 200 mL or less 19 Fennel oil when included in Schedule 5 200 mL or less 20 Hydrocarbons, liquid, when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid 5 L or less 21 Hydrochloric acid when included in Schedule 6 5 L or less 22 Leptospermum scoparium oil (manuka oil) when included in Schedule 6 200 mL or less 23 Marjoram oil when included in Schedule 5 200 mL or less 24 Melaleuca oil (tea-tree oil) when included in Schedule 6 200 mL or less 25 Methylated spirit excluding preparations or admixtures 5 L or less 26 Methyl salicylate and preparations containing more than 50% of methyl salicylate 200 mL or less 27 Nicotine in liquid preparations when included in Schedule 4. All sizes 28 Nutmeg oil when included in Schedule 5 200 mL or less 29 Oil of turpentine 5 L or less 30 Paracetamol included in Schedule 4, when packed and labelled for the treatment of animals All sizes 31 Pennyroyal oil when included in Schedule 6 200 mL or less 32 Potassium hydroxide as such 2.5 L or less 33 Potassium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs 5 L or less Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 3 Containers Section 50 30 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be closed with a child-resistant closure Item Column 1 Poison Column 2 Nominal capacity of container 34 D-Pulegone when included in Schedule 6 200 mL or less 35 Sage oil (Dalmatian) when included in Schedule 6 200 mL or less 36 Sodium hydroxide as such 2.5 L or less 37 Sodium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs 5 L or less 38 Thujone when included in Schedule 6 200 mL or less 39 Thyme oil when included in Schedule 5 200 mL or less (2) This section does not apply to a poison included in therapeutic goods that are packaged in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act. 50 Poisons included in Schedule 8 (1) If a poison included in Schedule 8 is supplied, it must be packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs. (2) This paragraph does not apply to the supply of a poison included in Schedule 8: (a) by an authorised prescriber or other authorised supplier; or (b) by a pharmacist on the prescription of an authorised prescriber; or (c) by a pharmacist employed at a hospital, on the written requisition of: (i) a medical practitioner or dental practitioner; or (ii) the nurse or midwife in charge of the ward in which the poison is to be used or stored; or (d) by a nurse or midwife on the direction in writing of an authorised prescriber. 51 Exemptions (1) Subsections 46(1) and (3) and section 47 do not apply to the immediate container of a poison prepared, packed and sold: (a) for human internal or animal internal use; or (b) as a solid or semi-solid preparation for human external or animal external use; or (c) as a paint, other than a paint for therapeutic or cosmetic use; or (d) in containers having a nominal capacity of 15 mL or less; or (e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or (f) solely for dispensary, industrial, laboratory or manufacturing purposes. (2) Section 49 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes. Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Containers Division 3 Section 52 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 31 (3) The tactile identification or embossing required by subsections 46(1) and (3) and section 47 or Australian Standard AS 2216-1997, Packaging for poisonous substances, do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet. 52 Camphor and naphthalene (1) The container requirements of subsection 46(1) do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device: (a) in normal use, prevents removal or ingestion of its contents; and (b) is incapable of reacting with the poison; and (c) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and (d) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it. (2) Camphor or naphthalene must not be supplied in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents. 53 Prohibitions—use of containers for poisons (1) A poison must not be supplied in a container that is embossed or indelibly marked with the name of another poison. (2) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply a poison for internal use. (3) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply food (including a condiment) or drink. (4) A poison must not be supplied in a container that is not readily distinguishable from a container in which food (including a condiment) or drink is sold. Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 4 Storage Section 54 32 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Division 4—Storage 54 General storage requirements Poisons included in Schedule 2 (1) A poison included in Schedule 2 that is stored at premises for supply to the public must be stored in such a way that public access to advice from a pharmacist is available if required. Poisons included in Schedules 3 and 4 (2) A poison included in Schedule 3 or 4 that is stored at premises for supply to the public must be stored in a part of the premises to which the public does not have access. Poisons included in Schedule 6 (3) A poison included in Schedule 6 that is stored at premises for supply by way of retail sale must be stored in such a way as to prevent access by children. Poisons included in Schedule 7 (4) A poison included in Schedule 7 that is stored at premises for supply by retail sale must be stored in an area of the premises, and in a manner, that allows physical access only by the following: (a) the owner of the retail establishment; (b) an employee of the owner; (c) a person who is legally permitted to purchase the poison and is under the supervision of the owner or an employee of the owner. Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Disposal Division 5 Section 55 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 33 Division 5—Disposal 55 General disposal requirements A poison included in Schedule 5, 6 or 7 must not be disposed of in any place or manner that constitutes or is likely to constitute a risk to public health or safety. Note: Controls on the disposal of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation. Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 6 Record keeping Section 56 34 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Division 6—Record keeping 56 General record-keeping requirements (1) If a poison included in Schedule 7 is supplied, a record of the following must be kept: (a) the name and address of the supplier and of the purchaser; (b) the date of the order and supply; (c) the approved name or trade name of the poison; (d) the quantity supplied or sold; (e) if an authorisation is required for purchase of the poison under the law of the jurisdiction in which the purchaser purchases the poison—proof that the purchaser has the required authorisation. (2) The records mentioned in subsection (1) must be kept for at least 5 years. Note: Controls on record keeping for the supply of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation. Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Advertising Division 7 Section 57 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 35 Division 7—Advertising 57 General advertising requirements Poisons included in Schedule 3, 4 and 8 (1) A reference to a poison included in: (a) Schedule 3, unless included in Appendix H; or (b) Schedule 4; or (c) Schedule 8; must not be included in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry. Poisons included in Schedules 9 and 10 (2) A reference to a poison included in Schedule 9 or Schedule 10 must not be included in any advertisement. Note: Schedule 10 includes poisons previously listed in Appendix C. Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 8 Supply, prescribing, possession or use Section 58 36 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Division 8—Supply, prescribing, possession or use 58 Poisons included in Schedule 2 (1) A poison included in Schedule 2 must not be supplied by a person other than: (a) a person who: (i) is a pharmacist (or an assistant under the direction of a pharmacist) or a medical practitioner, dental practitioner or veterinarian; and (ii) is acting in the lawful practice of the person’s profession; or (b) a person who is licensed to supply the poison under the law of the jurisdiction from which the person will supply the poison. (2) A person is not eligible to be granted a licence to supply a poison included in Schedule 2 unless: (a) the person is carrying on the business of supplying goods by retail sale; and (b) the premises from which the poison will be supplied is more than 25 km by the shortest practicable route from the nearest pharmacy; and (c) if required by the law of the jurisdiction from which the person will supply the poison—the person produces evidence that the person is a fit and proper person to be so licensed. (3) Subsection (1) does not apply to the supply of a poison included in Schedule 2 by way of wholesale dealing to: (a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison. 59 Poisons included in Schedule 3 (1) A poison included in Schedule 3 must not be supplied by a person other than a person who: (a) is a pharmacist, medical practitioner, dental practitioner or veterinarian; and (b) is acting in the lawful practice of the person’s profession. (2) The following requirements apply if a poison included in Schedule 3 is supplied: (a) adequate instructions for use, either written or verbal, must be provided at the time of supply; (b) the container of the poison must be labelled with: (i) the name of the supplier or the name of the pharmacy (as applicable); and (ii) the address from which it was supplied; (c) if required by the law of the jurisdiction from which the supplier supplies the poison—a record of the transaction must be made in a prescription book or other approved recording system. (3) This section does not apply to the supply of a poison included in Schedule 3 by way of wholesale dealing to: (a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Supply, prescribing, possession or use Division 8 Section 60 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 37 (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison. 60 Poisons included in Schedule 4 (1) A poison included in Schedule 4 must not be supplied by a person other than: (a) a person who: (i) is a medical practitioner, dental practitioner or veterinarian; and (ii) is acting in the lawful practice of the person’s profession; or (b) a pharmacist dispensing a legal prescription for the poison; or (c) a pharmacist supplying the poison without a prescription as permitted by subsection (2). (2) A poison included in Schedule 4 may be supplied to a person (the patient) by a pharmacist without a prescription if: (a) the poison is not excepted from this provision by the law of the jurisdiction from which the pharmacist supplies the poison; and (b) the patient is under medical treatment with the poison and continuation of medication is essential; and (c) the quantity supplied does not exceed 3 days’ medication; and (d) the pharmacist is satisfied that an emergency exists. (3) Subsection (1) does not apply to the supply of a poison included in Schedule 4 by way of wholesale dealing to: (a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison. 61 Poisons included in Schedules 5 and 6 (1) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in any manner unless the recipient has the opportunity to refuse at the time of supply. (2) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in an unsolicited manner (for example by post or by attaching the sample to another product). (3) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in a manner that does not promote disposal in accordance with Division 5. 62 Poisons included in Schedule 7 Possession or use for domestic or domestic garden purposes prohibited (1) A poison included in Schedule 7 must not be possessed or used for domestic or domestic garden purposes. Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 8 Supply, prescribing, possession or use Section 63 38 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Supply for domestic or domestic garden purposes prohibited (2) A poison included in Schedule 7 must not be supplied for domestic or domestic garden purposes. Supply of liquid preparations containing paraquat (3) A poison included in Schedule 7 that is a liquid preparation containing paraquat must not be supplied unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell. Supply if authorisation required by appropriate authority (4) A poison included in Schedule 7 for which an authorisation to purchase, possess or use is required by the appropriate authority must not be supplied unless the purchaser produces the required authorisation. Product samples prohibited (5) A product sample containing a poison included in Schedule 7 must not be supplied. Supply of poisons included in Appendix J (6) A poison included in Schedule 7 that is included in the table in clause 1 of Appendix J may be supplied only in accordance with that clause. 63 Poisons included in Schedule 10 A poison included in Schedule 10 must not be possessed, supplied or used for a purpose indicated in relation to that poison in Schedule 10. Note: Schedule 10 includes poisons previously listed in Appendix C. 64 Poisons included in Schedule 4 or 8 and Appendix D (1) This section applies to a poison included in Schedule 4 or 8. Supply or prescribing (2) A poison included in a table in clause 1, 2, 3, 4, 6 or 7 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with the clause that contains the table. (3) A poison referred to in clause 8 or 10 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with clause 8 or 10 (as applicable) of Appendix D. Possession (4) A poison included in the table in clause 5 of Appendix D must not be possessed by a person without authority under the law of the jurisdiction in which the possession occurs. Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Supply, prescribing, possession or use Division 8 Section 65 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 39 Storage (5) A poison included in the table in clause 9 of Appendix D must be stored in a locked container to prevent unauthorised access. 65 Hawking A poison included in Schedule 7 must not be supplied by way of hawking. Note: Controls on supply by way of hawking of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation. Authorised Version F2024L00589 registered 30/05/2024 Part 2 Controls on substances Division 9 Paints and tinters Section 66 40 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Division 9—Paints and tinters Note: Paints and tinters are poisons that were previously listed in Appendix I. 66 General requirements (1) A first group paint must not be manufactured, supplied or used for application to: (a) a roof or any surface to be used for the collection or storage of potable water; or (b) furniture; or (c) any fence, wall, post, gate or building (interior or exterior) other than a building that is used exclusively for industrial purposes or mining or as an oil terminal; or (d) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption. (2) An anti-fouling paint containing more than 0.1% lead (the proportion of lead for the purposes of this section is calculated as a percentage of the element present in the non-volatile content of the paint) must not be manufactured, supplied or used. (3) A paint (other than an anti-fouling paint) or tinter containing more than 0.009% lead (calculated as a percentage of the element present in the non-volatile content of the paint) must not be manufactured, supplied or used. (4) A paint for application to toys must not be manufactured, supplied or used unless it complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012, Safety of toys Part 3: Migration of certain elements (ISO 8124-03:2010, MOD), published jointly by, or on behalf of, Standards Australia and Standards New Zealand. (5) A paint or tinter containing a pesticide other than a fungicide, algaecide, bactericide or antifouling agent must not be manufactured, supplied or used. 67 Definition of first group paint A paint containing a substance mentioned in column 1 of an item in the following table in the proportion (calculated as a percentage of the element present in the non-volatile content of the paint) specified in column 2 of the item is a first group paint. First group paints Item Column 1 Substance Column 2 Proportion 1 ANTIMONY or antimony compounds other than antimony titanate pigments more than 5% 2 BARIUM salts except barium sulfate or barium metaborate more than 5% 3 CADMIUM or cadmium compounds more than 0.1% 4 CHROMIUM as chromates of ammonia, barium, potassium sodium, strontium or zinc more than 5% 5 SELENIUM or selenium compounds more than 0.1% Authorised Version F2024L00589 registered 30/05/2024 Controls on substances Part 2 Paints and tinters Division 9 Section 68 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 41 68 Definition of second group paint A paint containing a substance mentioned in column 1 of an item in the following table in the proportion specified in column 2 of the item is a second group paint. Second group paints Item Column 1 Substance Column 2 Proportion 1 DICHLOROMETHANE (methylene chloride) more than 5% by weight 2 ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates more than 10% by volume 3 HEXYLOXYETHANOL more than 10% by volume 4 TOLUENE more than 50% by volume 5 XYLENE more than 50% by volume Authorised Version F2024L00589 registered 30/05/2024 Schedule 1 Blank 42 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 1—Blank Note: Schedule 1 is intentionally blank. Authorised Version F2024L00589 registered 30/05/2024 Pharmacy medicines Schedule 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 43 Schedule 2—Pharmacy medicines Note: See section 16, subsection 54(1) and section 58. ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) for therapeutic use. ACETYLCYSTEINE in preparations for oral use except when labelled with a recommended daily dose of 1 g or less of acetylcysteine. ACONITUM spp. for therapeutic use in adults: (a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids; or (b) in preparations for dermal use containing 0.02% or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids. ALIMEMAZINE when combined with one or more other therapeutically active substances in solid oral preparations when: (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or (b) in a day-night pack containing alimemazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper; except in preparations for the treatment of children under 2 years of age. ALOXIPRIN. AMOROLFINE in preparations for topical use except in preparations for the treatment of tinea pedis. ANTAZOLINE in eye drops. ASPIRIN except when: (a) included in Schedule 4, 5 or 6; or (b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are: (i) enclosed in a primary pack that contains 12 or less individually wrapped powders or sachets of granules; and (ii) compliant with the requirements of the required advisory statements for medicine labels; or (c) in tablets or capsules containing aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are: (i) either: (A) packed in blister or strip packing; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 2 Pharmacy medicines 44 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (B) in a container with a child-resistant closure; and (ii) either: (A) in a primary pack that contains not more than 25 tablets or capsules, each containing 325 mg or less of aspirin; or (B) in a primary pack that contains not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; or (C) in a primary pack that contains not more than 100 tablets or capsules, each containing 100 mg or less of aspirin, and that is labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and (iii) compliant with the requirements of the required advisory statements for medicine labels. ASTODRIMER SODIUM when used in a nasal spray. ATROPA BELLADONNA (belladonna): (a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or (b) for oral use: (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids. ATROPINE (excluding atropine methonitrate) for oral use: (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids. AZELAIC ACID in dermal preparations. AZELASTINE: (a) in preparations for nasal use; or (b) in topical eye preparations containing 0.05% or less of azelastine. BECLOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of beclometasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or Authorised Version F2024L00589 registered 30/05/2024 Pharmacy medicines Schedule 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 45 less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over. BENZOCAINE in preparations for topical use other than eye drops: (a) containing 10% or less of total local anaesthetic substances, except in dermal preparations containing 2% or less of total local anaesthetic substances; or (b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit. BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10% or less of benzoyl peroxide except in preparations containing 5% or less of benzoyl peroxide. BENZYDAMINE in preparations for topical use, except: (a) in preparations for dermal use; or (b) in divided topical oral preparations containing 3 mg or less of benzydamine; or (c) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL. BEPHENIUM SALTS. BIFONAZOLE in preparations for dermal use except: (a) in preparations containing 1% or less of bifonazole for the treatment of the scalp; or (b) in preparations for the treatment of tinea pedis. BILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 20 mg bilastine for the treatment of adults and children aged 12 years and over. BRIMONIDINE in ophthalmic preparations for adult use containing not more than 0.025% of brimonidine. BROMHEXINE. BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when: (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or (b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper; except in preparations for the treatment of children under 2 years of age. BUDESONIDE in aqueous nasal sprays delivering 64 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 Authorised Version F2024L00589 registered 30/05/2024 Schedule 2 Pharmacy medicines 46 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over. CARBETAPENTANE except in preparations containing 0.5% or less of carbetapentane. CARBOCISTEINE. CETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when: (a) in a primary pack containing not more than 10 days’ supply; and (b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine. CHLOPHEDIANOL. CHLORBUTANOL for human use in topical preparations containing 5% or less of chlorbutanol except in preparations containing 0.5% or less of chlorbutanol. CHLOROFORM in preparations for therapeutic use except: (a) when included in Schedule 4; or (b) in preparations containing 0.5% or less of chloroform. CHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when: (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or (b) in a day-night pack containing chlorphenamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper; except in preparations for the treatment of children under 2 years of age. CHOLINE SALICYLATE in preparations for oromucosal use. CICLOPIROX: (a) in preparations for dermal use containing 2% or less of ciclopirox except in preparations for the treatment of tinea pedis; or (b) in preparations for application to the nails containing 8% or less of ciclopirox. CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5% or less of total local anaesthetic substances. CINNAMEDRINE. CLOTRIMAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis. CREOSOTE derived from wood other than beechwood for human therapeutic use, except in preparations containing 10% or less of creosote derived from wood other than beechwood. Authorised Version F2024L00589 registered 30/05/2024 Pharmacy medicines Schedule 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 47 DATURA spp. for oral use: (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; except when separately specified in these Schedules. DATURA STRAMONIUM (stramonium) for oral use when: (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; except for smoking or burning. DATURA TATULA (stramonium) for oral use: (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; except for smoking or burning. DELPHINIUM STAPHISAGRIA except in preparations containing 0.2% or less of Delphinium staphisagria. DESLORATADINE in preparations for oral use. DEXCHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when: (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or (b) in a day-night pack containing dexchlorphenamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper; except in preparations for the treatment of children under 2 years of age. DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan. DIBROMOPROPAMIDINE for ophthalmic use. Authorised Version F2024L00589 registered 30/05/2024 Schedule 2 Pharmacy medicines 48 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DICLOFENAC when: (a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac; or (b) in preparations for dermal use containing 4% or less of diclofenac except in preparations for dermal use containing 2% or less of diclofenac or for the treatment of solar keratosis; or (c) in transdermal preparations for topical use containing 140 mg or less of diclofenac. DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age. DIPHENHYDRAMINE in oral preparations: (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or (b) when combined with one or more other therapeutically active substances when: (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or (ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper; except in preparations for the treatment of children under 2 years of age. DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when: (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or (b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper; except in preparations for the treatment of children under 2 years of age. DUBOISIA LEICHHARDTII for oral use: (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids. DUBOISIA MYOPOROIDES for oral use: (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or Authorised Version F2024L00589 registered 30/05/2024 Pharmacy medicines Schedule 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 49 (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids. ECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis. ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days’ supply. ETAFEDRINE. ETHER for therapeutic use except: (a) when included in Schedule 4; or (b) in preparations containing 10% or less of ether. ETHYLMORPHINE when: (a) compounded with one or more other therapeutically active substances: (i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or (ii) in undivided preparations containing 0.25% or less of ethylmorphine; and (b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine. ETOFENAMATE in preparations for external use. FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply. FELBINAC in preparations for external use. FEXOFENADINE in preparations for oral use except in divided preparations: (a) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when: (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and (ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or (b) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when: (i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and (ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or (c) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when: Authorised Version F2024L00589 registered 30/05/2024 Schedule 2 Pharmacy medicines 50 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and (ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine. FLUORIDES for human use: (a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or (b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure: (i) for therapeutic use when compliant with the requirements of the required advisory statements for medicine labels except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of required advisory statements for medicine labels; or (ii) for non-therapeutic use when labelled with warnings to the following effect: (A) Do not swallow; and (B) Do not use [this product/insert name of product] in children 6 years of age or less; except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect: (C) Do not swallow; and (D) Do not use [this product/insert name of product] in children 6 years of age or less; except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority. FLURBIPROFEN in preparations for topical oral use when: (a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit except when: (i) in a primary pack containing not more than 16 dosage units; and (ii) labelled only for the treatment of adults and children over 12 years; or (b) in undivided preparations containing either: (i) 0.25% or less of flurbiprofen per dose; or (ii) 10 mg or less of flurbiprofen per dose; except when: (iii) in a primary pack containing not more than 15 mL; and (iv) labelled only for the treatment of adults 18 years and over. FLUTICASONE PROPIONATE (excluding derivatives) in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended Authorised Version F2024L00589 registered 30/05/2024 Pharmacy medicines Schedule 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 51 daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over. FOLIC ACID for human therapeutic use except: (a) when included in Schedule 4; or (b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose. FOLINIC ACID for human therapeutic use except: (a) when included in Schedule 4; or (b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose. FORMALDEHYDE (excluding its derivatives) for human therapeutic use except: (a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or (b) in other preparations containing 0.2% or less of free formaldehyde. GELSEMIUM SEMPERVIRENS. GLUTARAL for human therapeutic use. GUAIFENESIN in a modified release dosage form of 1200 mg or less of guaifenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age. HEXACHLOROPHENE in preparations for human use containing 3% or less of hexachlorophene except: (a) in preparations for use on infants, as specified in Schedule 4; or (b) in preparations for cosmetic use, as specified in Schedule 6; or (c) in other preparations containing 0.75% or less of hexachlorophene. HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use: (a) for dermal use in preparations containing 0.5% or less of hydrocortisone, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or (b) for dermal use in preparations containing 1% or less of hydrocortisone, in packs containing 15 g or less of such preparations, containing an antifungal substance and no other therapeutically active constituent: (i) for the treatment of tinea (tinea pedis, tinea cruris, tinea corporis) and other fungal skin infections; and (ii) not labelled for the treatment of children under 12 years of age; or (c) for rectal use in preparations containing 0.5% or less of hydrocortisone, when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents: Authorised Version F2024L00589 registered 30/05/2024 Schedule 2 Pharmacy medicines 52 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (i) in undivided preparations in packs of 35 g or less; or (ii) in packs containing 12 or less suppositories. HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2% or less of hydroquinone except: (a) in hair preparations containing 0.3% or less of hydroquinone; or (b) in cosmetic nail preparations containing 0.02% or less of hydroquinone. HYOSCINE: (a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or (b) for oral use: (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids. HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide. HYOSCYAMINE: (a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or (b) for oral use: (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids. HYOSCYAMUS NIGER for oral use: (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or (b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; except in a pack containing 0.03 mg or less of total solanaceous alkaloids. Authorised Version F2024L00589 registered 30/05/2024 Pharmacy medicines Schedule 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 53 IBUPROFEN in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen, when: (a) in liquid preparations that are sold in the manufacturer’s original pack containing 8 g or less of ibuprofen; or (b) in divided immediate release preparations: (i) each containing 400 mg or less of ibuprofen in a primary pack containing not more than 12 dosage units; and (ii) that are labelled not for the treatment of children under 12 years; or (c) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units except when: (i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and (ii) packed in blister or strip packaging or in a container with a child-resistant closure; and (iii) in a primary pack containing not more than 25 dosage units; and (iv) compliant with the requirements of the required advisory statements for medicine labels; and (v) not labelled for the treatment of children 6 years or under; and (vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years. INDANAZOLINE. INDOMETACIN in preparations for external use containing 1% or less of indometacin. IODINE: (a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or (b) in preparations for human external therapeutic use containing more than 2.5% of available iodine (excluding salts, derivatives or iodophors); except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority. IPRATROPIUM in preparations for nasal use. IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1% or less of total iron oxides) for human internal use except: (a) when included in Schedule 4; or (b) when labelled with a recommended daily dose of 24 mg or less of iron: Authorised Version F2024L00589 registered 30/05/2024 Schedule 2 Pharmacy medicines 54 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or (ii) in divided preparations: (A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or (B) containing 5 mg or less of iron per dosage unit. ISOCONAZOLE for human use in dermal preparations. ISOPROPAMIDE in preparations for dermal use containing 2% or less of isopropamide. KETOCONAZOLE in preparations for dermal use except: (a) in preparations containing 1% or less of ketoconazole for the treatment of the scalp; or (b) in preparations for the treatment of tinea pedis. KETOTIFEN for ophthalmic use in preparations containing 0.025% or less of ketotifen. LANSOPRAZOLE in oral preparations 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days’ supply. LEVOCABASTINE in topical eye or nasal preparations. LEVOCETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when: (a) in a primary pack containing not more than 5 days’ supply; and (b) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine. LIDOCAINE in preparations for topical use other than eye drops: (a) containing 10% or less of total local anaesthetic substances, except: (i) in dermal preparations containing 2% or less of total local anaesthetic substances; or (ii) in aqueous sprays for oromucosal use containing 0.6% or less of total local anaesthetic substances; or (b) in divided preparations containing 200 mg or less of total local anaesthetic substances, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit. LINDANE in preparations for human external therapeutic use containing 2% or less of lindane. LITHIUM in preparations for dermal use containing 1% or less of lithium except: (a) when present as an excipient at 0.25% or less of lithium; or (b) in preparations containing 0.01% or less of lithium. Authorised Version F2024L00589 registered 30/05/2024 Pharmacy medicines Schedule 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 55 LOBELIA INFLATA except for smoking or burning. LOBELINE except in preparations for smoking or burning. LODOXAMIDE in preparations for ophthalmic use. LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less except in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less. LORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis when: (a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and (b) labelled with a recommended daily dose not exceeding 10 mg of loratadine. MACROGOLS in preparations for oral use as a liquid concentrate for laxative use. MEBENDAZOLE for human therapeutic use. MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age. MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea. MEPYRAMINE for dermal use. MERCUROCHROME in preparations for external use containing 2% or less of mercurochrome except when included in Schedule 6. MERCURY for external use in preparations containing 0.5% or less of mercury. METHOXAMINE in preparations for external use except in preparations containing 1% or less of methoxamine. METHOXYPHENAMINE. METHYLEPHEDRINE. MICONAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis. MINOXIDIL in preparations for dermal use containing 5% or less of minoxidil. MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over. Authorised Version F2024L00589 registered 30/05/2024 Schedule 2 Pharmacy medicines 56 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 NAPHAZOLINE. NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units. NICLOSAMIDE for human therapeutic use. NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply. NOSCAPINE. NYSTATIN in dermal preparations. OLOPATADINE in preparations for nasal use delivering 600 micrograms or less of olopatadine per dose when the maximum recommended daily dose is no greater than 4,800 micrograms for the treatment of allergic rhinitis or rhinoconjunctivitis for up to 6 months in adults and children 12 years of age and over. OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days’ supply. OXETACAINE (oxethazaine) in preparations for internal use. OXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis. OXYMETAZOLINE. OXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, except in preparations for external use containing 1% or less of such substances. PAPAVERINE except when included in Schedule 4. PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days’ supply. PARACETAMOL for therapeutic use: (a) in liquid preparations for oral use containing a maximum of 10 g of paracetamol per container; or (b) when combined with ibuprofen in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided doses in a primary pack containing no more than 12 dosage units per pack; or (c) in tablets or capsules enclosed in a primary pack containing not more than 100 tablets or capsules; or (d) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine pack and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or Authorised Version F2024L00589 registered 30/05/2024 Pharmacy medicines Schedule 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 57 (e) in individually wrapped powders or sachets of granules enclosed in a primary pack containing not more than 50 wrapped powders or sachets of granules; or (f) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules intended only as a bulk medicine pack and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or (g) in other preparations except: (i) when included in Schedule 3 or 4; or (ii) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when: (A) enclosed in a primary pack that contains not more than 10 such powders or sachets of granules; (B) compliant with the requirements of the required advisory statements for medicine labels; (C) not labelled for the treatment of children 6 years of age or less; and (D) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin; or (iii) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when: (A) packed in blister or strip packaging or in a container with a child-resistant closure; (B) in a primary pack containing not more than 20 tablets or capsules; (C) compliant with the requirements of the required advisory statements for medicine labels; (D) not labelled for the treatment of children 6 years of age or less; and (E) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin. PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use except: (a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or (b) in other preparations containing 0.2% or less of free formaldehyde. PHEDRAZINE. PHENAZONE for human external use. PHENIRAMINE: (a) in eye drops; or (b) when combined with one or more other therapeutically active substances in oral preparations when: Authorised Version F2024L00589 registered 30/05/2024 Schedule 2 Pharmacy medicines 58 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or (ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper; except in preparations for the treatment of children under 2 years of age. PHENOL, or any homologue boiling below 220°C, for human therapeutic use except: (a) when included in Schedule 4; or (b) in preparations for external use containing 1% or less of phenol and in preparations for external use containing 3% or less of cresols and xylenols and other homologues of phenol. PHENYLEPHRINE except: (a) when included in Schedule 4; or (b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or (c) in topical eye or nasal preparations containing 1% or less of phenylephrine. PHOLCODINE: (a) in liquid preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or (b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine. PIPERAZINE for human therapeutic use. PODOPHYLLOTOXIN in preparations containing 0.5% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts. PODOPHYLLUM EMODI (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts. PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts. POTASSIUM CHLORATE for therapeutic use except in preparations containing 10% or less of potassium chlorate. PRILOCAINE in preparations for dermal use containing 10% or less of total local anaesthetic substances. PROCYCLIDINE in preparations containing 5% or less of procyclidine for dermal use. PROMETHAZINE in oral preparations: Authorised Version F2024L00589 registered 30/05/2024 Pharmacy medicines Schedule 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 59 (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or (b) when combined with one or more other therapeutically active substances when: (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or (ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper; except in preparations for the treatment of children under 2 years of age. PROPAMIDINE for ophthalmic use. PYRANTEL for human therapeutic use. PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10% of such substances. PYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels. RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 7 days’ supply. RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days’ supply except: (a) in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units; or (b) in divided preparations for oral use containing 300 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units. SALICYLAMIDE except when included in Schedule 4. SELENIUM in preparations for human therapeutic use except: (a) for topical use containing 3.5% or less of selenium sulfide; (b) when included in Schedule 4; or (c) for oral use with a recommended daily dose of 150 micrograms or less. SILVER for therapeutic use except: (a) in solutions for human oral use containing 0.3% or less of silver when compliant with the requirements of the required advisory statements for medicine labels; or (b) in other preparations containing 1% or less of silver. Authorised Version F2024L00589 registered 30/05/2024 Schedule 2 Pharmacy medicines 60 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use. SODIUM NITRITE for therapeutic use (excluding when present as an excipient). SQUILL except in preparations containing 1% or less of squill. SULCONAZOLE in preparations for dermal use. TERBINAFINE for dermal use except in preparations for the treatment of tinea pedis. TETRACAINE in preparations for topical use other than eye drops, containing 10% or less of total local anaesthetic substances except in dermal preparations containing 2% or less of total local anaesthetic substances. TETRACHLOROETHYLENE for human therapeutic use. TETRYZOLINE. THIABENDAZOLE for human therapeutic use. TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis. TRAMAZOLINE. TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over. TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when: (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or (b) in a day-night pack containing triprolidine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper; except in preparations for the treatment of children under 2 years of age. TUAMINOHEPTANE. TYMAZOLINE. XYLOMETAZOLINE. ZINC CHLORIDE for human dermal use except in preparations containing 5% or less of zinc chloride. Authorised Version F2024L00589 registered 30/05/2024 Pharmacist only medicines Schedule 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 61 Schedule 3—Pharmacist only medicines Note: See sections 16 and 31, subsections 54(2) and 57(1) and section 59. ADAPALENE in topical preparations containing 0.1% or less of adapalene for the treatment of acne vulgaris in adults and in children over 12 years of age. ADRENALINE in preparations containing 1% or less of adrenaline except in preparations that are not for injection containing 0.02% or less of adrenaline. ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of alclometasone in packs containing 30 g or less of the preparation. ALIMEMAZINE: (a) in solid oral preparations except when included in Schedule 2; or (b) in liquid oral preparations containing 10 mg or less of alimemazine per 5 mL; except in preparations for the treatment of children under 2 years of age. AMINOPHYLLINE in liquid oral preparations containing 2% or less of aminophylline. AMYL NITRITE when in preparations for human therapeutic use and packaged in containers with child-resistant closures. ASTODRIMER SODIUM except: (a) when included in Schedule 2; or (b) in a condom lubricant. AZATADINE in oral preparations. BILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 10 mg of bilastine for the treatment of children 6-11 years of age except when included in Schedule 2. BROMPHENIRAMINE in oral preparations except: (a) when included in Schedule 2; or (b) for the treatment of children under 2 years of age. BUCLIZINE in oral preparations. BUTOCONAZOLE in preparations for vaginal use. CANNABIDIOL in oral, oromucosal and sublingual preparations included in the Register when: (a) the cannabidiol is either plant derived or, when synthetic, only contains the (-)-CBD enantiomer; and Authorised Version F2024L00589 registered 30/05/2024 Schedule 3 Pharmacist only medicines 62 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) the cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and (c) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation and of which tetrahydrocannabinol (THC) can only comprise 1% of the total cannabinoid content; and (d) the maximum recommended daily dose is 150 mg or less of cannabidiol; and (e) packed in blister or strip packaging or in a container fitted with a child-resistant closure; and (f) in packs containing not more than 30 days’ supply; and (g) for persons aged 18 years and over. CELECOXIB in tablets or capsules each containing 200 mg or less of celecoxib, in a primary pack containing not more than 10 dosage units for the short-term treatment of acute pain due to primary dysmenorrhea or musculoskeletal or soft tissue injuries in adults. CHLORAMPHENICOL for ophthalmic use only. CHLORBUTANOL in preparations for human use except: (a) when included in Schedule 2; or (b) in preparations containing 0.5% or less of chlorbutanol. CHLORPHENAMINE in oral preparations except: (a) when included in Schedule 2; or (b) for the treatment of children under 2 years of age. CICLOPIROX in preparations for dermal use and for application to the nails except: (a) when included in Schedule 2; or (b) in preparations for the treatment of tinea pedis. CIMETIDINE in a primary pack containing not more than 14 days’ supply. CLEMASTINE in preparations for oral use. CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of clobetasone in packs containing 30 g or less of the preparation. CLOTRIMAZOLE in preparations for vaginal use. CYCLIZINE in divided preparations for oral use in primary packs containing 6 dosage units or less. CYPROHEPTADINE in oral preparations. DEXCHLORPHENAMINE in oral preparations except: Authorised Version F2024L00589 registered 30/05/2024 Pharmacist only medicines Schedule 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 63 (a) when included in Schedule 2; or (b) for the treatment of children under 2 years of age. DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units except when included in Schedule 2. DIHYDROCODEINE when indicated for cough suppression and compounded with one or more other therapeutically active substances: (a) in divided preparations containing 10 mg or less of dihydrocodeine per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or (b) in undivided preparations containing 0.25% or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine. DIIODOHYDROXYQUINOLINE (iodoquinol) for vaginal use. DIMENHYDRINATE in oral preparations except when included in Schedule 2. DIMETHINDENE in oral preparations. DIPHENHYDRAMINE in oral preparations except: (a) when included in Schedule 2; or (b) for the treatment of children under 2 years of age. DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate. DITHRANOL for therapeutic use. DOXYLAMINE in oral preparations except: (a) when included in Schedule 2; or (b) for the treatment of children under 2 years of age. ECONAZOLE in preparations for vaginal use. ELETRIPTAN for oral use in tablets containing 40 mg or less per tablet and when in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms. ERYTHRITYL TETRANITRATE for therapeutic use. FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores). FLAVOXATE. FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis. Authorised Version F2024L00589 registered 30/05/2024 Schedule 3 Pharmacist only medicines 64 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FLUORIDES for human topical use: (a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure except when included in or expressly excluded from Schedule 2; or (b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion except: (i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the required advisory statements for medicine labels; or (ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect: (A) Do not swallow; and (B) Do not use [this product/name of product] in children six years of age or less; or (iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority. GLUCAGON. GLYCERYL TRINITRATE: (a) in preparations for oral use; or (b) in preparations for rectal use. GLYCOPYRRONIUM except when included in Schedule 4. HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1% or less of hydrocortisone: (a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or (b) for dermal use, in packs containing 2 g or less of such preparations, containing no other therapeutically active constituent other than aciclovir (5% w/w or less) in adults and adolescents (12 years of age and older); or (c) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents: (i) in undivided preparations, in packs of 35 g or less; or (ii) in packs containing 12 or less suppositories; except when included in Schedule 2. HYOSCINE BUTYLBROMIDE in undivided preparations for oral use with a recommended single dose not exceeding 20 mg of hyoscine butylbromide in a pack containing 100 mg or less of hyoscine butylbromide when labelled for adults and children 6 years and over. Authorised Version F2024L00589 registered 30/05/2024 Pharmacist only medicines Schedule 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 65 IBUPROFEN when: (a) either: (i) in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units; or (ii) in a modified release dosage form, each containing 600 mg of ibuprofen, in a primary pack containing not more than 32 dosage units; and (b) labelled: (i) with a recommended daily dose of 1200 mg or less of ibuprofen; and (ii) not for the treatment of children under 12 years; except when: (c) included in Schedule 2; or (d) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when: (i) ibuprofen is the only therapeutically active constitutent, other than phenylephrine or when combined with an effervescent agent; and (ii) packed in a blister or strip packaging or in a container with a child-resistant closure; and (iii) in a primary pack containing not more than 25 dosage units; and (iv) compliant with the requirements of the required advisory statements for medicine labels; and (v) not labelled for the treatment of children 6 years or under; and (vi) when combined with phenylephrine—not labelled for the treatment of children under 12 years. INOSITOL NICOTINATE. ISOCONAZOLE in preparations for vaginal use. ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit. KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units. LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2. LEVONORGESTREL for emergency post-coital contraception. MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures. Authorised Version F2024L00589 registered 30/05/2024 Schedule 3 Pharmacist only medicines 66 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MAGNESIUM SULFATE for human therapeutic use in divided oral preparations except when containing 1.5 g or less of magnesium sulfate per recommended daily dose. MALATHION in preparations for human external use except in preparations containing 2% or less of malathion. MANNITYL HEXANITRATE for therapeutic use. MELATONIN in: (a) modified release tablets containing 2 mg or less of melatonin for monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep for adults aged 55 or over, in packs containing not more than 30 tablets; or (b) immediate release preparations containing 5 mg or less of melatonin for the treatment of jet lag in adults 18 years and over, in a primary pack containing no more than 10 dosage units. MEPYRAMINE in oral preparations. METHDILAZINE in oral preparations. METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units. MICONAZOLE for human use in topical preparations: (a) for the treatment of oral candidiasis; or (b) for vaginal use. MOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.1% or less of mometasone in packs containing 15 g or less. NALOXONE when used for the treatment of opioid overdose. NAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment of children under 12 years of age. NARATRIPTAN when in divided oral preparations containing 2.5 mg or less of naratriptan per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms. NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit except: (a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or (b) nicotinamide. NICOTINYL ALCOHOL except in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit. Authorised Version F2024L00589 registered 30/05/2024 Pharmacist only medicines Schedule 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 67 NYSTATIN in preparations for topical use except when included in Schedule 2. OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2. ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit. OXICONAZOLE in preparations for vaginal use. PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2. PARACETAMOL: (a) when combined with ibuprofen in a primary pack containing 30 dosage units or less except when included in Schedule 2; or (b) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing not more than 100 tablets or capsules; or (c) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or (d) in liquid preparations for oral use except when in Schedule 2. PHENIRAMINE in oral preparations except: (a) when included in Schedule 2; or (b) for the treatment of children under 2 years of age. PODOPHYLLOTOXIN in preparations containing 1% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2. PODOPHYLLUM EMODI (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2. PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2. PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine. PROMETHAZINE in oral preparations except: (a) when included in Schedule 2; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 3 Pharmacist only medicines 68 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) in preparations for the treatment of children under 2 years of age. PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack: (a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or (b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent). RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2. RIZATRIPTAN when in divided oral preparations containing 5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of migraine symptoms. SALBUTAMOL as the only therapeutically active substance: (a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or (b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose. SALICYLIC ACID in preparations for dermal use except in preparations containing 40% or less of salicylic acid. SANTONIN. SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures. SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures. SULFACETAMIDE in preparations for ophthalmic use containing 10% or less of sulfacetamide. SUMATRIPTAN when in divided oral preparations containing 50 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms. TERBUTALINE as the only therapeutically active substance: (a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or (b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose. THEOPHYLLINE in liquid oral preparations containing 2% or less of theophylline. Authorised Version F2024L00589 registered 30/05/2024 Pharmacist only medicines Schedule 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 69 TIOCONAZOLE in preparations for vaginal use. TRIAMCINOLONE for buccal use in preparations containing 0.1% or less of triamcinolone in a pack of 5 g or less. TRIPROLIDINE in oral preparations except: (a) when included in Schedule 2; or (b) for the treatment of children under 2 years of age. ULIPRISTAL for emergency post-coital contraception. VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose except in preparations containing 25 micrograms or less of vitamin D per recommended daily dose. ZOLMITRIPTAN when in divided oral preparations containing 2.5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 70 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 4—Prescription only medicines and prescription animal remedies Note 1: See sections 16, 28, 31 and 49, subsections 54(2) and 57(1) and section 60. Note 2: Substances marked # are listed in Appendix D. ABACAVIR. ABATACEPT. ABIRATERONE ACETATE. ABCIXIMAB. ABEMACICLIB. ABROCITINIB. ACALABRUTINIB. ACAMPROSATE CALCIUM. ACARBOSE. ACEBUTOLOL. ACEPROMAZINE. ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use. ACETARSOL. ACETAZOLAMIDE. ACETOHEXAMIDE. ACETYL ISOVALERYLTYLOSIN. ACETYLCARBROMAL. ACETYLCHOLINE. ACETYLCYSTEINE except: (a) when included in Schedule 2; or (b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 71 ACETYLDIGITOXIN. ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE. ACETYLSTROPHANTHIDIN. ACICLOVIR except in preparations containing 5% or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less. ACIPIMOX. # ACITRETIN. ACLIDINIUM BROMIDE. ACOKANTHERA OUABAIO. ACOKANTHERA SCHIMPERI. ACONITUM spp. except: (a) when included in Schedule 2; or (b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or (c) in preparations for dermal use in adults containing 0.02% or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids. ACRIVASTINE. ADALIMUMAB. ADAPALENE except when included in Schedule 3. ADEFOVIR. ADENOSINE for human therapeutic use in preparations for injection. ADIPHENINE. ADONIS VERNALIS. ADRAFINIL. ADRENALINE in: (a) topical preparations for the treatment of wounds in humans; or (b) all other preparations containing adrenaline except when included in or expressly excluded from Schedule 3. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 72 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ADRENOCORTICAL HORMONES except when separately specified in these Schedules. AFAMELANOTIDE. AFATINIB DIMALEATE. AFLIBERCEPT. AGALSIDASE. AGLEPRISTONE. AGOMELATINE. ALANYLGLUTAMINE. ALATROFLOXACIN MESILATE. ALBENDAZOLE except: (a) when included in Schedule 5 or 6; or (b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals. ALCLOFENAC. ALCLOMETASONE except when included in Schedule 3. ALCURONIUM. ALDESLEUKIN. ALDOSTERONE. ALECTINIB. # ALEFACEPT. ALEMTUZUMAB. ALENDRONIC ACID. ALFACALCIDOL. ALFUZOSIN. ALGLUCERASE. ALGLUCOSIDASE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 73 ALIMEMAZINE except when included in Schedule 2 or 3. ALIROCUMAB. ALISKIREN. ALKYL NITRITES except when separately specified in these schedules. ALLERGENS for therapeutic use. ALLOPURINOL. ALLYLESTRENOL. ALOGLIPTIN. ALOSETRON. ALPELISIB. ALPHA1-PROTEINASE INHIBITOR (HUMAN). ALPHADOLONE. ALPHAXALONE. ALPRENOLOL. ALPROSTADIL. ALSEROXYLON. ALTEPLASE. ALTRENOGEST. ALTRETAMINE (hexamethylmelamine). AMANTADINE. AMBENONIUM CHLORIDE. # AMBRISENTAN. AMBUCETAMIDE. AMBUTONIUM BROMIDE. AMCINONIDE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 74 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 AMIFAMPRIDINE. AMIFOSTINE. AMIKACIN. AMILORIDE. AMINOCAPROIC ACID. AMINOGLUTETHIMIDE. 5-AMINOLEVULINIC ACID. AMINOMETRADINE. AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals. AMINOPHYLLINE except when included in Schedule 3. AMINOPTERIN. 4-AMINOPYRIDINE for therapeutic use. AMINOREX. AMINOSALICYLIC ACID. AMIODARONE. AMIPHENAZOLE. AMISOMETRADINE. AMISULPRIDE. AMITRIPTYLINE. AMLODIPINE. AMMI VISNAGA. AMMONIUM BROMIDE for therapeutic use. AMOBARBITAL when packed and labelled for injection. AMODIAQUINE. AMOROLFINE except: (a) when included in Schedule 2; or Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 75 (b) in preparations for the treatment of tinea pedis. AMOXAPINE. AMOXICILLIN. AMPHOMYCIN. AMPHOTERICIN B. AMPICILLIN. AMPRENAVIR. AMRINONE. AMSACRINE. AMYL NITRITE except when included in Schedule 3. AMYLOCAINE. # ANABOLIC STEROIDAL AGENTS. ANAGRELIDE. ANAKINRA. ANASTROZOLE. ANCESTIM. ANCROD and its immunoglobulin antidote. ANDEXANET ALFA. ANECORTAVE. # ANDROGENIC STEROIDAL AGENTS. # ANDROISOXAZOLE. # ANDROSTANOLONE. # ANDROSTENEDIOL. # ANDROSTENEDIONE. ANGIOTENSIN AMIDE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 76 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ANIDULAFUNGIN. ANIRACETAM. ANISTREPLASE. ANTAZOLINE except when included in Schedule 2. ANTIBIOTIC SUBSTANCES except: (a) when separately specified in these Schedules; or (b) nisin. ANTIGENS for human therapeutic use except when separately specified in this Schedule. ANTIHISTAMINES except: (a) when included in Schedule 2 or 3; or (b) when separately specified in this Schedule. ANTIMONY for therapeutic use except when separately specified in these Schedules. ANTISERA (immunosera) for human use by injection except when separately specified in these Schedules. # AOD-9604 (CAS No. 221231-10-3). APALUTAMIDE. APIXABAN. APOCYNUM spp. APOMORPHINE. APRACLONIDINE. APRAMYCIN. APREMILAST. APREPITANT. APROTININ. ARBUTIN (BETA) in oral preparations except herbal preparations containing 500 mg or less beta-arbutin per recommended daily dose. ARECOLINE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 77 ARIPIPRAZOLE. ARMODAFINIL. ARSENIC for human therapeutic use except when separately specified in these Schedules. ARTEMETHER. ARTICAINE. ASCIMINIB. ASENAPINE. ASFOTASE ALFA. ASPARAGINASE. ASPIRIN when: (a) combined with caffeine, paracetamol or salicylamide; or (b) combined with any derivative of the substances mentioned in paragraph (a); or (c) for injection. ASTEMIZOLE. ASUNAPREVIR. # ATAMESTANE. ATAZANAVIR. ATENOLOL. ATEZOLIZUMAB. ATIPAMEZOLE. ATOMOXETINE. ATORVASTATIN. ATOSIBAN. ATOVAQUONE. ATRACURIUM BESILATE. ATROPA BELLADONNA (belladonna) except when included in Schedule 2. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 78 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ATROPINE except when included in Schedule 2. ATROPINE METHONITRATE. AURANOFIN. AUROTHIOMALATE SODIUM. AVACOPAN. AVATROMBOPAG. AVELUMAB. AVILAMYCIN except: (a) in animal feed premixes containing 15% or less of avilamycin activity; or (b) in animal feeds containing 50 mg/kg or less of avilamycin activity. AVIPTADIL. AXITINIB. AVOPARCIN. AZACITIDINE. AZACYCLONOL. AZAPERONE. AZAPROPAZONE. AZARIBINE. AZATADINE except when included in Schedule 3. AZATHIOPRINE. AZELAIC ACID except: (a) when included in Schedule 2; or (b) in preparations containing 1% or less of azelaic acid for non-human use. AZELASTINE except when included in Schedule 2. AZITHROMYCIN. AZLOCILLIN. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 79 AZTREONAM. BACAMPICILLIN. BACITRACIN. BACLOFEN. BALOXAVIR MARBOXIL. BALSALAZIDE. BAMBERMYCIN (flavophospholipol) except: (a) when included in Schedule 6; or (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances. BAMBUTEROL. BAMETHAN. BAMIPINE. BARBITURATES except when separately specified in these Schedules. BARICITINIB. BASILIXIMAB. BAZEDOXIFENE. BECAPLERMIN. BECLAMIDE. BECLOMETASONE except when included in Schedule 2. BELATACEPT. BELIMUMAB. BELUMOSUDIL. BELZUTIFAN. BEMEGRIDE. BENACTYZINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 80 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BENAZEPRIL. BENDAMUSTINE. BENDROFLUAZIDE. BENETHAMINE PENICILLIN. BENORYLATE. BENOXAPROFEN. BENPERIDOL. BENRALIZUMAB. BENSERAZIDE. BENZATHINE PENICILLIN. BENZILONIUM. BENZOCAINE except: (a) when included in Schedule 2; or (b) in dermal preparations containing 2% or less of total local anaesthetic substances; or (c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit. # BENZODIAZEPINE derivatives except when separately specified in these Schedules. BENZOYL PEROXIDE in preparations for human therapeutic use except: (a) when included in Schedule 2; or (b) in preparations for external use containing 5% or less of benzoyl peroxide. BENZPHETAMINE. BENZTHIAZIDE. BENZATROPINE. BENZYDAMINE except: (a) when included in Schedule 2; or (b) in preparations for dermal use; or (c) in divided topical oral preparations containing 3 mg or less of benzydamine; or Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 81 (d) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL. BENZYLPENICILLIN. BEPRIDIL. BERACTANT. BESIFLOXACIN. BETAHISTINE. BETAMETHASONE. BETAXOLOL. BETHANECHOL CHLORIDE. BETHANIDINE. BEVACIZUMAB. BEVANTOLOL. # BEXAROTENE. BEZAFIBRATE. BEZLOTOXUMAB. BICALUTAMIDE. BICTEGRAVIR. BIFONAZOLE except: (a) when included in Schedule 2; or (b) in preparations for dermal use containing 1% or less of bifonazole for the treatment of the scalp; or (c) in preparations for dermal use for the treatment of tinea pedis. BILASTINE except when included in Schedule 2 or 3. BIMATOPROST. BINIMETINIB. BIPERIDEN. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 82 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BISMUTH COMPOUNDS for cosmetic use, except: (a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5% or less; or (b) bismuth oxychloride. BISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth. BISOPROLOL. BIVALIRUDIN. BLEOMYCIN. BLINATUMOMAB. BOCEPREVIR. # BOLANDIOL. # BOLASTERONE. # BOLAZINE. # BOLDENONE (dehydrotestosterone). # BOLENOL. # BOLMANTALATE. BORON, including boric acid and borax, for human therapeutic use except: (a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose; or (b) in preparations for dermal use containing 0.35% or less of boron, which are not for paediatric or antifungal use; or (c) when present as an excipient. BORTEZOMIB. # BOSENTAN. BOSUTINIB. BOTULINUM TOXINS for human use except when separately specified in these Schedules. # BPC-157. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 83 BRENTUXIMAB VEDOTIN. BRETYLIUM TOSILATE. BREXPIPRAZOLE. BRIGATINIB. BRIMONIDINE except when included in Schedule 2. BRINZOLAMIDE. BRIVARACETAM. # BROMAZEPAM. BROMIDES, inorganic, for therapeutic use except when separately specified in these Schedules. BROMOCRIPTINE. BROMOFORM for therapeutic use. BROMPHENIRAMINE except when included in Schedule 2 or 3. BROMVALETONE. BRUGMANSIA spp. BUCLIZINE except when included in Schedule 3. BUDESONIDE except when included in Schedule 2. BUFEXAMAC. BULEVIRTIDE. BUMETANIDE. BUPHENINE. BUPIVACAINE except when included in Schedule 5. BUPROPION. BUSERELIN. BUSPIRONE. BUSULPHAN. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 84 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BUTACAINE. BUTAMBEN except in dermal preparations containing 2% or less of total local anaesthetic substances. BUTOCONAZOLE except when included in Schedule 3. BUTRACONAZOLE. BUTYLCHLORAL HYDRATE. BUTYL NITRITE. CABAZITAXEL. CABERGOLINE. CABOTEGRAVIR. CABOZANTINIB. CADMIUM COMPOUNDS for human therapeutic use. CAFFEINE for internal therapeutic use except: (a) in divided preparations when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or (b) in undivided preparations with a concentration of less than 5% of caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine. CALCIFEDIOL for human internal therapeutic use except in preparations containing 10 micrograms or less of calcifediol per recommended daily dose. CALCIPOTRIOL. CALCITONIN. CALCITONIN SALMON. CALCITRIOL. CALCIUM CARBIMIDE for therapeutic use. CALCIUM HYDROXYLAPATITE in preparations for injection or implantation: (a) for tissue augmentation; or (b) for cosmetic use. CALCIUM POLYSTYRENE SULPHONATE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 85 CALOTROPIS GIGANTEA. CALOTROPIS PROCERA. # CALUSTERONE. CAMPHORATED OIL for therapeutic use. CAMPHOTAMIDE. CANAGLIFLOZIN. CANAKINUMAB. CANDESARTAN CILEXETIL. CANDICIDIN. CANINE TICK ANTI-SERUM. CANNABIDIOL in preparations for therapeutic use or analytical and scientific research where: (a) cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and (b) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation; except when: (c) included in Schedule 3; or (d) in hemp seed oil at a concentration of 75 mg/kg or less. CANTHARIDIN. CAPECITABINE. CAPREOMYCIN. # CAPROMORELIN. CAPTODIAME. CAPTOPRIL. CAPURIDE. CARAMIPHEN. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 86 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CARBACHOL. CARBAMAZEPINE. CARBARYL for human therapeutic use. CARBAZOCHROME. CARBENICILLIN. CARBENOXOLONE for internal use. CARBETOCIN. CARBIDOPA. CARBIMAZOLE. CARBOCROMEN. CARBOPLATIN. CARBOPROST. CARBROMAL. CARBUTAMIDE. CARBUTEROL. CARFILZOMIB. CARGLUMIC ACID (N-carbamoyl-L-glutamic acid). CARINDACILLIN. CARIPRAZINE. CARISOPRODOL. CARMUSTINE. CARNIDAZOLE. CARPROFEN. CARVEDILOL. CASIRIVIMAB. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 87 CASPOFUNGIN. CATHINE. CATUMAXOMAB. CEDAZURIDINE. CEFACETRILE. CEFACLOR. CEFADROXIL. CEFALEXIN. CEFALORIDINE. CEFALOTIN. CEFAMANDOLE. CEFAPIRIN. CEFAZOLIN. CEFEPIME. CEFETAMET. CEFIXIME. CEFODIZIME. CEFONICID. CEFOPERAZONE. CEFOTAXIME. CEFOTETAN. CEFOTIAM. CEFOVECIN for veterinary use. CEFOXITIN. CEFPIROME. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 88 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CEFPODOXIME. CEFQUINOME. CEFTAROLINE FOSAMIL. CEFSULODIN. CEFTAZIDIME. CEFTIBUTEN. CEFTIOFUR. CEFTRIAXONE. CEFUROXIME. CELECOXIB except when included in Schedule 3. CELIPROLOL. CENEGERMIN. CEPHAELIS ACUMINATA (ipecacuanha) except in preparations containing 0.2% or less of emetine. CEPHAELIS IPECACUANHA except in preparations containing 0.2% or less of emetine. CEPHALONIUM. CEPHRADINE. CERITINIB. CERIVASTATIN. CERLIPONASE ALFA. CERTOLIZUMAB PEGOL. CERULETIDE. CETIRIZINE except (a) when included in Schedule 2; or (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when: (i) in a primary pack containing not more than 10 days’ supply; and Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 89 (ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine. CETRORELIX. CETUXIMAB. CHENODEOXYCHOLIC ACID. CHLORAL FORMAMIDE. CHLORAL HYDRATE except in preparations for topical use containing 2% or less of chloral hydrate. CHLORALOSE except when included in Schedule 6. CHLORAMBUCIL. CHLORAMPHENICOL except when included in Schedule 3. # CHLORANDROSTENOLONE. CHLORAZANIL. CHLORCYCLIZINE. # CHLORDIAZEPOXIDE. CHLORMERODRIN. CHLORMETHIAZOLE. CHLORMEZANONE. CHLOROFORM for use in anaesthesia. # 4-CHLOROMETHANDIENONE. 2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE. CHLOROQUINE. CHLOROTHIAZIDE. CHLOROTRIANISENE. # CHLOROXYDIENONE. CHLORPHENAMINE except when included in Schedule 2 or 3. CHLORPHENTERMINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 90 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CHLORPROMAZINE. CHLORPROPAMIDE. CHLORPROTHIXENE. CHLORQUINALDOL for human topical use. CHLORTALIDONE. CHLORTETRACYCLINE except when included in Schedule 5. CHLORZOXAZONE. CHOLERA VACCINE. CHOLIC ACID. CHYMOPAPAIN for human therapeutic use. CICLACILLIN. CICLESONIDE. CICLOPIROX except: (a) when included in Schedule 2 or 3; or (b) in preparations for the treatment of tinea pedis. CICLOSPORIN. CIDOFOVIR. CILASTATIN. CILAZAPRIL. CILGAVIMAB. CILOSTAZOL. CIMETIDINE except when included in Schedule 3. CIMICOXIB. CINACALCET. CINCHOCAINE except when included in Schedule 2. CINNARIZINE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 91 CINOXACIN. CIPROFLOXACIN. CISAPRIDE. CISATRACURIUM BESILATE. CISPLATIN. CITALOPRAM. # CJC-1295 (CAS No. 863288-34-0). CLADRIBINE. CLANOBUTIN. CLARITHROMYCIN. CLASCOTERONE. CLAVULANIC ACID. CLEMASTINE except when included in Schedule 3. CLEMIZOLE. CLENBUTEROL. CLEVIDIPINE. CLIDINIUM BROMIDE. CLINDAMYCIN. CLIOQUINOL and other halogenated derivatives of oxyquinoline for human topical use except when separately specified in this Schedule. CLOBAZAM. CLOBETASOL. CLOBETASONE (clobetasone-17-butyrate) except when included in Schedule 3. CLOCORTOLONE. CLODRONIC ACID (includes sodium clodronate). CLOFARABINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 92 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CLOFAZIMINE. CLOFENAMIDE. CLOFIBRATE. # CLOMIFENE. CLOMIPRAMINE. CLOMOCYCLINE. # CLONAZEPAM. CLONIDINE. CLOPAMIDE. CLOPIDOGREL. CLOPROSTENOL. # CLORAZEPATE. CLOREXOLONE. CLORPRENALINE. # CLOSTEBOL (4-chlorotestosterone). CLOTRIMAZOLE except: (a) when included in Schedule 2, 3 or 6; or (b) in preparations for dermal use for the treatment of tinea pedis. CLOXACILLIN. # CLOZAPINE. COBALT for human therapeutic use except as dicobalt edetate in preparations for the treatment of cyanide poisoning. COBICISTAT. COBIMETINIB. CODEINE when compounded with one or more other therapeutically active substances: (a) in divided preparations containing 30 mg or less of codeine per dosage unit; or (b) in undivided preparations containing 1% or less of codeine. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 93 CO-DERGOCRINE. COLCHICINE. COLCHICUM AUTUMNALE. COLESTIPOL. COLESTYRAMINE for human therapeutic use. COLFOSCERIL PALMITATE for human therapeutic use. COLISTIN. COLLAGEN in preparations for injection or implantation: (a) for tissue augmentation; or (b) for cosmetic use. COLLAGENASE CLOSTRIDIUM HISTOLYTICUM. COLURACETAM. CONCIZUMAB. CONVALLARIA KEISKI. CONVALLARIA MAJALIS. COPPER COMPOUNDS for human use except: (a) when separately specified in these Schedules; or (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or (c) in other preparations containing 5% or less of copper compounds. # CORIFOLLITROPIN ALFA. CORONILLA spp. CORTICOSTERONE. CORTICOTROPHIN. CORTISONE. CO-TRIMOXAZOLE. COUMARIN for therapeutic use (excluding when present as an excipient). Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 94 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CRISABOROLE. CRIZOTINIB. CROFELEMER. CUPRIMYXIN. CURARE. CYCLANDELATE. CYCLIZINE except when included in Schedule 3. CYCLOBENZAPRINE. # CYCLOFENIL. CYCLOHEXIMIDE. CYCLOPENTHIAZIDE. CYCLOPENTOLATE. CYCLOPHOSPHAMIDE. CYCLOPROPANE for therapeutic use. CYCLOSERINE. CYCLOTHIAZIDE. CYCRIMINE. CYMARIN. CYPROHEPTADINE except when included in Schedule 3. CYPROTERONE. CYTARABINE. DABRAFENIB MESILATE. DABIGATRAN. DACARBAZINE. DACLATASVIR. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 95 DACLIZUMAB. DACTINOMYCIN. DALFOPRISTIN. DALTEPARIN (includes dalteparin sodium). DANAPAROID (includes danaparoid sodium). # DANAZOL. DANTHRON for human use. DANTROLENE. DAPAGLIFLOZIN. DAPOXETINE. DAPSONE. DAPTOMYCIN. DARATUMUMAB. # DARBEPOETIN. DARIFENACIN. DAROLUTAMIDE. DARUNAVIR. DATURA spp. except: (a) when included in Schedule 2; or (b) when separately specified in this Schedule. DASABUVIR. DASATINIB. DATURA STRAMONIUM (stramonium) except: (a) when included in Schedule 2; or (b) for smoking or burning. DATURA TATULA (stramonium) except: (a) when included in Schedule 2; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 96 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) for smoking or burning. DAUNORUBICIN. DEANOL for therapeutic use. DEBRISOQUINE. DECAMETHONIUM. DECITABINE. DEFERASIROX. DEFERIPRONE. DEFIBROTIDE. DEFLAZACORT. DEGARELIX. # DEHYDROCHLOROMETHYLTESTOSTERONE. DEHYDROCORTICOSTERONE. DELAVIRDINE MESILATE. DEMBREXINE except when included in Schedule 5. DEMECARIUM. DEMECLOCYCLINE. DENGUE VACCINE. DENOSUMAB. DEOXYCHOLIC ACID. DEOXYCORTONE. DEOXYRIBONUCLEASE except: (a) when separately specified in this Schedule; or (b) for external use. DERACOXIB. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 97 DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT. DESFERRIOXAMINE. DESFLURANE. DESIPRAMINE. DESIRUDIN. DESLANOSIDE. DESLORATADINE except when included in Schedule 2. DESLORELIN. DESMOPRESSIN (D.D.A.V.P.). DESOGESTREL. DESONIDE. DESOXYMETHASONE. DESVENLAFAXINE. DETOMIDINE. DEUCRAVACITINIB. DEUTETRABENAZINE. DEXAMETHASONE. DEXCHLORPHENAMINE except when included in Schedule 2 or 3. DEXFENFLURAMINE. DEXMEDETOMIDINE. DEXTROMETHORPHAN (excluding its stereoisomers) except when included in Schedule 2. # DEXTROPROPOXYPHENE: (a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or (b) liquid preparations containing 2.5% or less of dextropropoxyphene. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 98 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DEXTRORPHAN (excluding its stereoisomers). DIAMTHAZOLE. DIAVERIDINE. # DIAZEPAM. DIAZOXIDE. DIBENZEPIN. DIBOTERMIN. DIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2. DICHLORALPHENAZONE. DICHLOROPHEN for human therapeutic use. DICHLORPHENAMIDE. DICLOFENAC except: (a) when included in Schedule 2 or 3; or (b) in preparations for dermal use unless: (i) for the treatment of solar keratosis; or (ii) containing more than 4% of diclofenac. DICLOXACILLIN. DICYCLOMINE. DIDANOSINE. DIENESTROL. DIENOGEST. DIETHAZINE. DIETHYLCARBAMAZINE for human therapeutic use. DIETHYLPROPION. DIFELIKEFALIN. DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5% of the dose of difenoxin. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 99 DIFLORASONE. DIFLOXACIN. DIFLUCORTOLONE. DIFLUNISAL. DIGITALIS LANATA. DIGITALIS PURPUREA. DIGITOXIN. DIGOXIN. DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab). DIHYDRALAZINE. DIHYDROCODEINE when compounded with one or more other therapeutically active substances: (a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or (b) in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine; except when included in Schedule 3. DIHYDROERGOTOXINE. # DIHYDROLONE. DIHYDROSTREPTOMYCIN. DIHYDROTACHYSTEROL. DIIODOHYDROXYQUINOLINE (iodoquinol) except: (a) when included in Schedule 3; or (b) for human internal use. DIISOPROPYLAMINE DICHLOROACETATE. DILTIAZEM. DIMENHYDRINATE except when included in Schedule 2 or 3. DIMERCAPROL. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 100 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 # DIMETHANDROSTANOLONE. # DIMETHAZINE. DIMETHINDENE except when included in Schedule 3. DIMETHOTHIAZINE. DIMETHOXANATE. DIMETHYL FUMARATE. DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use except: (a) when included in Schedule 6; or (b) in in vitro test kits; or (c) when used as a flavour component in compliance with the current Therapeutic Goods (Permissible Ingredients) determination for listed medicines. DIMETRIDAZOLE. DIMIRACETAM. 2,4-DINITROCHLOROBENZENE for therapeutic use. DINITROCRESOLS for therapeutic use except when separately specified in these Schedules. DINITRONAPHTHOLS for therapeutic use except when separately specified in these Schedules. DINITROPHENOLS for therapeutic use. DINITROTHYMOLS for therapeutic use except when separately specified in these Schedules. # DINOPROST. # DINOPROSTONE. DIPERODON. DIPHEMANIL except in preparations for dermal use. DIPHENHYDRAMINE except when included in Schedule 2 or 3. DIPHENIDOL. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 101 DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate except when included in Schedule 3. DIPHENYLPYRALINE. DIPHTHERIA TOXOID. DIPIVEFRIN. DIPYRIDAMOLE. DIRITHROMYCIN. DIRLOTAPIDE. DIROXIMEL FUMARATE. DISOPHENOL. DISOPYRAMIDE. DISTIGMINE. DISULFIRAM for therapeutic use. DISULPHAMIDE. DITHIAZANINE except when included in Schedule 6. DITIOCARB. DOBUTAMINE. DOCETAXEL. DOFETILIDE. DOLASETRON. DOLUTEGRAVIR. DOMPERIDONE. DONEPEZIL. DOPAMINE. DOPEXAMINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 102 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DORAVIRINE. DORIPENEM. DORNASE. DORZOLAMIDE. DOSULEPIN. DOXANTRAZOLE. DOXAPRAM. DOXAZOSIN. DOXEPIN. DOXORUBICIN. DOXYCYCLINE. DOXYLAMINE except when included in Schedule 2 or 3. DRONEDARONE. DROPERIDOL. DROSPIRENONE. # DROSTANOLONE. DROTRECOGIN. DUBOISIA LEICHHARDTII except when included in Schedule 2. DUBOISIA MYOPOROIDES except when included in Schedule 2. DULAGLUTIDE. DULOXETINE. DUPILUMAB. DURVALUMAB. DUTASTERIDE. DYDROGESTERONE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 103 ECONAZOLE except: (a) when included in Schedule 2, 3 or 6; or (b) in preparations for dermal use for the treatment of tinea pedis. ECOTHIOPATE (includes ecothiopate iodide). ECTYLUREA. ECULIZUMAB. EDARAVONE. EDETIC ACID for human therapeutic use except: (a) in preparations containing 0.25% or less of edetic acid; or (b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or (c) in contact lens preparations. EDOXUDINE. EDROPHONIUM. EFALIZUMAB. EFAVIRENZ. EFLORNITHINE. ELBASVIR. ELETRIPTAN except when included in Schedule 3. ELEXACAFTOR. ELOSULFASE ALFA. ELOTUZUMAB. ELRANATAMAB. ELTENAC. ELTROMBOPAG. ELUXADOLINE. ELVITEGRAVIR. EMEPRONIUM. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 104 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 EMETINE except in preparations containing 0.2% or less of emetine. EMPAGLIFLOZIN. EMTRICITABINE. ENALAPRIL. ENASIDENIB. ENCORAFENIB. # ENESTEBOL. ENFLURANE for therapeutic use. ENFORTUMAB VEDOTIN. ENFUVIRTIDE. # ENOBOSARM. ENOXACIN. ENOXAPARIN. ENOXIMONE. ENPROSTIL. ENROFLOXACIN. ENTACAPONE. ENTECAVIR. ENTRECTINIB. ENZALUTAMIDE. EPHEDRA spp. except in preparations containing 0.001% or less of ephedrine. # EPHEDRINE. EPICILLIN. EPINASTINE. EPIRUBICIN. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 105 # EPITIOSTANOL. EPLERENONE. # EPOETINS. EPOPROSTENOL. EPROSARTAN. EPTIFIBATIDE. ERENUMAB. ERGOMETRINE. ERGOT. ERGOTAMINE. ERGOTOXINE. ERIBULIN MESILATE. ERLOTINIB. ERTAPENEM. ERTUGLIFLOZIN. ERYSIMUM spp. ERYTHROMYCIN. # ERYTHROPOIETIN. # ERYTHROPOIETINS except when separately specified in these Schedules. ESCITALOPRAM. ESLICARBAZEPINE ACETATE. ESMOLOL. ESOMEPRAZOLE except when included in Schedule 2. ESTETROL MONOHYDRATE. ESTRADIOL except when included in Schedule 5. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 106 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ESTRIOL. ESTRAMUSTINE. ESTROGENS except when separately specified in these Schedules. ESTRONE. ESTROPIPATE (piperazine estrone sulfate). ETACRYNIC ACID. ETANERCEPT. ETHAMBUTOL. ETHAMIVAN. ETHCHLORVYNOL. ETHER for use in anaesthesia. ETHINAMATE. ETHINYLESTRADIOL. ETHIONAMIDE. # ETHISTERONE. ETHOGLUCID. ETHOHEPTAZINE. ETHOPROPAZINE. ETHOSUXIMIDE. ETHOTOIN. ETHOXZOLAMIDE. ETHYL CHLORIDE for human therapeutic use. # ETHYLDIENOLONE. ETHYLMORPHINE when compounded with one or more other therapeutically active substances: (a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 107 (b) in undivided preparations with a concentration of not more than 2.5% of ethylmorphine; except when included in Schedule 2. # ETHYLESTRENOL. ETIDOCAINE. ETIDRONIC ACID (includes etidronate disodium): (a) for internal use; or (b) in topical preparations except in preparations containing 1% or less of etidronic acid. ETILEFRIN. ETIPROSTON. ETODOLAC. ETOFENAMATE except when included in Schedule 2. ETONOGESTREL. ETOPOSIDE. ETORICOXIB. ETRANACOGENE DEZAPARVOVEC. ETRASIMOD. ETRAVIRINE. # ETRETINATE. ETYNODIOL. EVEROLIMUS. EXEMESTANE. EXENATIDE. EZETIMIBE. FAMCICLOVIR except when included in Schedule 3. FAMOTIDINE except when included in Schedule 2. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 108 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FARICIMAB. FASORACETAM. FEBUXOSTAT. FELBINAC except when included in Schedule 2. FELODIPINE. FELYPRESSIN. FENBUFEN. FENCAMFAMIN. FENCLOFENAC. FENFLURAMINE. FENOFIBRATE. FENOLDOPAM. FENOPROFEN. FENOTEROL. FENPIPRAMIDE. FENPIPRANE. FENPROPOREX. FENPROSTALENE. FERRIC DERISOMALTOSE. FEXOFENADINE except: (a) when included in Schedule 2; or (b) in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when: (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and (ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 109 (c) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when: (i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and (ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or (d) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when: (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and (ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine. FEZOLINETANT. FIBRINOLYSIN except for external use. # FIBROBLAST GROWTH FACTORS. FIDAXOMICIN. FILGOTINIB. FILGRASTIM. FINASTERIDE. FINERENONE. FINGOLIMOD. FIROCOXIB. FLECAINIDE. FLEROXACIN. FLOCTAFENINE. FLORFENICOL. FLUANISONE. FLUCLOROLONE. FLUCLOXACILLIN. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 110 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FLUCONAZOLE except when included in Schedule 3. FLUCYTOSINE. FLUDARABINE. FLUDROCORTISONE. FLUFENAMIC ACID. FLUMAZENIL. FLUMETASONE. FLUMETHIAZIDE. FLUNISOLIDE. FLUNIXIN MEGLUMINE. FLUOCINOLONE. FLUOCINONIDE. FLUOCORTIN. FLUOCORTOLONE. FLUORESCEIN in preparations for injection. FLUORIDES in preparations for human use except when included in or expressly excluded from Schedule 2 or 3. FLUOROMETHOLONE. FLUOROURACIL. FLUOXETINE. # FLUOXYMESTERONE. FLUPENTIXOL. FLUPHENAZINE. FLUPROSTENOL. FLURALANER in injectable preparations for use in companion animals. FLURANDRENOLONE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 111 # FLURAZEPAM. FLURBIPROFEN except when: (a) included in Schedule 2; or (b) in divided preparations for topical oral use that contain 10 mg or less of flurbiprofen per dosage unit and that are: (i) in a primary pack containing not more than 16 dosage units; and (ii) labelled only for the treatment of adults and children over 12 years; or (c) in undivided preparations for topical oral use containing either: (i) 0.25% or less of flurbiprofen per dose; or (ii) 10 mg or less of flurbiprofen per dose; and that are: (iii) in a primary pack containing not more than 15 Ml; and (iv) labelled only for the treatment of adults 18 years and over. FLUROXENE for human therapeutic use. FLUSPIRILENE. FLUTAMIDE. FLUTICASONE except when included in Schedule 2. FLUVASTATIN. FLUVOXAMINE. FOLIC ACID in preparations for human use for injection. FOLINIC ACID in preparations for human use for injection. FOLLICLE-STIMULATING HORMONE except when separately specified in this Schedule. # FOLLISTATIN. # FOLLITROPIN ALFA. # FOLLITROPIN BETA. # FOLLITROPIN DELTA. FOMEPIZOLE. FOMIVIRSEN. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 112 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FONDAPARINUX. # FORMEBOLONE. FORMESTANE. FORMOTEROL FOSAMPRENAVIR. FOSAPREPITANT. FOSCARNET. FOSFESTROL (diethylstilbestrol diphosphate). FOSFOMYCIN. FOSINOPRIL. FOSNETUPITANT. FOSPHENYTOIN. FOSTEMSAVIR. FOTEMUSTINE. FRAMYCETIN. FULVESTRANT. FURALTADONE. # FURAZABOL. FURAZOLIDONE. FUROSEMIDE (frusemide). FUSIDIC ACID. GABAPENTIN. GALANTAMINE. GALANTHUS spp. GALCANEZUMAB. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 113 GALLAMINE. GALSULFASE. GANCICLOVIR. GANIRELIX. GATIFLOXACIN. GRAZOPREVIR. GEFITINIB. GEMCITABINE. GEMEPROST. GEMFIBROZIL. GEMIFLOXACIN. GEMTUZUMAB OZOGAMICIN. GENTAMICIN. GESTODENE. GESTONORONE. # GESTRINONE. GHRH INJECTABLE PLASMID. GILTERITINIB. GITALIN. GIVOSIRAN. GLATIRAMER ACETATE. GLECAPREVIR. GLIBENCLAMIDE. GLIBORNURIDE. GLICLAZIDE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 114 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 GLIMEPIRIDE. GLIPIZIDE. GLIPTINS except when separately specified in these Schedules. GLISOXEPIDE. GLOFITAMAB. GLUTATHIONE for parenteral use. # GLUTETHIMIDE. GLYCERYL TRINITRATE except when included in Schedule 3. GLYCOPYRRONIUM. GLYMIDINE. GnRH VACCINE. GOLIMUMAB. GONADORELIN. GONADOTROPHIC HORMONES except when separately specified in this Schedule. GOSERELIN. GRAMICIDIN. GRANISETRON. GRAPIPRANT. GREPAFLOXACIN. GRISEOFULVIN. # GROWTH HORMONE RELEASING HORMONES* (GHRHs). # GROWTH HORMONE RELEASING PEPTIDES (GHRPs). # GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6). # GROWTH HORMONE SECRETAGOGUES* (GHSs). GUAIFENESIN for human therapeutic use except: (a) when included in Schedule 2; or Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 115 (b) in oral liquid preparations containing 2% or less of guaifenesin; or (c) in divided preparations containing 200 mg or less of guaifenesin per dosage unit. GUANABENZ. GUANACLINE. GUANETHIDINE. GUANFACINE. GUANIDINE for therapeutic use. GUSELKUMAB. HACHIMYCIN. HAEMATIN. HAEMOPHILUS INFLUENZAE VACCINE. HALCINONIDE. HALOFANTRINE. HALOFENATE. HALOFUGINONE in preparations containing 0.1% or less of halofuginone for the treatment of animals. HALOPERIDOL. HALOTHANE for therapeutic use. HEMEROCALLIS (Hemerocallis flava). HEPARINS for internal use except when separately specified in this Schedule. HEPATITIS A VACCINE. HEPATITIS B VACCINE. HETACILLIN. HEXACHLOROPHENE: (a) in preparations for use on infants; or (b) in other preparations except: (i) when included in Schedule 2 or 6; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 116 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (ii) in preparations containing 0.75% or less of hexachlorophene. HEXAMETHONIUM. # HEXARELIN. HEXETIDINE for human internal use. HEXOBENDINE. HEXOCYCLIUM. HEXOPRENALINE. HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE). HISTAMINE for therapeutic use except in preparations containing 0.5% or less of histamine. HMG-CoA REDUCTASE INHIBITORS (including "statins") except when separately specified in these Schedules. HOMATROPINE. HUMAN CHORIONIC GONADOTROPHIN except in pregnancy test kits. HUMAN PAPILLOMAVIRUS VACCINE. HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation. HYDRALAZINE. HYDRARGAPHEN. HYDROCHLOROTHIAZIDE. HYDROCORTISONE: (a) for human use except when included in Schedule 2 or 3; or (b) for the treatment of animals. HYDROCYANIC ACID for therapeutic use. HYDROFLUMETHIAZIDE. HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use except: (a) when included in Schedule 2; or (b) in hair preparations containing 0.3% or less of hydroquinone; or Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 117 (c) in cosmetic nail preparations containing 0.02% or less of hydroquinone. HYDROXYCARBAMIDE. # HYDROXYCHLOROQUINE. HYDROXYEPHEDRINE. HYDROXYPHENAMATE. HYDROXYPROGESTERONE. # HYDROXYSTENOZOL. HYDROXYZINE. HYGROMYCIN. HYOSCINE except when included in Schedule 2. HYOSCYAMINE except when included in Schedule 2. HYOSCINE BUTYLBROMIDE except when included in Schedule 2 or Schedule 3. HYOSCYAMUS NIGER except: (a) when included in Schedule 2; or (b) in a pack containing 0.03 mg or less of total solanaceous alkaloids. HYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule. HYPROMELLOSE in preparations for injection. IBAFLOXACIN for veterinary use. IBANDRONIC ACID. IBOGAINE. IBRITUMOMAB. IBRUTINIB. IBUFENAC. IBUPROFEN except when: (a) included in Schedule 2 or 3; or (b) in preparations for dermal use; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 118 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (c) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when: (i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and (ii) packed in blister or strip packaging or in a container with a child-resistant closure; and (iii) in a primary pack containing not more than 25 dosage units; and (iv) compliant with the requirements of the required advisory statements for medicine labels; and (v) not labelled for the treatment of children 6 years and under; and (vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years. # IBUTAMOREN. IBUTEROL. IBUTILIDE. ICATIBANT. IDARUBICIN. IDARUCIZUMAB. IDEBENONE. IDOXURIDINE except in preparations containing 0.5% or less of idoxuridine for dermal use. IDURSULFASE. IFOSFAMIDE. ILOPROST. IMATINIB. IMDEVIMAB. IMEPITOIN. IMIDAPRIL. IMIGLUCERASE. IMIPENEM. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 119 IMIPRAMINE. IMIQUIMOD. IMLIFIDASE. IMMUNOGLOBULINS for human parenteral use except when separately specified in these Schedules. INCLISIRAN. INDACATEROL. INDAPAMIDE. INDINAVIR. INDOMETACIN except when included in Schedule 2. INDOPROFEN. INDORAMIN. INFIGRATINIB. INFLIXIMAB. INFLUENZA AND CORYZA VACCINES: (a) for parenteral use; or (b) for nasal administration. INGENOL MEBUTATE. INOTUZUMAB OZOGAMICIN. INSULIN DEGLUDEC. INSULIN GLARGINE. # INSULIN-LIKE GROWTH FACTOR I. # INSULIN-LIKE GROWTH FACTORS except when separately specified in this Schedule. INSULINS. INTERFERONS. INTERLEUKINS except when separately specified in these Schedules. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 120 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 IODOTHIOURACIL. # IPAMORELIN. IPILIMUMAB. IPRATROPIUM except when included in Schedule 2. IPRIFLAVONE. IPRINDOLE. IPRONIAZID. IRBESARTAN. IRINOTECAN. IRON COMPOUNDS in injectable preparations for human use. ISAVUCONAZOLE. ISOAMINILE. ISOAMYL NITRITE. ISOBUTYL NITRITE. ISOCARBOXAZID. ISOCONAZOLE except when included in Schedule 2, 3 or 6. ISOETARINE. ISOFLURANE for therapeutic use. ISOMETHEPTENE. ISONIAZID. ISOPRENALINE. ISOPRINOSINE. ISOPROPAMIDE except when included in Schedule 2. ISOSORBIDE DINITRATE except when included in Schedule 3. ISOSORBIDE MONONITRATE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 121 # ISOTRETINOIN. ISOXICAM. ISOXSUPRINE. ISRADIPINE. ITRACONAZOLE. IVABRADINE. IVACAFTOR. IVERMECTIN: (a) for human use; or (b) for the treatment of mange in dogs. IVOSIDENIB. IXABEPILONE. IXAZOMIB. IXEKIZUMAB. JAPANESE ENCEPHALITIS VACCINE. KANAMYCIN. KETANSERIN except in topical veterinary preparations containing 0.5% or less of ketanserin. # KETAZOLAM. KETOCONAZOLE except: (a) when included in Schedule 2; or (b) in preparations for dermal use containing 1% or less of ketoconazole for the treatment of the scalp; or (c) in preparations for dermal use for the treatment of tinea pedis. KETOPROFEN except: (a) in preparations for dermal use; or (b) when included in Schedule 3. KETOROLAC (includes ketorolac trometamol). Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 122 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 KETOTIFEN except when included in Schedule 2. KHELLIN. KITASAMYCIN except: (a) when included in Schedule 5; or (b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances. LABETALOL. LACIDIPINE. LACOSAMIDE. LAMIVUDINE. LAMOTRIGINE. LANADELUMAB. LANATOSIDES. LANREOTIDE. LANSOPRAZOLE except when included in Schedule 2 or 3. LANTHANUM for therapeutic use. LAPATINIB. LARONIDASE. LAROPIPRANT. LAROTRECTINIB. LATAMOXEF. LATANOPROST. LAUDEXIUM. LAUROMACROGOLS in preparations for injection except: (a) when present as an excipient; or (b) when separately specified in these Schedules. LEBRIKIZUMAB. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 123 LECANEMAB. LEDIPASVIR. LEFETAMINE. LEFLUNOMIDE. LEMBOREXANT. LENACAPAVIR. # LENALIDOMIDE. LENOGRASTIM. LENVATINIB. LEPIRUDIN. LEPTAZOL. LERCANIDIPINE. LESINURAD. LETERMOVIR. LETROZOLE. LEUPRORELIN. LEVALLORPHAN. LEVAMISOLE: (a) for human therapeutic use; or (b) in preparations for the prevention or treatment of heartworm in dogs. LEVETIRACETAM. LEVOBUNOLOL. LEVOBUPIVACAINE. LEVOCABASTINE except when included in Schedule 2. LEVOCETIRIZINE except: (a) when included in Schedule 2; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 124 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when: (i) in a primary pack containing not more than 5 days’ supply; and (ii) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine. LEVODOPA. LEVOMEPROMAZINE. LEVOMILNACIPRAN. LEVONORGESTREL except when included in Schedule 3. LEVOSIMENDAN. LIDOCAINE except: (a) when included in Schedules 2 or 5; or (b) in dermal preparations containing 2% or less of total local anaesthetic substances per dosage unit; or (c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit. LIDOFLAZINE. LIFITEGRAST. LINACLOTIDE. LINAGLIPTIN. LINCOMYCIN. LINDANE for human therapeutic use except when included in Schedule 2. LINEZOLID. LIOTHYRONINE. LIPEGFILGRASTIM. LIRAGLUTIDE. LISINOPRIL. LISURIDE. LITHIUM for therapeutic use except: Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 125 (a) when included in Schedule 2; or (b) when present as an excipient in preparations for dermal use containing 0.25% or less of lithium; or (c) in preparations containing 0.01% or less of lithium. LIXISENATIDE. LODOXAMIDE except when included in Schedule 2. LOFEXIDINE. LOGIPARIN for internal use. LOMEFLOXACIN. LOMUSTINE. LOPERAMIDE except: (a) when included in Schedule 2; or (b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less. LOPINAVIR. # LOPRAZOLAM. LORACARBEF. LORATADINE except: (a) when included in Schedule 2; or (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, when: (i) in a primary pack containing 10 dosage units or less; and (ii) labelled with a recommended daily dose not exceeding 10 mg of loratadine. # LORAZEPAM. LORLATINIB. # LORMETAZEPAM. LOSARTAN. LOTEPREDNOL. LOXAPINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 126 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 LUMACAFTOR. LUMEFANTRINE. LUMIRACOXIB. LURASIDONE. LURBINECTEDIN. LUSPATERCEPT. # LUTEINISING HORMONE except in ovulation test kits. LYMECYCLINE. MACITENTAN for human use. MAFENIDE except when included in Schedule 6. MANDRAGORA OFFICINARUM. MANNOMUSTINE. MAPROTILINE. MARAVIROC. MARBOFLOXACIN. MARIBAVIR. MAROPITANT. MAVACAMTEN. MAVACOXIB. MAZINDOL. MEASLES VACCINE. MEBANAZINE. MEBEVERINE. MEBHYDROLIN. # MEBOLAZINE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 127 MEBUTAMATE. MECAMYLAMINE. MECASERMIN. MECILLINAM. MECLOCYCLINE. MECLOFENAMATE. MECLOFENOXATE. MECLOZINE except when included in Schedule 2. # MEDAZEPAM. MEDETOMIDINE. MEDIGOXIN (methyldigoxin). MEDROXYPROGESTERONE. MEDRYSONE. MEFENAMIC ACID except when included in Schedule 2. MEFENOREX. MEFLOQUINE. MEFRUSIDE. MEGESTROL. MELAGATRAN. MELANOTAN II. MELATONIN for human use except when included in Schedule 3. MELENGESTROL except when included in Schedule 6. MELOXICAM except when included in Schedule 6. MELPHALAN. MEMANTINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 128 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MENINGOCOCCAL VACCINE. MENINGOCOCCAL GROUP B VACCINE. MENOTROPHIN. MEPACRINE. MEPENZOLATE. MEPHENESIN. MEPHENTERMINE. MEPINDOLOL. # MEPITIOSTANE. MEPIVACAINE. MEPROBAMATE. MEPTAZINOL. MEPYRAMINE except when included in Schedule 2 or 3. MEQUITAZINE. MERCAPTAMINE for human therapeutic use. MERCAPTOMERIN. MERCAPTOPURINE. MERCUROCHROME except when included in Schedule 2 or 6. MERCURY for cosmetic or therapeutic use except: (a) when separately specified in these Schedules; or (b) in a sealed device which prevents access to the mercury. MEROPENEM. MERSALYL. # MESABOLONE. MESALAZINE. MESNA. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 129 # MESTANOLONE (androstalone). # MESTEROLONE. MESTRANOL. # METANDIENONE. METARAMINOL. # METENOLONE. METERGOLINE. METFORMIN. METHACHOLINE. METHACYCLINE. METHALLENESTRIL. # METHANDRIOL. METHANTHELINIUM. METHAZOLAMIDE. METHDILAZINE except when included in Schedule 3. # METHENOLONE. METHICILLIN. METHIMAZOLE. METHISAZONE. METHIXENE. METHOCARBAMOL. METHOHEXITONE. METHOIN. METHOTREXATE. METHOXAMINE except: (a) when included in Schedule 2; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 130 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) in preparations for external use containing 1% or less of methoxamine. METHOXSALEN. METHOXYFLURANE. METHSUXIMIDE. METHYCLOTHIAZIDE. METHYL AMINOLEVULINATE. #METHYLANDROSTANOLONE. # METHYLCLOSTEBOL. METHYLDOPA. METHYLENE BLUE in preparations for injection. METHYLERGOMETRINE. METHYLMERCURY for therapeutic use. METHYLNALTREXONE. METHYLPENTYNOL. METHYLPHENOBARBITAL. METHYLPHENYLPIRACETAM. METHYLPREDNISOLONE. METHYLROSANILINIUM CHLORIDE for human use except when used as a dermal marker. METHYL SALICYLATE in preparations for internal therapeutic use. # METHYLTESTOSTERONE. METHYLTHIOURACIL. # METHYLTRIENOLONE. METHYPRYLONE. METHYSERGIDE. METOCLOPRAMIDE except when included in Schedule 3. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 131 METOLAZONE. METOPROLOL. # METRIBOLONE. METRIFONATE (trichlorfon) for human therapeutic use. METRONIDAZOLE. METYRAPONE. MEXILETINE. MEZLOCILLIN. MIANSERIN. MIBEFRADIL. # MIBOLERONE. MICAFUNGIN. MICONAZOLE except: (a) when included in Schedule 2, 3 or 6; or (b) in preparations for dermal use for the treatment of tinea pedis. # MIDAZOLAM. MIDOSTAURIN. MIDODRINE. MIFEPRISTONE. MIGALASTAT. MIGLITOL. MIGLUSTAT. MILBEMYCIN OXIME except when included in Schedule 5. MILNACIPRAN. MILRINONE. MINOCYCLINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 132 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MINOXIDIL except when included in Schedule 2. MIRABEGRON. MIRIKIZUMAB. MIRTAZAPINE. MISOPROSTOL. MITOBRONITOL. MITOMYCIN. MITOTANE. MITOXANTRONE. MITRATAPIDE. MIVACURIUM CHLORIDE. MOBOCERTINIB. MOCLOBEMIDE. MODAFINIL. MOLGRAMOSTIM. MOLINDONE. MOLNUPIRAVIR. MOMETASONE except when included in Schedule 2 or Schedule 3. MONENSIN except: (a) when included in Schedule 5 or 6; or (b) in animal feeds containing 360 mg/kg or less of antibiotic substances. MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use except in cosmetic nail preparations containing 0.02% or less of monobenzone or alkyl ethers of hydroquinone. MONOCLONAL ANTIBODIES for therapeutic use except: (a) in diagnostic test kits; or (b) when separately specified in these Schedules. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 133 MONOETHANOLAMINE in preparations for injection. MONTELUKAST. MOPERONE. MORAZONE. MORICIZINE. MOTRAZEPAM. MOTRETINIDE. MOXIDECTIN in preparations for injection containing 10% or less of moxidectin except when included in Schedule 5 or 6. MOXIFLOXACIN. MOXONIDINE. MUMPS VACCINE. MUPIROCIN. MURAGLITAZAR. MUROMONAB. MUSTINE (nitrogen mustard). MYCOPHENOLIC ACID (includes mycophenolate mofetil). NABUMETONE. NADOLOL. NADROPARIN. NAFARELIN. NAFTIDROFURYL. NALBUPHINE. NALIDIXIC ACID. NALMEFENE. NALORPHINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 134 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 NALOXEGOL. NALOXONE except when in Schedule 3. NALTREXONE. # NANDROLONE. NAPROXEN except when included in Schedule 2 or 3. NARASIN except: (a) when included in Schedule 6; or (b) in animal feeds containing 100 mg/kg or less of antibiotic substances. NARATRIPTAN except when included in Schedule 3. NATALIZUMAB. NATAMYCIN except for use as a food additive. NATEGLINIDE. NEBACUMAB. NEBIVOLOL. NEBRACETAM. NEDOCROMIL. NEFAZODONE. NEFIRACETAM. NEFOPAM. NELARABINE. NELFINAVIR (includes nelfinavir mesilate). NEOMYCIN. NEOSTIGMINE. NEPAFENAC. NERATINIB. NERIUM OLEANDER. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 135 NESIRITIDE. NETILMICIN. NETUPITANT. NEVIRAPINE. NIALAMIDE. NICARDIPINE. NICERGOLINE. NICOFURANOSE. NICORANDIL. # NICOTINE in preparations for human use except: (a) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tobacco smoking or nicotine vaping; or (b) in tobacco prepared and packed for smoking. NICOTINIC ACID for human therapeutic use except: (a) when separately specified in these Schedules; or (b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or (c) nicotinamide. NICOUMALONE. NIFEDIPINE. NIFENAZONE. NIKETHAMIDE. NILOTINIB. NILUTAMIDE. NIMESULIDE. NIMODIPINE. NIMORAZOLE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 136 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 NINTEDANIB. NIRAPARIB. NIRIDAZOLE. NIRMATRELVIR. NIRSEVIMAB. NISOLDIPINE. NITISINONE. # NITRAZEPAM. NITRENDIPINE. NITRIC OXIDE for human therapeutic use. NITROFURANTOIN. NITROFURAZONE. NITROUS OXIDE for therapeutic use. NITROXOLINE. NIVOLUMAB. NIZATIDINE except when included in Schedule 2. NOMEGESTROL. NOMIFENSINE. NORADRENALINE. # 19-NORANDROSTENEDIOL. # 19-NORANDROSTENEDIONE. # NORANDROSTENOLONE. # NORBOLETHONE. # NORCLOSTEBOL. NORELGESTROMIN. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 137 # NORETHANDROLONE. NORETHISTERONE. NORFLOXACIN. NORGESTREL. NORIBOGAINE. NORMAL HUMAN IMMUNOGLOBULIN. # NORMETHANDRONE. NORTRIPTYLINE. NOVOBIOCIN. NOXIPTYLINE. NUSINERSEN. NYSTATIN except when included in Schedule 2 or 3. OBETICHOLIC ACID. OCLACITINIB. OCRELIZUMAB. OCRIPLASMIN. OCTAMYLAMINE. OCTATROPINE. OCTREOTIDE. OCTYL NITRITE. OFATUMUMAB. OFLOXACIN. OLANZAPINE. OLAPARIB. OLARATUMAB. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 138 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 OLEANDOMYCIN except: (a) when included in Schedule 5; or (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances. OLEANDRIN. OLIPUDASE ALFA. OLMESARTAN. OLODATEROL. OLOPATADINE except when included in Schedule 2. OLSALAZINE. OMALIZUMAB. OMBERACETAM. OMBITASVIR. OMEGA-3-ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post-myocardial infarction and/or hypertriglyceridaemia. OMEPRAZOLE except when included in Schedule 2 or 3. ONASEMNOGENE ABEPARVOVEC. ONDANSETRON. OPICAPONE. OPIPRAMOL. ORBIFLOXACIN. ORCIPRENALINE. ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except: (a) when separately specified in these Schedules; or (b) in preparations containing 2% or less of malathion for external use. ORLISTAT except when included in Schedule 3. ORNIDAZOLE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 139 ORNIPRESSIN. ORPHENADRINE. ORTHOPTERIN. OSELTAMIVIR. OSILODROSTAT. OSIMERTINIB. OUABAIN. # OVANDROTONE. # OXABOLONE. OXACILLIN. OXALIPLATIN. # OXANDROLONE. OXAPROZIN. # OXAZEPAM. OXCARBAZEPINE. OXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine. OXETACAINE (oxethazaine) except when included in Schedule 2. OXICONAZOLE except: (a) when included in Schedule 2 or 3; or (b) in preparations for the treatment of tinea pedis. OXIRACETAM. OXITROPIUM. OXOLAMINE. OXOLINIC ACID. OXPRENOLOL. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 140 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 OXYBUPROCAINE. OXYBUTYNIN. # OXYMESTERONE. # OXYMETHOLONE. OXYPHENBUTAZONE. OXYPHENCYCLIMINE. OXYPHENONIUM. OXYTETRACYCLINE except when included in Schedule 5. OXYTOCIN. OZANIMOD. PACLITAXEL. PALBOCICLIB. PALIFERMIN. PALIPERIDONE. PALIVIZUMAB. PALONOSETRON. PALOVAROTENE. PAMAQUIN. PAMIDRONIC ACID (includes pamidronate disodium). PANCREATIC ENZYMES except: (a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or (b) when separately specified in these Schedules. PANCURONIUM. PANITUMUMAB. PANOBINOSTAT. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 141 PANTOPRAZOLE except when included in Schedule 2 or 3. PAPAVERINE in preparations for injection. PARACETAMOL: (a) when combined with aspirin or salicylamide or any derivative of these substances except when separately specified in these Schedules; or (b) when combined with ibuprofen in a primary pack containing more than 30 dosage units; or (c) in modified release tablets or capsules containing more than 665 mg paracetamol; or (d) in non-modified release tablets or capsules containing more than 500 mg paracetamol; or (e) in individually wrapped powders or sachets of granules each containing more than 1000 mg paracetamol; or (f) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules except in Schedule 2 or Schedule 3; or (g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules except when included in Schedule 2; or (h) for injection; or (i) for the treatment of animals. PARALDEHYDE. PARAMETHADIONE. PARAMETHASONE. PARECOXIB. PARICALCITOL. PARITAPREVIR. PAROMOMYCIN. PAROXETINE. PASIREOTIDE. PATIROMER SORBITEX CALCIUM. PATISIRAN. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 142 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PAZOPANIB. PECAZINE. PEFLOXACIN. PEGAPTANIB. PEGASPARGASE. PEGCETACOPLAN. PEGFILGRASTIM. PEGINTERFERON. PEGVALIASE. PEGVISOMANT. PEMBROLIZUMAB. PEMETREXED. PEMIGATINIB. PEMOLINE. PEMPIDINE. PENBUTOLOL. PENCICLOVIR except in preparations containing 1% or less of penciclovir for the treatment of herpes labialis in packs containing 10 g or less. PENETHAMATE. PENICILLAMINE. PENTAERYTHRITYL TETRANITRATE. PENTAGASTRIN. PENTAMETHONIUM. PENTAMIDINE (includes pentamidine isetionate). PENTHIENATE. # PENTOBARBITAL when packed and labelled for injection. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 143 PENTOLINIUM. PENTOSAN POLYSULFATE SODIUM. PENTOXIFYLLINE. PERAMIVIR. # PERAMPANEL. PERGOLIDE. PERHEXILINE. PERICIAZINE. PERINDOPRIL. PERMETHRIN for human therapeutic use except in preparations containing 5% or less of permethrin. PERPHENAZINE. PERTUSSIS ANTIGEN. PERTUZUMAB. PHENACEMIDE. PHENACETIN for therapeutic use (excluding when present as an excipient). PHENAGLYCODOL. PHENAZONE except when included in Schedule 2 or 5. PHENAZOPYRIDINE. PHENELZINE. PHENETICILLIN. PHENFORMIN. PHENGLUTARIMIDE. PHENINDIONE. PHENIRAMINE except when included in Schedule 2 or 3. PHENISATIN. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 144 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PHENOBARBITAL. PHENOL in preparations for injection. PHENOLPHTHALEIN for human therapeutic use. PHENOXYBENZAMINE. PHENOXYMETHYLPENICILLIN. PHENSUXIMIDE. # PHENTERMINE. PHENTHIMENTONIUM. PHENTOLAMINE. PHENYLBUTAZONE. PHENYLEPHRINE: (a) in preparations for injection; or (b) in preparations for human ophthalmic use containing 5% or more of phenylephrine. PHENYLPIRACETAM. PHENYLPROPANOLAMINE. PHENYLTOLOXAMINE. PHENYTOIN. PHLEUM PRATENSE POLLEN EXTRACT (Timothy-grass pollen extract). PHOLCODINE: (a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or (b) in undivided preparations containing 2.5% or less of pholcodine; except when included in Schedule 2. PHOSPHODIESTERASE TYPE 5 INHIBITORS except: (a) when separately specified in these Schedules; or (b) when present as an unmodified, naturally occurring substance. PHTHALYLSULFATHIAZOLE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 145 PHYSOSTIGMINE. PIBRENTASVIR. PICROTOXIN. PILOCARPINE except in preparations containing 0.025% or less of pilocarpine. PIMECROLIMUS. PIMOBENDAN. PIMOZIDE. PINACIDIL. PINDOLOL. PIOGLITAZONE. PIPECURONIUM. PIPEMIDIC ACID. PIPENZOLATE. PIPER METHYSTICUM (kava) in preparations for human use except when included on the Register in preparations: (a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and: (i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or (ii) the amount of dried whole or peeled rhizome and/or root in the teabag does not exceed 3 g; and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the required advisory statements for medicine labels; or (b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome and/or root or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome and/or root; or (c) in dermal preparations. PIPERACILLIN. PIPERIDINE. PIPERIDOLATE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 146 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PIPOBROMAN. PIPOTHIAZINE. PIPRADROL. PIRACETAM. PIRBUTEROL. PIRENOXINE (catalin). PIRENZEPINE. PIRETANIDE. PIRFENIDONE. PIROXICAM except in preparations for dermal use. PIRPROFEN. PITAVASTATIN. PITUITARY HORMONES except when separately specified in these Schedules. PIVAMPICILLIN. PIZOTIFEN. PLICAMYCIN. PLITIDEPSIN. PLERIXAFOR. PNEUMOCOCCAL VACCINE. PODOPHYLLOTOXIN for human use: (a) internally; or (b) in preparations for the treatment of anogenital warts; or (c) in other preparations except when included in Schedule 2 or 3. PODOPHYLLUM EMODI (podophyllin) for human use: (a) internally; or (b) in preparations for the treatment of anogenital warts; or (c) in other preparations except when included in Schedule 2 or 3. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 147 PODOPHYLLUM PELTATUM (podophyllin) for human use: (a) internally; or (b) in preparations for the treatment of anogenital warts; or (c) in other preparations except when included in Schedule 2 or 3. POLIDEXIDE. POLIOMYELITIS VACCINE. POLYACRYLAMIDE in preparations for injection or implantation: (a) for tissue augmentation; or (b) for cosmetic use; or (c) for veterinary use. POLYCAPROLACTONE in preparations for injection or implantation: (a) for tissue augmentation; or (b) for cosmetic use. POLYESTRADIOL. POLYLACTIC ACID in preparations for injection or implantation: (a) for tissue augmentation; or (b) for cosmetic use. POLYMYXIN. POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, except when separately specified in these Schedules. POLYTHIAZIDE. POMALIDOMIDE. PONATINIB. PONESIMOD. PORACTANT. POSACONAZOLE. POTASSIUM BROMIDE for therapeutic use. POTASSIUM CHLORIDE in oral preparations for human therapeutic use except: Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 148 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (a) when containing less than 550 mg of potassium chloride per dosage unit; or (b) in preparations for oral rehydration therapy; or (c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or (d) in preparations for enteral feeding. POTASSIUM PERCHLORATE for therapeutic use. PRACTOLOL. PRADOFLOXACIN. PRALATREXATE. PRALIDOXIME. PRAMIPEXOLE. PRAMIRACETAM. PRAMOCAINE. # PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2 (GHRP-2)). PRALSETINIB. PRAMPINE. # PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone). PRASUGREL. PRAVASTATIN. # PRAZEPAM. PRAZIQUANTEL for human therapeutic use. PRAZOSIN. PREDNISOLONE. PREDNISONE. PREGABALIN. PREGNENOLONE. PRENALTEROL. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 149 PRENYLAMINE. PRILOCAINE except when included in Schedule 2. PRIMAQUINE. PRIMIDONE. PROBENECID. PROBUCOL. PROCAINAMIDE. PROCAINE. PROCAINE BENZYLPENICILLIN. PROCARBAZINE. PROCHLORPERAZINE except when included in Schedule 3. PROCYCLIDINE except when included in Schedule 2. PROGESTERONE except when included in Schedule 5. PROGESTOGENS except when separately specified in these Schedules. PROGLUMIDE. PROGUANIL. PROLINTANE. PROMAZINE. PROMETHAZINE except when included in Schedule 2 or 3. PROMOXOLANE. PROPAFENONE. PROPAMIDINE for therapeutic use except when included in Schedule 2. PROPANIDID. PROPANTHELINE. PROPENTOFYLLINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 150 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 # PROPETANDROL. PROPIONIBACTERIUM ACNES for therapeutic use. PROPOFOL. PROPRANOLOL. PROPYLHEXEDRINE. PROPYLTHIOURACIL. PROPYPHENAZONE. PROQUAZONE. PROSCILLARIDIN. PROSTAGLANDINS except when separately specified in this Schedule. PROSTIANOL. PROTAMINE. PROTHIONAMIDE. PROTHIPENDYL. PROTIRELIN. PROTOVERATRINES. PROTRIPTYLINE. PROXYMETACAINE. PRUCALOPRIDE. PSEUDOEPHEDRINE except when included in Schedule 3. PYRAZINAMIDE. PYRIDINOLCARBAMATE. PYRIDOSTIGMINE. PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use except: (a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the required advisory statements for medicine labels; or Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 151 (b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose. PYRIMETHAMINE. PYROVALERONE. PYRVINIUM. # QUAZEPAM. QUETIAPINE. QUINAGOLIDE. QUINAPRIL. # QUINBOLONE. QUINETHAZONE. QUINIDINE. QUININE for human therapeutic use except when the maximum recommended daily dose is 50 mg or less of quinine. QUINISOCAINE (dimethisoquin). QUINUPRISTIN. RABEPRAZOLE except when included in Schedule 2 or 3. RABIES VACCINE. RACETAMS except when separately specified in these Schedules. RACTOPAMINE except when included in Schedule 5. RALOXIFENE. RALTEGRAVIR. RALTITREXED. RAMIPRIL. RAMUCIRUMAB. RANIBIZUMAB. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 152 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 RANITIDINE except: (a) when included in Schedule 2; or (b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not more than 14 dosage units; or (c) in divided preparations for oral use containing 300mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units. RANOLAZINE. RAPACURONIUM. RASAGILINE. RASBURICASE. RAUWOLFIA SERPENTINA. RAUWOLFIA VOMITORIA. RAZOXANE. REBOXETINE. RED YEAST RICE for human therapeutic use. REMDESIVIR. REGDANVIMAB. REGORAFENIB. RELUGOLIX. REMOXIPRIDE. REPAGLINIDE. RESERPINE. RESLIZUMAB. RETAPAMULIN. RETEPLASE. RETIGABINE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 153 RIBAVIRIN. RIBOCICLIB. RIDAFOROLIMUS. RIFABUTIN. RIFAMPICIN. RIFAMYCIN. RIFAPENTINE. RIFAXIMIN. RILPIVIRINE. RILUZOLE. RIMEGEPANT. RIMEXOLONE. RIMITEROL. RIMONABANT. # RIOCIGUAT. RIPRETINIB. RISANKIZUMAB. RISDIPLAM. RISEDRONIC ACID. RISPERIDONE. RITODRINE. RITONAVIR. RITUXIMAB. RIVAROXABAN. RIVASTIGMINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 154 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 RIZATRIPTAN except when included in Schedule 3. ROBENACOXIB. ROCURONIUM. ROFECOXIB. ROFLUMILAST. ROLITETRACYCLINE. ROLZIRACETAM. ROMIDEPSIN. ROMIFIDINE. ROMIPLOSTIM. ROMOSOZUMAB. RONIDAZOLE. ROPINIROLE. ROPIVACAINE. ROSIGLITAZONE. ROSOXACIN. ROSUVASTATIN. ROTIGOTINE. # ROXIBOLONE. ROXITHROMYCIN. RUBELLA VACCINE. RUBOXISTAURIN. RUFINAMIDE. RUPATADINE. RUXOLITINIB. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 155 SACITUZUMAB GOVITECAN. SACUBITRIL. SAFINAMIDE. SALBUTAMOL except when included in Schedule 3. SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances. SALINOMYCIN except: (a) when included in Schedule 6; or (b) in animal feeds containing 60 mg/kg or less of antibiotic substances. SALMETEROL. SAPROPTERIN. SAQUINAVIR. SARILUMAB. SARS-COV-2 (COVID-19) VACCINE. SAXAGLIPTIN. SCHOENOCAULON OFFICINALE (sabadilla) except in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of Schoenocaulon officinale. SCOPOLIA CARNIOLICA for therapeutic use. SEBELIPASE ALFA. SECUKINUMAB. # SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM). SELEGILINE. SELENIUM: (a) for human oral use with a recommended daily dose of more than 300 micrograms; or (b) for the treatment of animals except: (i) when included in Schedule 6 or 7; or (ii) in solid, slow release bolus preparations containing 300 mg or less of selenium per dosage unit; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 156 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit; or (iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or (v) in feeds containing 1 g/tonne or less of selenium. SELETRACETAM. SELEXIPAG. SELINEXOR. SELPERCATINIB. SELUMETINIB. SEMAGLUTIDE. SERELAXIN. SERMORELIN. SERTINDOLE. SERTRALINE. SEVELAMER. SEVOFLURANE. SEX HORMONES and all substances having sex hormonal activity except when separately specified in these Schedules. SIBUTRAMINE. # SILANDRONE. SILDENAFIL. SILICONES for intra-ocular use. SILODOSIN. SILTUXIMAB. SILVER SULFADIAZINE. SIMEPREVIR. SIMVASTATIN. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 157 SIPONIMOD. SIROLIMUS. SISOMICIN (sisomycin). SITAGLIPTIN. # SITAXENTAN. SODIUM BROMIDE for therapeutic use. SODIUM CELLULOSE PHOSPHATE for human internal use. SODIUM CROMOGLYCATE except when included in Schedule 2. SODIUM GLYCEROPHOSPHATE HYDRATE. SODIUM MORRHUATE in preparations for injection. SODIUM NITROPRUSSIDE for human therapeutic use. SODIUM PHENYLBUTYRATE. SODIUM PHOSPHATE in preparations for oral laxative use. SODIUM POLYSTYRENE SULPHONATE for human therapeutic use. SODIUM SALICYLATE in preparations for internal use for the treatment of animals. SODIUM TETRADECYLSULFATE in preparations for injection. SODIUM ZIRCONIUM CYCLOSILICATE. SOFOSBUVIR. SOLASODINE. SOLIFENACIN. SOMAPACITAN. SOMATOSTATIN. SOMATOTROPIN EQUINE. # SOMATROPIN (human growth hormone). SONIDEGIB. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 158 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 SONTOQUINE. SORAFENIB. SOTALOL. SOTORASIB. SOTROVIMAB. SPARFLOXACIN. SPARTEINE. SPECTINOMYCIN. SPESOLIMAB. SPIRAMYCIN. SPIRAPRIL. SPIRONOLACTONE. # STANOLONE. # STANOZOLOL. STAVUDINE. # STENABOLIC (SR9009) and other synthetic REV-ERB agonists. # STENBOLONE. STEROID HORMONES except when separately specified in these Schedules. STILBESTROL (diethylstilbestrol). STIRIPENTOL. STREPTODORNASE. STREPTOKINASE. STREPTOMYCIN. STRONTIUM RANELATE. STROPHANTHINS. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 159 STROPHANTHUS spp. STRYCHNINE in preparations containing 1.5% or less of strychnine for the treatment of animals. STRYCHNOS spp. except in preparations containing 1 mg or less per litre or per kilogram of strychnine. STYRAMATE. SUCCIMER. SUCROFERRIC OXYHYDROXIDE. SUGAMMADEX. SULBACTAM. SULCONAZOLE except when included in Schedule 2. SULFACETAMIDE except when included in Schedule 3 or 5. SULFADIAZINE except when included in Schedule 5. SULFADIMETHOXINE. SULFADIMIDINE except when included in Schedule 5. SULFADOXINE. SULFAFURAZOLE. SULFAGUANIDINE. SULFAMERAZINE except when included in Schedule 5. SULFAMETHIZOLE. SULFAMETHOXAZOLE. SULFAMETHOXYDIAZINE. SULFAMETHOXYPYRIDAZINE. SULFAMETROLE. SULFAMONOMETHOXINE. SULFAMOXOLE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 160 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 SULFAPHENAZOLE. SULFAPYRIDINE. SULFAQUINOXALINE. SULFASALAZINE. SULFATHIAZOLE except when included in Schedule 5. SULFATROXAZOLE. SULFINPYRAZONE. SULFOMYXIN. SULFONAMIDES except: (a) when separately specified in this Schedule; or (b) when included in Schedule 3, 5 or 6; or (c) when packed and labelled solely for use as a herbicide. SULFONMETHANE (sulfonal) and alkyl sulfonals. SULINDAC. SULTAMICILLIN. SULTHIAME. SUMATRIPTAN except when included in Schedule 3. SUNIFIRAM. SUNITINIB. SUPROFEN. SUTILAINS. SUXAMETHONIUM. SUXETHONIUM. SUVOREXANT. TACRINE. TACROLIMUS. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 161 TADALAFIL. TAFAMIDIS. TAFASITAMAB. TAFENOQUINE SUCCINATE. TAFLUPROST. TAGRAXOFUSP. TALAZOPARIB. TALIGLUCERASE ALFA. TALIMOGENE LAHERPAREPVEC. TAMOXIFEN. TAMSULOSIN. TANACETUM VULGARE except in preparations containing 0.8% or less of oil of tansy. TASONERMIN. TAZAROTENE. TAZOBACTAM. # TB-500. T-CELL RECEPTOR ANTIBODY. TEBENTAFUSP. TECLISTAMAB. TEDUGLUTIDE. TEGAFUR. TEGASEROD. TELAPREVIR. TELITHROMYCIN. TEICOPLANIN. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 162 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TELBIVUDINE. TELMISARTAN. TELOTRISTAT ETHYL. # TEMAZEPAM. TEMOZOLOMIDE. TEMSIROLIMUS. TENECTEPLASE. TENIPOSIDE. TENOFOVIR. TENOXICAM. TEPOTINIB. TEPOXALIN. TERAZOSIN. TERBINAFINE except: (a) when included in Schedule 2; or (b) in preparations for dermal use for the treatment of tinea pedis. TERBUTALINE except when included in Schedule 3. TERFENADINE. TERIFLUNOMIDE. # TERIPARATIDE. TERLIPRESSIN. TERODILINE. TEROPTERIN. # TESTOLACTONE. # TESTOSTERONE except when included in Schedule 6. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 163 TETANUS ANTITOXIN except when used for short-term protection or treatment of tetanus in animals. TETANUS TOXOID for human use. TETRABENAZINE. TETRACAINE except: (a) when included in Schedule 2; or (b) in dermal preparations containing 2% or less of total local anaesthetic substances. TETRACOSACTIDE. TETRACYCLINE except when included in Schedule 5. TETRAETHYLAMMONIUM. TETROXOPRIM. TEZACAFTOR. # THALIDOMIDE. THENYLDIAMINE. THEOPHYLLINE except when included in Schedule 3. THEVETIA PERUVIANA. THEVETIN. THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs. THIAMBUTOSINE. THIAZOSULFONE. THIETHYLPERAZINE. THIOACETAZONE. THIOCARLIDE. # THIOMESTERONE (tiomesterone). THIOPENTAL. THIOPROPAZATE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 164 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 THIOPROPERAZINE. THIORIDAZINE. THIOSTREPTON. THIOTEPA. THIOTHIXENE. THIOURACIL. THIOUREA for therapeutic use except in preparations containing 0.1% or less of thiourea. # THYMOSIN BETA 4 (THYMOSIN β4). THYMOXAMINE (includes thymoxamine hydrochloride). THYROID except when separately specified in this Schedule. THYROTROPHIN. THYROXINE (includes thyroxine sodium). TIAGABINE. TIAMULIN. # TIANEPTINE. TIAPROFENIC ACID. TIARAMIDE. TIBOLONE. TICAGRELOR. TICARCILLIN. TICLOPIDINE. TIEMONIUM. TIENILIC ACID. TIGECYCLINE. TIGILANOL TIGLATE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 165 TIGLOIDINE. TILDIPIROSIN. TILETAMINE. TILMANOCEPT. TILMICOSIN. TILUDRONIC ACID (includes disodium tiludronate). TIMOLOL. TINIDAZOLE. TINZAPARIN (includes tinzaparin sodium). TIOCONAZOLE except: (a) when included in Schedule 2 or 3; or (b) in preparations for dermal use for the treatment of tinea pedis. TIOGUANINE. TIOTROPIUM. TIPEPIDINE. TIPIRACIL. TIPRANAVIR. TIRBANIBULIN. TIRILAZAD. TIROFIBAN. TIRZEPATIDE. TISLELIZUMAB. TIXAGEVIMAB. TOBRAMYCIN. TOCAINIDE. TOCERANIB. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 166 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TOCILIZUMAB. TOFACITINIB. TOLAZAMIDE. TOLAZOLINE. TOLBUTAMIDE. TOLCAPONE. TOLFENAMIC ACID. TOLMETIN. TOLONIUM. TOLPROPAMINE. TOLRESTAT. TOLTERODINE. TOLVAPTAN. TOPIRAMATE. TOPOTECAN. TORASEMIDE. TOREMIFENE. TOXOIDS for human parenteral use except when separately specified in these Schedules. TRABECTEDIN. TRAMADOL. TRANDOLAPRIL. TRAMETINIB DIMETHYL SULFOXIDE. TRANEXAMIC ACID except in preparations containing 3% or less of cetyl tranexamate hydrochloride for dermal cosmetic use. TRANYLCYPROMINE. TRASTUZUMAB. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 167 TRASTUZUMAB DERUXTECAN. TRASTUZUMAB EMTANSINE. TRAVOPROST. TRAZODONE. # TRENBOLONE (trienbolone, trienolone) except when included in Schedule 5. TREOSULPHAN. TREPROSTINIL. # TRESTOLONE. TRETAMINE. # TRETINOIN except the ester hydroxypinacolone retinoate in preparations for dermal use containing 0.5% or less of hydroxypinacolone retinoate. TRIACETYLOLEANDOMYCIN. TRIAMCINOLONE except when included in Schedule 2 or 3. TRIAMTERENE. TRIAZIQUONE. # TRIAZOLAM. TRICHLORMETHIAZIDE. TRICHLOROACETIC ACID for human dermal use except when in preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts. TRICHLOROETHYLENE for therapeutic use. TRICLOFOS. TRICYCLAMOL. TRIDIHEXETHYL. TRIENTINE. TRIFAROTENE. TRIFLUOPERAZINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 168 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TRIFLUPERIDOL. TRIFLUPROMAZINE. TRIFLURIDINE. TRIHEXYPHENIDYL. TRILOSTANE. TRIMETAPHAN. TRIMETHOPRIM. TRIMIPRAMINE. TRIMUSTINE. TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use. TRIOXYSALEN. TRIPELENNAMINE. TRIPROLIDINE except when included in Schedule 2 or 3. TRIPTORELIN. TROGLITAZONE. TROLAMINE when in preparations for tattoo removal. TROMETAMOL in preparations for injection except in preparations containing 3% or less of trometamol. TROPICAMIDE. TROPISETRON. TROVAFLOXACIN. TROXIDONE. TRYPTOPHAN for human therapeutic use except in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan. TUBERCULIN. TUBOCURARINE. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 169 TUCATINIB. TULATHROMYCIN. TULOBUTEROL. TYLOSIN. TYPHOID VACCINE. ULIPRISTAL except when included in Schedule 3. UMECLIDINIUM. UNIFIRAM. UNOPROSTONE. UPADACITINIB. URACIL. URAPIDIL. URETHANE (excluding its derivatives) for therapeutic use. # UROFOLLITROPIN. UROKINASE. URSODEOXYCHOLIC ACID. USTEKINUMAB. VACCINES for human therapeutic use except when separately specified in this Schedule. VACCINES for veterinary live virus except: (a) poultry vaccines; or (b) pigeon pox vaccine; or (c) scabby mouth vaccine; or (d) bovine ephemeral fever vaccine; or (e) bovine herpesvirus-1 vaccine. VACCINES – PLASMID DNA for animal use except when separately specified in these Schedules. VACCINIA VIRUS VACCINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 170 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 # VADADUSTAT. VALACICLOVIR. VALDECOXIB. VALGANCICLOVIR. VALNOCTAMIDE. VALPROIC ACID. VALSARTAN. VANCOMYCIN. VANDETANIB. VARDENAFIL. VARENICLINE. VARICELLA VACCINE. RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN. VASOPRESSIN. VECURONIUM. VEDAPROFEN. VEDOLIZUMAB. VELAGLIFLOZIN. VELAGLUCERASE ALFA. VELPATASVIR. VEMURAFENIB. VENETOCLAX. VENLAFAXINE. VERAPAMIL. VERATRUM spp. except when separately specified in this Schedule. Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 171 VERICIGUAT. VERNAKALANT. VERTEPORFIN. VIDARABINE. VIGABATRIN. VILANTEROL. VILDAGLIPTIN. VILOXAZINE. VINBLASTINE. VINCAMINE. VINCRISTINE. VINDESINE. VINFLUNINE. VINORELBINE. VINYL ETHER for therapeutic use. VIRGINIAMYCIN except when included in Schedule 5. VISMODEGIB. VISNADINE. VITAMIN A for human therapeutic or cosmetic use except: (a) in preparations for topical use containing 1% or less of Vitamin A; or (b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or (c) in preparations for parenteral nutrition replacement. VITAMIN D for human internal therapeutic use except: (a) in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or (b) when included in Schedule 3. Authorised Version F2024L00589 registered 30/05/2024 Schedule 4 Prescription only medicines and prescription animal remedies Substances marked # are listed in Appendix D 172 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 VORAPAXAR. VORETIGENE NEPARVOVEC. VORICONAZOLE. VORINOSTAT. VORTIOXETINE. VOSORITIDE. VOXILAPREVIR. WARFARIN for therapeutic use. XAMOTEROL. XANTHINOL NICOTINATE. XIMELAGATRAN. XIPAMIDE. XYLAZINE. YOHIMBINE. ZAFIRLUKAST. ZALCITABINE. ZALEPLON. ZANAMIVIR. ZANUBRUTINIB. ZERANOL except when included in Schedule 6. ZIDOVUDINE. ZILPATEROL. ZILUCOPLAN. ZIMELDINE. ZINC COMPOUNDS for human internal use except: (a) in preparations with a recommended daily dose of 25 mg or less of zinc; or Authorised Version F2024L00589 registered 30/05/2024 Prescription only medicines and prescription animal remedies Schedule 4 Substances marked # are listed in Appendix D Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 173 (b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the required advisory statements for medicine labels. ZIPRASIDONE. ZOLAZEPAM. ZOLEDRONIC ACID. ZOLMITRIPTAN except when included in Schedule 3. ZOLPIDEM. ZONISAMIDE. ZOPICLONE. ZOXAZOLAMINE. ZUCLOPENTHIXOL. Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 174 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 5—Caution Note: See paragraph (e) of the definition of designated solvent in section 6, paragraph 7(j), sections 16 and 25, subsection 26(2) and sections 42, 46, 47, 49, 55 and 61. ABAMECTIN (a) in preparations, for internal use for the treatment of animals, containing 1% or less of abamectin; or (b) in gel formulations containing 0.05% or less of abamectin in applicators containing 50 mg or less of abamectin. ABSCISIC ACID. ACEQUINOCYL. ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30% of acetic acid (CH3COOH) except: (a) when included in Schedule 2 or 6; or (b) for therapeutic use. ACETONE except in preparations containing 25% or less of designated solvents. ACRIFLAVINIUM CHLORIDE in preparations for veterinary use containing 2.5% or less of acriflavinium chloride. AFOXOLANER in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit (a) for the treatment and prevention of flea infestations and control of ticks in dogs; or (b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with milbemycin oxime. AKLOMIDE. ALBENDAZOLE for the treatment of animals, in preparations containing 12.5% or less of albendazole except in intraruminal implants each containing 3.85 g or less of albendazole. ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination: (a) in solid orthodontic device cleaning preparations, tHE pH of which as an “in-use” aqueous solution is more than 11.5; or (b) in solid automatic dishwashing preparations, tHE pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5; or (c) in other solid preparations, tHE pH of which in a 10 g/L aqueous solution is more than 11.5; or Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 175 (d) in liquid or semi-solid preparations, tHE pH of which is more than 11.5, unless: (i) in food additive preparations for domestic use; or (ii) in automatic dish washing preparations for domestic use with A pH of more than 12.5; except when separately specified in these Schedules. ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50% or less of alkoxylated fatty alkylamine polymer except in preparations containing 20% or less of alkoxylated fatty alkylamine polymer. ALLETHRIN in preparations containing 10% or less of allethrin except: (a) in insecticidal mats; or (b) in other preparations containing 1% or less of allethrin. ALLOXYDIM. ALPHA-CYPERMETHRIN: (a) in aqueous preparations containing 3% or less of alpha-cypermethrin; or (b) in other preparations containing 1.5% or less of alpha-cypermethrin. AMETRYN. AMINES for use as curing agents for epoxy resins except when separately specified in these Schedules. AMINOACRIDINE in preparations for veterinary use containing 2.5% or less of aminoacridine. AMINOCYCLOPYRACHLOR except in preparations containing 25% or less of aminocyclopyrachlor. AMINOPYRALID in preparations containing 22% or less of aminopyralid. AMISULBROM. AMITROLE. AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5% or less of ammonia except: (a) in preparations for human internal therapeutic use; or (b) in preparations for inhalation when absorbed in an inert solid material; or (c) in preparations containing 0.5% or less of free ammonia. AMMONIUM THIOCYANATE except in preparations containing 10% or less of ammonium thiocyanate. Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 176 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins except when separately specified in these Schedules. ANISE OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning: KEEP OUT OF REACH OF CHILDREN; or (c) in preparations containing 50% or less of anise oil. ASPIRIN for the treatment of animals, that is in divided preparations, when: (a) packed in blister or strip packaging; or (b) in a container with a child-resistant closure. ATRAZINE. AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5% or less of total limonoids, for agricultural use. AZOXYSTROBIN. BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas fluorescens. BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm. BASIL OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning: KEEP OUT OF REACH OF CHILDREN; or (c) in preparations containing 5% or less of methyl chavicol. BEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFu)/mL or less of Beauveria bassiana. BENALAXYL. BENDIOCARB in preparations containing 2% or less of bendiocarb. Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 177 BENTAZONE. BENZALKONIUM CHLORIDE in preparations containing 10% or less of benzalkonium chloride except in preparations containing 5% or less of benzalkonium chloride. BENZOFENAP. BENZOIC ACID (excluding its salts and derivatives) in preparations for agricultural use except preparations containing 1% or less of benzoic acid. BENZOYL PEROXIDE except: (a) when included in Schedule 2 or 4; or (b) in preparations containing 5% or less of benzoyl peroxide. BERGAMOT OIL except: (a) when steam distilled or rectified; or (b) in preparations for internal use; or (c) in preparations containing 0.4% or less of bergamot oil; or (d) in soaps or bath or shower gels that are washed off the skin; or (e) in medicines for human therapeutic use when compliant with the requirements of the required advisory statements for medicine labels; or (f) in other preparations when packed in containers labelled with the statement: Application to the skin may increase sensitivity to sunlight. BETACYFLUTHRIN: (a) in aqueous preparations containing 2.5% or less of betacyfluthrin; or (b) in solid preparations containing 8% or less of betacyfluthrin in a plastic matrix. BICYCLOPYRONE in preparations containing 20% or less of bicyclopyrone. BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3% or less of total bifluorides. BIOALLETHRIN in preparations containing 10% or less of bioallethrin except in preparations containing 1% or less of bioallethrin. BIORESMETHRIN except in preparations containing 10% or less of bioresmethrin. BISPYRIBAC except in preparations containing 10% or less of bispyribac. BIXAFEN. BORIC ACID except: (a) when included in Schedule 4; or (b) in cosmetic hand cleaning preparations when labelled with a warning to the following effect: Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 178 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words: NOT TO BE USED ON PEELING OR IRRITATED SKIN; or (c) in cosmetic talc preparations containing 5% or less calculated as boric acid when labelled with a warning to the following effect: NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words: NOT TO BE USED ON PEELING OR IRRITATED SKIN; or (d) in cosmetic oral hygiene preparations containing 0.1% or less calculated as boric acid when labelled with a warning to the following effect: NOT TO BE SWALLOWED. NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; or (e) in other cosmetic preparations containing 3% or less calculated as boric acid when labelled with a warning to the following effect: NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words: NOT TO BE USED ON PEELING OR IRRITATED SKIN; or (f) in preparations, other than insect baits, containing 6% or less calculated as boric acid. BORON TRIFLUORIDE in preparations containing 0.1% or less of boron trifluoride (BF3). BROFLANILIDE in preparations containing 0.3% or less of broflanilide. BROMUCONAZOLE in preparations containing 20% or less of bromuconazole. BUPIVACAINE in aqueous gel preparations containing 0.5% or less of bupivacaine, for the dermal spray-on administration to the wounds of animals. BUPROFEZIN except in preparations containing 40% or less of buprofezin. BUTHIDAZOLE. BUTOXYCARBOXIM in solid preparations containing 10% or less of butoxycarboxim. BUTRALIN. BUTROXYDIM. n-BUTYL ALCOHOL in preparations containing 10% or less of n-butyl alcohol except: (a) in preparations containing 5% or less of n-butyl alcohol; or (b) in preparations for cosmetic or therapeutic use other than spray form. Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 179 CAMPHOR as a natural component in essential oils containing 10% or less of camphor except: (a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (c) in rosemary oil, sage oil (Spanish), or lavandin oils; or (d) in preparations containing 2.5% or less of camphor. CARBAMIDE PEROXIDE in preparations containing 18% or less of carbamide peroxide except in preparations containing 9% or less of carbamide peroxide. CARBARYL: (a) in preparations containing 10% or less of carbaryl except when included in Schedule 4; or (b) when impregnated into plastic resin material containing 20% or less of carbaryl. CASSIA OIL except: (a) in food additives; or (b) in preparations for dermal use as a rubefacient containing 5% or less of cassia oil; or (c) in other preparations containing 2% or less of cassia oil. CHLORFENAC. CHLORFENAPYR. in preparations containing 0.5% or less of chlorfenapyr. CHLORFENSON. CHLORHEXIDINE in preparations containing 3% or less of chlorhexidine except: (a) in preparations containing 1% or less of chlorhexidine; or (b) when in solid preparations. CHLORINATING COMPOUNDS containing 20% or less of available chlorine, except: (a) when separately specified in these Schedules; or (b) sodium hypochlorite preparations with A pH of less than 11.5; or (c) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements: Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 180 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or (d) liquid preparations containing less than 2% of available chlorine; or (e) other preparations containing 4% or less of available chlorine. CHLORNIDINE. CHLOROCRESOL except in preparations containing 3% or less of chlorocresol. CHLORPROPHAM. CHLORPYRIFOS: (a) in aqueous preparations containing 20% or less of microencapsulated chlorpyrifos; or (b) in controlled release granular preparations containing 10% or less of chlorpyrifos; or (c) in other preparations containing 5% or less of chlorpyrifos; except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre. CHLORSULFURON. CHLORTETRACYCLINE in preparations: (a) for topical application to animals for ocular use only; or (b) containing 40% or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only. CHLORTHAL-DIMETHYL. CINMETHYLIN. CINNAMON BARK OIL except: (a) in food additives; or (b) in preparations containing 2% or less of cinnamon bark oil. CIS-JASMONE when prepared and packaged as an agricultural chemical except when present as a fragrance. CLETHODIM. CLIMBAZOLE in preparations containing 40% or less of climbazole except: (a) in leave-on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or (b) in other preparations (that are not leave-on cosmetic preparations) containing 2% or less of climbazole. Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 181 CLOFENTEZINE. CLOPYRALID. CLOQUINTOCET. CLORSULON. CLOTHIANIDIN in preparations containing 20% or less of clothianidin except in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin. CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil except in preparations containing 25% or less of clove oil. COPPER ACETATE in preparations containing 20% or less of copper acetate except in preparations containing 5% or less of copper acetate. COPPER COMPOUNDS in animal feed additives containing 5% or less of copper except in preparations containing 1% or less of copper. COPPER HYDROXIDE in preparations containing 50% or less of copper hydroxide except in preparations containing 12.5% or less of copper hydroxide. COPPER OXIDES in preparations containing 25% or less of copper oxides except: (a) in preparations for internal use; or (b) in marine paints; or (c) in other preparations containing 5% or less of copper oxides. COPPER OXYCHLORIDE in preparations containing 50% or less of copper oxychloride except in preparations containing 12.5% or less of copper oxychloride. COPPER SULFATE in preparations containing 15% or less of copper sulfate except: (a) in preparations for internal use; or (b) in other preparations containing 5% or less of copper sulfate. COUMATETRALYL in rodenticides containing 0.05% or less of coumatetralyl. 4-CPA. CYANATRYN. CYANOACRYLATE ESTERS in contact adhesives except: (a) when labelled with the warning: KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 182 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters: (i) labelled with the approved name or trade name of the poison, the quantity and the warning: Can cause eye injury. Instantly bonds skin; and enclosed in a primary pack labelled with the warning: KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water. CYANTRANILIPROLE. CYANURIC ACID (excluding its salts and derivatives). CYAZOFAMID. CYCLOHEXANONE PEROXIDE. CYCLOPROTHRIN except in preparations containing 10% or less of cycloprothrin. CYCLOXYDIM. CYFLUFENAMID. CYFLUMETOFEN. CYFLUTHRIN: (a) in wettable powders containing 10% or less of cyfluthrin; or (b) in emulsifiable concentrates containing 2% or less of cyfluthrin; or (c) in emulsions containing 5% or less of cyfluthrin. CYHALOFOP-BUTYL. CYMIAZOLE. CYPERMETHRIN in preparations containing 10% or less of cypermethrin. CYPHENOTHRIN in preparations containing 10% or less of cyphenothrin. CYPROCONAZOLE except in preparations containing 10% or less of cyproconazole. CYPRODINIL. CYTHIOATE for the treatment of animals: Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 183 (a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or (b) in undivided preparations containing 5% or less of cythioate. 2,4-D in preparations containing 20% or less of 2,4-D. DAMINOZIDE. 2,4-DB. DECOQUINATE: DELTAMETHRIN: (a) when impregnated in plastic resin strip material containing 4% or less of deltamethrin; or (b) in aqueous preparations containing 5% or less of deltamethrin when no organic solvent other than a glycol is present; or (c) in wettable granular preparations containing 25% or less of deltamethrin when packed in child-resistant packaging each containing 3 g or less of the formulation; or (d) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or (e) in other preparations containing 0.5% or less of deltamethrin; except: (f) in factory prepared mosquito nets containing 1% or less deltamethrin; or (g) in preparations containing 0.1% or less of deltamethrin. DEMBREXINE in oral preparations for the treatment of animals. 2,4-DES. DIAFENTHIURON. N,N-DIALLYLDICHLOROACETAMIDE except in preparations containing 10% or less of N,N-diallyldichloroacetamide. DIAZINON in dust preparations containing 2% or less of diazinon. DICAMBA (including its salts and derivatives) in preparations containing 20% or less of dicamba. DICHLONE. p-DICHLOROBENZENE. DICHLOROISOCYANURIC ACID containing 40% or less of available chlorine, except in: Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 184 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (a) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements: WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or (b) liquid preparations containing less than 2% of available chlorine; or (c) other preparations containing 4% or less of available chlorine. DICHLOROMETHANE (methylene chloride) except: (a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10% or less of dichloromethane; or (b) in other preparations in pressurised spray packs; or (c) in paints and tinters containing 5% or less of dichloromethane; or (d) in preparations for human therapeutic use. DICHLOROPHEN for the treatment of animals. DICHLORVOS: (a) when impregnated in plastic resin strip material containing 20% or less of dichlorvos; or (b) in sustained release resin pellets containing 20% or less of dichlorvos for the treatment of animals; or (c) in pressurised spray packs containing 10 g or less of dichlorvos. DICLOBUTRAZOL. DICLORAN. DICOFOL. DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of diethanolamine except in preparations containing 5% or less of diethanolamine. DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except: (a) in paints or paint tinters; or (b) in toothpastes or mouthwashes containing more than 0.25% of diethylene glycol; or (c) in other preparations containing 2.5% or less of diethylene glycol. DIETHYLENE GLYCOL MONOBUTYL ETHER except in preparations containing 10% or less of diethylene glycol monobutyl ether. DIETHYLTOLUAMIDE (DEET) except: Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 185 (a) in medicines for human therapeutic use containing 20% or less of diethyltoluamide, when compliant with the requirements of the required advisory statements for medicine labels; or (b) in preparations for human use, other than medicines, containing 20% or less of diethyltoluamide, when labelled with the warning statement: WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or (c) in preparations other than for human use containing 20% or less of diethyltoluamide. DIFENOCONAZOLE. DIFLUBENZURON. DIMETHICODIETHYLBENZALMALONATE except when included in preparations containing 10% or less of dimethicodiethylbenzalmalonate. DIMETHIRIMOL. DIMETHOMORPH except in preparations containing 10% or less of dimethomorph. DIMETHYLACETAMIDE in preparations containing 20% or less of dimethylacetamide. DIMETHYLFORMAMIDE in preparations containing 10% or less of dimethylformamide except in silicone rubber mastic containing 2% or less of dimethylformamide. 3,7-DIMETHYL-2,6-OCTADIENAL and its isomers in cosmetic and household cleaning preparations except in preparations containing 5% or less of 3,7-dimethyl-2,6,-octadienal isomers. DIMPROPYRIDAZ in preparations containing 13% or less of dimpropyridaz. DINICONAZOLE. DINOTEFURAN except in preparations containing 1% or less of dinotefuran. DI-n-PROPYL ISOCINCHOMERONATE except in preparations containing 25% or less of di-n-propyl isocinchomeronate. DIPHENAMID. DIRECT RED 254 in preparations containing 30% or less of Direct Red 254 calculated as free acid. DITHIOPYR. N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50% or less of N-(N-dodecyl)-2-pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 186 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 N-(N-octyl)-2-pyrrolidone except in preparations containing 25% or less of designated solvents. DORAMECTIN for internal use for the treatment of animals, in preparations containing 2% or less of doramectin. EMAMECTIN in preparations containing 2% or less of emamectin. EMODEPSIDE in preparations: (a) containing 2.5% or less of emodepside for the external treatment of animals; or (b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals. EPOXICONAZOLE. EPOXY RESINS, LIQUID. EPRINOMECTIN in preparations containing 0.5% or less of eprinomectin. ESBIOTHRIN in preparations containing 10% or less of esbiothrin except in pressurised spray packs containing 1% or less of esbiothrin. ESFENVALERATE in preparations containing 0.1% or less of esfenvalerate. ESTRADIOL in implant preparations for growth promotion in animals. 1,2-ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL) OXIRANE AND N-METHYLMETHANAMINE. ETHER in preparations containing more than 10% of ether for use in internal combustion engines. ETHOFUMESATE. ETHOXYQUIN except in preparations containing 10% or less of ethoxyquin. ETHOXYSULFURON. ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except: (a) in paints or paint tinters; or (b) in toothpastes or mouthwashes containing more than 0.25% of ethylene glycol; or (c) in other preparations containing 2.5% or less of ethylene glycol. ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use except in preparations containing 1% or less of ethyl methacrylate as residual monomer in a polymer. ETRIDIAZOLE. Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 187 EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol except in preparations containing 25% or less of eugenol. EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (Corymbia citriodora), except in preparations containing 40% or less of extract of lemon eucalyptus. FENARIMOL. FENBENDAZOLE for the treatment of animals. FENBUCONAZOLE. FENCHLORAZOLE-ETHYL. FENNEL OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of an instrument made under subsection 3(5A) of the Act relating to medicine advisory statements; or (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning: KEEP OUT OF REACH OF CHILDREN; or (c) in preparations containing 5% or less of methyl chavicol. FENOPROP. FENOXAPROP-ETHYL. FENOXAPROP-p-ETHYL. FENPYRAZAMINE except in preparations containing 40% or less of fenpyrazamine. FENSON. FENTHION: (a) in preparations containing 25% or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or (b) in preparations containing 10% or less of fenthion. FIPRONIL in preparations containing 10% or less of fipronil except in preparations containing 0.05% or less of fipronil. FLAMPROP-METHYL. FLAMPROP-M-METHYL. FLAZASULFURON. Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 188 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FLORASULAM. FLUAZAINDOLIZINE in preparations containing 50% or less fluazaindolizine. FLUAZURON. FLUBENDAZOLE for the treatment of animals. FLUBENDIAMIDE. FLUCHLORALIN. FLUDIOXONIL except in preparations containing 10% or less of fludioxonil. FLUMETHRIN: (a) when impregnated in plastic resin strip material containing 3% or less of flumethrin; or (b) in oil based preparations containing 1% or less of flumethrin. FLUMICLORAC PENTYL. FLUOPYRAM except in preparations containing 50% or less of fluopyram. FLUORIDES in preparations containing 3% or less of fluoride ion except: (a) in preparations for human use; or (b) in preparations containing 15 mg/kg or less of fluoride ion. FLURALANER except when included in Schedule 4. FLUVALINATE in aqueous preparations containing 25% or less of fluvalinate. FLUXAPYROXAD. FORAMSULFURON. FORMIC ACID (excluding its salts and derivatives) except in preparations containing 0.5% or less of formic acid. FOSPIRATE when impregnated in plastic resin strip material containing 20% or less of fospirate. FURALAXYL. FURATHIOCARB in microencapsulated suspensions containing 50% or less of furathiocarb. GAMMA-CYHALOTHRIN in aqueous preparations containing 15% or less of microencapsulated gamma-cyhalothrin. GLUFOSINATE-AMMONIUM. Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 189 GLUTARAL in preparations containing 5% or less of glutaral except: (a) when included in Schedule 2; or (b) in preparations containing 0.5% or less of glutaral when labelled with the statements: (A) IRRITANT; and (B) Avoid contact with eyes. GLYPHOSATE. HALOSULFURON-METHYL. HEXACONAZOLE except in preparations containing 5% or less of hexaconazole. HEXAZINONE in preparations containing 25% or less of hexazinone. HYDRAMETHYLNON in solid baits containing 2% or less of hydramethylnon in welded plastic labyrinths. HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), except: (a) toluene and xylene when included in Schedule 6; or (b) benzene and liquid aromatic hydrocarbons when included in Schedule 7; or (c) food grade and pharmaceutical grade white mineral oils; or (d) in solid or semi-solid preparations; or (e) in preparations containing 25% or less of designated solvents; or (f) in preparations packed in pressurised spray packs; or (g) in adhesives packed in containers each containing 50 g or less of adhesive; or (h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or (i) in other preparations when packed in containers with a capacity of 2 mL or less. HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of hydrochloric acid (HCl) except: (a) in preparations containing 0.5% or less of hydrochloric acid (HCl); or (b) for therapeutic use. HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1% or less of hydrogen fluoride. HYDROGEN PEROXIDE (excluding its salts and derivatives): (a) in hair dye preparations containing 12% or less of hydrogen peroxide except in hair dyes containing 6% or less of hydrogen peroxide; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 190 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) in other preparations containing 6% (20 volume) or less of hydrogen peroxide except in preparations containing 3% (10 volume) or less of hydrogen peroxide. HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1% or less of hydrosilicofluoric acid (H2SiF6). 2-HYDROXYETHYL METHACRYLATE except: (a) when included in dental restorative preparations for therapeutic use; or (b) in nail preparations when labelled “Avoid contact with skin”; or (c) in other preparations containing 0.1% or less of 2-hydroxyethyl methacrylate when labelled “Avoid contact with skin”. 2-HYDROXYPROPYL METHACRYLATE in nail preparations except when labelled “Avoid contact with skin”. IMAZALIL. IMAZAMOX except in preparations containing 25% or less of imazamox. IMAZAPIC except in preparations containing 25% or less of imazapic. IMAZAPYR except in preparations containing 25% or less of imazapyr. IMAZETHAPYR except in preparations containing 25% or less of imazethapyr. IMIDACLOPRID in preparations containing 20% or less of imidacloprid except in preparations containing 5% or less of imidacloprid. IMIPROTHRIN in preparations containing 50% or less of imiprothrin except in preparations containing 10% or less of imiprothrin. INDOXACARB (includes the R and S enantiomers) in preparations containing 1% or less of indoxacarb. 3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10% or less of 3-iodo-2-propynyl butyl carbamate except: (a) in aqueous preparations not for cosmetic use containing 10% or less 3-iodo-2-propynyl butyl carbamate; or (b) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3-iodo-2-propynyl butyl carbamate. IODOSULFURON-METHYL-SODIUM. IPCONAZOLE in preparations containing 2% or less of ipconazole. IRON COMPOUNDS: (a) for the treatment of animals (excluding up to 1% of iron oxides when present as an excipient): Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 191 (i) in preparations for injection containing 20% or less of iron except in preparations containing 0.1% or less of iron; or (ii) in other preparations containing 4% or less of iron except: (A) in liquid or gel preparations containing 0.1% or less of iron; or (B) in animal feeds or feed premixes; or (b) for use as agricultural chemicals except in preparations containing 4% or less of iron. ISOEUGENOL in preparations not intended for skin contact containing 25% or less of isoeugenol except in preparations containing 10% or less of isoeugenol. ISOPHORONE. ISOXABEN. ISOXAFLUTOLE. IVERMECTIN for use in animals: (a) in preparations for the prophylaxis of heartworm in cats and dogs; or (b) in intraruminal implants containing 160 mg or less of ivermectin; or (c) in preparations containing 3.5% or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or (d) in other preparations containing 2% or less of ivermectin. KITASAMYCIN in animal feed premixes for growth promotion containing 2% or less of antibiotic substances. LAMBDA-CYHALOTHRIN: (a) in aqueous preparations containing 1% or less of lambda- cyhalothrin; or (b) in aqueous preparations containing 10% or less of microencapsulated lambda-cyhalothrin. LASIODIPLODIA PSEUDOTHEOBROMAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule. LEMON OIL except: (a) when steam distilled or rectified; or (b) in preparations for internal use; or (c) in preparations containing 0.05% or less of lemon oil; or (d) in soaps or bath or shower gels that are washed off the skin; or (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or (f) in other preparations when packed in containers labelled with the statement: Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 192 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Application to the skin may increase sensitivity to sunlight. LEMONGRASS OIL in cosmetic and household cleaning preparations except in preparations containing 5% or less of 3,7-dimethyl-2,6-octadienal. LEVAMISOLE in preparations containing 15% or less of levamisole for the treatment of animals except: (a) when included in Schedule 4; or (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole. LIDOCAINE: (a) in aqueous gel preparations containing 4.5% or less of lidocaine, for the dermal spray-on administration to the wounds of animals; or (b) in injectable preparations containing 2% or less of lidocaine when packaged in a container with a tamper resistant cartridge which can only be dispensed through a rubber ring applicator for tail docking and castration of lambs; or castration of calves. LIME OIL except: (a) when steam distilled or rectified; or (b) in preparations for internal use; or (c) in preparations containing 0.5% or less of lime oil; or (d) in soaps or bath or shower gels that are washed off the skin; or (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or (f) in other preparations when packed in containers labelled with the statement: Application to the skin may increase sensitivity to sunlight. LINDANE in preparations containing 10% or less of lindane except when included in Schedule 2 or 4. LOTILANER. LUFENURON except: (a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or (b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals. MACROPHOMINA PHASEOLINA except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule. MADURAMICIN in animal feed premixes containing 1% or less of antibiotic substances. Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 193 MAGNESIUM CHLORATE except in preparations containing 10% or less of magnesium chlorate. MALACHITE GREEN in preparations for veterinary use containing 10% or less of malachite green. MALATHION in preparations containing 10% or less of malathion except: (a) for human therapeutic use; or (b) in dust preparations containing 2% or less of malathion. MANCOZEB. MANDESTROBIN except in preparations containing 25% or less of mandestrobin. MANDIPROPAMID. MARJORAM OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning: KEEP OUT OF REACH OF CHILDREN; or (c) in preparations containing 50% or less of marjoram oil. MCPA: (a) in preparations containing 25% or less of MCPA (acid); or (b) in preparations containing 50% or less of the salts and esters of MCPA. MEBENDAZOLE for the treatment of animals: (a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or (b) in undivided preparations containing 25% or less of mebendazole. MECLOFENAMIC ACID for the treatment of animals. MECOPROP in preparations containing 2% or less of mecoprop. MEFENPYR-DIETHYL. MEFENTRIFLUCONAZOLE except in preparations containing 7.5% or less of mefentrifluconazole. MEPIQUAT. Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 194 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MERCAPTAMINE in cosmetic preparations containing 6% or less of mercaptamine except in preparations containing 1% or less of mercaptamine. MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations containing 20% or less of mercaptoacetic acid or its salts (as mercapturic acid), except in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid) MESOTRIONE. METAFLUMIZONE. METALAXYL in preparations containing 35% or less of metalaxyl. METALDEHYDE in preparations containing 2% or less of metaldehyde. METAZACHLOR. METHABENZTHIAZURON. METHANOL (excluding its derivatives) in preparations containing 10 % or less of methanol except: (a) when included in Schedule 10; or (b) in preparations containing 2% or less of methanol; or (c) when methanol is present only as a denaturant of ethanol. METHENAMINE in cosmetic preparations, except in preparations containing 0.15% or less of methenamine. METHIOCARB in pelleted preparations containing 2% or less of methiocarb. METHIOZOLIN. METHOXYCHLOR. METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) except: (a) when included in preparations or admixtures; or (b) when packed in containers having a capacity of more than 5 L. METHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners”. METHYLENE BLUE in preparations for veterinary use containing 50% or less of methylene blue. METHYL ETHYL KETONE except in preparations containing 25% or less of designated solvents. METHYL ETHYL KETONE PEROXIDE. Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 195 METHYL ISOAMYL KETONE except in preparations containing 25% or less of designated solvents. METHYL ISOBUTYL KETONE except in preparations containing 25% or less of designated solvents. N-METHYL-2-PYRROLIDONE: (a) when packed in single use containers having a capacity of 2 mL or less; or (b) in preparations containing 50% or less of N-methyl-2-pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N-methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone except in preparations containing 25% or less of designated solvents. METHYL SALICYLATE in preparations containing 25% or less of methyl salicylate except: (a) in preparations for therapeutic use; or (b) in preparations containing 5% or less of methyl salicylate. 2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5 TRIAZINE. METIRAM. METOBROMURON except in preparations containing 50% or less of metobromuron. METOFLUTHRIN: (a) in impregnated fabric mosquito repellent preparations for use in a vaporiser containing 15 mg or less of metofluthrin per disk; or (b) when impregnated into a polyethylene slow release matrix containing 250 mg or less of metofluthrin. METOLACHLOR. METRAFENONE in preparations containing 50% or less of metrafenone. MILBEMECTIN in preparations containing 1% or less of milbemectin. MILBEMYCIN OXIME (a) for the prophylaxis of heartworm in dogs and cats; or (b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with afoxolaner, in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit. MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin. MONEPANTEL. Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 196 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MONOETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of monoethanolamine except: (a) when included in Schedule 4; or (b) in preparations containing 5% or less of monoethanolamine. MORANTEL in preparations containing 25% or less of morantel except in preparations containing 10% or less of morantel. MOXIDECTIN: (a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5% or less of moxidectin; or (b) in preparations for external use for the treatment of cats and dogs, containing 2.5% or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or (c) for internal use for the treatment of animals: (i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or (ii) in other preparations containing 2% or less of moxidectin. MYCLOBUTANIL. NAA except in preparations containing 25% or less of NAA. NALED when impregnated in plastic resin strip material containing 20% or less of naled. NAPTALAM. NEOSCYTALIDIUM NOVAEHOLLANDIAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule. NETOBIMIN for the treatment of animals, in preparations containing 12.5% or less of netobimin. NITRIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of nitric acid (HNO3) except in preparations containing 0.5% or less of nitric acid. NITROSCANATE for the treatment of animals. NONANOIC ACID: (a) when used in a pesticide; or (b) in other preparations except in preparations containing 10% or less of nonanoic acid. NONOXINOL 9 in preparations containing 25% or less of nonoxinol 9 except: (a) when labelled with the statements: (i) IRRITANT; and (ii) Avoid contact with eyes; or Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 197 (b) in preparations containing 12.5% or less of nonoxinol 9; or (c) in preparations for human use. NORBORMIDE. NUTMEG OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning: KEEP OUT OF REACH OF CHILDREN; or (c) in preparations containing 50% or less of nutmeg oil. N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE except in preparations containing 10% or less of N-octyl bicycloheptene dicarboximide. N-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50% or less of: (a) N-(N-octyl)-2-pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone; or (b) N-(N-dodecyl)-2-pyrrolidone except in preparations containing 25% or less of designated solvents. OLEANDOMYCIN in animal feed premixes for growth promotion. OMETHOATE in pressurised spray packs containing 0.2% or less of omethoate. ORANGE OIL (BITTER) except: (a) when steam distilled or rectified; or (b) in preparations for internal use; or (c) in preparations containing 1.4% or less of orange oil (bitter); or (d) in soaps or bath or shower gels that are washed off the skin; or (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or (f) in other preparations when packed in containers labelled with the statement: Application to the skin may increase sensitivity to sunlight. OXADIARGYL. OXADIXYL. OXANTEL EMBONATE for the treatment of animals. OXFENDAZOLE for the treatment of animals. Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 198 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 OXIBENDAZOLE for the treatment of animals. OXYCARBOXIN. OXYTETRACYCLINE in preparations: (a) for topical application to animals for ocular use only; or (b) containing 40% or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only. OXYTHIOQUINOX. PACLOBUTRAZOL. PENCONAZOLE. PENDIMETHALIN. PENFLUFEN. PENTHIOPYRAD except in preparations containing 20% or less of penthiopyrad. PERACETIC ACID in concentrations of 10% or less of peracetic acid. PERMETHRIN (excluding preparations for human therapeutic use): (a) in preparations containing 25% or less of permethrin; or (b) in preparations for external use, for the treatment of dogs, containing 50% or less of permethrin when packed in single use containers having a capacity of 4 mL or less; except in preparations containing 2% or less of permethrin. PETROL except preparations containing 25% or less of petrol. PHENAZONE for the external treatment of animals. PHENISOPHAM. PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15% or less of such substances, except in preparations containing 1% or less of phenol and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol. PHENYL METHYL KETONE except in preparations containing 25% or less of designated solvents. o-PHENYLPHENOL except in preparations containing 5% or less of o-phenylphenol. PHOSPHONIC ACID (excluding its salts and derivatives) except in preparations containing 10% or less of phosphonic acid (H3PO3). Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 199 PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35% or less of phosphoric acid (H3PO4) except: (a) in preparations containing 15% or less of phosphoric acid (H3PO4); or (b) in solid or semi-solid preparations; or (c) in professional dental kits. o-PHTHALALDEHYDE in preparations containing 1% or less of o-phthalaldehyde. PICARIDIN except in preparations containing 20% or less of picaridin. PINE OILS in preparations containing 25% or less of pine oils when packed and labelled as a herbicide. PINOXADEN in preparations containing 10% or less of pinoxaden. PIPERAZINE for animal use. PIRIMICARB in preparations containing 0.5% or less of pirimicarb. POLIXETONIUM SALTS in preparations containing 60% or less of polixetonium salts except in preparations containing 1% or less of polixetonium salts. POLYETHANOXY (15) TALLOW AMINE. POLYOXIN D ZINC SALT. POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL] α -HYDROXY-,MONO-C13-15-ALKYL ETHERS. POTASSIUM CHLORATE except: (a) when included in Schedule 2; or (b) in preparations containing 10% or less of potassium chlorate. POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of potassium hydroxide being: (a) solid preparations, tHE pH of which in a 10 g/L aqueous solution is more than 11.5; or (b) liquid or semi-solid preparations, tHE pH of which is more than 11.5 except in food additive preparations for domestic use. POTASSIUM METABISULPHITE when packed for domestic use except in preparations containing 10% or less of potassium metabisulphite. POTASSIUM NITRITE in preparations containing 1% or less of potassium nitrite except: (a) in preparations containing 0.5% or less of potassium nitrite; (b) when present as an excipient in preparations for therapeutic use; or (c) in aerosols. Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 200 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5% or less of potassium peroxomonosulfate triple salt being: (a) solid preparations, tHE pH of which in a 10 g/L aqueous solution is less than 2.5; or (b) liquid or semi-solid preparations, tHE pH of which is less than 2.5. POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide. PRALLETHRIN (cis:trans=20:80) in preparations containing 10% or less of prallethrin except in insecticidal mats containing 1% or less of prallethrin. PROFOXYDIM except in preparations containing 20% or less of profoxydim. PROGESTERONE: (a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or (b) in implant preparations for growth promotion in cattle. PROHEXADIONE CALCIUM. PROMETRYN. PROPAMOCARB. PROPANIL. PROPAQUIZAFOP. PROPICONAZOLE in preparations containing 20% or less of propiconazole. PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80% or less of propionic acid, except: (a) in preparations containing 30% or less of propionic acid; or (b) for therapeutic use. PROPOXUR: (a) when impregnated in plastic resin strip material containing 10% or less of propoxur; or (b) in dust preparations containing 3% or less of propoxur; or (c) in granular sugar-based fly baits containing 1% or less of propoxur, a dark colouring agent and a separate bittering agent; or (d) in pressurised spray packs containing 2% or less of propoxur; or (e) in printed paper sheets for pest control containing 0.5% or less of propoxur and in any case not more than 100 mg of propoxur per sheet. n-PROPYL ALCOHOL in preparations containing 10% or less of n-propyl alcohol except: Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 201 (a) in preparations containing 5% or less of n-propyl alcohol; or (b) in preparations for cosmetic or therapeutic use other than in spray form. PROPYZAMIDE. PROTHIOCONAZOLE-DESCHLORO except in preparations containing 0.5% or less of prothioconazole-deschloro. PROTHIOCONAZOLE-TRIAZOLIDINETHIONE except in preparations containing 0.5% or less of prothioconazole-triazolidinethione. PYMETROZINE. PYRACLOSTROBIN. PYRAFLUFEN-ETHYL. PYRASULFOTOLE. PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except: (a) in preparations for human therapeutic use; or (b) in preparations containing 10% or less of such substances. PYRIDABEN in preparations containing 25% or less of pyridaben. PYRIFENOX. PYRITHIOBAC SODIUM. PYRITHIONE ZINC in paints containing 0.5% or less of pyrithione zinc calculated on the non-volatile content of the paint except in paints containing 0.1% or less of pyrithione zinc calculated on the non-volatile content of the paint. PYRIOFENONE in preparations containing 30% or less of pyriofenone. QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20% or less of quaternary ammonium compounds except: (a) when separately specified in these Schedules; or (b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or (c) in preparations containing 5% or less of such quaternary ammonium compounds. QUINCLORAC. QUININE in preparations for veterinary use containing 1% or less of quinine. QUINTOZENE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 202 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 QUIZALOFOP-p-ETHYL in aqueous preparations containing 40% or less of quizalofop-p-ethyl. RACTOPAMINE in animal feed premixes containing 10% or less of ractopamine. RESMETHRIN in preparations containing 10% or less of resmethrin. RIMSULFURON. ROBENIDINE except in preparations containing 20% or less of robenidine. ROSIN when packaged for use as a soldering flux or in flux-cored solder. SAFLUFENACIL in water dispersible granules or a water-based suspension concentrate. SALICYLANILIDE. SAROLANER for veterinary use in divided preparations each containing 120 mg or less of sarolaner per dosage unit. SEDAXANE. SELAMECTIN except in preparations containing 12% or less of selamectin. SETHOXYDIM. SIDURON. SILICOFLUORIDES in preparations containing 3% or less of fluoride ion except: (a) barium silicofluoride when separately specified in this Schedule; or (b) in preparations containing 15 mg/kg or less of fluoride ion. SINBIOALLETHRIN in preparations containing 10% or less of sinbioallethrin except in preparations containing 1% or less of sinbioallethrin. SODIUM BROMIDE except when included in Schedule 4. SODIUM CHLORATE except in preparations containing 10% or less of sodium chlorate. SODIUM DIACETATE except in preparations containing 60% or less of sodium diacetate. SODIUM DODECYLBENZENE SULFONATE except in preparations containing 30% or less of sodium dodecylbenzene sulfonate. SODIUM HYDROGEN SULFATE except in preparations containing 10% or less of sodium hydrogen sulfate. SODIUM HYDROSULFITE when packed for domestic use except in preparations containing 10% or less of sodium hydrosulfite. Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 203 SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of sodium hydroxide being: (a) solid preparations, tHE pH of which in a 10 g/L aqueous solution is more than 11.5; or (b) liquid or semi-solid preparations, tHE pH of which is more than 11.5 except in food additive preparations for domestic use. SODIUM LAURETH-6 CARBOXYLATE except in preparations containing 1% or less of sodium laureth-6 carboxylate. SODIUM METABISULPHITE when packed for domestic use except in preparations containing 10% or less of sodium metabisulphite. SODIUM NITRITE in preparations containing 1% or less of sodium nitrite except: (a) in preparations containing 0.5% or less of sodium nitrite; or (b) when present as an excipient in preparations for therapeutic use; or (c) in aerosols. SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35% or less of sodium percarbonate except in preparations containing 15% or less of sodium percarbonate. SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use except in preparations containing 10% or less of sodium polystyrene sulphonate. SODIUM STANNATE except in preparations for cosmetic use containing 1% or less of sodium stannate. SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide. SPINETORAM. SPINOSAD except in aqueous suspensions containing 25% or less of spinosad. SPIROMESIFEN for agricultural use. STAR ANISE OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning: KEEP OUT OF REACH OF CHILDREN; or (c) in preparations containing 50% or less of star anise oil. STYRENE (excluding its derivatives). Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 204 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only. SULFADIAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only. SULFADIMIDINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only. SULFAMERAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only. SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of sulfamic acid (H3NO3S). SULFATHIAZOLE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only. SULFOMETURON-METHYL. SULFOXAFLOR in preparations containing 25% or less of sulfoxaflor. SYMPHYTUM spp. (Comfrey) for dermal therapeutic or dermal cosmetic use. 2,3,6-TBA. TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) in preparations containing 10% or less of TDE. TEBUCONAZOLE. TEBUFENOZIDE. TEFLUTHRIN in preparations containing 2% or less of tefluthrin. TEMEPHOS: (a) in liquid preparations containing 10% or less of temephos; or (b) in powders containing 2% or less of temephos; or (c) in preparations containing 40% or less of temephos when packed in single use containers having a capacity of 2 mL or less. TEPRALOXYDIM. TERBUTRYN. TETRACHLOROETHYLENE in preparations containing 5% or less of tetrachloroethylene except: (a) when included in Schedule 2; or (b) in preparations for the treatment of animals; or Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 205 (c) when absorbed into an inert solid. TETRACHLORVINPHOS except in animal feeds containing 0.2% or less of tetrachlorvinphos. TETRACONAZOLE in preparations containing 20% or less of tetraconazole. TETRACYCLINE in preparations: (a) for topical application to animals for ocular use only; or (b) containing 40% or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only. TETRAMETHRIN [(R, cis): (R, trans) = 20:80] except in pressurised spray packs. TETRANILIPROLE except in preparations containing 20% or less tetraniliprole. THIABENDAZOLE: (a) for the treatment of animals; or (b) when packed and labelled for use as a fungicide except in preparations containing 50% or less of thiabendazole. THIAMETHOXAM in preparations containing 60% or less of thiamethoxam. THIAZOPYR. THIFENSULFURON. THIOBENCARB. THIODICARB in pelleted preparations containing 1.5% or less of thiodicarb. THIOPHANATE-METHYL in preparations containing 25% or less of thiophanate-methyl. THYME OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning: KEEP OUT OF REACH OF CHILDREN; or (c) in preparations containing 50% or less of thyme oil. TIGOLANER in preparations containing 10% or less of tigolaner. TIOCARBAZIL. TOLCLOFOS-METHYL. Authorised Version F2024L00589 registered 30/05/2024 Schedule 5 Caution 206 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TOLTRAZURIL. TOPRAMEZONE TRALKOXYDIM. TRENBOLONE in implant preparations for growth promotion in animals. TRIADIMEFON in wettable powders containing 25% or less of triadimefon. TRIADIMENOL. TRI-ALLATE. TRIBENURON-METHYL. TRICHLOROACETIC ACID, alkali salts of. 1,1,1-TRICHLOROETHANE except: (a) in preparations packed in pressurised spray packs; or (b) in preparations containing 25% or less of designated solvents; or (c) in preparations, other than writing correction fluids or thinners for writing correction fluids in containers having a capacity of 50 mL or less; or (d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with: (i) the word “Trichloroethane” written in letters not less than 1 mm in height and in distinct contrast to the background; and (ii) the expression: WARNING – DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU; written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background. TRIDIPHANE. TRIETAZINE. TRIFLOXYSTROBIN. TRIFLUDIMOXAZIN except in preparations containing 12.5% or less. TRIFLUMIZOLE. TRIFLUMURON. TRIISOPROPANOLAMINE LAURYL ETHER SULFATE except in preparations containing 30% or less of triisopropanolamine lauryl ether sulfate when labelled with the statements: Authorised Version F2024L00589 registered 30/05/2024 Caution Schedule 5 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 207 (a) Avoid contact with eyes and skin; and (b) Wash hands after handling. TRINEXAPAC-ETHYL except: (a) when packed in a sealed water-soluble measure pack; or (b) in solid preparations containing 25% or less of trinexapac-ethyl in packs of 50 g or less. 3,6,9-TRIOXAUNDECANEDIOIC ACID except in preparations containing 5% or less of 3,6,9-trioxaundecanedioic acid, tHE pH of which is 3.5 or greater. TRITICONAZOLE. TROLAMINE (excluding its salts and derivatives) except: (a) when in Schedule 4; or (b) in preparations containing 5% or less of trolamine. TURPENTINE OIL except in preparations containing 25% or less of turpentine oil. VIRGINIAMYCIN in animal feed additives containing 1% or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less. VERNOLATE. WARFARIN in rodent baits containing 0.1% or less of warfarin. ZINEB. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 208 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 6—Poisons Note: See section 16, subsection 46(2), section 49, subsection 54(3) and sections 55 and 61. ABAMECTIN: (a) in preparations for pesticidal use containing 4% or less of abamectin except when included in Schedule 5; or (b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin. ACEPHATE. ACETAMIPRID except in preparations containing 1% or less of acetamiprid. ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) except when included in Schedule 2. ACETIC ANHYDRIDE excluding its derivatives. ACIFLUORFEN. ACINITRAZOLE except in preparations containing 20% or less of acinitrazole. ACLONIFEN. ALBENDAZOLE for the treatment of animals except: (a) when included in Schedule 5; or (b) in intraruminal implants each containing 3.85 g or less of albendazole. ALDRIN. ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use: (a) in solid automatic dishwashing preparations, tHE pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or (b) in liquid or semi-solid automatic dishwashing preparations, tHE pH of which is more than 12.5. ALKOXYLATED FATTY ALKYLAMINE POLYMER except: (a) when included in Schedule 5; or (b) in preparations containing 20% or less of alkoxylated fatty alkylamine polymer. ALLETHRIN except: (a) when included in Schedule 5; or (b) in insecticidal mats containing 20% or less of allethrin; or (c) in other preparations containing 1% or less of allethrin. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 209 ALLYL ESTERS (excluding derivatives) being: (a) ALLYL CYCLOHEXANEACETATE (CAS No. 4728-82-9); or (b) ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705-87-5); or (c) ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142-19-8); or (d) ALLYL HEXANOATE (CAS No. 123-68-2); or (e) ALLYL ISOVALERATE (CAS No. 2835-39-4); or (f) ALLYL NONANOATE (CAS No. 7493-72-3); or (g) ALLYL OCTANOATE (CAS No. 4230-97-1); or (h) ALLYL PHENYLACETATE (CAS No. 1797-74-6); or (i) ALLYL TRIMETHYLHEXANOATE (CAS No. 68132-80-9); in preparations containing 0.1% or less of free allyl alcohol by weight of allyl ester except in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl esters. ALPHA-CYPERMETHRIN: (a) in aqueous preparations containing 30% or less of alpha-cypermethrin; or (b) in other preparations containing 10% or less of alpha-cypermethrin; except when included in Schedule 5. AMICARBAZONE. AMIDITHION. AMIDOPROPYL BETAINES except: (a) in cosmetic wash-off preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines when labelled with a warning to the following effect: IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or (b) in cosmetic leave-on preparations containing 1.5% or less of amidopropyl betaines; or (c) in other preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines, when labelled with warnings to the following effect: (i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and (ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER. 2-AMINO-6-CHLORO-4-NITROPHENOL in hair dye and eyebrow/eyelash colouring preparations, except: (a) in preparations containing 2% or less of 2-amino-6-chloro-4-nitrophenol when applied directly to the hair, or containing 2% or less of Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 210 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 2-amino-6-chloro-4-nitrophenol after mixing and when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; (b) in eyelash and eyebrow tinting products containing 1.5% or less of 2-amino-6-chloro-4-nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statement: WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5mm in height. 4-AMINO-m-CRESOL in hair dyes and eyebrow/eyelash colouring preparations except: (a) in hair dye preparations containing 1.5% or less of 4-amino-m-cresol after mixing for use when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5mm in height; or (b) in eyelash and eyebrow tinting products containing 1.5% or less of 4-amino-m-cresol after mixing for use when the immediate container and primary pack are labelled with the following statement: WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5mm in height. 2-AMINO-5-ETHYLPHENOL in hair dye preparations except in preparations containing 1% or less of 2-amino-5-ethylphenol when the immediate container and primary pack are labelled with the following statements: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes and eyebrows; to do so may be injurious to the eye; Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 211 written in letters not less than 1.5 mm in height. 4-AMINO-2-HYDROXYTOLUENE in hair dyes and eyebrow/eyelash colouring products except: (a) in hair dye preparations containing 1.5% or less of 4-amino-2-hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5mm in height; or (b) in eyelash and eyebrow tinting products containing 1.5% or less of 4-amino-2-hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statement: WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5mm in height. AMINOCARB in preparations containing 25% or less of aminocarb. AMINOETHOXYVINYLGLYCINE except in preparations containing 15% or less of aminoethoxyvinylglycine. 1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE. 4-AMINO-3-NITROPHENOL except: (a) in non-oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4-amino-3-nitrophenol when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height; or (b) in oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4-amino-3-nitrophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 212 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height. 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL (including its salts) except: (a) in non-oxidative hair dye preparations containing 2.5% or less of 2,2'-[(4-amino-3-nitrophenyl)imino]bisethanol after mixing when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height; or (b) in oxidative hair dye preparations containing 1.25% or less of 2,2'-[(4-amino-3-nitrophenyl)imino]bisethanol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height. m-AMINOPHENOL except when used in hair dye and eyebrow/eyelash preparations at a concentration of 1.2% or less of m-aminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height. p- AMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of p-aminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 213 AMINOPYRALID except when included in Schedule 5. AMITRAZ. AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) except: (a) when included in Schedule 5; or (b) in preparations for human internal therapeutic use; or (c) in preparations for inhalation when absorbed in an inert solid material; or (d) in preparations containing 0.5% or less of ammonia. AMMONIUM COCOYL ISETHIONATE, except in cosmetic rinse-off preparations containing 30% or less of ammonium cocoyl isethionate and, if containing more than 5% of ammonium cocoyl isethionate, when labelled with a warning to the following effect: IF IN EYES WASH OUT IMMEDIATELY WITH WATER. AMMONIUM PERSULFATE in hair preparations. ANILINE (excluding its salts and derivatives) except in preparations containing 1% or less of aniline. ANTIMONY COMPOUNDS except: (a) when included in Schedule 4; or (b) antimony chloride in polishes; or (c) antimony titanate pigments in paint; or (d) in paints or tinters containing 5% or less of antimony calculated on the non-volatile content of the paint or tinter. ARBUTIN (ALPHA) except: (a) in preparations for application to the face containing 2% or less alpha-arbutin with hydroquinone levels of 10mg/kg or less; or (b) in preparations for application to the body containing 0.5% or less alpha-arbutin with hydroquinone levels of 10mg/kg or less. ARBUTIN (BETA) except: (a) when included in Schedule 4; or (b) oral herbal preparations containing 500 mg or less beta-arbutin per recommended daily dose; or (c) in preparations for application to the face containing 7% or less beta-arbutin with hydroquinone levels of 10mg/kg or less. ARBUTIN (DEOXY OR OTHER DERIVATIVES). ARSENIC: (a) in ant poisons containing 0.4% or less of arsenic; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 214 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) in animal feed premixes containing 4% or less of arsenic; or (c) in preparations for the treatment of animals except thiacetarsamide when included in Schedule 4, except when separately specified in this Schedule. ASPIRIN for the treatment of animals except when included in Schedule 4 or 5. AZACONAZOLE except in preparations containing 1% or less of azaconazole. AZADIRACHTA INDICA (Neem) including its extracts and derivatives except: (a) when included in Schedule 5; or (b) in preparations for human internal use; or (c) debitterised neem seed oil; or (d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (e) in preparations for dermal use containing 1% or less of cold pressed neem seed oil. AZAMETHIPHOS. AZOBENZENE. BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2% or less of antibiotic substances. BARIUM SALTS except: (a) when included in Schedule 5; or (b) barium sulfate; or (c) in paints or tinters containing 5% or less of barium calculated on the non-volatile content of the paint or tinter. BASIC BLUE 26 (CAS No. 2580-56-5) except when used as a colourant in cosmetics not intended to be in contact with mucous membranes. BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) except: (a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or (b) in hair dye preparations containing 1% or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; (ii) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and (iii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 215 be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height. BASIC RED 76 (CAS No. 68391-30-0) in non-oxidative hair dye preparations and eyebrow/eyelash colouring products containing 2% or less of Basic Red 76 and 0.001% or less of free o-anisidine. BAY OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (e) in preparations containing 25% or less of bay oil. BEAUVERIA BASSIANA except when included in Schedule 5. BENDIOCARB: (a) in wettable powders containing 80% or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb; or (b) in wettable powders containing 20% or less of bendiocarb and not less than 0.002% of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation; or (c) in insoluble granular preparations containing 5% or less of bendiocarb; or (d) when impregnated in plastic resin strip material containing 10% or less of bendiocarb; except when included in Schedule 5. BENQUINOX. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 216 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BENSULIDE. BENZALKONIUM CHLORIDE except: (a) when included in Schedule 5; or (b) in preparations containing 5% or less of benzalkonium chloride. 1,2-BENZENEDIOL. BENZOVINDIFLUPYR. 6-BENZYLADENINE except in preparations containing 10% or less of 6-benzyladenine. BERYLLIUM. BETACYFLUTHRIN in preparations containing 12.5% or less of betacyfluthrin except when included in Schedule 5. BETA-CYPERMETHRIN. BHC (excluding lindane). BICYCLOPYRONE except when included in Schedule 5. BIFENTHRIN in preparations containing 25% or less of bifenthrin except in preparations containing 0.5% or less of bifenthrin. BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3% or less of total bifluorides except when included in Schedule 5. BIOALLETHRIN except: (a) when included in Schedule 5; or (b) in preparations containing 1% or less of bioallethrin. 1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE (including its salts) except when in hair dye preparations containing 1.2% or less of 1,3-bis(2,4-diaminophenoxy)propane after mixing when the immediate container and primary pack are labelled with the following statements: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height. BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER except in rinse-off cosmetic products containing 1% or less of bis-isobutyl PEG/PPG-20/35/amodimeticone copolymer when labelled with a warning to the following effect: Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 217 IF IN EYES, WASH OUT IMMEDIATELY WITH WATER. N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE except in preparations containing 1% or less of N,N-bis(phenylmethylene)-bicyclo (2.2.1)heptane-2,5-dimethanamine, or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of: (a) IRRITANT; and (b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and (c) Avoid contact with eyes; and (d) Avoid contact with skin; and (e) Wear protective gloves when mixing or using; and (f) Ensure adequate ventilation when using. N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE except in preparations containing 1% or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of: (a) IRRITANT; and (b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and (c) Avoid contact with eyes; and (d) Avoid contact with skin; and (e) Wear protective gloves when mixing or using; and (f) Ensure adequate ventilation when using. BITHIONOL for the treatment of animals. BORON TRIFLUORIDE in preparations containing 1% or less of boron trifluoride (BF3) except when included in Schedule 5. BRODIFACOUM in preparations containing 0.25% or less of brodifacoum. BROFLANILIDE except when included in Schedule 5. BROMADIOLONE in preparations containing 0.25% or less of bromadiolone. BROMETHALIN in rodent baits containing 0.01% or less of bromethalin. BROMOFORM except when included in Schedule 4. BROMOPHOS. BROMOPHOS-ETHYL. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 218 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BROMOXYNIL. BROMUCONAZOLE except when included in Schedule 5. BROTIANIDE. BUNAMIDINE. BUTACARB. BUTOXYCARBOXIM except when included in Schedule 5. 2-BUTOXYETHANOL and its acetates except: (a) in plant growth regulator preparations containing 20% or less of such substances; or (b) in other preparations containing 10% or less of such substances. 2-BUTOXY-2'-THIOCYANODIETHYL ETHER. n-BUTYL ALCOHOL except: (a) when included in Schedule 5; or (b) in preparations containing 5% or less of n-butyl alcohol; or (c) in preparations for cosmetic or therapeutic use other than in spray form. BUTYRIC ACID in preparations for use as insect lures. CACODYLIC ACID: (a) in animal feed premixes containing 4% or less of arsenic; or (b) in herbicide or defoliant preparations containing 10% or less of cacodylic acid. CADMIUM COMPOUNDS except: (a) when included in Schedule 4; or (b) in paints or tinters containing 0.1% or less of cadmium calculated on the non-volatile content of the paint or tinter. CADUSAFOS in aqueous preparations containing 20% or less of microencapsulated cadusafos. CAFFEINE except: (a) when included in Schedule 4; or (b) in divided preparations for internal human therapeutic use when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or (c) in undivided preparations for internal human therapeutic use with a concentration of less than 5% of total caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or (d) in preparations for external use; or Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 219 (e) in other preparations with a concentration of less than 5% of caffeine. CAJUPUT OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (e) in preparations containing 25% or less of cajuput oil; or (f) in oils containing 25% or less of cajuput oil. CALCIFEROL in rodent baits containing 0.1% or less of calciferol. CAMBENDAZOLE. CAMPHOR except: (a) when included in Schedule 4 or 5; or (b) when enclosed in an inhaler device which prevents ingestion of its contents; or (c) in solid or semi-solid preparations containing 12.5% or less of camphor; or (d) in liquid preparations containing 2.5% or less of camphor; or (e) in essential oils when the camphor is present as a natural component of the oil: (i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 220 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: (A) KEEP OUT OF REACH OF CHILDREN; and (B) NOT TO BE TAKEN; or (iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (A) KEEP OUT OF REACH OF CHILDREN; and (B) NOT TO BE TAKEN; or (f) in rosemary oil, sage oil (Spanish), or lavandin oil as such. CAPTAN. CARBARYL except when included in Schedule 4 or 5. CARBON DISULFIDE. CARBAMIDE PEROXIDE except: (a) when included in Schedule 5; or (b) in other preparations containing 9% or less of carbamide peroxide. CARBETAMIDE. CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use except in wash-off preparations containing 1% or less of castor oil, monomaleate. CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide. CHLORDANE. CHLORFENAPYR in preparations containing 36% or less of chlorfenapyr except when included in Schedule 5. CHLORFENETHOL. CHLORHEXIDINE in preparations containing 7% or less of chlorhexidine except: (a) when included in Schedule 5; or (b) in preparations containing 1% or less of chlorhexidine; or (c) when in solid preparations. CHLORINATING COMPOUNDS except: (a) when included in Schedule 5; or (b) when separately specified in these Schedules; or Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 221 (c) sodium hypochlorite preparations with A pH of less than 11.5; or (d) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements: WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or (e) in liquid preparations containing less than 2% of available chlorine; or (f) in other preparations containing 4% or less of available chlorine. CHLORMEQUAT. CHLOROACETAMIDE (a) in preparations for cosmetic use; or (b) in preparations for topical therapeutic use; or (c) in other preparations containing more than 0.3% of chloroacetamide. 2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL except: (a) in non-oxidative hair dye preparations containing 3% or less of 2-chloro-6-(ethylamino)-4-nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height; or (b) in oxidative hair dye preparations containing 1.5% or less of 2-chloro-6-(ethylamino)-4-nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height. CHLOROFORM except: (a) when included in Schedule 2 or 4; or (b) in preparations containing 10% or less of chloroform. ALPHA-CHLOROHYDRIN. CHLOROPHACINONE. (E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-E N-3-OL (uniconazole-p) except in preparations containing 5% or less of (E)-(S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 222 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CHLOROPICRIN in preparations containing 5% or less of chloropicrin. CHLOROTHALONIL except in water-based paint containing 0.5% or less of chlorothalonil. 2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE. CHLORPYRIFOS except: (a) when included in Schedule 5; or (b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre. CHLORPYRIFOS-METHYL. CHLORTHIAMID. CHROMATES (including dichromates) except in paints or tinters containing 5% or less of chromium as the ammonium, barium, calcium, iron, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter. CHROMIUM TRICHLORIDE HEXAHYDRATE except in preparations containing 0.5% or less chromium. CHROMIUM TRIOXIDE (excluding its salts and derivatives). CHRYSOIDINE BASE except when in Schedule 10. CINEOLE except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (e) in preparations containing 25% or less of cineole; or (f) in oils containing 25% or less of cineole; or Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 223 (g) in rosemary oil or camphor oil (white). CINNAMON LEAF OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (e) in preparations containing 25% or less of cinnamon leaf oil. CLIMBAZOLE except: (a) when included in Schedule 5; or (b) in leave-on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or (c) in other preparations (that are not leave-on cosmetic preparations) containing 2% or less of climbazole. CLODINAFOP-PROPARGYL. CLOMAZONE. CLOSANTEL. CLOTHIANIDIN except (a) when included in Schedule 5; or (b) when in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin. CLOTRIMAZOLE for the external treatment of animals. CLOVE OIL except: (a) when included in Schedule 5; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 224 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (f) in preparations containing 25% or less of clove oil. N-COCO-1,3-DIAMINOPROPANE. COCOYL GLYCINATE in cosmetic preparations except: (a) in leave-on preparations containing 5% or less of cocoyl glycinate; or (b) in wash-off preparations containing 30% or less of cocoyl glycinate and, when containing more than 5% of cocoyl glycinate labelled with a warning to the following effect: IF IN EYES WASH OUT IMMEDIATELY WITH WATER. COPPER ACETATE except: (a) when included in Schedule 5; or (b) in preparations containing 5% or less of copper acetate. COPPER COMPOUNDS except: (a) when separately specified in these Schedules; or (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or (c) pigments where the solubility of the copper compound(s) in water is 1 g per litre or less; or (d) in feed additives containing 1% or less of copper; or (e) in other preparations containing 5% or less of copper compounds. COPPER HYDROXIDE except: (a) when included in Schedule 5; or Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 225 (b) in preparations containing 12.5% or less of copper hydroxide. COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep. COPPER OXIDES except: (a) when included in Schedule 5; or (b) in preparations for internal use; or (c) in marine paints; or (d) in other preparations containing 5% or less of copper oxides. COPPER OXYCHLORIDE except: (a) when included in Schedule 5; or (b) in preparations containing 12.5% of less of copper oxychloride. COPPER SULFATE except: (a) when included in Schedule 5; or (b) in preparations for internal use; or (c) in other preparations containing 5% or less of copper sulfate. COUMAPHOS: (a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or (b) in other preparations containing 5% or less of coumaphos. COUMATETRALYL in rodenticides containing 1% or less of coumatetralyl except when included in Schedule 5. CREOSOTE derived from wood other than beechwood except: (a) when included in Schedule 2; or (b) in preparations for human therapeutic use containing 10% or less of creosote derived from wood other than beechwood; or (c) in other preparations containing 3% or less of phenols and homologues of phenol boiling below 220°C. CROTOXYPHOS. CRUFOMATE. CYANAMIDE. CYANAZINE. CYCLANILIDE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 226 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM. CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) when presented in a wipe and when packaged in a container with a child-resistant closure, with chemical resistant gloves and labelled with the following effect: (a) DO NOT USE WITHOUT PROTECTIVE GLOVES; and (b) KEEP OUT OF EYES. CYFLUTHRIN except: (a) when included in Schedule 5; or (b) in pressurised spray packs containing 1% or less of cyfluthrin. CYOMETRINIL. CYPERMETHRIN except when included in Schedule 5. CYPHENOTHRIN except when included in Schedule 5. CYTHIOATE except when included in Schedule 5. 2,4-D except when included in Schedule 5. DAZOMET. DELTAMETHRIN: (a) in aqueous preparations containing 25% or less of deltamethrin, when no organic solvent, other than 10% or less of a glycol, is present; or (b) in wettable granular preparations containing 25% or less of deltamethrin; or (c) in water-dispersible tablets each containing 500 mg or less of deltamethrin; or (d) in emulsifiable concentrates containing 11% or less of deltamethrin in a solvent containing 40% or less of acetophenone and 45% or less of liquid hydrocarbons; or (e) in other preparations containing 3% or less of deltamethrin; except: (f) when included in Schedule 5; or (g) in factory prepared mosquito nets containing 1% or less of deltamethrin; or (h) in preparations containing 0.1% or less of deltamethrin. DERQUANTEL. 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL DERIVATIVES except: Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 227 (a) in cosmetic rinse-off preparations containing 8% or less of 1-deoxy-1-(methylamino)-d-glucitol N-coco acyl derivatives when labelled with the following statement: IF IN EYES WASH OUT IMMEDIATELY WITH WATER, or (b) in household cleaning preparations, other than those intended to be sprayed, containing 10% or less of 1-deoxy-1-(methylamino)-d-glucitol N-coco acyl derivatives when labelled with the following statement: IF IN EYES WASH OUT IMMEDIATELY WITH WATER. 2,4-DIAMINOPHENOXYETHANOL except when used in hair dye and eyebrow/eyelash preparations at concentrations of 2% or less of 2,4-diaminophenoxyethanol after mixing for use when the immediate container and primary pack are labelled with the following statements: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height. DIAZINON except when included in Schedule 5. DICAMBA (including its salts and derivatives) except when included in Schedule 5. DICHLOBENIL. DICHLOFENTHION. DICHLOFLUANID. o-DICHLOROBENZENE. DICHLOROETHYL ETHER. DICHLOROISOCYANURIC ACID except: (a) when included in Schedule 5; or (b) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements: WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or (c) in liquid preparations containing less than 2% of available chlorine; or (d) in other preparations containing 4% or less of available chlorine. 4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE. DICHLOROPHEN except: (a) when included in Schedule 4 or 5; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 228 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) in fabrics other than when: (i) for human therapeutic use; or (ii) as part of a registered pesticidal product. 1,2-DICHLOROPROPANE. 2,4-DICHLORPROP (including the R and S enantiomers). DICHLORVOS in preparations containing 50% or less of dichlorvos except when included in Schedule 5. DICLOFOP-METHYL. DICYCLANIL except in preparations containing 6.5% or less of dicyclanil. DIDECYLDIMETHYLAMMONIUM SALTS except in preparations containing 1% or less of didecyldimethylammonium salts labelled with the statement: Avoid contact with eyes. DIELDRIN. DIETHANOLAMINE (excluding its salts and derivatives) except: (a) when included in Schedule 5; or (b) in preparations containing 5% or less of diethanolamine. DIETHYLENE GLYCOL (excluding its salts and derivatives) except: (a) when included in Schedule 5; or (b) in paints or paint tinters; or (c) in toothpastes or mouthwashes containing more than 0.25% of diethylene glycol; or (d) in other preparations containing 2.5% or less of diethylene glycol. DIETHYLENE GLYCOL MONOMETHYL ETHER. DIFENACOUM in preparations containing 0.25% or less of difenacoum. DIFENZOQUAT. DIFETHIALONE in rodent baits containing 0.0025% or less of difethialone. 5,6-DIHYDROXYINDOLINE. DIMETHENAMID-P. DIMETHIPIN. DIMETHOATE. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 229 2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 0.25% or less of 2,6-dimethoxy-3,5-pyridinediamine after mixing for use when the immediate container and primary pack are labelled with the following statements: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height. DIMETHYLACETAMIDE except when included in Schedule 5. N,N-DIMETHYLDECANAMIDE. DIMETHYLFORMAMIDE except: (a) when included in Schedule 5; or (b) in silicone rubber mastic containing 2% or less of dimethylformamide. 4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL except: (a) in leave-on cosmetic preparations containing 0.1% or less of 4,4-dimethyl-1-cyclohexene-1-propanal; or (b) in rinse-off cosmetic preparations containing 0.5% or less of 4,4-dimethyl-1-cyclohexene-1-propanal; or (c) in other preparations containing 1% or less of 4,4-dimethyl-1-cyclohexene-1-propanal. 3,7-DIMETHYL-2,6-OCTADIEN-1-OL and its isomers except in products containing 5% or less 3,7-dimethyl-2,6-octadien-1-ol and its isomers. N,N-DIMETHYLOCTANAMIDE. DIMETHYL SULFOXIDE (excluding dimethyl sulfone): (a) when not for therapeutic use; or (b) in cosmetic preparations; or (c) for the treatment of animals: (i) when combined with no other therapeutic substance(s); or (ii) in liquid preparations containing copper salicylate and 1% or less of methyl salicylate as the only other therapeutic substances; or (iii) in clay poultices containing 2% or less of dimethyl sulfoxide; or (d) in other preparations except when containing 10% or less of dimethyl sulfoxide. DIMPROPYRIDAZ except when included in Schedule 5. DINITROCRESOLS and their homologues in preparations containing 5% or less of such compounds except: Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 230 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (a) when included in Schedule 4; or (b) when separately specified in this Schedule. DINITROPHENOLS and their homologues in preparations containing 5% or less of such compounds except: (a) when included in Schedule 4; or (b) when separately specified in this Schedule. DIOXACARB. DIOXANE except: (a) in preparations for cosmetic or human internal therapeutic use containing 0.001% or less of dioxane; or (b) in other preparations containing 0.01% or less of dioxane. DIPHACINONE. DIQUAT in preparations containing 20% or less of diquat. DIRECT RED 254 except when included in Schedule 5. DISPERSE YELLOW 3 except when in Schedule 10. DISULFIRAM except when included in Schedule 4. DISULFOTON in granular preparations containing 5% or less of disulfoton. DITHIANON. DITHIAZANINE in preparations containing 2% or less of dithiazanine for the treatment of animals. DIUREDOSAN. N-(N-DODECYL)-2-PYRROLIDONE except: (a) when included in Schedule 5; or (b) in preparations containing 25% or less of designated solvents. DODINE. DORAMECTIN for external use for the treatment of animals, in preparations containing 2% or less of doramectin. DSMA in herbicide or defoliant preparations containing 10% or less of DSMA. ECONAZOLE for the external treatment of animals. EMAMECTIN in preparations containing 5% or less of emamectin except when included in Schedule 5. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 231 EMODEPSIDE for the treatment of animals except when included in Schedule 5. ENDOSULFAN in aqueous preparations containing 33% or less of microencapsulated endosulfan. ENDOTHAL in preparations containing 20% or less of endothal. EPRINOMECTIN for internal use in preparations containing 5% or less of eprinomectin except when included in Schedule 5. EPTC. ESBIOTHRIN except: (a) when included in Schedule 5; or (b) in pressurised spray packs containing 1% or less of esbiothrin. ESFENVALERATE except when included in Schedule 5. ETHEPHON (excluding its salts and derivatives). ETHER except: (a) when included in Schedule 2, 4 or 5; or (b) in preparations containing 10% or less of ether. ETHIOFENCARB. ETHOATE-METHYL. ETHOPROPHOS in granular formulations containing 10% or less of ethoprophos and 2% of linseed oil. ETHYL BROMIDE. ETHYLENE CHLOROHYDRIN. ETHYLENE DICHLORIDE. ETHYLENE GLYCOL (excluding its salts and derivatives) except: (a) when included in Schedule 5; or (b) in paints or paint tinters; or (c) in toothpastes or mouthwashes containing more than 0.25% of ethylene glycol; or (d) in other preparations containing 2.5% or less of ethylene glycol. ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, except: (a) when separately specified in these Schedules; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 232 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) in preparations containing 10% or less of such substances. ETHYL FORMATE when packed and labelled for use as a fumigant. ETHYLHEXANEDIOL except in preparations containing 5% or less of ethylhexanediol. 2-ETHYLHEXANOIC ACID and its alkyl esters except in preparations containing 5% or less calculated as 2-ethylhexanoic acid. ETRIMFOS. EUCALYPTUS OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (e) in preparations containing 25% or less of eucalyptus oil. EUGENOL except: (a) when included in Schedule 5; or (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 233 (ii) NOT TO BE TAKEN; or (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (f) in preparations containing 25% or less of eugenol. FAMOXADONE. FAMPHUR in preparations containing 20% or less of famphur. FEBANTEL except: (a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or (b) in undivided preparations containing 10% or less of febantel. FENAMIPHOS in granular preparations containing 5% or less of fenamiphos. FENAZAFLOR. FENBUTATIN OXIDE. FENCHLORPHOS. FENITROTHION. FENOXACRIM in preparations for the treatment of carpets during manufacture. FENPROPIDIN. FENPYROXIMATE. FENTHION in preparations containing 60% or less of fenthion except when included in Schedule 5. FENVALERATE. FIPRONIL except: (a) when included in Schedule 5; or (b) in preparations containing 0.05% or less of fipronil. FLOCOUMAFEN in preparations containing 0.005% or less of flocoumafen. FLONICAMID. FLUAZAINDOLIZINE except when included in Schedule 5. FLUAZIFOP-BUTYL. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 234 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FLUAZIFOP-p-BUTYL. FLUAZINAM. FLUCOFURON in preparations for the treatment of carpets during manufacture. FLUENSULFONE. FLUMETHRIN except when included in Schedule 5. FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets. FLUORIDES except: (a) when included in Schedule 5; or (b) in preparations for human use; or (c) in preparations containing 15 mg/kg or less of fluoride ion. FLUPROPANATE. FLUPYRADIFURONE. FLUQUINCONAZOLE. FLUSILAZOL. FLUTRIAFOL except in fertilisers containing 0.5% or less of flutriafol. FLUVALINATE except when included in Schedule 5. FOMESAFEN SODIUM. FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde except: (a) for human therapeutic use; or (b) in oral hygiene preparations; or (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or (d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement: PROTECT CUTICLES WITH GREASE OR OIL; (e) in all other cosmetic preparations; or (f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement: CONTAINS FORMALDEHYDE. FORMOTHION. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 235 FOSPIRATE except when included in Schedule 5. FUMAGILLIN. FURFURAL except in preparations containing 0.1% or less of furfural. GLUTARAL except: (a) when included in Schedule 2 or 5; or (b) in preparations containing 0.5% or less of glutaral when labelled with the statements: IRRITANT; and Avoid contact with eyes. GLYCERYL THIOGLYCOLLATE in hair waving preparations except when labelled with directions for use that include the statement: Wear protective gloves when using. Keep out of eyes. GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical except: (a) in cosmetic preparations for salon use only, when labelled in accordance with requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time; or (b) in preparations containing 5% or less of glycolic acid; or (c) in preparations containing 20% or less of glycolic acid with A pH of 3.5 or greater. GUANIDINE except: (a) when included in Schedule 4; or (b) in preparations containing 1% or less of guanidine. GUAZATINE. HALOXON. HALOXYFOP. HC VIOLET 1 except: (a) in non-oxidative hair dye preparations containing 0.28% or less of HC Violet 1 after mixing when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 236 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) in oxidative hair dye preparations containing 0.25% or less of HC Violet 1 after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height. HEPTACHLOR. HEXACHLOROPHENE: (a) in preparations for the treatment of animals; or (b) for cosmetic use. HEXAZINONE except when included in Schedule 5. HEXYLOXYETHANOL except in preparations containing 10% or less of hexyloxyethanol. HYDRAMETHYLNON except when included in Schedule 5. HYDRAZINE. HYDROCHLORIC ACID (excluding its salts and derivatives) except: (a) when included in Schedule 5; or (b) in preparations for therapeutic use; or (c) in preparations containing 0.5% or less of hydrochloric acid (HCl). HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1% or less of hydrogen fluoride except when included in Schedule 5. HYDROGEN PEROXIDE (excluding its salts and derivatives) except: (a) when included in Schedule 5; or (b) in hair dye preparations containing 6% (20 volume) or less of hydrogen peroxide; or (c) in other preparations containing 3% (10 volume) or less of hydrogen peroxide. HYDROQUINONE except: (a) when included in Schedule 2 or 4; or (b) in preparations containing 10% or less of hydroquinone. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 237 HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1% or less of hydrosilicofluoric acid (H2SiF6) except when included in Schedule 5. HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE (including its salts) except in oxidative hair dye preparations containing 1.5% or less of hydroxyethyl-3,4-methylenedioxyaniline after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height. IMIDACLOPRID except: (a) when included in Schedule 5; or (b) in preparations containing 5% or less of imidacloprid. IMIDOCARB. IMINOCTADINE TRIALBESILATE. IMIPROTHRIN except: (a) when included in Schedule 5; or (b) in preparations containing 10% or less of imiprothrin. INDAZIFLAM. INDOXACARB (includes the R and S enantiomers) except when included in Schedule 5. INPYRFLUXAM. IODINE (excluding its salts, derivatives and iodophors) except: (a) when included in Schedule 2; or (b) in solid or semi-solid preparations containing 2.5% or less of available iodine. IODOPHORS except in preparations containing 1.5% or less of available iodine. 3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) except: (a) when included in Schedule 5; or (b) in aqueous preparations not for cosmetic use containing 10% or less of 3-iodo-2-propynyl butyl carbamate (Iodocarb); or (c) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3-iodo-2-propynyl butyl carbamate. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 238 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 IOXYNIL. IPCONAZOLE except when included in Schedule 5. IRON COMPOUNDS (excluding up to 1% of iron oxides when present as an excipient) for the treatment of animals except: (a) when included in Schedule 5; or (b) in liquid or gel preparations containing 0.1% or less of iron; or (c) in animal feeds or feed premixes. ISOCONAZOLE for the external treatment of animals. ISOCYANATES, free organic, boiling below 300° C, except in: (a) viscous polyurethane adhesives; or (b) viscous polyurethane sealants; containing not more than 0.7% of free organic isocyanates boiling below 300°C. ISOCYCLOSERAM. ISOEUGENOL except: (a) when included in Schedule 5; or (b) in preparations not intended for skin contact containing 10% or less of isoeugenol; or (c) in preparations intended for skin contact containing 0.02% or less of isoeugenol. ISOPYRAZAM. ISOTIANIL. LAMBDA-CYHALOTHRIN: (a) in aqueous preparations containing 25% or less of microencapsulated lambda-cyhalothrin; or (b) in emulsifiable granule formulations containing 25% or less lambda-cyhalothrin; or (c) in other preparations containing 1.6% or less of lambda-cyhalothrin; except when included in Schedule 5. LASALOCID except in animal feeds containing 100 mg/kg or less of antibiotic substances. LAURETH CARBOXYLIC ACIDS (excluding their salts and derivatives) except: (a) in leave-on preparations containing 1.5% or less of laureth carboxylic acids; or (b) in wash-off preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with a warning to the following effect: Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 239 IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or (c) in other preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with warnings to the following effect: (i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and (ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER. LAURYL ISOQUINOLINIUM BROMIDE. LAURYL SULFATE SALTS (excluding their derivatives) except: (a) in wash-off preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with a warning to the following effect: IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or (b) in leave-on preparations containing 1.5% or less of lauryl sulfates; or (c) in toothpaste and oral hygiene preparations containing 5% or less of lauryl sulfates; or (d) in other preparations for animal use containing 2% or less of lauryl sulfates; or (e) in other preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with warnings to the following effect: (i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and (ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER. LEAD COMPOUNDS except: (a) when included in, or expressly excluded from, Schedule 10; or (b) in preparations for cosmetic use containing 10 mg/kg or less of lead; or (c) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 25 mg/kg or less of lead; or (d) in ceramic glazes when labelled with the warning statement: CAUTION – Harmful if swallowed. Do not use on surfaces which contact food or drink; written in letters not less than 1.5 mm in height. LEPTOSPERMUM SCOPARIUM OIL (manuka oil) except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 240 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings; (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (e) in preparations containing 25% or less of Leptospermum scoparium oil. LEVAMISOLE for the treatment of animals except: (a) when included in Schedule 4 or 5; or (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole. LINDANE except when included in Schedule 2, 4 or 5. MAFENIDE when packed and labelled for the treatment of ornamental fish only. MALATHION except: (a) when included in Schedule 5; or (b) for human therapeutic use; or (c) in dust preparations containing 2% or less of malathion. MCPA except when included in Schedule 5. MCPB. MEBENDAZOLE for the treatment of animals except when included in Schedule 5. MECOPROP except when included in Schedule 5. MECOPROP-P. MEFLUIDIDE. MELALEUCA OIL (tea tree oil) except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 241 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (e) in preparations containing 25% or less of melaleuca oil. MELENGESTROL ACETATE when used as an animal feed additive. MELOXICAM in: (a) oral transmucosal preparations containing 1% or less of meloxicam for pre-surgical treatment and pain management in livestock during routine husbandry procedures; or (b) injectable vaccines containing bacterial antigens and 1% or less of meloxicam for single use in lambs undergoing husbandry procedures at marking. MENAZON. MERCAPTAMINE for cosmetic use except: (a) when included in Schedule 5; or (b) in preparations containing 1% or less of mercaptamine. MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations except: (a) when included in Schedule 5; or (b) in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid). 2-MERCAPTOETHANOL in preparations for use as insect lures. MERCURIC OXIDE for the treatment of animals, in preparations for ocular use. MERCUROCHROME for the treatment of animals, in preparations for topical use. METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 242 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 METALAXYL except when included in Schedule 5. METALDEHYDE except when included in Schedule 5. METHACRIFOS in preparations containing 60% or less of methacrifos. METHAM. METAMITRON. METHANOL (excluding its derivatives) except: (a) when included in Schedule 5; or (b) when included in Schedule 10; or (c) in preparations containing 2% or less of methanol. METHIOCARB in preparations containing 20% or less of methiocarb except when included in Schedule 5. METHOMYL in fly-baits containing 1% or less of methomyl and not less than 0.002% of denatonium benzoate as a bittering agent. 6-METHOXY-N2-METHYL-2,3-PYRIDINEDIAMINE except when used in oxidative or non- oxidative hair dyes at a concentration of 1% or less when the immediate container and primary pack are labelled with the following statements: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye. written in letters not less than 1.5 mm in height. 2-METHOXY-5-NITROPHENOL. METHYLCHLOROISOTHIAZOLINONE except: (a) in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off application containing 0.0015% or less of methylchloroisothiazolinone and methylisothiazolinone in total; or (b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylchloroisothiazolinone and methylisothiazolinone in total. METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10% or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure. METHYLDIBROMO GLUTARONITRILE except when in Schedule 10. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 243 METHYLENE BISTHIOCYANATE except in preparations containing 1% or less of methylene bisthiocyanate. METHYLEUGENOL except in preparations containing 1% or less of methyleugenol. METHYL ETHYL KETONE OXIME except: (a) in viscous silicone adhesives or viscous silicone sealants containing 2.5% or less of methyl ethyl ketone oxime; or (b) in other preparations containing 1% or less of methyl ethyl ketone oxime. p-METHYLAMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of p-methylaminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height. METHYL ISOTHIOCYANATE. METHYL METHACRYLATE (excluding its derivatives) except: (a) for cosmetic use; or (b) in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer. METHYL NEODECANAMIDE except in liquid preparations containing 2% or less of methyl neodecanamide. METHYLISOTHIAZOLINONE except: (a) in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off application containing 0.0015% or less of methylisothiazolinone; or (b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylisothiazolinone METHYLNORBORNYLPYRIDINE. N-METHYL-2-PYRROLIDONE except: (a) when included in Schedule 5; or (b) in preparations containing 25% or less of designated solvents. 2-METHYLRESORCINOL except: (a) in non-oxidative hair dye preparations containing 1.8% or less of 2-methylresorcinol when the immediate container and primary pack are labelled with the following statements: Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 244 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height; or (b) in oxidative hair dye preparations containing 1.8% or less of 2-methylresorcinol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letter not less than 1.5 mm in height. METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet CAS No. 548-62-9) and the following TRIARYLMETHANE DYES: (a) Acid Violet 49 (CAS No. 1694-09-3); (b) Ethyl Violet (CAS No. 2390-59-2); (c) Basic Blue 7 (CAS No. 2390-60-5); (d) Methylium, 4-(dimethylamino)phenylbis4-(ethylamino)-3-methylphenyl-, acetate (CAS No. 72102-55-7); except when included in Schedule 4 or Schedule 10. METHYL SALICYLATE except: (a) when included in Schedule 5; or (b) in preparations for therapeutic use; or (c) in preparations containing 5% or less of methyl salicylate. METOFLUTHRIN except when included in Schedule 5. METOSULAM. METRAFENONE except when included in Schedule 5. METRIBUZIN. MICONAZOLE for the external treatment of animals. MILBEMECTIN except when included in Schedule 5. MOMFLUOROTHRIN except in preparations containing 0.2% or less of momfluorothrin. MONENSIN: (a) in animal feed premixes containing 12.5% or less of antibiotic substances; or (b) in stockfeed supplements, blocks or licks containing 0.75% or less of antibiotic substances. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 245 MONOETHANOLAMINE (excluding its salts and derivatives) except: (a) when included in Schedule 4 or 5; or (b) in preparations containing 5% or less of monoethanolamine. MORANTEL except: (a) when included in Schedule 5; or (b) in preparations containing 10% or less of morantel. MOXIDECTIN: (a) in preparations for external use containing 2.5% or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or (b) in preparations for external use containing 2% or less of moxidectin for the treatment of animals; or (c) in preparations for internal use containing 10% or less of moxidectin for the treatment of sheep or cattle; except when included in Schedule 5. MSMA in herbicide or defoliant preparations containing 10% or less of MSMA. NALED except when included in Schedule 5. NAPHTHALENE (excluding its derivatives) except in liquid hydrocarbons. 1,5-NAPHTHALENEDIOL except: (a) in non-oxidative hair dye preparations containing 1% or less of 1,5-naphthalenediol when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height; or (b) in oxidative hair dye preparations containing 1% or less of 1,5-naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 246 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 2,7-NAPHTHALENEDIOL except: (a) in non-oxidative hair dye preparations containing 1% or less of 2,7-naphthalenediol when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height; or (b) in oxidative hair dye preparations containing 1% or less of 2,7-naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height. 1-NAPHTHOL except in hair dye preparations containing 1% or less of 1-naphthol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height. NAPHTHALOPHOS in preparations containing 80% or less of naphthalophos. NARASIN in animal feed premixes containing 12% or less of narasin. NETOBIMIN for the treatment of animals except when included in Schedule 5. NICKEL SULFATE. NIMIDANE in preparations containing 25% or less of nimidane. NITENPYRAM except in divided preparations containing 100 mg or less of nitenpyram. NITRIC ACID (excluding its salts and derivatives) except: Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 247 (a) when included in Schedule 5; or (b) in preparations containing 0.5% or less of nitric acid (HNO3). NITROBENZENE except: (a) in solid or semi-solid polishes; or (b) in soaps containing 1% or less of nitrobenzene; or (c) in other preparations containing 0.1% or less of nitrobenzene. 3-NITRO-p-HYDROXYETHYLAMINOPHENOL except (a) in non-oxidative hair dye preparations containing 1.85% or less of 3-nitro-p-hydroxyethylaminophenol after mixing when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height; or (b) in oxidative hair dye preparations containing 3% or less of 3-nitro-p-hydroxyethylaminophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height. NITROPHENOLS, ortho, meta and para, except when separately specified in these Schedules. NITROPRUSSIDES in preparations containing 2.5% or less of nitroprussides except when included in Schedule 4. NITROUS OXIDE except when included in Schedule 4. NITROXYNIL. NONOXINOL 9 except: (a) when included in Schedule 5; or (b) in preparations containing 25% or less of nonoxinol 9 when labelled with the statements: Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 248 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (i) IRRITANT; and (ii) Avoid contact with eyes; or (c) in preparations containing 12.5% or less of nonoxinol 9; or (d) in preparations for human use. 1-OCTEN-3-OL except in preparations containing 5% or less of 1-octen-3-ol. OCTHILINONE except in paints, jointing compounds and sealants containing 1% or less of octhilinone calculated on the non-volatile content. N-(N-OCTYL)-2-PYRROLIDONE except: (a) when included in Schedule 5; or (b) in preparations containing 25% or less of designated solvents. OLAQUINDOX except in preparations containing 10% or less of olaquindox. N-OLEYL-1,3-DIAMINOPROPANE. OMETHOATE in preparations containing 30% or less of omethoate except when included in Schedule 5. OXADIAZON. OXALIC ACID except (a) in dental care preparations, including mouthwashes, containing 3% or less of soluble salts of oxalic acid; or (b) its insoluble salts. OXYCLOZANIDE. PAECILOMYCES LILACINUS STRAIN 251. PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde except: (a) for human therapeutic use; or (b) in oral hygiene preparations; or (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or (d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement: PROTECT CUTICLES WITH GREASE OR OIL; or (e) in all other cosmetic preparations; or (f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement: CONTAINS FORMALDEHYDE. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 249 PARATHION-METHYL in aqueous preparations containing 45% or less of microencapsulated parathion-methyl. PARBENDAZOLE. PEBULATE. PENNYROYAL OIL except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (c) in preparations containing 4% or less of D-pulegone. PENTACHLOROPHENOL in preparations containing 1.5% or less of pentachlorophenol. PERACETIC ACID except when included in Schedule 5. PERFLUIDONE. PERMANGANATES except potassium permanganate in aqueous solutions containing 1% or less of potassium permanganate. PERMETHRIN except: (a) when included in Schedule 4 or 5; or (b) in preparations for human therapeutic use containing 5% or less of permethrin; or (c) in preparations containing 2% or less of permethrin. 2-PHENOXYETHANOL except: (a) in cosmetic preparations containing 1% or less of 2-phenoxyethanol; or (b) in other preparations containing 15% or less of 2-phenoxyethanol. PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, except: (a) when separately specified in these Schedules; or (b) in preparations containing 1% or less of phenols, and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol. PHENOTHIAZINE (excluding its derivatives) except in preparations containing 10% or less of phenothiazine. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 250 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PHENOXYMETHYL OXIRANE. PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives not elsewhere specified in these Schedules: (a) in preparations packed and labelled for photographic purposes; or (b) in preparations packed and labelled for testing water except tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”; or (c) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height; or (d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement: WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height. PHENYL METHYL PYRAZOLONE except when used in hair dye and eyebrow/eyelash preparations at a concentration of 0.25% or less after mixing for use when the immediate container and primary pack are labelled with warning statements to the following effect: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. written in letters not less than 1.5 mm in height. PHOSALONE. PHOSMET. PHOSPHORIC ACID (excluding its salts and derivatives) except: (a) when included in Schedule 5; or (b) in preparations containing 15% or less of phosphoric acid (H3PO4); or (c) in solid or semi-solid preparations; or Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 251 (d) in professional dental kits. PHOXIM. o-PHTHALALDEHYDE except when included in Schedule 5. PICRAMIC ACID including its salts (excluding other derivatives) except when used in hair dye products at a concentration of 0.6% or less of picramic acid after mixing for use when the immediate container and primary pack are labelled with the following statements: (a) KEEP OUT OF REACH OF CHILDREN; and (b) WARNING ‒ This product contains ingredients which may cause skin allergy to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height. PINDONE. PINE OILs when packed and labelled as a herbicide except when included in Schedule 5. PINOXADEN except when included in Schedule 5. PIPEROPHOS. PIRIMICARB except when included in Schedule 5. PIRIMIPHOS-ETHYL. PIRIMIPHOS-METHYL. POLIHEXANIDE except: (a) in cosmetic preparations containing 0.3% or less of polihexanide; or (b) when packed and labelled for therapeutic use; or (c) in other preparations containing 5% or less of polihexanide. POLIXETONIUM SALTS except: (a) when included in Schedule 5; or (b) in preparations containing 1% or less of polixetonium salts. POTASSIUM AZELOYL DIGLYCINATE except in preparations for cosmetic use containing 1% or less of potassium azeloyl diglycinate. POTASSIUM BROMATE except in preparations containing 0.5% or less of potassium bromate. POTASSIUM CYANATE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 252 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 POTASSIUM HYDROXIDE (excluding its salts and derivatives) except: (a) when included in Schedule 5 or Schedule 10; or (b) in preparations containing 5% or less of potassium hydroxide being: (i) solid preparations, tHE pH of which in a 10 g/L aqueous solution is 11.5 or less; or (ii) liquid or semi-solid preparations, tHE pH of which is 11.5 or less. POTASSIUM NITRITE in preparations containing 40% or less of potassium nitrite except: (a) when included in Schedule 5; or (b) in preparations containing 0.5% or less of potassium nitrite; or (c) when present as an excipient in preparations for therapeutic use; or (d) in aerosols containing 2% or less of potassium nitrite. POTASSIUM PEROXOMONOSULFATE TRIPLE SALT except: (a) when included in Schedule 5; or (b) in solid orthodontic device cleaning preparations, tHE pH of which as an “in-use” aqueous solution is 2.5 or more, but not more than 11.5; or (c) in preparations containing 5% or less of potassium peroxomonosulfate triple salt being: (i) solid preparations, tHE pH of which in a 10 g/L aqueous solution is 2.5 or more; or (ii) liquid or semi-solid preparations, tHE pH of which is 2.5 or more. POTASSIUM PERSULFATE in hair preparations. PRALLETHRIN (cis:trans=20:80) except: (a) when included in Schedule 5; or (b) in insecticidal mats containing 1% or less of prallethrin. PROCHLORAZ. PROFENOFOS. PROMACYL. PROPACHLOR. PROPARGITE. PROPETAMPHOS. PROPICONAZOLE except when included in Schedule 5. PROPINEB. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 253 PROPIONIC ACID (excluding its salts and derivatives) except: (a) when included in Schedule 5; or (b) in preparations containing 30% or less of propionic acid; or (c) for therapeutic use. PROPOXUR except when included in Schedule 5. n-PROPYL ALCOHOL except: (a) when included in Schedule 5; or (b) in preparations containing 5% or less of n-propyl alcohol; or (c) in preparations for cosmetic or therapeutic use other than in spray form. PROQUINAZID. PROSULFOCARB. PROSULFURON. PROTHIOFOS. D-PULEGONE except in preparations containing 4% or less of d-pulegone. PYRACLOFOS. PYRAZOPHOS. PYRIDABEN except when included in Schedule 5. PYRIDALYL. PYRIDATE. PYRIPROLE. PYRITHIONE COPPER. PYRITHIONE ZINC except: (a) when included in Schedule 2 or 5; or (b) for human use in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels; or (c) in semi-solid hair preparations for animal use; or (d) in shampoos for animal use containing 2% or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with water”; or (e) when immobilised in solid preparations containing 0.5% or less of pyrithione zinc; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 254 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (f) in paints, jointing materials or sealants containing 0.1% or less of pyrithione zinc calculated on the non-volatile content. PYRIOFENONE except when included in Schedule 5. PYROXASULFONE. PYROXSULAM. QUATERNARY AMMONIUM COMPOUNDS except: (a) when separately specified in these Schedules; or (b) when included in Schedule 5; or (c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or (d) in preparations containing 5% or less of such quaternary ammonium compounds. QUININE in cosmetic preparations except: (a) in rinse-off hair preparations containing 0.5% or less of quinine calculated as free base; or (b) in leave-on hair preparations containing 0.2% or less of quinine calculated as free base. QUINOLINE and its salts (excluding other derivatives). QUIZALOFOP ETHYL. QUIZALOFOP-p-ETHYL except when included in Schedule 5. QUIZALOFOP-p-TEFURYL. RESCALURE for agricultural use except when enclosed in a vapour releasing device which in normal use prevents access to its contents. RESMETHRIN except when included in Schedule 5. RESORCINOL except: (a) in preparations for human therapeutic use; or (b) in oxidative hair dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 255 written in letters not less than 1.5 mm in height; or (c) in oxidative eyelash and eyebrow dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height; or (d) in hair lotions/shampoo products containing 0.5% or less of resorcinol when the immediate container and primary pack are labelled with the following statement: WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals; written in letters not less than 1.5 mm in height. ROTENONE except in solid or semi-solid preparations containing 2% or less of rotenone. SAFROLE except: (a) for internal use; or (b) in other preparations containing 1% or less of safrole. SAGE OIL (Dalmatian) except: (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) NOT TO BE TAKEN; or (c) in preparations containing 4% or less of thujone. SALINOMYCIN in animal feed premixes containing 12% or less of antibiotic substances. SAROLANER except when included in Schedule 5. SASSAFRAS OIL except: (a) for internal use; or (b) in other preparations containing 1% or less of safrole. SELENIUM: (a) in preparations containing 2.5% or less of selenium when packed and labelled: Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 256 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (i) for the blueing of gun barrels; or (ii) for photographic purposes; or (iii) for the colouring of lead or lead alloys; or b) in coated granules containing 1% or less of selenium for application to pasture except in fertilisers containing 200 g/tonne or less of selenium; or (c) for the treatment of animals: (i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5% or less of selenium; or (ii) in animal feed premixes containing 2% or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium; or (iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or (iv) as barium selenate in preparations for injection containing 5% or less of selenium. SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5% or less of antibiotic substances. SILICOFLUORIDES except: (a) when included in Schedule 5; or (b) in preparations containing 15 mg/kg or less of fluoride ion. SILVER NITRATE except: (a) when included in or expressly excluded from Schedule 2; or (b) in preparations containing 1% or less of silver. SINBIOALLETHRIN except: (a) when included in Schedule 5; or (b) in preparations containing 1% or less of sinbioallethrin. SODIUM ALUMINATE (excluding its salts and derivatives) except: (a) in solid preparations, tHE pH of which in a 10 g/L aqueous solution is 11.5 or less; or (b) in liquid preparations, tHE pH of which is 11.5 or less. SODIUM BROMATE except in preparations containing 0.5% or less of sodium bromate. SODIUM HYDROXIDE (excluding its salts and derivatives) except: (a) when included in Schedule 5 or Schedule 10; or (b) in preparations containing 5% or less of sodium hydroxide being: (i) solid preparations, tHE pH of which in a 10 g/L aqueous solution is 11.5 or less; or Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 257 (ii) liquid or semi-solid preparations, tHE pH of which is 11.5 or less. SODIUM NITRITE: (a) in preparations containing 15% or less of sodium nitrite except: (i) when included in Schedule 2 or 5; or (ii) in preparations containing 0.5% or less of sodium nitrite; or (iii) when present as an excipient in preparations for therapeutic use; or (iv) in aerosols containing 2% or less of sodium nitrite; or (b) for use in closed-loop water treatment systems (products). SODIUM PERCARBONATE (CAS No. 15630-89-4) except: (a) when included in Schedule 5; or (b) in preparations containing 15% or less of sodium percarbonate. SODIUM PERSULFATE: (a) in hair preparations; or (b) in products for the treatment of water for swimming pools and spas. SODIUM SULFIDE in preparations for use as insect lures. SPIROPIDION. SPIROTETRAMAT. SPIROXAMINE. SULCOFURON in preparations for the treatment of carpets during manufacture. SULFAMIC ACID (excluding its salts and derivatives) except when included in Schedule 5. SULFLURAMID. SULFOXAFLOR except when included in Schedule 5. SULFURIC ACID (excluding its salts and derivatives) except: (a) in fire extinguishers; or (b) in preparations containing 0.5% or less of sulfuric acid (H2SO4). SULFURYL FLUORIDE. SULPROFOS. 2,4,5-T. N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES. TAR ACIDS distilling within the range 230-290°C inclusive. Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 258 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TCMTB (2-[thiocyanomethylthio]benzothiazole). TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) except when included in Schedule 5. TEBUFENPYRAD. TEBUTHIURON. TEMEPHOS except when in Schedule 5. TERBUTHYLAZINE except in preparations containing 5% or less of terbuthylazine. TERPENES, CHLORINATED. TESTOSTERONE in implant preparations for use in animals. TETRACHLOROETHYLENE except: (a) when included in Schedule 2 or 5; or (b) in preparations containing 6% or less of tetrachloroethylene when absorbed into an inert solid; or (c) in preparations for the treatment of animals. TETRACONAZOLE except when included in Schedule 5. TETRADIFON. TETRAHYDROFURFURYL ALCOHOL (excluding its derivatives). 2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2% or less of 2,2',6,6'-tetraisopropyl-diphenyl-carbodiimide. TETRAMISOLE in preparations for the treatment of animals. THIACLOPRID. THIAMETHOXAM except when included in Schedule 5. THIAZAFLURON. THIODICARB except when included in Schedule 5. THIOMETON. THIOPHANATE-METHYL except when included in Schedule 5. THIOUREA AND ALKYL THIOUREAS except: (a) when separately specified in these Schedules; or (b) for therapeutic use. THIRAM except in paint containing 0.5% or less of thiram. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 259 THUJONE except in preparations containing 4% or less of thujone. THYMOL when packed and labelled for use as a pesticide. TIGOLANER except when in Schedule 5. TOLUENE (excluding its derivatives) except in preparations containing 50% or less of toluene or toluene and xylene. TOLUENEDIAMINES not elsewhere specified in these Schedules: (a) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements: (i) KEEP OUT OF REACH OF CHILDREN; and (ii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye; written in letters not less than 1.5 mm in height; or (b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement: WARNING – This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use; written in letters not less than 1.5 mm in height; or (c) in nail polish preparations containing 2,5-toluenediamine except when labelled “avoid contact with skin”. TOLYLFLUANID. TRANSFLUTHRIN except: (a) in preparations containing 1% or less of transfluthrin; or (b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge. TRIADIMEFON except: (a) when included in Schedule 5; or (b) in fertilisers containing 5 g/kg or less of triadimefon. TRICHLORFON except metrifonate included in Schedule 4. TRICHLOROACETIC ACID except: (a) when included in Schedule 4 or 5; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 6 Poisons 260 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) in human dermal preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts. TRICHLOROETHYLENE except when included in Schedule 4. TRICHLOROPHENOL. TRICLABENDAZOLE except in preparations containing 20% or less of triclabendazole. TRICLOPYR. TRICLOSAN in cosmetic preparations for human use containing more than 0.3% of triclosan. TRIDEMORPH. TRIETHYL PHOSPHATE. TRIFLUOROMETHANESULFONIC ACID. TRINITROPHENOL (excluding its derivatives) except: (a) in preparations for human therapeutic use; or (b) in preparations containing 5% or less of trinitrophenol. TRISODIUM NITRILOTRIACETATE except in preparations containing 20% or less of trisodium nitrilotriacetate. VAMIDOTHION. VINYL ACETATE MONOMER (excluding its derivatives) except: (a) in preparations for therapeutic use; or (b) in cosmetic preparations containing 0.01% or less of vinyl acetate as residual monomer in a polymer; or (c) in other preparations containing 1% or less of vinyl acetate. WARFARIN except when included in Schedule 4 or 5. XYLENE (excluding its derivatives) except in preparations containing 50% or less of xylene or xylene and toluene. ZERANOL in ear implants for use as a growth promotant in steer cattle. ZETA-CYPERMETHRIN in preparations containing 10% or less of zeta-cypermethrin. ZINC BORATE (excluding its derivatives) for use as an agricultural chemical. ZINC CHLORIDE except: (a) when included in Schedule 2; or (b) in preparations containing 5% or less of zinc chloride. Authorised Version F2024L00589 registered 30/05/2024 Poisons Schedule 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 261 ZINC para-PHENOLSULFONATE except in preparations containing 5% or less of zinc para-phenolsulfonate. ZINC LACTATE in toothpaste except in toothpaste preparations containing 2.5% or less of zinc lactate and labelled with the statement: Not recommended for children under twelve years of age. ZINC SULFATE except: (a) when included in or expressly excluded from Schedule 4; or (b) in other preparations containing 5% or less of zinc sulfate. ZIRAM in granular preparations. Authorised Version F2024L00589 registered 30/05/2024 Schedule 7 Dangerous poisons 262 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 7—Dangerous poisons Note: See section 16, subsection 54(4) and sections 55, 56, 62 and 65. ABAMECTIN except when included in Schedule 5 or 6. ACIBENZOLAR-S-METHYL. ACRIFLAVINIUM CHLORIDE for veterinary use except when in Schedule 5. ACROLEIN. ACRYLONITRILE. ALACHLOR. ALDICARB. ALDOXYCARB. ALLYL ALCOHOL except: (a) in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl ester; or (b) when separately specified in these Schedules. ALPHA-CYPERMETHRIN except when included in Schedule 5 or 6. AMINOACRIDINE for veterinary use except when included in Schedule 5. AMINOCARB except when included in Schedule 6. 2-AMINO-5-METHYLPHENOL except when included in Schedule 10. 4-AMINOPROPIOPHENONE. 4-AMINOPYRIDINE except when included in Schedule 4. AMITON. ARPRINOCID. ARSENIC except: (a) when separately specified in this Schedule; or (b) when included in Schedule 4 or 6; or (c) as selenium arsenide in photocopier drums; or (d) as 10,10'-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic; or Authorised Version F2024L00589 registered 30/05/2024 Dangerous poisons Schedule 7 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 263 (e) as 10,10'-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles: (i) in contact with foodstuffs, animal feeds or potable water; or (ii) of clothing and footwear in contact with the skin; or (iii) used as infant wear; or (iv) intended for use as packaging materials; or (f) in animal feeds containing 75 g/tonne or less of arsenic; or (g) in paints containing 0.1% or less of arsenic calculated on the non-volatile content of the paint. AZAFENIDIN. AZINPHOS-ETHYL. AZINPHOS-METHYL. AZOCYCLOTIN. AZO DYES that are derivatives by diazotisation of any of the following substances: (a) p-aminoazobenzene (CAS No. 60-09-3); (b) o-aminoazotoluene (CAS No. 97-56-3); (c) o-anisidine (CAS No. 90-04-0); (d) p-chloroaniline (CAS No. 106-47-8); (e) 4-chloro-o-toluidine (CAS No. 95-69-2); (f) 2,4-diaminoanisole (CAS No. 615-05-4); (g) 6-methoxy-m-toluidine (p-cresidine) (CAS No. 120-71-8); (h) 4,4-methylenedianiline (CAS No. 101-77-9); (i) 2-naphthylamine (CAS No. 91-59-8); (j) 5-nitro-o-toluidine (CAS No. 99-55-8); (k) 2,4-toluenediamine (CAS No. 95-80-7); (l) o-toluidine (CAS No. 95-53-4); (m) 2,4,5-trimethylaniline (CAS No. 137-17-7); except for BASIC RED 76 (CAS No. 68391-30-0) when included in Schedule 6. BENDIOCARB except when included in Schedule 5 or 6. BENOMYL except in paints containing 0.5% or less of benomyl. BENZENE (excluding its derivatives) except: (a) preparations containing 15 mL/L or less of benzene; or Authorised Version F2024L00589 registered 30/05/2024 Schedule 7 Dangerous poisons 264 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (b) petrol containing 50 mL/L or less of benzene. BENZIDINE-BASED AZO DYES being: (a) 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[N-(4-chlorophenyl)-3-oxobutanamide] (CAS No. 94249-03-3); or (b) Acid Red 85 (Acid Fast Red A): 1,3-Naphthalenedisulfonic acid, 7-hydroxy-8-[[4'-[[4-[[(4-methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'-biphenyl]-4 yl]azo]-, disodium salt (CAS No. 3567-65-5); or (c) C.I Acid Black 29: (CAS No. 12217-14-0); or (d) C.I. Direct Orange 1: (CAS No. 54579-28-1); or (e) Direct Black 38: 2,7-Naphthalenedisulfonic acid, 4-amino-3-[[4'-[(2,4-diaminophenyl)azo][1,1'-biphenyl]-4-yl]azo]-5-hydroxy-6-(p henylazo)-, disodium salt (CAS No. 1937-37-7); or (f) Direct Blue 2: 2,7-Naphthalenedisulfonic acid, 5-amino-3-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4 yl]azo]-4-hydroxy-, trisodium salt (CAS No. 2429-73-4); or (g) Direct Blue 6: 2,7-Naphthalenedisulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[5-amino-4-hydroxy-, tetrasodium salt (CAS No. 2602-46-2); or (h) Direct Brown 2: 5-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo] 2-hydroxy- benzoic acid disodium salt (CAS No. 2429-82-5); or (i) Direct Brown 95: Cuprate(2-), [5-[[4'-[[2,6-dihydroxy-3-[(2-hydroxy-5-sulfophenyl)azo]phenyl]azo][1,1'-bipheny l]-4-yl]azo]-2-hydroxybenzoato(4-)]-, disodium salt (CAS No. 16071-86-6); or (j) Direct Green 1: 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-6-(phe nylazo)-, disodium salt (CAS No. 3626-28-6); or (k) Direct Green 6: 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-6-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-3-[(4 nitrophenyl)azo]-, disodium salt (CAS No. 4335-09-5); or (l) Direct Red 28 (Congo Red): 1-Naphthalenesulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[4-amino-, disodium salt (CAS No. 573-58-0); or (m) Direct Red 37: 1,3-Naphthalenedisulfonic acid, 8-[[4'-[(4-ethoxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-7-hydroxy-, disodium salt (CAS No. 3530-19-6). BENZIDINE-CONGENER (3,3'-disubstituted) AZO DYES. BETACYFLUTHRIN except when included in Schedule 5 or 6. BIFENTHRIN except: (a) when included in Schedule 6; or Authorised Version F2024L00589 registered 30/05/2024 Dangerous poisons Schedule 7 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 265 (b) in preparations containing 0.5% or less of bifenthrin. BIFLUORIDES (including ammonium, potassium and sodium salts) except when included in Schedule 5 or 6. BORON TRIFLUORIDE except when included in Schedule 5 or 6. BRODIFACOUM except when included in Schedule 6. BROMADIOLONE except when included in Schedule 6. BROMETHALIN except when included in Schedule 6. BROMINE (excluding its salts and derivatives). BRUCINE except in alcohol containing 0.02% or less of brucine as a denaturant. CACODYLIC ACID except: (a) when included in Schedule 6; or (b) in animal feeds containing 75 g/tonne or less of arsenic. CADUSAFOS except when included in Schedule 6. CALCIFEROL for use as a rodenticide except when included in Schedule 6. CAPTAFOL. CARBADOX. CARBENDAZIM except in paints, jointing compounds and sealants containing 0.1% or less of carbendazim. CARBOFURAN. CARBON TETRACHLORIDE except in chlorinated rubber based paint containing 1% or less of carbon tetrachloride. CARBONYL SULFIDE when packed and labelled for use as a fumigant. CARBOPHENOTHION. CARBOSULFAN. CHLORDECONE. CHLORDIMEFORM. CHLORFENAPYR except when included in Schedule 5 or 6. CHLORFENVINPHOS. Authorised Version F2024L00589 registered 30/05/2024 Schedule 7 Dangerous poisons 266 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CHLORINE (excluding its salts and derivatives). CHLORHEXIDINE except: (a) when included in Schedule 5 or 6; or (b) in preparations containing 1% or less of chlorhexidine; or (c) in solid preparations. CHLOROMETHIURON. 5-CHLORO-3-METHYL-4-NITROPYRAZOLE. 4-CHLORO-o-TOLUIDINE. CHLOROPICRIN except when included in Schedule 6. CHLORTHIOPHOS. COLECALCIFEROL for use as a rodenticide. COUMAPHOS except when included in Schedule 6. COUMATETRALYL except when included in Schedule 5 or 6. CREOSOTE derived from coal. CREOSOTE derived from beechwood. CYANIDES, metallic except: (a) ferricyanides; or (b) ferrocyanides; or (c) when separately specified in these Schedules. CYANOGEN. CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) except when included in Schedule 6. CYHALOTHRIn (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50. CYHEXATIN. DELTAMETHRIN except: (a) when included in Schedule 5 or 6; or (b) in factory prepared mosquito nets containing 1% or less of deltamethrin; or (c) in preparations containing 0.1% or less of deltamethrin. Authorised Version F2024L00589 registered 30/05/2024 Dangerous poisons Schedule 7 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 267 DEMETON. DEMETON-O-METHYL. DEMETON-S-METHYL. DIALIFOS. 4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline). 1,2-DIBROMO-3-CHLOROPROPANE. 1,3-DICHLOROPROPENE except in biocidal preparations containing 0.3% or less of 1,3-dichloropropene. DICHLORVOS except when included in Schedule 5 or 6. DICROTOPHOS. DIFENACOUM except when included in Schedule 6. DIFETHIALONE except when included in Schedule 6. DIMEFOX. 4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine). DIMETHYL SULFATE. DIMETILAN. DINITROCRESOLS except when included in Schedule 4 or 6. DINITROPHENOLS except when included in Schedule 4, 6 or 10. DINOCAP. DINOSEB. DIQUAT except when included in Schedule 6. DISULFOTON except when included in Schedule 6. DORAMECTIN except when included in Schedule 5 or 6. DSMA except when included in Schedule 6. EMAMECTIN except when included in Schedule 5 or 6. ENDOSULFAN except when included in Schedule 6. ENDOTHAL except when included in Schedule 6. Authorised Version F2024L00589 registered 30/05/2024 Schedule 7 Dangerous poisons 268 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ENDRIN. EPICHLOROHYDRIN. EPIDERMAL GROWTH FACTOR except in preparations for human therapeutic use. EPRINOMECTIN except when included in Schedule 5 or 6. ETACONAZOLE. ETHALFLURALIN. ETHION. ETHOPROPHOS except when included in Schedule 6. 2-ETHOXYETHANOL and its acetates except in preparations containing 0.5% or less of 2-ethoxyethanol. ETHYLENE DIBROMIDE. ETHYLENE OXIDE. FAMPHUR except when included in Schedule 6. FENAMIPHOS except when included in Schedule 6. FENOXACRIM except: (a) when included in Schedule 6; or (b) in treated carpets. FENSULFOTHION. FENTHION except when included in Schedule 5 or 6. FENTHION-ETHYL. FLOCOUMAFEN except when included in Schedule 6. FLUCOFURON except: (a) when included in Schedule 6; or (b) in treated carpets. FLUCYTHRINATE. FLUMIOXAZIN except when included in Schedule 6. FLUOROACETAMIDE. FLUOROACETIC ACID. Authorised Version F2024L00589 registered 30/05/2024 Dangerous poisons Schedule 7 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 269 FOLPET. FORMETANATE. FOSTHIAZATE. FURATHIOCARB except when included in Schedule 5. GAMMA-CYHALOTHRIN except when included in Schedule 5. HALOFUGINONE except when included in Schedule 4. HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS. HCB. HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C except: (a) when in solid polymers; or (b) when containing 1% or less of total polycyclic aromatic compounds as measured by IP 346; or (c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95. HYDROCYANIC ACID except: (a) when included in Schedule 4; or (b) its salts and derivatives other than cyanides separately specified in this Schedule. HYDROFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6. HYDROGEN SULFIDE. HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6. IODOMETHANE. ISOCARBOPHOS. ISOFENPHOS. ISOPROTURON. IVERMECTIN except when included in Schedule 4 or 5. LAMBDA-CYHALOTHRIN except when included in Schedule 5 or 6. LEPTOPHOS. Authorised Version F2024L00589 registered 30/05/2024 Schedule 7 Dangerous poisons 270 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 LITHIUM PERFLUOROOCTANE SULFONATE except in sealed bait stations containing 1% or less of lithium perfluorooctane sulfonate. MADURAMICIN except: (a) when included in Schedule 5; or (b) in animal feeds containing 5 mg/kg or less of antibiotic substances. MALACHITE GREEN for veterinary use except when included in Schedule 5. MAZIDOX. MECARBAM. 2-METHOXYETHANOL and its acetates except in preparations containing 0.5% or less of 2-methoxyethanol. MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes. MERCURY except: (a) when separately specified in this Schedule; or (b) when included in Schedule 2, 4 or 6; or (c) in preparations containing 0.01% or less of mercury in organic form as a preservative; or (d) mercury (metallic) in scientific instruments; or (e) dental amalgams; or (f) in a sealed device, for therapeutic use, which prevents access to the mercury. METHACRIFOS except when included in Schedule 6. METHAMIDOPHOS. METHAPYRILENE. METHAZOLE. METHIDATHION. METHIOCARB except when included in Schedule 5 or 6. METHOMYL except when included in Schedule 6. METHOXYETHYLMERCURIC ACETATE. METHOXYETHYLMERCURIC CHLORIDE. METHYL BROMIDE. Authorised Version F2024L00589 registered 30/05/2024 Dangerous poisons Schedule 7 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 271 METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL except: (a) when included in Schedule 6; or (b) when used in laboratory analysis; or (c) when packed for industrial use in containers with a nominal capacity of 100 L or more. 4,4'-METHYLENEBIS[2-CHLOROANILINE] (MOCA). METHYLENE BLUE for veterinary use except when included in Schedules 4 or 5. MEVINPHOS. MIPAFOX. MIREX. MOLINATE. MONOCROTOPHOS. MOXIDECTIN except when included in Schedule 4, 5 or 6. MSMA except when included in Schedule 6. NAPHTHALOPHOS except when included in Schedule 6. NICOTINE except: (a) when included in Schedule 4; or (b) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tobacco smoking or nicotine vaping; or (c) in tobacco prepared and packed for smoking. NIMIDANE except when included in Schedule 6. NITROFEN. NITROPRUSSIDES except when included in Schedule 4 or 6. 2-NITROTOLUENE. OMETHOATE except when included in Schedule 5 or 6. OXAMYL. OXYDEMETON METHYL. PARAQUAT. Authorised Version F2024L00589 registered 30/05/2024 Schedule 7 Dangerous poisons 272 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PARATHION. PARATHION-METHYL except when included in Schedule 6. PENTACHLOROPHENOL except when included in Schedule 6. PHENYLMERCURIC ACETATE except in preparations containing 0.01% or less of mercury as a preservative. PHORATE. PHOSFOLAN. PHOSPHIDES, METALLIC. PHOSPHINE. PHOSPHORUS, YELLOW (excluding its salts and derivatives). POTASSIUM NITRITE except: (a) when included in Schedule 5 or 6; or (b) in preparations containing 0.5% or less of potassium nitrite; or (c) when present as an excipient in preparations for therapeutic use; or (d) in aerosols containing 2% or less of potassium nitrite. PROCYMIDONE. PROPYLENE OXIDE. PYRINURON. QUININE for veterinary use except when included in Schedule 5. SAFLUFENACIL except when included in Schedule 5. SCHRADAN. SELENIUM except: (a) when included in Schedule 6; or (b) as selenium arsenide in photocopier drums; or (c) in preparations for therapeutic use other than: (i) drench concentrates containing 2.5% or less of selenium; or (ii) pour-on preparations containing 0.5% or less of selenium; or (d) in paints or tinters containing 0.1% or less of selenium calculated on the non-volatile content of the paint or tinter; or (e) in fertilisers containing 200 g/tonne or less of selenium. Authorised Version F2024L00589 registered 30/05/2024 Dangerous poisons Schedule 7 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 273 SEMDURAMICIN except: (a) when included in Schedule 6; or (b) in animal feeds containing 25 mg/kg or less of antibiotic substances. SODIUM NITRITE except: (a) when included in Schedule 2, 5 or 6; or (b) in preparations containing 0.5% or less of sodium nitrite; or (c) when present as an excipient in preparations for therapeutic use; or (d) in aerosols containing 2% or less of sodium nitrite. STRYCHNINE except when included in Schedule 4. SULCOFURON except: (a) when included in Schedule 6; or (b) in treated carpets. SULFENTRAZONE. SULFOTEP. TEFLUTHRIN except when included in Schedule 5. TEPP. TERBUFOS. TETRACHLOROETHANE. 2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE except when included in Schedule 6. THALLIUM. THIOFANOX. TIN ORGANIC COMPOUNDS, being dialkyl, trialkyl and triphenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl except: (a) when separately specified in this Schedule; or (b) in plastics; or (c) in semi-solid sealants, adhesives or elastomers containing 1% or less of the dialkyl, trialkyl or triphenyl tin component; or (d) in paint containing 1% or less of such compounds calculated as tin in the non-volatile content of the paint. o-TOLIDINE except in solid-state diagnostic therapeutic reagents. Authorised Version F2024L00589 registered 30/05/2024 Schedule 7 Dangerous poisons 274 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TRIAMIPHOS. TRIAZBUTIL. TRIBUFOS (S,S,S-tributylphosphorotrithioate). VINCLOZOLIN. VINYL CHLORIDE. ZETA-CYPERMETHRIN except when included in Schedule 6. ZIRAM except when included in Schedule 6. Authorised Version F2024L00589 registered 30/05/2024 Controlled drugs Schedule 8 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 275 Schedule 8—Controlled drugs Note 1: See paragraph 7(b), sections 16, 17, 28, 31, 50 and subsection 57(1). Note 2: Substances marked # are listed in Appendix D. ACETYLDIHYDROCODEINE. ACETYLMETHADOL. ACETYLMORPHINES. ALFENTANIL. ALPHACETYLMETHADOL. ALPHAPRODINE. # ALPRAZOLAM. AMFETAMINE. AMOBARBITAL except when included in Schedule 4. ANILERIDINE. BENZYLMORPHINE. BEZITRAMIDE. BUPRENORPHINE. BUTOBARBITAL. BUTORPHANOL. # CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when: (a) cultivated or produced, or in products manufactured1, in accordance with the Narcotic Drugs Act 1967; and/or (b) for use in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or (c) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or (d) in therapeutic goods supplied in accordance with the Act; except: 1 “Cultivation”, “production” and “manufacture” have the same meaning as in the Narcotic Drugs Act 1967 Authorised Version F2024L00589 registered 30/05/2024 Schedule 8 Controlled drugs 276 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (e) when it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or (f) when separately specified in the NABIXIMOLS entry in this Schedule; or (g) when captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or (h) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols. CARFENTANYL. COCAINE. CODEINE except when included in Schedule 4. CODEINE-N-OXIDE. CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids). 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A). CYCLOBARBITAL. DEXAMFETAMINE. DEXTROMORAMIDE. # DEXTROPROPOXYPHENE except when included in Schedule 4. DIFENOXIN except when included in Schedule 4. DIHYDROCODEINE except when included in Schedule 3 or 4. DIHYDROMORPHINE. # N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human therapeutic use for the treatment of post-traumatic stress disorder. DIPHENOXYLATE except when included in Schedule 3 or 4. DIPIPANONE. # DRONABINOL (delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use. DROTEBANOL. ESKETAMINE. ETHYLAMFETAMINE. Authorised Version F2024L00589 registered 30/05/2024 Controlled drugs Schedule 8 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 277 ETHYLMORPHINE except when included in Schedule 2 or 4. FENTANYL. # FLUNITRAZEPAM. HYDROCODONE. HYDROMORPHINOL. HYDROMORPHONE. KETAMINE. LEVAMFETAMINE. LEVOMETHAMFETAMINE. LEVOMORAMIDE. LEVORPHANOL (excluding its stereoisomers). LISDEXAMFETAMINE. METHADONE. METAMFETAMINE. METHYLDIHYDROMORPHINE. METHYLPHENIDATE. 1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C). MORPHINE. MORPHINE METHOBROMIDE. MORPHINE-N-OXIDE. NABILONE. # NABIXIMOLS (botanical extract of Cannabis sativa which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90% of the total cannabinoid content) in a buccal spray for human therapeutic use. NORCODEINE. NORMETHADONE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 8 Controlled drugs 278 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 OPIUM except the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4. OXYCODONE. OXYMORPHONE. PENTAZOCINE. # PENTOBARBITAL except when included in Schedule 4. PETHIDINE. PHENDIMETRAZINE. PHENMETRAZINE. PHENOPERIDINE. 4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B). PHOLCODINE except when included in Schedule 2 or 4. PIRITRAMIDE. PROPIRAM. # PSILOCYBINE in preparations for human therapeutic use for the treatment of treatment-resistant depression. RACEMORAMIDE. REMIFENTANIL. SECBUTOBARBITAL. SECOBARBITAL. # SODIUM OXYBATE for human therapeutic use. SUFENTANIL. TAPENTADOL. # TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use, when: (a) included in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or (b) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or Authorised Version F2024L00589 registered 30/05/2024 Controlled drugs Schedule 8 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 279 (c) in therapeutic goods supplied in accordance with the Act; except when: (d) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or (e) separately specified in the NABIXIMOLS entry in this Schedule; or (f) captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or (g) in hemp seed oil at a concentration of 10 mg/kg or less. THEBACON. THEBAINE. TILIDINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 9 Prohibited substances 280 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 9—Prohibited substances Note 1: See paragraph 7(b) and subsection 57(2). Note 2: Trivial or unofficial names are marked *. ACETORPHINE. ACETYL-ALPHA-METHYLFENTANYL. ALKOXYAMFETAMINES and substituted alkoxyamfetamines except when separately specified in these Schedules. ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines except when separately specified in these Schedules. ALKYLTHIOAMFETAMINES and substituted alkylthioamfetamines except when separately specified in these Schedules. ALLYLPRODINE. ALPHAMEPRODINE. ALPHA-METHYLFENTANYL. ALPHA-METHYLTHIOFENTANYL. ALPHAMETHADOL. ALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP). 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE *(STP or DOM). 5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans except when separately specified in these Schedules. BENZETHIDINE. BENZOYLINDOLES except when separately specified in these Schedules. BENZYLPIPERAZINE *(BZP). BETACETYLMETHADOL. BETA-HYDROXYFENTANYL. BETA-HYDROXY-3-METHYLFENTANYL. BETAMEPRODINE. BETAMETHADOL. Authorised Version F2024L00589 registered 30/05/2024 Prohibited substances Schedule 9 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 281 BETAPRODINE. 1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE *(Bromo-Dragonfly). 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA). BUFOTENINE. BUTONITAZENE. CANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when packed or prepared), except: (a) when separately specified in these Schedules; or (b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols and hemp fibre products manufactured from such fibre; or (c) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols. CATHINONES except when separately specified in these Schedules. CLONAZOLAM. CLONITAZENE. COCA LEAF. CODOXIME. 4-CYANO-2-DIMETHYLAMINO-4,4'-DIPHENYLBUTANE. CYCLOHEXYLPHENOLS except: (a) when separately specified in these Schedules; or (b) in preparations containing 0.5% or less of cyclohexylphenols. DESCHLOROETIZOLAM. DESOMORPHINE. N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES except when separately specified in these Schedules. N,N-DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES except when separately specified in these Schedules. DIAMPROMIDE. DIBENZOPYRANS except when separately specified in these Schedules. Authorised Version F2024L00589 registered 30/05/2024 Schedule 9 Prohibited substances 282 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-METHYLBENZ AMIDE (U-47700). 3,4-DICHLORO-N-{[1- (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH-7921). DICLAZEPAM. DIETHYLTHIAMBUTENE. N,N-DIETHYLTRYPTAMINE *(DET). 2,5-DIHYDRO-2-(1-METHYL-1-PHENYLETHYL)-5-PENTYL-1H-PYRIDO[4,3-B]INDO L-1-ONE (SGT-151). DIMENOXADOL. DIMEPHEPTANOL. 2,5-DIMETHOXYAMFETAMINE *(DMA). 2,5-DIMETHOXY-4-BROMOAMFETAMINE *(DOB). 2,5-DIMETHOXY-4-ETHYL-a-AMFETAMINE *(DOET). 2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2). 2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I). 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7). 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN). 3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9 TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(DMHP). N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) except when included in Schedule 8. N,N-DIMETHYLAMFETAMINE (Dimetamfetamine). DIMETHYLTHIAMBUTENE. N,N-DIMETHYLTRYPTAMINE *(DMT). DIOXAPHETYL BUTYRATE. ECGONINE. N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE *(N-ETHYL MDA). Authorised Version F2024L00589 registered 30/05/2024 Prohibited substances Schedule 9 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 283 ETHYLMETHYLTHIAMBUTENE. ETICYCLIDINE *(PCE). ETODESNITAZENE. ETONITAZENE. ETONITAZEPIPNE. ETONITAZEPYNE. ETORPHINE. ETOXERIDINE. FENETYLLINE. 4-FLUORO-N-METHYLAMFETAMINE. FLUBROMAZEPAM. FLUBROMAZOLAM. FLUNITAZENE. 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE *(AM-694). FURETHIDINE. HARMALA ALKALOIDS except in herbs, or preparations, for therapeutic use: (a) containing 0.1% or less of harmala alkaloids; or (b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose. HEROIN. 3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(PARAHEXYL). 4-HYDROXYBUTANOIC ACID and its salts except for sodium oxybate when in Schedule 8. *(GAMMA HYDROXYBUTYRATE (GHB)). 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL *(Cannabicyclohexanol or CP 47,497 C8 homologue). 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL *(CP 47,497). HYDROXYPETHIDINE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 9 Prohibited substances 284 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 IBOTENIC ACID. ISOMETHADONE. ISOTONITAZENE. KETOBEMIDONE. LEVOMETHORPHAN (excluding its stereoisomers). LEVOPHENACYLMORPHAN. LYSERGIC ACID. LYSERGIDE. MECLONAZEPAM. MECLOQUALONE. METAZOCINE. METHAQUALONE. METHCATHINONE. 5-METHOXY- α –METHYLTRYPTAMINE *(5-MeO-AMT). 5-METHOXY-3,4-METHYLENEDIOXYAMFETAMINE *(MMDA). 4-METHOXY- α –METHYLPHENYLETHYLAMINE *(PMA). 2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE *(JWH-250). METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FUR YL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE *(SALVINORIN A). 4-METHYLAMINOREX. METHYLDESORPHINE. 3,4-METHYLENEDIOXYAMFETAMINE *(MDA). 3,4-METHYLENEDIOXYPYROVALERONE *(MDPV). 3-METHYLFENTANYL. 4-METHYLMETHCATHINONE *(MEPHEDRONE). N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE *(N-HYDROXY MDA). Authorised Version F2024L00589 registered 30/05/2024 Prohibited substances Schedule 9 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 285 N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE *(MBDB). 2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate). METHYLONE *(MDMC). 1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP). 4-METHYLTHIOAMFETAMINE. 3-METHYLTHIOFENTANYL. METODESNITAZENE. METONITAZENE. METOPON. MITRAGYNA SPECIOSA. MITRAGYNINE. MORPHERIDINE. (1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE *(JWH-200). MUSCIMOL. MYROPHINE. NAPHTHOYLINDOLES except when separately specified in these Schedules. NAPHTHYLMETHYLINDOLES except when separately specified in these Schedules. NAPHTHOYLPYRROLES except when separately specified in these Schedules. NAPHTHYLMETHYLINDENES except when separately specified in these Schedules. NAPHTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE *(JWH-073). NICOCODINE. NICODICODINE. NICOMORPHINE. NIFOXIPAM. NORACYMETHADOL. Authorised Version F2024L00589 registered 30/05/2024 Schedule 9 Prohibited substances 286 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 NORLEVORPHANOL. NORMORPHINE. NORPIPANONE. PARA-FLUOROFENTANYL. 1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. *(JWH-122). 1-PENTYL-3-(1-NAPHTHOYL)INDOLE *(JWH-018). PHENADOXONE. PHENAMPROMIDE. PHENAZOCINE. PHENCYCLIDINE *(PCP). PHENIBUT. N-PHENETHYL-4-PIPERIDONE. PHENOMORPHAN. PHENYLACETYLINDOLES except when separately specified in these Schedules. 1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP). PIMINODINE. PROHEPTAZINE. PROPERIDINE. PROTONITAZENE. PSILOCYBINE except when included in Schedule 8. PYRAZOLAM. RACEMETHORPHAN. RACEMORPHAN. ROLICYCLIDINE *(PHP or PCPY). SALVIA DIVINORUM. SYNTHETIC CANNABINOMIMETICS except when separately specified in these Schedules. Authorised Version F2024L00589 registered 30/05/2024 Prohibited substances Schedule 9 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 287 TENOCYCLIDINE *(TCP). TETRAHYDROCANNABINOLS and their alkyl homologues, except: (a) when included in Schedule 4 or Schedule 8; or (b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or (c) in hemp seed oil at a concentration of 10 mg/kg or less. THIOFENTANYL. 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP). TRIMEPERIDINE. 3,4,5-TRIMETHOXY- α –METHYLPHENYLETHYLAMINE *(TMA). 3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy-phenylethylamine except: (a) methoxyphenamine; or (b) when separately specified in this Schedule. 1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE. Authorised Version F2024L00589 registered 30/05/2024 Schedule 10 Substances of such danger to health as to warrant prohibition of supply and use 288 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 10—Substances of such danger to health as to warrant prohibition of supply and use Note 1: See subsection 57(2) and section 63. Note 2: Schedule 10 contains substances previously included in Appendix C. ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use. ACORUS CALAMUS (calamus) for human therapeutic use. ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use: (a) in liquid or semi-solid food additive preparations, tHE pH of which is more than 11.5; or (b) in solid automatic dishwashing preparations, tHE pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or (c) in liquid or semi-solid automatic dishwashing preparations, tHE pH of which is more than 12.5. ALKYLAMINES WITH STIMULANT PROPERTIES except when separately specified in these schedules. 2-AMINO-5-METHYLPHENOL in preparations for cosmetic use. AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use. AMYGDALIN for therapeutic use. ANCHUSA OFFICINALIS for therapeutic use. o-ANISIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001% or less of o-anisidine. APRONAL for therapeutic use. ARISTOLOCHIA spp. for therapeutic use. ARISTOLOCHIC ACID(S) for human therapeutic use. ASARUM spp. containing aristolochic acid(s) for human therapeutic use. AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use except “debitterised neem seed oil”. BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows. Authorised Version F2024L00589 registered 30/05/2024 Substances of such danger to health as to warrant prohibition of supply and use Schedule 10 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 289 1,2-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing). 1,3-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing). BITHIONOL for human therapeutic use. BORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis. BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use. BUCLOSAMIDE for therapeutic use. BUNIODYL SODIUM for therapeutic use. 1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use. BUTYL BENZYL PHTHALATE for cosmetic use. CACALIA spp. for therapeutic use. CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18% of carbamide peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice. CARDARINE. CHRYSOIDINE BASE in preparations for use in hair dyes. CINCHOPHEN and its derivatives for therapeutic use. CLIOQUINOL and other halogenated derivatives of oxyquinoline for human internal use except or when being used solely for experimental purposes in humans and where such use: (a) is in accordance with: (i) an approval granted under paragraph 19(1)(b) of the Act, including any conditions specified in the notice of approval; and (ii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(1A) of the Act; and (iii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(4A) of the Act; or (b) is in accordance with the requirements of item 3 of Schedule 5A to the Therapeutic Goods Regulations 1990. COAL TAR for cosmetic use other than in therapeutic goods. Authorised Version F2024L00589 registered 30/05/2024 Schedule 10 Substances of such danger to health as to warrant prohibition of supply and use 290 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CONIUM MACULATUM (coniine) for therapeutic use. COTARNINE for therapeutic use. CROTALARIA spp. for therapeutic use. CROTON TIGLIUM for therapeutic use. CYNOGLOSSUM spp. for therapeutic use. DIBUTYL PHTHALATE for cosmetic use. DICOPHANE (DDT) for therapeutic use. DIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25% or less of diethylene glycol. DIETHYLENE GLYCOL MONOMETHYL ETHER for cosmetic use. DIETHYLHEXYL PHTHALATE for cosmetic use. DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5% or less of diethylphthalate. 5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2% of 5,6-dihydroxyindoline. DIIODOHYDROXYQUINOLINE (iodoquinol) for human internal use. DIISOBUTYL PHTHALATE for cosmetic use. 1,3-DIMETHYLAMYLAMINE (DMAA). 1,3-DIMETHYLBUTYLAMINE (DMBA) except when separately specified in these schedules. 1-(1,1-DIMETHYLETHYL)-2-METHOXY-4-METHYL-3,5-DINITROBENZENE (musk ambrette). 1,5-DIMETHYLHEXYLAMINE (DMHA) except when separately specified in these schedules. DI(METHYLOXYETHYL) PHTHALATE for cosmetic use. 1,4-DIMETHYLPENTYLAMINE (DMPA). DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5% or less of dimethylphthalate. 2,4-DINITROPHENOL for human use. Authorised Version F2024L00589 registered 30/05/2024 Substances of such danger to health as to warrant prohibition of supply and use Schedule 10 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 291 DISPERSE YELLOW 3 for use in hair dyes. DULCIN for therapeutic use. ETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25% or less of ethylene glycol. EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use. FARFUGIUM JAPONICUM for therapeutic use. FORMALDEHYDE (excluding its derivatives): (a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or (b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or (d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde except in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement: CONTAINS FORMALDEHYDE. GAMMA BUTYROLACTONE (excluding its derivatives) in non-polymerised form in preparations for domestic and cosmetic use. HELIOTROPIUM spp. for therapeutic use. HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6% (20 volume) of hydrogen peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice. ISOPROPYL NITRITE. JUNIPERUS SABINE [savin(e)] for therapeutic use. KAMBO. LEAD COMPOUNDS: (a) in anti-fouling paints except in preparations containing 0.1% or less of lead calculated on the non-volatile content of the paint; or (b) in paints (other than anti-fouling paints), tinters, inks or ink additives except in preparations containing 0.009% or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive; or (c) for human therapeutic use except in preparations containing 10 mg/kg or less of lead. LIGULARIA DENTATA for therapeutic use. Authorised Version F2024L00589 registered 30/05/2024 Schedule 10 Substances of such danger to health as to warrant prohibition of supply and use 292 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MELIA AZEDARACH including its extracts and derivatives. METHANOL in hand sanitiser preparations containing more than 5% methanol. METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use. METHYL METHACRYLATE for cosmetic use except in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer. METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet) and the following TRIARYLMETHANE DYES – for use in hair dyes: (a) Acid Violet 49; or (b) Ethyl Violet; or (c) Basic Blue 7; or (d) Basic Blue 26 (CI 44045). NAPHTHALENE (excluding derivatives) in preparations in block, ball, disc, pellet or flake form for domestic use except when enclosed in a device which, in normal use, prevents removal or ingestion of its contents. OXYPHENISATIN for therapeutic use. PARAFORMALDEHYDE (excluding its derivatives): (a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or (b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or (d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde except in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement: CONTAINS FORMALDEHYDE. PETASITES spp. for therapeutic use. PHENPROMETHAMINE. PHENYLENEDIAMINES, including alkylated, arylated, halogenated and nitro derivatives, in preparations for skin colouration, tattooing and dyeing of eyelashes or eyebrows except when included in Schedule 6. POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, tHE pH of which is more than 11.5. n-PROPYL NITRITE. PTERIDIUM spp. for therapeutic use. Authorised Version F2024L00589 registered 30/05/2024 Substances of such danger to health as to warrant prohibition of supply and use Schedule 10 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 293 PULMONARIA spp. for therapeutic use. SAFROLE for internal therapeutic use except in preparations containing 0.1% or less of safrole. SANGUINARIA CANADENSIS (bloodroot) in preparations for human use except in preparations containing 0.01% or less of SANGUINARINE. SENECIO spp. for therapeutic use. SILICONES for injection or implantation except when included in Schedule 4. SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, tHE pH of which is more than 11.5. SYMPHYTUM spp. (Comfrey) in preparations for human or animal use except when in Schedule 5. 2,4-TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows. TOLUENEDIAMINES in preparations for skin colouration (including tattooing) and dyeing of eyelashes or eyebrows except when included in Schedule 6. o-TOLUIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001% or less of o-toluidine. 1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use. TRICHODESMA AFRICANA for therapeutic use. TRIPARANOL for therapeutic use. TUSSILAGO FARFARA for therapeutic use. Authorised Version F2024L00589 registered 30/05/2024 Appendix A General exemptions Clause 1 294 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix A—General exemptions Note: See paragraph 11(a). 1 Exempt preparations and products The following table specifies preparations and products for the purposes of paragraph 11(a). Exempt preparations and products Item Column 1 Preparation or product 1 ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that are not agricultural chemical products or veterinary chemical products 2 BACTERIAL CULTURE MEDIA containing antibiotics 3 CERAMICS 4 CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4-2003, Safety of toys, Part 4: Experimental sets for chemistry and related activities 5 COPPER COMPOUNDS in paints 6 DEXTRANS, GELATIN - SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/blood volume expanders 7 ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS 8 ELECTRONIC COMPONENTS 9 ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging 10 EXPLOSIVES 11 FOOD except: (a) food additives before incorporation into food; or (b) when used as a means of administering a poison for therapeutic use 12 FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non-migratory component of glassy solid flakes or granules 13 GLASS (including CRYSTAL WARE) 14 GLAZED POTTERY 15 HUMAN BLOOD PRODUCTS including: (a) whole blood; (b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and (c) the following plasma-derived therapeutic proteins; and their equivalent recombinant alternatives: (i) albumin; (ii) anticoagulation complex; (iii) C1 esterase inhibitors; (iv) clotting factors; (v) fibrinogen; (vi) protein C; (vii) prothrombin complex concentrate (PCC); Authorised Version F2024L00589 registered 30/05/2024 General exemptions Appendix A Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 295 Exempt preparations and products Item Column 1 Preparation or product (viii) thrombin 16 IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001% or less of a poison included in Schedules 1 to 8 17 INTRAOCULAR VISCOELASTIC PRODUCTS 18 LUBRICANTS in preparations that provide a lubricating action between machinery parts, except soluble oils and solvent-deposited lubricating agents 19 MATCHES 20 MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS 21 MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the Therapeutic Goods (Medical Devices) Regulation 2002, except the following: (a) injectable tissue reconstructive, augmentation and restoration materials, including collagen; (b) medical devices which include anticoagulants; (c) artificial tears; (d) urinary catheters; (e) intra-articular fluids 22 MOTOR, HEATING or FURNACE FUELS except the following: (a) when the contrary intention appears in any Schedule; (b) when containing methanol; (c) toy or hobby fuels; or (d) petrol or kerosene when packed in containers having a capacity of 20 L or less 23 NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION 24 PAPER except: (a) when prepared for pesticidal use; or (b) when containing a poison included in Schedule 8 or 9 25 PHOTOGRAPHIC PAPER or FILM 26 PIGMENTS when immobilised in a polymer 27 PORCELAIN 28 PRINTING INKS or INK ADDITIVES except: (a) when containing a pesticide; or (b) preparations containing more than 0.009% of lead calculated on the non-volatile content of the ink or ink additive 29 RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use 30 RADIOISOTOPES for therapeutic use 31 SEEDS treated with seed protectants 32 SINGLE-USE TUBES for the estimation of alcohol content of breath 33 TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting 34 TIMBER or WALLBOARD 35 TREATMENT LAYERS OF COATED METAL ARTICLES except articles intended for use in the collection of drinking water when not compliant with the health and safety Authorised Version F2024L00589 registered 30/05/2024 Appendix A General exemptions Clause 1 296 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Exempt preparations and products Item Column 1 Preparation or product requirements of the Australian Standard AS 4020:2018, Testing of products for use in contact with drinking water 36 VITREOUS ENAMELS 37 WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Substances considered not to require control by scheduling Appendix B Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 297 Appendix B—Substances considered not to require control by scheduling Note: See paragraph 11(b). 1 Reasons for including substances in the table in clause 3 For the purposes of the table in clause 3, the letter specified in column 1 of an item of the following table represents the reason specified in column 2 of the item. Reasons for including substances in the table in clause 3 Item Column 1 Letter Column 2 Reason 1 a Low Toxicity 2 b Use pattern restricts hazard 3 c Presentation/packaging restricts hazard 4 d Industrial use only 2 Areas of use in relation to substances included in the table in clause 3 For the purposes of the table in clause 3, the number specified in column 1 of an item of the following table represents the area, sub-area or sub-sub-area of use specified in column 2, 3 or 4 (as applicable) of the item. Areas of use in relation to substances included in the table in clause 3 Item Column 1 Number Column 2 Area Column 3 Sub-area Column 4 Sub-sub-area 1 1 Agriculture 2 1.1 Herbicide 3 1.2 Insecticide 4 1.2.1 Insecticide for codling moth 5 1.2.2 Termiticide 6 1.3 Fungicide 7 1.3.1 On seed fungicide 8 1.4 Bird Repellent 9 1.5 Fertiliser 10 1.6 Plant Growth Regulator 11 1.7 Insect Pheromone 12 1.8 Mushroom Bactericide 13 1.9 Acaricide 14 1.10 Biological control agent 15 1.11 Adjuvant in agricultural products Authorised Version F2024L00589 registered 30/05/2024 Appendix B Substances considered not to require control by scheduling Clause 2 298 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Areas of use in relation to substances included in the table in clause 3 Item Column 1 Number Column 2 Area Column 3 Sub-area Column 4 Sub-sub-area 16 2 Veterinary 17 2.1 For animal use 18 2.2 Treatment of mastitis in cows 19 2.3 Coccidiostat 20 2.4 Feed additive 21 2.5 Antiseptic 22 2.6 Scabicide 23 2.7 Anthelmintic 24 2.8 Vitamin/Mineral 25 2.9 Growth Promotant 26 2.10 Ectoparasiticide 27 3 Domestic 28 3.1 Aromatherapy 29 3.2 Food additive 30 3.3 Cosmetic 31 3.4 Human use 32 3.5 Miticide 33 4 Industrial 34 4.1 Water treatment 35 4.2 Biological control agent 36 5 Environmental 37 5.1 Mosquito control 38 6 Human therapeutic use 39 6.1 Diagnostic agent 40 6.2 Medical device 41 6.3 Antiseptic 42 6.4 Sunscreen 43 6.5 External use 44 6.6 Laxative 45 6.7 Antiseborrheic 46 6.8 Cytoprotective 47 6.9 Vitamin/Mineral 48 6.10 Eye Drops 49 7 General 50 7.1 Any use 51 7.2 Excipient 52 7.3 Synergist 53 7.4 Flux 54 7.5 Pesticide Authorised Version F2024L00589 registered 30/05/2024 Substances considered not to require control by scheduling Appendix B Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 299 Areas of use in relation to substances included in the table in clause 3 Item Column 1 Number Column 2 Area Column 3 Sub-area Column 4 Sub-sub-area 55 7.6 Insect repellent 56 7.7 Solvent 57 7.8 Disinfectant 58 7.9 Preservative 59 7.10 Antioxidant 60 7.11 Resin activator/accelerant 61 7.12 Sweetener artificial 62 7.13 Food additive 3 Substances exempt in certain uses For the purposes of paragraph 11(b), the following table specifies: (a) substances; and (b) areas, sub-areas and sub-sub-areas of use in relation to those substances. Note: Columns 3 and 4 of the table are included for information only. Substances exempt in certain uses Item Column 1 Substance Column 2 Area, sub-area or sub-sub-area of use Column 3 Reason for inclusion Column 4 Date of inclusion 1 4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE 1.7 b Feb 2005 2 AFIDOPYROPEN 1.2 b Jun 2018 3 ALCOHOL, DEHYDRATED 6 b Aug 2000 4 ALUM 7.1 a May 1997 5 ALUMINIUM AMMONIUM SULFATE 7.1 a May 1997 6 ALUMINIUM POTASSIUM SULFATE 7.1 a May 1997 7 ALUMINIUM SILICATE 7.1 a Nov 1974 8 ALUMINIUM tris (ETHYLPHOSPHONATE) 1 a Aug 1986 9 AMETOCTRADIN 1.3 a May 2012 10 AMMONIUM PHOSPHATE 7.1 a Nov 1974 11 AMMONIUM THIOSULPHATE 7.1 a Nov 1974 12 AMPROLIUM 2.3 a Jun 1969 13 AMYL ACETATE 7.1 a Nov 1974 14 α -AMYLASE derived from Aspergillus niger 2.4 a Feb 2005 15 AMYL CINNAMALDEHYDE 3.3 a, b Feb 2017 16 ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT 2.1 a Jun 2004 17 ASPARTIC ACID 6 a Authorised Version F2024L00589 registered 30/05/2024 Appendix B Substances considered not to require control by scheduling Clause 3 300 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Substances exempt in certain uses Item Column 1 Substance Column 2 Area, sub-area or sub-sub-area of use Column 3 Reason for inclusion Column 4 Date of inclusion 18 ASULAM 1 a May 1986 19 AUREOBASIDIUM PULLULANS (strains DSM14940 and DSM14941) 1.3 a Oct 2017 20 AZIMSULFURON 1.1 a Jun 2003 21 BACILLUS AMYLOLIQUEFACIENS 1.3 a Jun 2018 22 BACILLUS SPHAERICUS, STRAIN 2362 5.1 a Feb 2003 23 BACILLUS THURINGIENSIS 5.1 a May 1992 24 BACILLUS THURINGIENSIS (excluding endotoxin) 2.10 a Jun 2003 25 BACILLUS TOYOI 2.9 a Aug 1980 26 BACULOVIRUS CYDIA POMONELLA 1.2 a Jun 2006 27 BENFLURALIN 1.1 a 28 BENSULFURON-METHYL 1 a Aug 1987 29 BENTONITE 7.1 a Jun 2002 30 BENZYL BENZOATE 1.2 a Aug 1989 31 BETAINE HYDROCHLORIDE 7.1 a Nov 1974 32 BIFENAZATE 1.9 a Oct 2002 33 BISMUTH SUBNITRATE 2.1 b, c Nov 1999 34 BISTRIFLURON 1.2.2 a Feb 2014 35 BIURET 2.4 a Nov 1974 36 BIXLOZONE 1.1 a Feb 2020 37 BLAD (banda de Lupinus albus doce) 1.3 a Feb 2016 38 BOSCALID 1.3 a June 2003 39 BOVINE SOMATOTROPHIN 2 a May 1992 40 BROMACIL 1 a Aug 1987 41 BROMOPROPYLATE 1 a Nov 1994 42 BUPIRIMATE 1 a Nov 1990 43 BUTAFENACIL 1 a May 2000 44 BUTOXYPOLYPROPYLENE GLYCOL 7.7 a Nov 1974 45 n-BUTYL BUTYRATE 7.1 a 46 n-BUTYL LACTATE 7.1 a 47 CARBOXIN 1 a Aug 1987 48 CARFENTRAZONE-ETHYL 1 a Aug 1998 49 CELLULASE derived from Aspergillus niger 2.4 a Feb 2005 50 CETYL ALCOHOL 7.1 a Nov 1974 51 CHAMOMILE OIL 3.1 a Feb 2000 52 CHINA CLAY 1.2 a Sep 2008 53 CHLORANTRANILIPROLE 1.2 a Sep 2008 Authorised Version F2024L00589 registered 30/05/2024 Substances considered not to require control by scheduling Appendix B Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 301 Substances exempt in certain uses Item Column 1 Substance Column 2 Area, sub-area or sub-sub-area of use Column 3 Reason for inclusion Column 4 Date of inclusion 54 CHLORFLUAZURON 1.2.2 a Oct 2005 55 CHLORFLURENOL 1.6 a Feb 1974 56 CHLORIDAZON 1 a May 1988 57 CHLOROXYLENOLS 7.8 a Feb 1975 58 CITRONELLA OIL 7.1 a Feb 2000 59 CLARY SAGE OIL 7.1 a Feb 2000 60 CLITORIA TERNATEA EXTRACT 1.2 a Feb 2016 61 CLOPIDOL 2.3 d Nov 1974 62 COBALT NAPHTHENATE 7.1 d 63 CROSPOVIDONE 2 a Aug 1996 64 CULICINOMYCES CLAVOSPORUS 5.1 a Nov 1982 65 CYCLAMIC ACID 7.1 a Nov 1971 66 CYCLANILIPROLE 1.2 a Oct 2016 67 CYCLOBUTRIFLURAM 1.3, 1.3.1 a Oct 2022 68 CYCLOHEXANE 7.7 a Nov 1974 69 CYCLOHEXANOL ACETATE 7.7 a 70 CYPRINID HERPESVIRUS-3 1.10 a Oct 2018 71 CYROMAZINE 2 a Nov 1980 72 DICLAZURIL 2.3 a Nov 2001 73 DIETHYL CARBONATE 7.1 a 74 DIFLUFENICAN 1 a Feb 1987 75 DIKEGULAC-SODIUM 1.6 a Mar 1980 76 DIMETHYL ETHER 4 d Nov 1988 77 DIMETICONE 7.1 a 78 DIPHENYLAMINE 1 a Feb 1988 79 DIPROPYLENE GLYCOL MONOMETHYL ETHER 4 a Nov 1987 80 DISODIUM MANGANESE EDTA 2.1 a Feb 2022 81 DIURON 1 a Nov 1987 82 DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE) 7.1 a Feb 1970 83 2,2-DPA 1 a Nov 1989 84 DROMETRIZOLE TRISILOXANE 6.4 a Oct 2003 85 DUDDINGTONIA FLAGRANS, STRAIN IAH 1297 2.7 a Feb 2018 86 EPSIPRANTEL 2 a Nov 1991 87 ETHAMETSULFURON-METHYL 1.1 a Nov 2000 88 ETHOPABATE 2.3 d Jun 1969 Authorised Version F2024L00589 registered 30/05/2024 Appendix B Substances considered not to require control by scheduling Clause 3 302 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Substances exempt in certain uses Item Column 1 Substance Column 2 Area, sub-area or sub-sub-area of use Column 3 Reason for inclusion Column 4 Date of inclusion 89 ETHYL ACETATE 7.1 a Nov 1974 90 ETHYL ALCOHOL 7.1 a Nov 1974 91 ETHYLBUTYLACETYL AMINOPROPRIONATE 3.4 a Aug 2000 92 ETHYL BUTYRATE 7.1 a 93 ETHYL LACTATE 7.1 a 94 ETOFENPROX 1.2 a Jun 2018 95 ETOXAZOLE 1.2 a Oct 2003 96 EUBACTERIUM sp. strain DSM11798 2.4 a Sep 2013 97 FENFURAM 1.3.1 a May 1977 98 FENHEXAMID 1 a Feb 1999 99 FENOXYCARB 1 a Feb 1988 100 FLORPYRAUXIFEN-BENZYL 1, 1.1 a Feb 2018 101 FLORYLPICOXAMID 1.3 a Feb 2021 102 FLUFENOXURON 1 a Feb 1997 103 FLUMETSULAM 1 a Feb 1992 104 FLUOMETURON 1 a Aug 1989 105 FLUOPICOLIDE 1.3 a Oct 2016 106 FLUOXAPIPROLIN 1.3 a Feb 2022 107 FLUTOLANIL 1.3 a Nov 2001 108 FLUROXYPYR 1 a, c May 1986 109 FORCHLORFENURON 1.6 a Feb 2005 110 FULLERS EARTH 7.1 a Nov 1974 111 FUNGAL PROTEASE derived from Aspergillus niger 2.4 a Feb 2005 112 GERANIUM OIL 7.1 a Feb 2000 113 GIBBERELLIC ACID 1.6 a Nov 1974 114 α-GLUCANASE derived from Aspergillus niger 2.4 a Feb 2005 115 HALAUXIFEN METHYL 1, 1.1 a Oct 2014 116 HELIONAL 7 a Feb 2023 117 HEXAFLURON 1 a Nov 1988 118 HEXYL ACETATE 7.7 a 119 HEXYL CINNAMALDEHYDE 3.3 a, b Feb 2017 120 HEXYTHIAZOX 1 a Feb 1988 121 HUMAN OSTEOGENIC PROTEIN-1 (OP-1) 6.2 b Aug 2001 122 HYDROPRENE 1 a Feb 1988 123 HYDROXYPROPYL CELLULOSE 7.1 a Nov 1982 124 ICODEXTRIN 6 b Nov 2000 Authorised Version F2024L00589 registered 30/05/2024 Substances considered not to require control by scheduling Appendix B Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 303 Substances exempt in certain uses Item Column 1 Substance Column 2 Area, sub-area or sub-sub-area of use Column 3 Reason for inclusion Column 4 Date of inclusion 125 INDOLE-3-ACETIC ACID 1.6 b Feb 1985 126 IPFLUFENOQUIN 1.3, 1.3.1 a Sep 2022 127 ISOPRENE ALCOHOL 7.1 a 128 IPRODIONE 1 a Feb 1997 129 ISETHIONATE, as mixed ammonium and ethanolamine salts of 2-hydroxyethanesulfonic acid 1.11 a, b Jun 2016 130 ISOFETAMID 1.3 a Feb 2018 131 ISOSTEARYL ALCOHOL ETHOXYLATE 5.1 a Nov 1999 132 KAOLIN 7.1 a Nov 1974 133 KINETIN 1.6 a Feb 2022 134 KRESOXIM-METHYL 1 a Aug 1999 135 KUNZEA OIL 7.1 a Feb 2000 136 LAURIC ACID 7.1 a Oct 2005 137 LAURYL ALCOHOL (1-DODECANOL) 7.1 a Nov 1974 138 LAVANDIN OIL 7.1 a Feb 2000 139 LAVENDER OIL 7.1 a Feb 2000 140 LEAD METALLIC 7.1 a 141 LEPIDOPTEROUS SEX PHEROMONES 1 a Nov 1990 142 LIMONENE (DIPENTENE) 7.1 a Jun 2002 143 LINOLEIC ACID 7.1 a Oct 2005 144 LINSEED FATTY ACIDS 2.1 a Aug 1990 145 LINURON 1 a Feb 1990 146 LIQUORICE, DEGLYCYRRHISINISED 7.1 a May 1999 147 MAGNESIUM HYDROXIDE 7.1 a Jun 2021 148 MALEIC HYDRAZIDE 1 a Nov 1992 149 MANGANESE DIOXIDE 1 b May 1999 150 MEGASPHAERA ELSDENII strain 41125 2.4 a Sep 2013 151 MESOSULFURON-METHYL 1.1 a Feb 2002 152 METARHIZIUM ANISOPLIAE 4.2 b Feb 2000 153 METARHIZIUM ANISOPLIAE 1.10 a Jun 2003 154 METCAMIFEN 1.1 a Feb 2020 155 METHOPRENE 1 a Aug 1987 156 METHOXYFENOZIDE 1 a Nov 2000 157 METHYL ACETATE 7.7 a 158 METHYL BENZOQUATE 2.3 d Nov 1974 159 1-METHYLCYCLOPROPENE 1.6 a Jun 2003 Authorised Version F2024L00589 registered 30/05/2024 Appendix B Substances considered not to require control by scheduling Clause 3 304 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Substances exempt in certain uses Item Column 1 Substance Column 2 Area, sub-area or sub-sub-area of use Column 3 Reason for inclusion Column 4 Date of inclusion 160 METHYL p-HYDROXYBENZOATE 7.9 a Nov 1974 161 METSULFURONMETHYL 1.1 a Nov 1985 162 MYRISTIC ACID 7.1 a Oct 2005 163 NAPROPAMIDE 1 a Aug 1987 164 NAPTHYL ACETAMIDE 1.6 a Nov 1974 165 NEROLI OIL 7.1 a Feb 2000 166 NICARBAZIN 2.3 d Jun 1969 167 NISIN 3.2 a Jun 2003 168 NORFLURAZON 1.1 a Nov 1983 169 NOVALURON 1 a Nov 2000 170 NUCLEAR POLYHEDROSIS VIRUS of Helicoverpa armigera occlusion bodies 1.2 a Feb 2004 171 OCTYL ALCOHOLS 7.1 a Nov 1974 172 OLEIC ACID 7.1 a Oct 2005 173 ORANGE OIL, SWEET 7.1 a Aug 2000 174 OXABETRINIL 1 a Feb 1987 175 OXATHIAPIPROLIN 1.3 a Jun 2016 176 OXYFLUORFEN 1 a May 2001 177 PALMAROSA OIL 7.1 a Feb 2000 178 PALMITIC ACID 7.1 a Oct 2005 179 PATCHOULI OIL 7.1 a Feb 2000 180 PECTINASE derived from Aspergillus niger 2.4 a Feb 2005 181 PEGBOVIGRASTIM 2.1 a Jun 2017 182 PENCYCURON 1 a Aug 1994 183 PENTADECANOIC ACID 7.1 a Oct 2005 184 PEPPERMINT OIL 7.1 a Feb 2000 185 PHENMEDIPHAM 1.1 a May 1989 186 D-PHENOTHRIN 7.5, 1.2 a Feb 1982 187 PHYTASE 2.4 a Feb 1996 188 PICLORAM 1 a Aug 1987 189 PICOLINAFEN 1 a May 2000 190 PIMELIC ACID 7.1 a Oct 2005 191 PIPERONYL BUTOXIDE 7.5 a Aug 1991 192 POLOXALENE 7.1 a Nov 1974 193 POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC) 4.1 a Nov 1997 194 POLYHEDROSIS VIRUS of Helico zea occlusion bodies 1 a Nov 1996 Authorised Version F2024L00589 registered 30/05/2024 Substances considered not to require control by scheduling Appendix B Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 305 Substances exempt in certain uses Item Column 1 Substance Column 2 Area, sub-area or sub-sub-area of use Column 3 Reason for inclusion Column 4 Date of inclusion 195 POLY (GNRF) OVALBUMIN 2 a Feb 1990 196 POLYSORBATE 20 1 a May 2001 197 PORCINE SOMATOTROPHIN 2 c Nov 1991 198 POTASSIUM SORBATE 1.3 a Oct 2004 199 POTASSIUM BICARBONATE 1 a Jun 2004 200 PROPYL ACETATES 7.1 a 201 PROPYLENE GLYCOL 7.1 a Nov 1974 202 2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER 4 a Nov 1987 203 PROTHIOCONAZOLE 1.3.1 a Jun 2005 204 PSEUDOMONAS FLUORESCENS 1.8 a May 1985 205 PYDIFLUMETOFEN 1.3 a Feb 2018 206 PYRIMETHANIL 1 a Feb 1996 207 PYRIPROXYFEN 1 a Aug 1994 208 QUASSIA 6, 2.1 d Nov 1974 209 QUINOXYFEN 1.3 a Nov 2001 210 RHIZOBIUM RHIZOGENES 1 b Nov 1989 211 ROSEMARY OIL 7.1 a Feb 2000 212 SAGE OIL (Spanish) 7.1 a Feb 2000 213 SANDALWOOD OIL 7.1 a Feb 2000 214 SEAWEED & UNFRACTIONED SEAWEED EXTRACTS 1.5 d Feb 1985 215 SILVER OXIDE 7.14 b Jun 2018 216 SIMAZINE 1.1 a Nov 1987 217 SODIUM BICARBONATE 1 a Jun 2004 218 SODIUM PROPIONATE 1.3 a Oct 2004 219 STERIC ACID 7.1 a Oct 2005 220 STREPTOMYCES LYDICUS WYEC 108 1.3 a Oct 2016 221 SUCRALFATE 6.8 a Aug 1982 222 SULESOMAB 6.1 b Jun 2002 223 SULFOSULFURON 1 a Feb 1998 224 SULPHATED POLYSACCHARIDES 7.1 a 225 TANNIC ACID 7.1 a Dec 1965 226 TANNIC ACID/BENZYL ALCOHOL PRODUCT 7.1 a Nov 1993 227 TERBACIL 1 a Aug 1987 228 THAUMATIN 3.2 a Nov 1990 229 THIDIAZURON 1 a Nov 1989 Authorised Version F2024L00589 registered 30/05/2024 Appendix B Substances considered not to require control by scheduling Clause 3 306 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Substances exempt in certain uses Item Column 1 Substance Column 2 Area, sub-area or sub-sub-area of use Column 3 Reason for inclusion Column 4 Date of inclusion 230 TIAFENACIL 1 a June 2019 231 TRIASULFURON 1 a Feb 1988 232 TRICHODERMA HARZIANUM 1 a May 1996 233 (Z)-9-TRICOSENE 1 a Aug 1991 234 TRIETHYLENE GLYCOL 7.1 a Nov 1974 235 TRIFLOXYSULFURON 1.1 a Feb 2002 236 TRIFLURALIN 1 a Aug 1990 237 TRIFORINE 1 a Aug 1987 238 ULOCLADIUM OUDEMANSII 1.10 a Oct 2003 239 UREA 7.1 a Nov 1974 240 13C-UREA 6.1 a May 2001 241 VETIVER OIL 7.1 a Feb 2000 242 VINYL ETHER 6 b Nov 1987 243 VITAMIN K 6.9, 2.8 a Jul 1963 244 XANTHOPHYLL (lutein) 7.1 a Nov 1974 245 XYLANASE derived from Aspergillus niger 2.4 a Feb 2005 246 YLANG YLANG OIL 7.1 a Feb 2000 247 ZINC NAPHTHENATE 1.3 a Authorised Version F2024L00589 registered 30/05/2024 Blank Appendix C Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 307 Appendix C—Blank Note 1: Appendix C is intentionally blank. Note 2: Appendix C previously included poisons now included in Schedule 10. Authorised Version F2024L00589 registered 30/05/2024 Appendix D Additional controls on possession or supply of poisons included in Schedule 4 or 8 Clause 1 308 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8 Note: See section 64. 1 Poisons available for human use only from or on the prescription or order of an authorised medical practitioner A poison specified in the following table may be supplied for human use only by, on the prescription or order of, an authorised medical practitioner. Item Poison 1 CANNABIS for human use 2 CLOMIFENE for human use 3 CLOZAPINE for human use 4 CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use 5 CYCLOFENIL for human use 6 DINOPROST for human use 7 DINOPROSTONE for human use 8 FOLLITROPIN ALFA (recombinant human follicle-stimulating hormone) for human use 9 FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use 10 FOLLITROPIN DELTA (recombinant human follicle-stimulating hormone) for human use 11 LUTEINISING HORMONE for human use 12 NABIXIMOLS for human use 13 SODIUM OXYBATE for human use 14 TETRAHYDROCANNABINOLS for human use 15 TERIPARATIDE for human use 16 UROFOLLITROPIN (human follicle-stimulating hormone) for human use 2 Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist A poison specified in the following table may be supplied for human use: (a) only by, or on the prescription or order of, a specialist physician or a dermatologist; and (b) if the person to whom the poison is to be supplied is a woman of child-bearing age—only if the specialist physician or dermatologist has: (i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and (ii) if the poison is acitretin or etretinate—advised the patient to avoid becoming pregnant during or for a period of 36 months after completion of treatment; and (iii) if the poison is bexarotene, isotretinoin or thalidomide—advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment. Authorised Version F2024L00589 registered 30/05/2024 Additional controls on possession or supply of poisons included in Schedule 4 or 8 Appendix D Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 309 Item Poison 1 ACITRETIN for human use 2 BEXAROTENE for human use 3 ETRETINATE for human use 4 ISOTRETINOIN for human oral use 5 THALIDOMIDE for human use 3 Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act A poison specified in the following table may be supplied only by, or on the prescription or order of, a medical practitioner for whom an approval or authority under section 19 of the Act that covers the poison is in force. Item Poison 1 DRONABINOL (delta-9-tetrahydrocannabinol) 4 Poisons available only from or on the order of a specialist physician A poison specified in the following table may be supplied: (a) only by, or on the prescription or order of, a specialist physician; and (b) if the person to whom the poison is to be supplied is a woman of child-bearing age—only if the specialist physician has: (i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and (ii) advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment. Item Poison 1 LENALIDOMIDE 2 POMALIDOMIDE 3 RIOCIGUAT for human use 4 TRETINOIN for human oral use 5 Poisons for which possession without authority is illegal The following table specifies poisons that must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription). Item Poison 1 ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4 2 ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4 3 AOD-9604 (CAS No. 221231-10-3) Authorised Version F2024L00589 registered 30/05/2024 Appendix D Additional controls on possession or supply of poisons included in Schedule 4 or 8 Clause 5 310 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Item Poison 4 BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8 5 BPC-157 6 CAPROMORELIN 7 CJC-1295 (CAS No. 863288-34-0) 8 DARBEPOETIN 9 DEXTROPROPOXYPHENE 10 N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) 11 EPHEDRINE 12 EPOETINS 13 ERYTHROPOIETIN 14 ERYTHROPOIETINS except when separately specified in this Appendix 15 FIBROBLAST GROWTH FACTORS 16 FOLLISTATIN 17 GLUTETHIMIDE 18 GROWTH HORMONE RELEASING HORMONES (GHRHs) including those separately specified in Schedule 4 19 GROWTH HORMONE RELEASING PEPTIDES (GHRPs) including those separately specified in Schedule 4 20 GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6) 21 GROWTH HORMONE SECRETAGOGUES including those separately specified in Schedule 4 22 HEXARELIN 23 IBUTAMOREN 24 INSULIN-LIKE GROWTH FACTORS 25 IPAMORELIN 26 NICOTINE 27 PERAMPANEL for human use 28 PHENTERMINE 29 PRALMORELIN ((GROWTH HORMONE RELEASING PEPTIDE-2) (GHRP-2)) 30 PSILOCYBINE 31 SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4 32 SOMATROPIN (human growth hormone) 33 STENABOLIC (SR9009) and other synthetic REV-ERB agonists 34 TB-500 35 THYMOSIN BETA 4 (THYMOSIN β4) 36 TIANEPTINE 37 VADADUSTAT Authorised Version F2024L00589 registered 30/05/2024 Additional controls on possession or supply of poisons included in Schedule 4 or 8 Appendix D Clause 6 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 311 6 Poisons available for human use only from or on the prescription or order of a specialist physician A poison specified in the following table may be supplied for human use: (a) only by, or on the prescription or order of, a specialist physician; and (b) if the person to whom the poison is to be supplied is a woman of child-bearing age—only if the specialist physician has: (i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and (ii) advised the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment. Item Poison 1 AMBRISENTAN for human use 2 BOSENTAN for human use 3 ENZALUTAMIDE for human use 4 MACITENTAN for human use 5 SITAXENTAN for human use 7 Poisons available for human use only from or on the prescription or order of a dermatologist A poison specified in the following table may be supplied for human use only by, or on the prescription or order of, a dermatologist. Item Poison 1 ALEFACEPT for human use 8 Poisons available for initial treatment of a patient only if authorised by certain health practitioners HYDROXYCHLOROQUINE may be supplied, for human use, for the initial treatment of a patient only if that treatment is authorised by: (a) a medical practitioner registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist in any of the following specialties or fields of specialty practice: (i) dermatology; (ii) emergency medicine; (iii) intensive care medicine; (iv) paediatrics and child health; (v) physician; or (b) a dental practitioner registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist in the specialty of oral medicine. Authorised Version F2024L00589 registered 30/05/2024 Appendix D Additional controls on possession or supply of poisons included in Schedule 4 or 8 Clause 9 312 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 9 Poisons which must be stored in a locked container to prevent unauthorised access The following table specifies poisons that must be stored in a locked container to prevent unauthorised access. Item Poison 1 PENTOBARBITAL in injectable preparations 10 Poisons available only when prescribed or authorised in certain circumstances N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human use may be supplied only for the treatment of post-traumatic stress disorder: (a) if MDMA is prescribed, or its supply is authorised, by a medical practitioner: (i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and (ii) for whom an authority under subsection 19(5) of the Act that covers MDMA is in force; or (b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act. PSILOCYBINE in preparations for human use may be supplied only for the treatment of treatment-resistant depression: (a) if psilocybine is prescribed, or its supply is authorised, by a medical practitioner: (i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and (ii) for whom an authority under subsection 19(5) of the Act that covers psilocybine is in force; or (b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act. Authorised Version F2024L00589 registered 30/05/2024 First aid instructions for poisons Appendix E Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 313 Appendix E—First aid instructions for poisons Note: See section 31. 1 Standard statements for first aid instructions For the purposes of the table in clause 3, the statement code specified in column 2 of an item of the following table represents: (a) the statement specified in column 3 of the item; or (b) a different statement that has the same intent as the statement specified in column 3 of the item. Standard statements for first aid instructions Item Column 1 Category Column 2 Statement code Column 3 Statement 1 Basic A For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once). 2 Basic Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. 3 General G1 Urgent hospital treatment is likely to be needed. (Note - the words “at once” to be added to instruction A). 4 General G2 If swallowed, give activated charcoal if instructed. (Note - the words “at once” to be added to instruction A). 5 General G3 If swallowed, do NOT induce vomiting. 6 General G4 Immediately give a glass of water. 7 General G5 Avoid giving milk or oils. 8 General G6 If sprayed in mouth, rinse mouth with water. 9 Eyes E1 If in eyes wash out immediately with water. 10 Eyes E2 If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes. 11 Respiratory system R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing. 12 Respiratory system R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area. 13 Skin S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. 14 Skin S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. Authorised Version F2024L00589 registered 30/05/2024 Appendix E First aid instructions for poisons Clause 2 314 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Standard statements for first aid instructions Item Column 1 Category Column 2 Statement code Column 3 Statement phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. 15 Skin S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. 16 Skin S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. 17 Skin S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766). 18 Special Purpose SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed. 2 Poisons information centre contact information in statements A statement required for a poison that includes a reference to a Poisons Information Centre must include: (a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and (b) immediately following the reference to a Poisons Information Centre: (i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or (ii) the telephone number for another poisons information centre: (A) that is attended by adequately trained staff for 24 hour emergency poisons information; and (B) calls to which are logged and submitted for incorporation into the official collection of poisoning data. Note: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766. 3 First aid instructions for poisons (1) For the purposes of subsection 31(1), and subject to subclause (2), the statement represented by each statement code specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item. (2) A statement required for a poison must: Authorised Version F2024L00589 registered 30/05/2024 First aid instructions for poisons Appendix E Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 315 (a) be modified for its use in relation to that poison as appropriate for the poison (for example if the poison is combined with other substances (whether toxic or non-toxic) or is in a particular physical form or presentation); and (b) if the statement refers to a Poisons Information Centre—comply with clause 2. Poisons that must be labelled with first aid instructions Item Column 1 Poison Column 2 Statement code 1 ACETIC ACID A, G3, E2, S1 2 ACETIC ANHYDRIDE A, G3, E2, S1 3 ACETONE A, G3 4 ACROLEIN A, G1, G2, G3, E2, R2, S2 5 ALKALINE SALTS A, G3, E2, S1 6 ALKYL NITRITES A 7 AMIDOPROPYL BETAINES—in cosmetic wash-off preparations when included in Schedule 6 E1 8 AMIDOPROPYL BETAINES—in other preparations when included in Schedule 6 E1, S1 9 AMINES for use as curing agents A, G3, E1, S1 10 2-AMINO-6-CHLORO-4-NITROPHENOL A, E1 11 4-AMINO-m-CRESOL A, E1 12 2-AMINO-5-ETHYLPHENOL A 13 4-AMINO-2-HYDROXYTOLUENE A, E1 14 4-AMINO-3-NITROPHENOL A 15 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL E1 16 m-AMINOPHENOL A, S1 17 p-AMINOPHENOL A, S1 18 4-AMINOPYRIDINE A, G1, G2, E1, S1 19 AMMONIA—5% or less A 20 AMMONIA—above 5% A, G3, E1, R1, S1 21 AMMONIUM COCOYL ISETHIONATE E1 22 AMMONIUM PERSULFATE A, G3, E2 23 AMMONIUM THIOCYANATE A 24 AMYL NITRITE A 25 ANHYDRIDES, organic acid, for use as curing agents for epoxy resins A, G3, E1, S1 26 ANILINE A, E2, R1, S1 27 ANISE OIL A, G3 28 ANITMONY CHLORIDE A, E2, S2 29 ANTIMONY COMPOUNDS, except antimony chloride A 30 ARBUTIN when included in Schedule 6 A, G2, G3, E2, R2, S1 Authorised Version F2024L00589 registered 30/05/2024 Appendix E First aid instructions for poisons Clause 3 316 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with first aid instructions Item Column 1 Poison Column 2 Statement code 31 AZADIRACHTA INDICA (neem) including its extracts and derivatives when included in Schedule 6 A, E1 32 AZO DYES (derivatives by diazotisation) A 33 BARIUM SALTS, except barium sulfate A 34 BASIC RED 76 A 35 BASIL OIL A, G3 36 BAY OIL A, G3 37 BENZALKONIUM CHLORIDE—when included in Schedule 5 A, G3, E2 38 BENZALKONIUM CHLORIDE—when included in Schedule 6 A, G3, E2, S1 39 BENZENE A, G3, E1, R1, S1 40 1,2-BENZENEDIOL (Catechol) A, E1, S1 41 BENZOYL PEROXIDE—above 20% A, E2, S1 42 BENZOYL PEROXIDE—above 10% up to 20% A, E1 43 BENZOYL PEROXIDE—10% or less A 44 BERGAMOT OIL A, G3 45 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5 A 46 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7 A, G3, E2, S5 47 1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE E1, S1 48 BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER A, E1 49 BORAX A 50 BORIC ACID A 51 BORON TRIFLUORIDE—when included in Schedule 5 A 52 BORON TRIFLUORIDE—when included in Schedule 6 or 7 A, G3, E2, S5 53 BROMOFORM A, G3, E2, R1, S2 54 BRUCINE A, G1, G2, G3, R2 55 2-BUTOXYETHANOL and its acetates A, E2, S1 56 n-BUTYL ALCOHOL A, E1, S1 57 BUTYL NITRITE A 58 CADMIUM COMPOUNDS A 59 CAJUPUT OIL A, G3 60 CAMPHOR A, G1, G3, G5 61 CARBAMIDE PEROXIDE—more than 9% up to 60% A, G3, E2, S1 62 CARBAMIDE PEROXIDE—more than 60% A, G1, G3, G4, E2, S1 63 CARBON DISULFIDE A, G3, E2, R1, S2 64 CARBON TETRACHLORIDE A, G3, E1, R1, S1 65 CASSIA OIL A, G3 Authorised Version F2024L00589 registered 30/05/2024 First aid instructions for poisons Appendix E Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 317 Poisons that must be labelled with first aid instructions Item Column 1 Poison Column 2 Statement code 66 CHLORINATING COMPOUNDS, except when separately specified—containing above 4% and below 10% of available chlorine A, G3, E1, S1 67 CHLORINATING COMPOUNDS, except when separately specified—containing 10% or more of available chlorine A, G3, E2, S1 68 CHLORIDE (gas) A, E1, R1 69 CHLOROACETAMIDE A 70 CHLOROCRESOL A, G3, E2, S2 71 2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL A, S1 72 CHLOROFORM A, G3, E1, R1, S1 73 CHROMATES A, G3, E2, S1 74 CHROMIUM TRIOXIDE A, G3, E2, S1 75 CHRYSOIDINE BASE A, S1, E1 76 CINEOLE A, G1, G3 77 CINNAMON BARK OIL A, G3 78 CINNAMON LEAF OIL A, G3 79 CLIMBAZOLE A 80 CLOVE OIL A, G1, G3, E2 81 COCOYL GLYCINATE E1 82 COPPER SULFATE A, G3, E2, S1 83 CREOSOTE A, G3, E2, S1 84 CRESOLS A, G3, E2, S3 85 CRESOLS in pressurised spray packs A, G6, E1, S1 86 CYANIDES A, G1, E1, R2 87 CYANOACRYLIC ACID ESTERS A 88 CYANURIC ACID A 89 CYCLOHEXANONE PEROXIDE A, G3, E2, S1 90 CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) A, E2, S1 91 CYCTEAMINE E1 92 1-DEOXY-1-(METHYLAMINO)-d-GLUCITOL N-COCO ACYL DERIVATIVES E1 93 2,4-DIAMINOPHENOXYETHANOL A, E2, S1 94 o-DICHLOROBENZENE A, G3, E1, S1 95 para-DICHLOROBENZENE (PDB) A 96 DICHLOROETHYL ETHER A, G3, E1, R1, S1 97 DICHLOROISOCYANURATES A, G3, E1, S1 98 DICHLOROMETHANE (methylene chloride) A, G3, G5, E1, R1, S1 Authorised Version F2024L00589 registered 30/05/2024 Appendix E First aid instructions for poisons Clause 3 318 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with first aid instructions Item Column 1 Poison Column 2 Statement code 99 DICHLOROMETHANE (methylene chloride)—in pressurised spray packs A, G6, S1 100 DICHROMATES A, G1, G3, E2, S1 101 DIDECYLDIMETHYLAMMONIUM SALTS A, G3 102 DIESEL (distillate) A, G3 103 DIETHANOLAMINE—when included in Schedule 5 A, G3 104 DIETHANOLAMINE—when included in Schedule 6 A, G3, E2, S1 105 DIETHYLENE GLYCOL MONOBUTYL ETHER A, E1, S1 106 5,6-DIHYDROXYINDOLINE E1 107 DIMETHYLFORMAMIDE—less than 75% A 108 DIMETHYLFORMAMIDE—75% or more A, E1, R1, S1 109 4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL A, E2 110 3,7-DIMETHYL-2,6-OCTADIEN-1-OL A, E1, S1 111 DIMETHYL SULFOXIDE A, G3, E1, S1 112 DINITROCRESOLS A, G1, E1, S1 113 DINITROPHENOLS A, G1, E1, S1 114 DIOXANE A, G3, E1, R1, S1 115 DISPERSE YELLOW 3 A, S1 116 DISTILLATE A, G3 117 N-(N-DODECYL)-2-PYRROLIDONE—when included in Schedule 5 A, G3, E1 118 N-(N-DODECYL)-2-PYRROLIDONE—when included in Schedule 6 A, G3, E2, S1 119 EPOXY RESINS liquid A, G3, E2, S1 120 Essential oils containing CAMPHOR as natural component unless otherwise specified A, G3 121 ETHER A, G3, E1, R1 122 ETHYL BROMIDE A, E2, S1, R1 123 ETHYLENE GLYCOL A 124 ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, except when separately specified A, G3, E2, S1 125 ETHYLENE OXIDE A, E2, R1 126 ETHYLHEXANEDIOL A, E2 127 2-ETHYLHEXANOIC ACID A 128 EUCALYPTUS OIL A, G1, G3 129 EUGENOL A, G1, G3, E2 130 FENNEL OIL A, G3 131 FLUORIDES except when separately specified—when included in Schedule 5 A 132 FLUORIDES except when separately specified—when included in Schedule 6 A, G1, G3, E2, S1 Authorised Version F2024L00589 registered 30/05/2024 First aid instructions for poisons Appendix E Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 319 Poisons that must be labelled with first aid instructions Item Column 1 Poison Column 2 Statement code 133 FORMALDEHYDE (see also paraformaldehyde) A, G3, E2, R1, S1 134 FORMIC ACID A, G3, E2, S1 135 FURFURAL A, E1, S1 136 GLUTARAL—below 5% A, G3, E1 137 GLUTARAL—5% or more A, G3, E2, S1 138 GLYCOLIC ACID A, G3, E2 139 GUANIDINE when included in Schedule 6 A, G3, E2, S1 140 HC VIOLET 1 E1 141 HEXACHLOROPHENE when included in Schedule 6 A 142 HEXYLOXYETHANOL A, G3, E2, S1 143 HYDRAZINE A, G1, G3, E2, R1, S1 144 HYDROCARBONS, liquid A, G3 145 HYDROCHLORIC ACID A, G3, E2, S1 146 HYDROCHLORIC ACID—when included in Schedule 5 A, G3 147 HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid—when included in Schedule 5 A 148 HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid—when included in Schedule 6 or 7 A, G3, E2, S5 149 HYDROGEN PEROXIDE—more than 3% up to 20% A, G3, E2, S1 150 HYDROGEN PEROXIDE—more than 20% A, G1, G3, G4, E2, S1 151 HYDROQUINONE—when included in Schedule 2 A 152 HYDROQUINONE—when included in Schedule 4 or 6 A, G2, G3, E2, R2, S1 153 HYDROSILICOFLUORIC ACID—when included in Schedule 5 A 154 HYDROSILICOFLUORIC ACID—when included in Schedule 6 or 7 A, G3, E2, S5 155 2-HYDROXYETHYL METHACRYLATE A, E1, S1 156 HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE E1, S1 157 IODINE (excluding salts, derivatives and iodophors)—2.5% or more for human external use A, E2 158 IODINE (excluding salts, derivatives and iodophors)—2.5% or more for other uses A, E2, S1 159 IODINE (excluding salts, derivatives and iodophors)—below 2.5% A 160 IODOPHORS A 161 ISOAMYL NITRITE A 162 ISOBUTYL NITRITE A 163 ISOCYANATES, free organic A, E2, S1 164 ISOEUGENOL A, E1, S1 165 ISOPHORONE A, G3, E2, S1 166 KEROSENE A, G3 Authorised Version F2024L00589 registered 30/05/2024 Appendix E First aid instructions for poisons Clause 3 320 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with first aid instructions Item Column 1 Poison Column 2 Statement code 167 LAURETH CARBOXYLIC ACIDS—leave-on or wash-off preparations above 5% E1 168 LAURETH CARBOXYLIC ACIDS—other preparations above 5% E1, S1 169 LAURYL ISOQUINOLINIUM BROMIDE A, E1 170 LEAD COMPOUNDS—in hair cosmetics A 171 LEAD COMPOUNDS—in other preparations A, S1 172 LEMON OIL A, G3 173 LEPTOSPERMUM SCOPARIUM OIL (manuka oil) A, G1, G3 174 LIME OIL A, G3 175 MAGNESIUM CHLORATE A 176 MALATHION at 20% or less A 177 MARJORAM OIL A, G3 178 MELALEUCA OIL A, G1, G3 179 MERCAPTOACETIC ACID A, E1 180 MERCURIC CHLORIDE—for external therapeutic use A 181 MERCURIC CHLORIDE—for other uses A, G1, G3, E2, R2, S1 182 MERCURIC IODIDE A, G1, G3, E2, R2, S1 183 MERCURIC NITRATE A, G1, G3, E2, R2, S1 184 MERCURIC OXIDE A, G1, G3 185 MERCURIC POTASSIUM IODIDE A, G1, G3, E2, R2, S1 186 MERCURIC THIOCYANATE A, G1, G3, E2, R2, S1 187 MERCUROCHROME A 188 MERCUROUS CHLORIDE A 189 MERCURY—metallic A 190 MERCURY—organic compounds A, S1 191 MERCURY—organic compounds in preparations for human external use A 192 METALDEHYDE A, E1, S1 193 METHANOL—above 10% A, G3 194 METHANOL—10% or less A 195 METHYLATED SPIRIT(S) A, G3 196 METHYLATED SPIRIT(S)—when packed and labelled as a “biofuel” suitable for use in “spirit burners” A, G3 197 METHYL ETHYL KETONE A, G3 198 METHYL ETHYL KETONE OXIME A, E1, S1 199 METHYL ETHYL KETONE PEROXIDE A, G3, E2, S1 200 METHYLEUGENOL A 201 METHYL ISOAMYL KETONE A, G3 202 METHYL ISOBUTYL KETONE A, G3 Authorised Version F2024L00589 registered 30/05/2024 First aid instructions for poisons Appendix E Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 321 Poisons that must be labelled with first aid instructions Item Column 1 Poison Column 2 Statement code 203 N-METHYL-2-PYRROLIDONE—when included in Schedule 5 A, G3, E1 204 N-METHYL-2-PYRROLIDONE—when included in Schedule 6 A, G3, E2 205 2-METHYLRESORCINOL A, E1 206 METHYL SALICYLATE LIQUID when included in Schedule 5 or 6 A, G3, E1 207 MONOETHANOLAMINE—when included in Schedule 5 A, G3, E1 208 MONOETHANOLAMINE—when included in Schedule 6 A, G3, E2, S1 209 1,5-NAPHTHALENEDIOL A, E1, S1 210 2,7-NAPHTHALENEDIOL A, E1, S1 211 NAPHTHALENE A, G1, G3 212 1-NAPHTHOL A, E1, S1 213 NITRIC ACID A, G3, E2, S1 214 NITROBENZENE A, G3, E1, S1 215 3-NITRO-p-HYDROXYETHYLAMINOPHENOL E1 216 NITROPHENOL A, G3, E2, S1 217 NITROPRUSSIDES—in aerosols A, G6, R1 218 NITROPRUSSIDES—in other preparations A, G3 219 NITROUS OXIDE A 220 NONOXINOL 9 A, E2 221 NUTMEG OIL A, G3 222 OCTHILINONE A, G3, E2, S1 223 OCTYL NITRITE A 224 N-(N-OCTYL)-2-PYRROLIDONE—when included in Schedule 5 A, G3, E1 225 N-(N-OCTYL)-2-PYRROLIDONE—when included in Schedule 6 A, G3, E2 226 ORANGE OIL (bitter) A, G3 227 OXALIC ACID A, G3, E2, S1 228 PARAFORMALDEHYDE A, G3, E2, R1, S1 229 PENNYROYAL OIL A, G3 230 PERACETIC ACID—when included in Schedule 5 A, G3, E1, S1 231 PERACETIC ACID—when included in Schedule 6 A, G3, E2, S1 232 PETROL A, G3, R1 233 2-PHENOXYETHANOL A, E1 234 PHENOL when included in Schedule 6 A, E1 235 PHENOLS—25% and less A, G3, E2, S3 236 PHENOLS—above 25% A, G3, E2, S4 237 PHENOLS—in pressurised spray packs A, E1 238 PHENOXYMETHYL OXIRANE A, E1 Authorised Version F2024L00589 registered 30/05/2024 Appendix E First aid instructions for poisons Clause 3 322 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with first aid instructions Item Column 1 Poison Column 2 Statement code 239 PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in hair dyes A, E1 240 PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in preparations other than hair dyes A, G1, G3, E1, S1 241 PHENYL METHYL KETONE as such, or in preparations of similar viscosity A, G3, E1 242 PHENYL METHYL PYRAZOLONE A, S1 243 N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE 2,5-DIMETHANAMINE A, E2, S1 244 N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE 2,6-DIMETHANAMINE A, E2, S1 245 o-PHENYLPHENOL A, G3, E2, S1 246 o-PHENYLPHENOL—in pressurised spray packs A, G6, E2, S1 247 PHOSPHONIC ACID A, G3, E2, S1 248 PHOSPHONIC ACID—neutralised to pH 6 (approx) A 249 PHOSPHONIC ACID—in spray packs A, E2, S1 250 PHOSPHORIC ACID A, G3, E2, S1 251 PHOSPHORUS, YELLOW A, G1, G3, E2, R2, S2 252 o-PHTHALALDEHYDE—when included in Schedule 5 A, E1 253 o-PHTHALALDEHYDE—when included in Schedule 6 A, G3, E2, S1 254 PICRAMIC ACID including its salts (excluding other derivatives) A, E1 255 PICRIC ACID A, G1, G3, E2, R1, S1 256 POLIHEXANIDE E1 257 POLYETHANOXY (15) TALLOW AMINE A, E2, S1 258 POLY(OXY-1,2-ETHANEDIYL), Α [2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL] Α -HYDROXY-,MONO-C13-15-ALKYL ETHERS A, E1 259 POTASSIUM BROMATE A 260 POTASSIUM CHLORATE A 261 POTASSIUM CYANATE A, E1, S1 262 POTASSIUM HYDROXIDE A, G3, E2, S1 263 POTASSIUM METABISULPHITE A 264 POTASSIUM NITRITE—when included in Schedule 7 A, G1, G3 265 POTASSIUM NITRITE—when included in Schedule 5 or 6 A, G3 266 POTASSIUM PEROXOMONOSULFATE TRIPLE SALT— when included in Schedule 5 A, G3, E1 267 POTASSIUM PEROXOMONOSULFATE TRIPLE SALT— when included in Schedule 6 A, G3, E2, S1 268 POTASSIUM PERSULFATE A, G3, E2 269 POTASSIUM SULFIDE A, G3, E2, S1 Authorised Version F2024L00589 registered 30/05/2024 First aid instructions for poisons Appendix E Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 323 Poisons that must be labelled with first aid instructions Item Column 1 Poison Column 2 Statement code 270 PROPIONIC ACID A, G3, E1, S1 271 n-PROPYL ALCOHOL A, E1 272 D-PULEGONE A, G3 273 PYRITHIONE ZINC A, E1 274 QUATERNARY AMMONIUM COMPOUNDS except when separately specified—above 20% A, G3, E2 275 QUATERNARY AMMONIUM COMPOUNDS except when separately specified—20% and below A, E2 276 QUATERNARY AMMONIUM COMPOUNDS except when separately specified—in pressurised spray packs A, E2, G6 277 QUINOLINE A, E1, S1 278 RESORCINOL A, E2, S1 279 SAFROLE A, G1, G3 280 SAGE OIL (Dalmatian) A, G3 281 SASSAFRAS OIL A, G1, G3 282 SELENIUM COMPOUNDS A, G1, E1, S1 283 SILICOFLUORIDES—when included in Schedule 5 A 284 SILICOFLUORIDES—when included in Schedule 6 A, G1, G3, E2, S1 285 SILVER SALTS A, E2 286 SODIUM ALUMINATE A, G3, E2, S1 287 SODIUM BROMATE A, G1 288 SODIUM CHLORATE A 289 SODIUM DIACETATE A, G3, E2, S1 290 SODIUM DICHLOROISOCYANURATE A, G3, E1, S1 291 SODIUM DODECYLBENZENE SULFONATE A, G3, E2, S1 292 SODIUM HYDROGEN SULFATE A, G3, E1, S1 293 SODIUMHYDROSULFITE A, G3, E2, S1 294 SODIUM HYDROXIDE A, G3, E2, S1 295 SODIUM LAURETH-6 CARBOXYLATE A 296 LAURYL SULFATE SALTS—leave-on or wash-off preparations above 5% E1 297 LAURYL SULFATE SALTS—other preparations above 5% E1, S1 298 SODIUM METABISULPHITE A, G3 299 SODIUM NITRITE—when included in Schedule 7 A, G1, G3 300 SODIUM NITRITE—when included in Schedule 5 or 6 A, G3 301 SODIUM PERCARBONATE—when included in Schedule 5 A, G3, S1 302 SODIUM PERCARBONATE—when included in Schedule 6 A, G3, E2, S1 303 SODIUM PERSULFATE A, G3, E2 304 SODIUM STANNATE A, E1 305 SODIUM SULFIDE A, G3, E2, S1 Authorised Version F2024L00589 registered 30/05/2024 Appendix E First aid instructions for poisons Clause 3 324 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with first aid instructions Item Column 1 Poison Column 2 Statement code 306 SODIUM TRICHLOROACETATE A 307 STRYCHNINE A, G1, G2, G3, R2 308 STYRENE A, G3, S1, E1 309 SULCOFURON A 310 SULFAMIC ACID A, G3, E2, S1 311 SULFURIC ACID A, G3, E2, S1 312 TERPENES, chlorinated A, G3 313 TETRACHLOROETHANE A, G3, E1, R1, S1 314 TETRACHLOROETHYLENE A, G3, E2, R1, S1 315 THIOUREA A 316 THUJONE A, G3 317 THYME OIL A, G3 318 o-TOLIDINE A 319 TOLUENE—above 75% A, G3, E1, R1, S1 320 TOLUENE—75% and below A, G3 321 TOLUENE—in pressurised spray packs A 322 TOLUENEDIAMINES—in hair dyes A, E1 323 TOLUENEDIAMINES—in other preparations A, G1, G3, E1, S1 324 TRICHLOROACETIC ACID A, G3, E2, S1 325 TRICHLOROACETIC ACID ALKALI SALTS A 326 1,1,1-TRICHLOROETHANE A, G3, E1, R1, S1 327 TRICHLOROETHYLENE A, G3, E1, R1, S1 328 TRICHLOROISOCYANURIC ACID A, G3, E1, S1 329 TRIETHYL PHOSPHATE A, E1 330 TRIFLUOROMETHANESULFONIC ACID A, G3, E2 331 TRIISOPROPANOLAMINE LAURYL ETHER SULFATE A, E1, S1 332 TROLAMINE A, G3, E1, S1 333 TURPENTINE (mineral) A, G3 334 TURPENTINE OIL (vegetable) A, G3, E2 335 VINYL ACETATE MONOMER A, R1 336 WHITE SPIRIT A, G3 337 XYLENE—above 75% A, G3, E1, R1, S1 338 XYLENE—75% and below A, G3 339 XYLENE—in pressurised spray packs A, G6, E1, S1 340 XYLENOLS in pressurised spray packs A, E1 341 ZINC CHLORIDE A, G3, E2, S1 342 ZINC SULFATE A, G3, E2, S1 Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 325 Appendix F—Warning statements and general safety directions for poisons Note: See sections 29 and 30, subsection 33(2) and section 42. 1 Warning statements For the purposes of the table in clause 4 of this Appendix and the table in clause 2 of Appendix L, the item number of an item of the following table represents the warning statement specified in column 1 of the item. Note: See section 30. Warning statements Item Column 1 Warning statement 1 Highly corrosive. 2 Corrosive. 3 Corrosive liquid. 4 Strongly alkaline. 5 Irritant. 6 May cause cancer. 7 WARNING – Causes birth defects. 8 WARNING – May be fatal to children. 9 Can be fatal to children if sucked or swallowed. 10 May produce severe burns. 11 WARNING – Vapour may be harmful. 12 Vapour is harmful to health on prolonged exposure. 13 May be fatal if inhaled, swallowed or absorbed through skin. 14 Dust will irritate and burn eyes, nose and skin. 15 Liquid will cause burns. 16 Forms dangerous gas near radiators or naked flames. 17 Contact with eyes even for short periods can cause blindness. 18 Product will irritate the eyes, nose, throat and skin. 19 WARNING – Skin contact may be dangerous. Take every precaution to avoid contact – wash off after spillage and after use. 20 May give off dangerous gas if mixed with other products. 21 WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye. 22 Highly reactive oxidising chlorine compound. 23 May cause fire or explosion. 24 For external washing only. Rinse skin thoroughly after use. Authorised Version F2024L00589 registered 30/05/2024 Appendix F Warning statements and general safety directions for poisons Clause 1 326 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Warning statements Item Column 1 Warning statement 25 Do not use on broken skin. Wash hands thoroughly after use. 26 (Powder) (and) (concentrated solutions) are dangerous if swallowed. 27 Not for therapeutic use. 28 (Over) (Repeated) exposure may cause sensitisation. 29 If congestion persists, consult your doctor or pharmacist. 30 WARNING – Do not use on face or on anal or genital areas. 31 WARNING – Do not use on face or on anal or genital areas except on doctor’s advice. 32 This preparation should be part of an overall treatment plan regularly assessed with your doctor. 33 Do not take for periods longer than four weeks except on medical advice. 34 WARNING – This medication may be dangerous when used in large amounts or for a long time (period). 35 CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful. or CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful. 36 For use under medical supervision only. 37 Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever. 38 CAUTION – Do not use for children under 2 years unless a doctor has told you to. 39 This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol. 40 This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery. 41 Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice. 42 WARNING – Overuse may stain the skin or mouth. 43 Use of this product is not necessary in areas supplied with fluoridated water. 44 WARNING – May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time. 45 WARNING – If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice. 46 WARNING – Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance). 47 WARNING – This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed. Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 327 Warning statements Item Column 1 Warning statement 48 WARNING – This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed. 49 WARNING – Do not mix with other medication except on veterinarian’s advice. 50 Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning. 51 Irritant to skin, eyes, mucous membranes and upper respiratory tract. 52 Breathing vapour or spray mist is harmful and may cause an asthma-like reaction. 53 CAUTION – (Name of substance) should not be used by pregnant women. 54 Seek medical advice before first course of treatment. 55 Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light. 56 WARNING – Can cause elevated blood pressure and interact adversely with other medication. 57 Not to be applied to infants under 12 months of age unless on doctor’s advice. 58 Highly reactive oxidising bromine and chlorine compound. 59 May cause allergy. 60 Do not mix with detergents or other chemicals. 61 WARNING - Can react with other medicines. Ask your doctor or pharmacist before taking. 62 Do not use if pregnant. 63 See a doctor if you are pregnant or diabetic. 64 See a doctor (or) (dentist) if no better after (Insert number of days as per approved Product Information) days. 65 If getting better, keep using for (Insert number of days as per approved Product Information) days. 66 See a doctor if problem returns. 67 Do not use if pregnant or likely to become pregnant. 68 If symptoms persist beyond 5 days consult a doctor (or) (dentist). 69 If symptoms recur within two weeks of completing the course, consult a doctor. 70 Use only under medical supervision if you are taking other medicines. 71 Do not use during the last three months of pregnancy. 72 Do not use in the eyes. 73 Do not use for acne. 74 Do not use under waterproof bandages unless a doctor has told you to. 75 Do not use for more than 7 days unless a doctor has told you to. 76 Do not become pregnant during use or within (Insert number of months as per approved Product Information) month(s) of stopping treatment. 77 WARNING - May cause birth defects. 78 Attacks skin and eyes. 79 Will irritate eyes. Authorised Version F2024L00589 registered 30/05/2024 Appendix F Warning statements and general safety directions for poisons Clause 1 328 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Warning statements Item Column 1 Warning statement 80 WARNING: Do not attempt to refill burner while it is in use or still warm; it could lead to serious burn injury. 81 (Intentionally blank) 82 (Intentionally blank) 83 This paint is dangerous to health, even when dry. For industrial use only. Do not use on toys or furniture. Do not use on, in or around the home. 84 Breathing the vapour is dangerous. Provide adequate ventilation during application. Do not use in the presence of a naked flame. Do not smoke. 85 This paint contains lead and is dangerous to health, even when dry. For industrial use only. Do not use on toys or furniture. Do not use for painting any building or fixed structure. Do not use where contact with food or drinking water is possible. 86 This tinter contains lead. Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water. 87 (Insert brand name) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor. 88 This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye. 89 Application to skin may increase sensitivity to sunlight. 90 This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol. 91 CAUTION – Total iodine intake may exceed recommended level when taking this preparation. 92 WARNING – Contains iodine - do not take when pregnant except on physician’s advice. 93 Causes severe burns, which are not likely to be immediately painful or visible. 94 WARNING – Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children. 95 CAUTION – Do not use for children under 12 years unless a doctor has told you to. 96 CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor. 97 Adults: Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor. 98 Children and adolescents: Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor. Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 329 Warning statements Item Column 1 Warning statement 99 If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage. 100 Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist. 101 Don’t use [this product/name of the product]: If you have a stomach ulcer. In the last 3 months of pregnancy. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.] If you are allergic to (name of substance) or anti-inflammatory medicines. 102 Unless a doctor has told you to, don’t use [this product/name of the product]: For more than a few days at a time. With other medicines containing aspirin or other anti-inflammatory medicines. If you have asthma. In children under 12 years of age. In children 12-16 years of age with or recovering from chicken pox, influenza or fever. If you are pregnant. 103 See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.] 104 Unless a doctor has told you to, don’t use [this product/name of the product]: For more than a few days at a time. With other medicines containing (name of substance) or other anti-inflammatory medicines. If you have asthma. If you are pregnant. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.] 105 Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less. 106 Contains formaldehyde. 107 Not recommended for children under twelve years of age. 108 Breathing of solder fumes is harmful and may cause asthma or sensitisation. 109 See your healthcare provider if you consider that you may be at risk of a Sexually Transmitted Infection (STI). 110 See a doctor if you plan to become pregnant, or are breastfeeding or plan to breastfeed. 111 Do not use if breastfeeding or planning to breastfeed. 112 WARNING – May cause irreversible nerve damage if inhaled. 2 Safety directions—general For the purposes of the table in clause 4, the item number of an item of the following table represents the safety direction specified in column 1 of the item. Note: See section 29. Authorised Version F2024L00589 registered 30/05/2024 Appendix F Warning statements and general safety directions for poisons Clause 2 330 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Safety directions Item Column 1 Safety direction 1 Avoid contact with eyes. 2 Attacks eyes - protect eyes when using. 3 Wear eye protection when mixing or using. 4 Avoid contact with skin. 5 Wear protective gloves when mixing or using. 6 Wash hands after use. 7 Wash hands thoroughly after use. 8 Avoid breathing dust (or) vapour (or) spray mist. 9 Use only in well ventilated area. 10 Ensure adequate ventilation when using. 11 No smoking. 12 Do not allow product to come into contact with other chemicals, especially acids. 13 Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene. 14 Do not allow to get damp. 15 Store under cover in a dry, clean, cool, well ventilated place away from sunlight. 16 Store and transport in an upright container. 17 Do not mix with other chemicals. 18 Do not mix with different types of chlorinating chemicals. 19 Use clean containers for dispensing. 20 Mix with water only. 21 Do not add water to product - add product to water, but in case of fire drench with water. 22 In case of spillage flush with large quantities of water. 23 Keep away from heat, sparks and naked flames. 24 Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes. 25 Avoid contact with food. 26 Avoid contact with clothing. 27 Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed. 28 Do not mix with hot water. 29 Obtain a supply of calcium gluconate gel. 30 (Intentionally blank) 31 Do not use on broken skin. 32 Do not use under occlusive dressing. 33 Mix strictly according to instructions. 34 May cause fire if it comes into contact with other chemicals, paper or other flammable materials. 35 Wash gloves thoroughly, immediately after use. 36 Protect cuticles with grease or oil. Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 3 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 331 Safety directions Item Column 1 Safety direction 37 Avoid breathing solder fumes. 38 Do not intentionally inhale contents. 3 Poisons information centre contact information in statements A statement required for a poison that includes a reference to a Poisons Information Centre must include: (a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and (b) immediately following the reference to a Poisons Information Centre: (i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or (ii) the telephone number for another poisons information centre: (A) that is attended by adequately trained staff for 24 hour emergency poisons information; and (B) calls to which are logged and submitted for incorporation into the official collection of poisoning data. Note: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766. 4 Poisons that must be labelled with warning statements and safety directions (1) For the purposes of subsections 29(1) and 30(1), and subject to subclauses (2) and (3), the following are required for a poison specified in column 1 of an item of the following table: (a) the warning statement represented by each item number specified in column 2 of the item; (b) the safety direction represented by each item number specified in column 3 of the item. (2) A warning statement or safety direction required for a poison must: (a) be completed or modified for its use in relation to that poison if the statement or direction indicates that such completion is required or such modification is appropriate; and (b) if the statement includes a reference to a Poisons Information Centre— comply with clause 3. Note: For paragraph (a), for example: (a) a statement or direction may require completion by including the name of the poison; and (b) a statement or direction may indicate that modification is appropriate by including different options for the text, or by stating that certain text is not needed in certain circumstances. (3) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate). Authorised Version F2024L00589 registered 30/05/2024 Appendix F Warning statements and general safety directions for poisons Clause 4 332 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 1 ACETIC ACID in concentrations of 80% or more except when included in Schedule 2 2 1, 4, 8 2 ACETIC ANHYDRIDE 2 1, 4, 8 3 ACETONE in concentrations greater than 75% 1, 4, 8 4 ACITRETIN—for oral use 7, 62, 76 5 ACITRETIN—for topical use 62, 77 6 ADAPALENE for topical use 62, 77 7 ALCLOMETASONE when included in Schedule 3 38, 72, 73, 74, 75 8 ALKALINE SALTS 4 1, 4 9 AMBRISENTAN 7, 62, 76 10 AMINES used as curing agents for epoxy resins 1, 3, 4, 5, 8 11 2-AMINO-6-CHLORO-4-NITROPHENOL 28 12 4-AMINO-m-CRESOL 28 13 2-AMINO-5-ETHYLPHENOL 21 14 4-AMINO-2-HYDROXYTOLUENE 28 15 4-AMINO-3-NITROPHENOL 28 16 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO] BISETHANOL 28 17 m-AMINOPHENOL 28 4, 8 18 p-AMINOPHENOL 28 19 AMMONIA/AMMONIUM HYDROXIDE in concentrations greater than 20% ammonia except in smelling salts 4 1, 4, 8 20 AMMONIUM PERSULFATE 5, 21, 25 1, 5, 23, 33, 34 21 ANHYDRIDES, organic acid, for use as curing agents for epoxy resins 1, 3, 4, 5, 8 22 ANILINE 13 1, 4, 8 23 ANTIHISTAMINES not separately specified in this Appendix except the following: (a) dermal, ocular, parenteral and paediatric preparations; (b) oral preparations of astemizole, azelastine, bilastine, cetirizine, desloratadine, fexofenadine, loratadine, or terfenadine; (c) nasal preparations of azelastine or olopatadine; (d) preparations for the treatment of animals 39 or 40 24 ARBUTIN when included in Schedule 6 45 1, 4 25 AROMATIC EXTRACT OILS 1, 3, 4, 5, 6 26 ASPIRIN—for inhibition of platelet aggregation 36 Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 4 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 333 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 27 ASPIRIN—in sustained release preparations containing 650 mg or more of aspirin 36 28 ASPIRIN—in other preparations 101, 102, 103 29 ASTEMIZOLE 61 30 ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis 63, 64, 69, 75, 109, 110 31 ASTODRIMER SODIUM—for the prevention of recurrent bacterial vaginosis 63, 75, 109, 110 32 AZADIRACHTA INDICA including its extracts and derivatives when included in Schedule 6 67 33 AZOCYCLOTIN 48 34 AZO DYES (derivatives by diazotisation) 6 5 35 BASIC RED 76 5 36 BENOMYL 46 37 BENZENE 12 1, 4, 9 38 1,2-BENZENEDIOL (Catechol) 51, 59 1, 4, 8 39 BENZOYL PEROXIDE—when included in Schedule 2 55 40 BENZOYL PEROXIDE—when included in Schedule 5 1, 4, 8 41 BERGAMOT OIL 89 42 BERYLLIUM 1, 4, 8 43 BEXAROTENE—for human use 7, 62, 76 44 BEXAROTENE—for topical use 62, 77 45 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5 1, 4 46 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7 1, 17, 93 1, 3, 4, 5, 8, 29, 35 47 1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE 28, 79 1 48 BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER 1 49 BITHIONOL for the treatment of animals 1, 4, 8 50 BORIC ACID when used in Schedule 5 25, 26 51 BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 5 2 1, 4 52 BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 6 or 7 1, 17, 93 1, 3, 4, 5, 8, 29, 35 53 BOSENTAN 7, 62, 76 54 BROMOFORM 1, 4, 8 55 2-BUTOXY-2'-THIOCYANODIETHYL ETHER 1, 4, 8 56 2-BUTOXYETHANOL and its acetates 1, 4, 8 Authorised Version F2024L00589 registered 30/05/2024 Appendix F Warning statements and general safety directions for poisons Clause 4 334 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 57 n-BUTYL ALCOHOL 5 2, 4, 8 58 CAMPHOR—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents 9 59 CAMPHOR—in other forms 9 1 60 CANNABIDIOL when included in Schedule 3 67, 111 61 CARBAMIDE PEROXIDE—more than 9% up to 30% 5 1 62 CARBAMIDE PEROXIDE—more than 30% up to 60% 5 2 63 CARBAMIDE PEROXIDE—more than 60% 2 2, 4 64 CARBON DISULFIDE 12 1, 4, 8, 9, 23 65 CARBON TETRACHLORIDE 12 1, 4, 8, 9 66 CASSIA OIL 4 67 CHLORINATING COMPOUNDS—in household cleaning or bleaching preparations 20 68 CHLORINATING COMPOUNDS—in preparations containing less than 10% of available chlorine 11 1, 4, 10 69 CHLORINATING COMPOUNDS—in liquid preparations containing 10% or more of available chlorine 3, 18 1, 4, 6, 8, 10, 15, 16, 17, 18, 19, 20, 22, 26 70 CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine 10, 18, 22, 23 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26 71 CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code 10, 18, 22 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26 72 CHLORINATING COMPOUNDS—in compressed block or tablets containing 10% or more of available chlorine except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid 10, 22, 23 12, 13, 14, 15, 17, 18, 19, 21 73 CHLORINATING COMPOUNDS—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid 10, 22 12, 13, 14, 15, 17, 18, 19, 21 74 CHLOROACETAMIDE 28 4 75 2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL 28 4 Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 4 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 335 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 76 CHLOROFORM when included in Schedule 6 1, 4, 8 77 alpha-CHLOROHYDRIN 13, 51 1, 4, 8, 9 78 CHROMATES (including dichromates) of alkali metals or ammonia 1, 4, 8 79 CHROMIUM TRIOXIDE 2, 14, 15, 23 1, 4, 8, 13 80 CIMETIDINE when included in Schedule 3 70, 96 81 CINNAMON BARK OIL 4 82 CLOBETASONE when included in Schedule 3 72, 73, 74, 75, 95 83 CLOTRIMAZOLE in vaginal preparations when included in Schedule 3 54, 63, 64, 66 84 CLOVE OIL 1 85 CYANIDES when included in Schedule 7 13 4, 8 86 CYANURIC ACID 1, 4, 8 87 CYCLOHEXANONE PEROXIDE 1, 4, 8 88 CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) 2, 10, 78 1, 4, 5, 35 89 CYCTEAMINE 1 90 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL DERIVATIVES 79 1 91 4,4-DIAMINODIPHENYLMETHANE (methylene dianiline) 1, 4, 8 92 2,4-DIAMINOPHENOXYETHANOL 28, 79 1, 4 93 o-DICHLOROBENZENE 1, 4, 8 94 para-DICHLOROBENZENE 1, 4 95 DICHLOROETHYLENE 1, 4, 8 96 DICHLOEOETHYL ETHER 1, 4, 8 97 DICHLOROISOCYANURATES—in household cleaning or bleaching preparations 20 98 DICHLOROISOCYANURATES—in preparations containing less than 10% of available chlorine 11 1, 4, 10 99 DICHLOROISOCYANURATES—in liquid preparations containing 10% or more of available chlorine 3, 18 1, 4, 6, 8, 10, 15, 16, 17, 18, 19, 20, 22, 26 100 DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine 10, 18, 22, 23 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26 Authorised Version F2024L00589 registered 30/05/2024 Appendix F Warning statements and general safety directions for poisons Clause 4 336 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 101 DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code 10, 18, 22 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26 102 DICHLOROISOCYANURATES—in anti-bacterial tablets containing 2.5 g or less of sodium dichloroisocyanurate 60 103 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine except in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only 10, 22, 23 12, 13, 14, 15, 17, 18, 19, 21 104 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code except in preparations containing 21 g less of sodium dichloroisocyanurate for use in toilet cisterns only 10, 22 12, 13, 14, 15, 17, 18, 19, 21 105 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage 10, 22, 23 12, 13, 14, 15, 17, 18, 21 106 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use 5 1, 4, 7, 12 107 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage 10, 22 12, 13, 14, 15, 17, 18, 21 108 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use 5 1, 4, 7, 12 Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 4 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 337 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 109 DICHLOROMETHANE (methylene chloride)—in paint or lacquer removers 12, 16 1, 4, 8, 11 110 DICHLOROMETHANE (methylene chloride)—other than in paint or lacquer removers 1, 4, 8, 25 111 DICLOFENAC 101, 104 112 DIENESTROL 67 113 DIETHANOLAMINE—when included in Schedule 5 5 1, 4 114 DIETHANOLAMINE—when included in Schedule 6 2, 11, 18 1, 4, 8 115 DIETHYLTOLUAMIDE for human use 44 116 DIETHYLENE GLYCOL MONOBUTYL ETHER 5 1, 4, 8, 9 117 5,6-DIHYDROXYINDOLINE 21, 28 118 2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE 28 119 DIMETHYLFORMAMIDE 1, 4, 8 120 4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL 5, 28 1, 2 121 3,7-DIMETHYL-2,6-OCTADIEN-1-OL 5 1, 4 122 DIMETHYL SULFATE 2 1, 4, 8 123 DIMETHYL SULFOXIDE—when not packed and labelled for therapeutic use 27 1, 4, 5, 8 124 DIMETHYL SULFOXIDE—when packed and labelled for the treatment of animals 49 1, 4, 5, 8 125 DINITROCRESOLS (and their homologues) except when for therapeutic use 1, 4, 8 126 DINITROPHENOLS (and their homologues) except when for therapeutic use 1, 4, 8 127 DINOCAP 47 128 DIOXANE 1, 4, 8 129 DIPHENOXYLATE when included in Schedule 3 39 or 40, 41 130 DISPERSE YELLOW 3 28 4 131 ECONAZOLE in vaginal preparations when included in Schedule 3 54, 63, 64, 66 132 ENZALUTAMIDE 7, 67, 87 133 EPHEDRINE in nasal preparations for topical use 29 134 EPICHLOROHYDRIN 2 1, 4, 8 135 EPOXY RESINS, liquid 1, 3, 4, 5, 8 136 ETHER when included in Schedule 5 or 6 1, 4, 8 137 2-ETHOXYETHANOL 77 1, 4, 8 138 ETHOXYETHYLMERCURIC CHLORIDE 1, 4 139 ETHYL BROMIDE 1, 4, 8 140 ETHYLENE CHLOROHYDRIN 1, 4, 8 Authorised Version F2024L00589 registered 30/05/2024 Appendix F Warning statements and general safety directions for poisons Clause 4 338 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 141 ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates except when separately specified 1, 4, 8 142 ETHYLENE OXIDE 1, 4, 8 143 ETHYLHEXANEDIOL 79 1 144 2-ETHYLHEXANOIC ACID 53 145 ETHYLMERCURIC CHLORIDE 1, 4 146 ETHYL METHACRYLATE 28 4, 9, 23 147 ETRETINATE 7, 62, 76 148 EUGENOL 1 149 FAMOTIDINE when included in Schedule 2 96 150 FENTEROL in metered aerosols 32 151 FLUCONAZOLE in oral preparations when included in Schedule 3 64 152 FLUORIDES (including silicofluorides) when included in Schedule 5 or 6 except when separately specified 1, 4 153 FORMALDEHYDE—in nail hardener cosmetics 106 1, 4, 8, 36 154 FORMALDEHYDE—in other preparations 106 1, 4, 8 155 FORMIC ACID 1, 4, 8 156 FURFURAL 5 1, 4 157 Glazing preparations containing LEAD COMPOUNDS 50 158 GLUTARAL except when included in Schedule 2—25% or less 5, 59 1, 4, 5 159 GLUTARAL except when included in Schedule 2—more than 25% 3, 59 1, 4, 5, 8 160 GLYCOLIC ACID 79 1, 5, 6, 31 161 HC VIOLET 1 28 162 HEXACHLOROPHENE in preparations for skin cleansing purposes containing 3% or less of hexachlorophene 24 163 HEXYLOXYETHANOL 2 1, 4, 8 164 HYDRAZINE 1, 4, 8 165 HYDROCHLORIC ACID—30% or less of HCl 1, 4 166 HYDROCHLORIC ACID—more than 30% of HCl 1, 4, 8 167 HYDROCORTISONE—for dermal use when included in Schedule 2 or 3 38, 72, 73, 74, 75 168 HYDROCORTISONE—for topical rectal use when included in Schedule 2 or 3 38, 75 169 HYDROCYANIC ACID when included in Schedule 7 13 4, 8 170 HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid)—when included in Schedule 5 2 1, 4 Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 4 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 339 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 171 HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid)—when included in Schedule 6 or 7 1, 17, 93 1, 3, 4, 5, 8, 29, 35 172 HYDROGEN PEROXIDE—more than 3% up to 10% 5 1 173 HYDROGEN PEROXIDE—more than 10% up to 20% 5 2 174 HYDROGEN PEROXIDE—more than 20% 2 2, 4 175 HYDROQUINONE—when included in Schedule 2 45 176 HYDROQUINONE—except when included in Schedule 2 or 4 1, 4 177 HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid)—when included in Schedule 5 2 1, 4 178 HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid)—when included in Schedule 6 or 7 1, 17, 93 1, 3, 4, 5, 8, 29, 35 179 2-HYDROXYETHYL METHACRYLATE 28 4 180 HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE 28 181 IBUPROFEN 101, 104 182 IODINE—more than 20% 1, 4, 8 183 IODINE—in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose 91, 92 184 IPRATROPIUM BROMIDE in metered aerosols 32 185 ISOCYANATES (free organic)—when in paint 28, 52 1, 5, 8, 10, 27 186 ISOCYANATES (free organic)—other than in paint 28, 52 1, 4, 8 187 ISOEUGENOL 19, 28, 79 1, 4 188 ISOPRENALINE in metered aerosols 32 189 ISOTRETINOIN—for human oral use 7, 62, 76 190 ISOTRETINOIN—for topical use 62, 77 191 LEAD COMPOUNDS—in hair cosmetics 25 192 LEAD COMPOUNDS—when included in Schedule 6 preparations that are not hair cosmetics 1, 4, 8 193 LEFLUNOMIDE 7, 62, 87 194 LEMON OIL 89 195 LENALIDOMIDE 7, 62, 76 196 LEVOCABASTINE—in eye or nasal preparations containing 0.5 mg/mL or less of levocabastine 62 197 LEVOCABASTINE—in other preparations 62 and either 39 or 40 198 LIME OIL 89 Authorised Version F2024L00589 registered 30/05/2024 Appendix F Warning statements and general safety directions for poisons Clause 4 340 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 199 LOPERAMIDE when included in Schedule 2 41 200 MAGNESIUM CHLORATE 1, 4 201 MEFENAMIC ACID 101, 104 202 MERCAPTOACETIC ACID 5, 28 1, 31 203 MERCURIC THIOCYANATE 1, 4 204 METACRESOLSULPHONIC ACID and formaldehyde condensation product for the treatment of animals 1, 4 205 METHANOL except in methylated spirit 1, 4, 8 206 METHOXAMINE in nasal preparations for topical use 29 207 2-METHOXYETHANOL 77 1, 4, 8 208 METHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners” 80 209 p-METHYLAMINOPHENOL 28 210 METHYL CHLORIDE 1, 4, 8 211 METHYL ETHYL KETONE 5 1, 4, 8 212 METHYL ETHYL KETONE OXIME 5, 28 1, 4 213 METHYL ETHYL KETONE PEROXIDE 2 2, 3, 4, 6 214 METHYL ISOAMYL KETONE 1, 4, 8 215 METHYL ISOBUTYL KETONE 1, 4, 8 216 METHYL ISOTHIOCYANATE 5, 12 1, 4, 8 217 METHYL METHACRYLATE 28 4, 9, 23 218 METHYLCHLOROISOTHIAZOLINONE 28 219 METHYLDIBROMO GLUTARONITRILE 28 1, 4, 7 220 METHYLENE BISTHIOCYANATE 1, 4 221 METHYLEUGENOL 1, 6 222 METHYLISOTHIAZOLINONE 28 223 METHYLNORBORNYLPYRIDINE 59 224 2-METHYLRESORCINOL 1 225 1-(BETA-METHYL SULPHONAMIDOETHYL) 2-AMINO-3-N,N-DIETHYLAMINOBENZENE 1, 4, 8 226 MICONAZOLE in vaginal preparations when included in Schedule 3 54, 63, 64, 66 227 MISOPROSTOL 53 228 MONOETHANOLAMINE when included in Schedule 5 5 1, 4 229 MONOETHANOLAMINE when included in Schedule 6 2, 11, 18 1, 4, 8 230 NAPHAZOLINE in nasal preparations for topical use 29 231 NAPHTHALENE—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents 9, 105 Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 4 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 341 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 232 NAPHTHALENE—in other forms 9, 105 1 233 1,5-NAPHTHALENEDIOL 28 1 234 2,7-NAPHTHALENEDIOL 28 1, 3 235 1-NAPHTHOL 28 1 236 NAPROXEN 101, 104 237 NICOTINE except when in tobacco 1, 4 238 NITRIC ACID—75% or less HNO3 2 1, 4 239 NITRIC ACID—more than 75% HNO3 2 1, 4, 8 240 NITROBENZENE 1, 4, 8 241 3-NITRO-p-HYDROXYETHYLAMINOPHENOL 28 242 NITROPHENOLS 1, 4 243 NITROPRUSSIDES in aerosols 84 8 244 NITROUS OXIDE 112 38 245 NIZATIDINE when included in Schedule 2 96 246 NORADRENALINE in metered aerosols 32 247 NYSTATIN in vaginal preparations when included in Schedule 3 54, 63, 64, 65, 66 248 ORANGE OIL (bitter) 89 249 ORCIPRENALINE in metered aerosols 32 250 OXALATES, metallic 4, 8 251 OXALIC ACID 2 4, 8 252 OXYMETAZOLINE in nasal preparations for topical use 29 253 OXYQUINOLINE (including salts and derivatives) when prepared for internal use 33 254 PAINT—first group paints 83 255 PAINT—second group paints 84 256 PALOVAROTENE 7, 62, 76, 111 257 PARACETAMOL 97 and/or 98, 99, 100 258 PENTACHLOROPHENOL 1, 4, 8 259 PERACETIC ACID 2 1, 4, 8 260 PERMANGANATES 2 24 261 2-PHENOXYETHANOL 5 1 262 PHENOL and any other homologue of phenol 1, 4 263 PHENOL when included in Schedule 6 3, 51 2, 4, 8 264 PHENOLS 5 265 PHENOXYMETHYL OXIRANE 12, 28, 51 1, 3, 4, 5, 7, 8, 9 Authorised Version F2024L00589 registered 30/05/2024 Appendix F Warning statements and general safety directions for poisons Clause 4 342 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 266 PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in hair dyes 21 267 PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in preparations other than hair dyes 28 1, 4, 8 268 PHENYL METHYL PYRAZOLONE 28 4 269 PHENYLEPHRINE in nasal preparations for topical use 29 270 POMALIDOMIDE 7, 62, 76 271 N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HE PTANE-2,5-DIMETHANAMINE 5, 28 1, 4, 5, 10 272 o-PHENYLPHENOL except when in antiseptics 1, 4 273 PHENYLPROPANOLAMINE 56 274 PHENYTOIN in pastes for the treatment of horses 9 275 PHOSPHONIC ACID 1, 4 276 PHOSPHORIC ACID 1, 4 277 PHOSPHORUS (yellow) 2 1, 4 278 o-PHTHALALDEHYDE—when included in Schedule 5 51, 52, 59 1, 4, 5, 8, 10 279 o-PHTHALALDEHYDE—when included in Schedule 6 51, 52, 59 2, 4, 5, 8, 10 280 PICRAMIC ACID including its salts (excluding other derivatives) 28 5 281 PICRIC ACID (more than 20%) 1, 4 282 PODOPHYLLIN—in preparations specifically for use on anal or genital area 36 283 PODOPHYLLIN—in other liquid preparations when included in Schedule 2 or 3 31 284 PODOPHYLLIN—in other solid or semi-solid preparations when included in Schedule 2 30 285 PODOPHYLLOTOXIN—in preparations specifically for use on anal or genital area 36 286 PODOPHYLLOTOXIN—in other liquid preparations when included in Schedule 2 or 3 31 287 PODOPHYLLOTOXIN—in other solid or semi-solid preparations when included in Schedule 2 30 288 POLIHEXANIDE 28 1, 4, 8 289 POLYETHANOXY (15) TALLOW AMINE 1, 4 290 POLY(OXY-1,2-ETHANEDIYL), Α [2-[(2-HYDROXYETHYL)AMINO] -2-OXOETHYL] Α -HYDROXY-,MONO-C13-15 -ALKYL ETHERS 5, 88 1, 5 291 POTASSIUM HYDROXIDE—in preparations containing 0.5% or less of potassium hydroxide 5 1, 4, 6 Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 4 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 343 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 292 POTASSIUM HYDROXIDE—in solid preparations containing more than 0.5% of potassium hydroxide 2, 10, 78 3, 5, 28 293 POTASSIUM HYDROXIDE—in liquid preparations containing more than 0.5% of potassium hydroxide 2, 10, 78 3, 5 294 POTASSIUM PERSULFATE 5, 21, 25 1, 5, 23, 33, 34 295 POTASSIUM SULFIDE 2 1, 4 296 PROPIONIC ACID when included in Schedule 6 2 1, 4 297 n-PROPYL ALCOHOL 5 1, 9 298 QUININE 28 299 QUINOLINE 79 1, 4 300 RANITIDINE when included in Schedule 2 96 301 RESORCINOL 19, 28, 79 1, 3, 4 302 ROSIN 108 37 303 SAFROLE—in preparations for therapeutic use 1 304 SAFROLE—other than for therapeutic use 1, 4 305 SALBUTAMOL in metered aerosols or in dry powder formulations 32 306 SALICYLAMIDE 34 or 35 307 SASSAFRAS OIL—in preparations for therapeutic use 1 308 SASSAFRAS OIL—other than for therapeutic use 1, 4 309 SELENIUM COMPOUNDS except when for therapeutic use (human or animal) 1, 4, 8 310 SILVER in smoking deterrents 42 311 SITAXENTAN 7, 62, 76 312 SODIUM ALUMINATE 2 1, 4 313 SODIUM CHLORATE 1, 4 314 SODIUM DODECYLBENZENE SULFONATE 79 1 315 SODIUM FLUORIDE in preparations for human ingestion when included in Schedule 2 43 316 SODIUM HYDROGEN SULFATE 1, 4, 8 317 SODIUM HYDROSULFITE (more than 50%) 5, 26 1, 4, 8 318 SODIUM HYDROXIDE—in preparations containing 0.5% or less of sodium hydroxide 5 1, 4, 6 319 SODIUM HYDROXIDE—in solid preparations containing more than 0.5% of sodium hydroxide 2, 10, 78 3, 5, 28 320 SODIUM HYDROXIDE—in liquid preparations containing more than 0.5% of sodium hydroxide 2, 10, 78 3, 5 321 SODIUM LAURETH-6 CARBOXYLATE 79 1 322 SODIUM METABISULPHITE (more than 50%) 5, 26 1, 4 323 SODIUM NITRITE in pickling or curing salts 94 Authorised Version F2024L00589 registered 30/05/2024 Appendix F Warning statements and general safety directions for poisons Clause 4 344 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 324 SODIUM PERSULFATE 5, 21, 25 1, 5, 23, 33, 34 325 SODIUM SULFIDE 2 1, 4 326 STYRENE 1, 4, 8 327 SULFAMIC ACID 2 1, 4 328 SULFURIC ACID 2 1, 4 329 SYMPHYTUM SPP. (Comfrey) when included in Schedule 5 31, 32 330 TAZAROTENE for topical use 77, 62 331 TERBUTALINE in metered aerosols or in dry powder formulations 32 332 TERFENADINE 61 333 TERIFLUNOMIDE 7, 62, 87 334 TERPENES, chlorinated 1, 4, 8 335 TETRACHLOROETHANE 12 8 336 TETRACHLOROETHYLENE when included in Schedule 5 or 6 12, 16 1, 4, 8, 11 337 TETRYZOLINE in nasal preparations for topical use 29 338 THALIDOMIDE 7, 62, 76 339 THIOUREA 1, 4 340 TOLUENE 1, 4, 8 341 TOLUENEDIAMINES—in hair dyes 21 342 TOLUENEDIAMINES—in preparations other than hair dyes 1, 4, 8 343 TRAMAZOLINE in nasal preparations for topical use 29 344 TRETINOIN—for human oral use 7, 62, 76 345 TRETINOIN—for topical use 62, 77 346 TRIAMCINOLONE when in topical preparations for the treatment of mouth ulcers 64 or 68 347 TRICHLOROACETIC ACID except when for therapeutic use 2 1, 4 348 1,1,1-TRICHLOROETHANE 8, 9 349 TRICHLOROETHYLENE except when for therapeutic use 12 1, 4, 5, 8, 9 350 TRICHLOROPHENOL 1, 4, 8 351 TRIETHYL PHOSPHATE 1, 4, 8 352 TRIFLUOROMETHANESULFONIC ACID—more than 10% 1, 17 1, 4, 8 353 TRIFLUOROMETHANESULFONIC ACID—10% or less 1, 4, 8 Authorised Version F2024L00589 registered 30/05/2024 Warning statements and general safety directions for poisons Appendix F Clause 4 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 345 Poisons that must be labelled with warning statements and safety directions Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number 354 TRIISOPROPANOLAMINE LAURYL ETHER SULFATE 1, 4, 6 355 3,6,9-TRIOXAUNDECANEDIOIC ACID 5 1 356 TROLAMINE 5 1, 4 357 TYMAZOLINE in nasal preparations for topical use 29 358 VINCLOZOLIN 46 359 VINYL ACETATE MONOMER 11 8, 9 360 XYLENE 1, 4, 8 361 XYLOMETAZOLINE in nasal preparations for topical use 29 362 ZINC CHLORIDE 1, 4 363 ZINC LACTATE 107 364 ZINC SULFATE when included in Schedule 6 1, 4 Authorised Version F2024L00589 registered 30/05/2024 Appendix G Dilute preparations Clause 1 346 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix G—Dilute preparations Note: See paragraph 11(c). 1 Substances exempt at or below certain concentrations For the purposes of paragraph 11(c), the following table specifies: (a) substances; and (b) concentrations in relation to those substances. Substances and concentrations Item Column 1 Substance Column 2 Concentration (quantity per litre or kilogram) 1 ACETYLCHOLINE 1 mg 2 ALDOSTERONE 10 micrograms 3 ANTIMONY COMPOUNDS 1 mg 4 APOMORPHINE 1 mg 5 ARSENIC 1 mg 6 ATROPA BELLADONNA (belladonna) 300 micrograms 7 ATROPINE 300 micrograms 8 CANTHARIDIN 10 micrograms 9 CHLORINE 5 mg 10 CROTON TIGLIUM (croton oil) 1 mg 11 EPIDERMAL GROWTH FACTOR 2 mg 12 ERYSIMUM spp. 1 mg 13 ESTRADIOL 10 micrograms 14 ESTRONE 100 micrograms 15 FOLLICLE-STIMULATING HORMONE 100 micrograms 16 GELSEMIUM SEMPERVIRENS 1 mg 17 GLUCAGON 100 micrograms 18 GLYCERYL TRINITRATE 100 micrograms 19 GROWTH HORMONE 10 micrograms 20 HALOPERIDOL 1 mg 21 HYDROCYANIC ACID 1 microgram 22 HYOSCINE 300 micrograms 23 HYOSCYAMINE 300 micrograms 24 HYOSCYAMUS NIGER 300 micrograms 25 HYPOTHALAMIC RELEASING FACTORS 10 micrograms 26 INDOMETACIN 1 mg 27 MERCURY 1 mg 28 METHYLMERCURY 300 micrograms 29 NAPHTHALENE 1 mg Authorised Version F2024L00589 registered 30/05/2024 Dilute preparations Appendix G Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 347 Substances and concentrations Item Column 1 Substance Column 2 Concentration (quantity per litre or kilogram) 30 NERIUM OLEANDER 1 mg 31 OXYTOCIN 1 microgram 32 PHOSPHORUS 1 mg 33 PODOPHYLLUM RESIN (podophyllin) 1 mg 34 PROGESTERONE 1 mg 35 PROPRANOLOL 1 mg 36 SELENIUM 100 micrograms 37 STROPHANTHUS spp. 1 mg 38 STRYCHNINE 1 mg 39 TESTOSTERONE 1 mg 40 THYROXINE 10 micrograms Authorised Version F2024L00589 registered 30/05/2024 Appendix H Schedule 3 medicines permitted to be advertised Clause 1 348 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix H—Schedule 3 medicines permitted to be advertised Note: See paragraph 57(1)(a). 1 Schedule 3 medicines permitted to be advertised The following table specifies poisons for the purposes of paragraph 57(1)(a). Schedule 3 medicines permitted to be advertised Item Column 1 Poison 1 ADAPALENE 2 ADRENALINE 3 ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis and for the prevention of recurrent bacterial vaginosis 4 BILASTINE 5 BUTOCONAZOLE 6 CELECOXIB 7 CICLOPIROX 8 CLOBETASONE 9 CLOTRIMAZOLE 10 DICLOFENAC 11 DIMENHYDRINATE—for the prevention and relief of motion sickness 12 DIPHENOXYLATE 13 ECONAZOLE 14 ELETRIPTAN 15 ESOMEPRAZOLE 16 FAMCICLOVIR 17 FLUCONAZOLE 18 FLUORIDES 19 GLUCAGON 20 GLYCERYL TRINITRATE 21 HYDROCORTISONE 22 HYOSCINE BUTYLBROMIDE 23 IBUPROFEN 24 ISOCONAZOLE 25 KETOPROFEN 26 LANSOPRAZOLE 27 LEVONORGESTREL 28 MELATONIN 29 MICONAZOLE 30 NALOXONE Authorised Version F2024L00589 registered 30/05/2024 Schedule 3 medicines permitted to be advertised Appendix H Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 349 Schedule 3 medicines permitted to be advertised Item Column 1 Poison 31 NAPROXEN 32 NARATRIPTAN 33 NYSTATIN 34 OMEPRAZOLE 35 OXICONAZOLE 36 PANTOPRAZOLE 37 PARACETAMOL 38 PODOPHYLLOTOXIN 39 PODOPHYLLUM EMODI (podophyllin) 40 PODOPHYLLUM PELTATUM (podophyllin) 41 RABEPRAZOLE 42 RIZATRIPTAN 43 SALICYLIC ACID 44 SUMATRIPTAN 45 TIOCONAZOLE 46 TRIAMCINOLONE 47 ULIPRISTAL—for emergency post-coital contraception 48 VITAMIN D 49 ZOLMITRIPTAN Authorised Version F2024L00589 registered 30/05/2024 Appendix I Blank Clause 1 350 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix I—Blank Note 1: Appendix I is intentionally blank. Note 2: Appendix I previously included poisons now dealt with in Division 9 of Part 2. Authorised Version F2024L00589 registered 30/05/2024 Conditions for availability and use of certain poisons included in Schedule 7 Appendix J Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 351 Appendix J—Conditions for availability and use of certain poisons included in Schedule 7 Note: See subsection 62(6). 1 Conditions for supply of certain poisons included in Schedule 7 For the purposes of subsection 62(6), a poison included in Schedule 7 that is specified in column 1 of an item of the following table may be supplied: (a) only to a person who is appropriately authorised or licensed under the law of the jurisdiction where the person will receive the poison; and (b) if “a” appears in column 2 of the item—only for analytical or research purposes; and (c) if “p” appears in column 2 of the item—only to a person who is authorised or licensed, under the law of the jurisdiction where the person will receive the poison, to possess and use the poison. Conditions for supply of certain poisons included in Schedule 7 Item Column 1 Poison Column 2 Condition 1 ABAMECTIN 2 ACIBENZOLAR-S-METHYL 3 ACROLEIN 4 ACRYLONITRILE 5 ALACHLOR a 6 ALLYL ALCOHOL 7 4-AMINOPROPIOPHENONE p 8 4-AMINOPYRIDINE 9 ARPRINOCID a 10 ARSENIC p 11 AZOCYCLOTIN a 12 BENZENE 13 BIFLUORIDE 14 BORON TRIFLUORIDE 15 BRODIFACOUM 16 BROMADIOLONE 17 BROMINE 18 BRUCINE 19 CALCIFEROL 20 CARBADOX 21 CARBON TETRACHLORIDE 22 CARBONYL SULFIDE 23 CHLORDECONE a Authorised Version F2024L00589 registered 30/05/2024 Appendix J Conditions for availability and use of certain poisons included in Schedule 7 Clause 1 352 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Conditions for supply of certain poisons included in Schedule 7 Item Column 1 Poison Column 2 Condition 24 CHLORDIMEFORM a 25 CHLORINE 26 CHLOROMETHIURON a 27 CHLOROPICRIN 28 4-CHLORO-o-TOLUIDINE a 29 COLECALCIFEROL 30 COUMATETRALYL 31 CYANOGEN 32 CYHEXATIN a 33 4,4-DIAMINODIPHENYLMETHANE 34 1,2-DIBROMO-3-CHLOROPROPANE a 35 1,3-DICHLOROPROPENE 36 DIFENACOUM 37 4-DIMETHYLAMINOAZOBENZENE a 38 DINITROCRESOLS a 39 DINITROPHENOLS a 40 DINOSEB a 41 EPICHLOROHYDRIN 42 EPIDERMAL GROWTH FACTOR 43 ETACONAZOLE a 44 ETHYLENE DIBROMIDE a 45 ETHYLENE OXIDE 46 FLUOROACETAMIDE p 47 FLUOROACETIC ACID p 48 FOLPET 49 HALOFUGINONE 50 HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS a 51 HCB a 52 HYDROCYANIC ACID AND CYANIDES p 53 HYDROFLUORIC ACID 54 HYDROSILICOFLUORIC ACID 55 IODOMETHANE 56 MADURAMICIN 57 MERCURY 58 METHACRIFOS 59 METHOXYETHYLMERCURIC ACETATE a 60 METHOXYETHYLMERCURIC CHLORIDE 61 METHYL BROMIDE 62 4,4'-METHYLENEBIS[2-CHLOROANILINE] Authorised Version F2024L00589 registered 30/05/2024 Conditions for availability and use of certain poisons included in Schedule 7 Appendix J Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 353 Conditions for supply of certain poisons included in Schedule 7 Item Column 1 Poison Column 2 Condition 63 MIREX a 64 MOLINATE 65 NICOTINE except when in tobacco 66 NITROFEN a 67 PHENYLMERCURIC ACETATE 68 PHOSPHIDE, metallic 69 PHOSPHINE 70 PROPYLENE OXIDE 71 PYRINURON a 72 STRYCHNINE p 73 SULCOFURON a 74 TETRACHLOROETHANE 75 2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE 76 THALLIUM p 77 o-TOLIDINE 78 VINYL CHLORIDE Authorised Version F2024L00589 registered 30/05/2024 Appendix K Human medicines required to be labelled with a sedation warning Clause 1 354 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix K—Human medicines required to be labelled with a sedation warning Note: See subsection 33(2). 1 Human medicines required to be labelled with a sedation warning The following table specifies poisons for the purposes of subsection 33(2). Human medicines required to be labelled with a sedation warning Item Column 1 Poison 1 ALIMEMAZINE 2 ALPRAZOLAM 3 AMISULPRIDE 4 AMITRIPTYLINE 5 AMOBARBITAL 6 ARIPIPRAZOLE 7 ASENAPINE 8 AZATADINE 9 BACLOFEN 10 BENZATROPINE 11 BREXPIPRAZOLE 12 BRIVARACETAM 13 BROMAZEPAM 14 BROMPHENIRAMINE 15 BUCLIZINE 16 BUPRENORPHINE 17 BUTOBARBITAL 18 CANNABIS except cannabidiol when included in Schedule 3 or 4 19 CETIRIZINE 20 CHLORAL HYDRATE 21 CHLORDIAZEPOXIDE 22 CHLORMETHIAZOLE 23 CHLORPHENAMINE 24 CHLORPROMAZINE 25 CLEMASTINE 26 CLOMIPRAMINE 27 CLONAZEPAM 28 CLONIDINE 29 CLORAZEPATE 30 CLOZAPINE Authorised Version F2024L00589 registered 30/05/2024 Human medicines required to be labelled with a sedation warning Appendix K Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 355 Human medicines required to be labelled with a sedation warning Item Column 1 Poison 31 CODEINE. 32 CYCLIZINE 33 CYCLOBARBITAL 34 CYCLOSERINE 35 CYPROHEPTADINE 36 DANTROLENE 37 DESIPRAMINE 38 DEUTETRABENAZINE. 39 DEXCHLORPHENAMINE 40 DEXTROMORAMIDE 41 DEXTROPROPOXYPHENE 42 DIAZEPAM 43 DIFELIKEFALIN 44 DIFENOXIN 45 DIHYDROCODEINE 46 DIMENHYDRINATE 47 DIMETHINDENE 48 DIPHENHYDRAMINE 49 DIPHENOXYLATE 50 DIPHENYLPYRALINE 51 DOSULEPIN 52 DOXEPIN 53 DOXYLAMINE 54 DRONABINOL (delta-9-TETRAHYDROCANNABINOL) 55 DROPERIDOL 56 DULOXETINE 57 ESKETAMINE 58 ETHYLMORPHINE 59 FENFLURAMINE 60 FENTANYL 61 FLUNITRAZEPAM 62 FLUPENTIXOL 63 FLUPHENAZINE 64 FLURAZEPAM 65 GABAPENTIN 66 GEMCITABINE 67 GLUTETHIMIDE 68 GUANFACINE 69 HALOPERIDOL Authorised Version F2024L00589 registered 30/05/2024 Appendix K Human medicines required to be labelled with a sedation warning Clause 1 356 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Human medicines required to be labelled with a sedation warning Item Column 1 Poison 70 HYDROCODONE 71 HYDROMORPHONE 72 HYDROXYZINE 73 IMIPRAMINE 74 LAMOTRIGINE 75 LEMBOREXANT. 76 LEVETIRACETAM 77 LEVOCABASTINE 78 LEVOCETIRIZINE 79 LORAZEPAM 80 LURASIDONE. 81 MAZINDOL 82 MEBHYDROLIN 83 MECLOZINE 84 MEDAZEPAM 85 MEPROBAMATE 86 MEPYRAMINE 87 MERCAPTAMINE 88 METHADONE 89 METHDILAZINE 90 METHOCARBAMOL 91 METHYLPHENOBARBITAL 92 MIANSERIN 93 MIDAZOLAM 94 MIRTAZAPINE 95 MORPHINE 96 NABIXIMOLS. 97 NALBUPHINE 98 NITRAZEPAM 99 NORMETHADONE 100 NORTRIPTYLINE 101 OLANZAPINE 102 OPIUM in any form except the alkaloids noscapine and papaverine 103 OXAZEPAM 104 OXYCODONE 105 PALIPERIDONE 106 PAPAVERETUM 107 PENTAZOCINE 108 PENTOBARBITAL Authorised Version F2024L00589 registered 30/05/2024 Human medicines required to be labelled with a sedation warning Appendix K Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 357 Human medicines required to be labelled with a sedation warning Item Column 1 Poison 109 PERAMPANEL 110 PERICIAZINE 111 PERPHENAZINE 112 PETHIDINE 113 PHENELZINE 114 PHENIRAMINE 115 PHENOBARBITAL 116 PHENOPERIDINE 117 PHENYLTOLOXAMINE 118 PHOLCODINE 119 PIMOZIDE 120 PIZOTIFEN 121 PRAZEPAM 122 PREGABALIN 123 PROCHLORPERAZINE 124 PROMAZINE 125 PROMETHAZINE 126 PROTRIPTYLINE 127 QUETIAPINE 128 RETIGABINE 129 RISPERIDONE 130 ROTIGOTINE 131 RUFINAMIDE 132 RUPATADINE 133 SAFINAMIDE 134 SECBUTOBARBITAL 135 SECOBARBITAL 136 SELETRACETAM 137 SODIUM OXYBATE 138 STIRIPENTOL 139 SUVOREXANT 140 TAPENTADOL 141 TEMAZEPAM 142 TETRAHYDROCANNABINOLS except cannabidiol when included in Schedule 3 or 4 143 THENYLDIAMINE 144 THIETHYLPERAZINE 145 THIOPROPAZATE 146 THIORIDAZINE 147 THIOTHIXENE Authorised Version F2024L00589 registered 30/05/2024 Appendix K Human medicines required to be labelled with a sedation warning Clause 1 358 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Human medicines required to be labelled with a sedation warning Item Column 1 Poison 148 TRABECTEDIN 149 TRAMADOL 150 TRANYLCYPROMINE 151 TRIFLUOPERAZINE 152 TRIMIPRAMINE 153 TRIPROLIDINE 154 ZIPRASIDONE 155 ZOLPIDEM 156 ZONISAMIDE 157 ZOPICLONE Authorised Version F2024L00589 registered 30/05/2024 Requirements for dispensing labels for medicines Appendix L Clause 1 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 359 Appendix L—Requirements for dispensing labels for medicines Note: See subsection 33(1) and paragraph 40(b). 1 General (1) This clause sets out requirements for the purposes of paragraph 40(b). (2) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 mm in height. (3) All symbols, numbers and words on a label must be in durable characters. (4) The label on a container of a substance for therapeutic use must contain the following details: (a) the name, address and telephone number of the dispenser supplying the substance; (b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula); (c) adequate directions for use; (d) the strength and form of the substance; (e) the total quantity of the goods in the container; (f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background; (g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background; (h) if the substance is a medicine for human use, the name of the person for whom it was dispensed; and (i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”. (5) The label on a container of a medicine for human use, or a veterinary chemical, that is supplied on prescription must also include: (a) the prescription reference number; and (b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and (c) the directions for use set out in the prescription. 2 Additional warning statements for certain human medicines (1) For the purposes of subsection 33(1), and subject to subclause (2), the warning statement represented by each item number specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item. Note: For the warning statements represented by the item numbers, see clause 1 of Appendix F. Authorised Version F2024L00589 registered 30/05/2024 Appendix L Requirements for dispensing labels for medicines Clause 2 360 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (2) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate). Additional warning statements for certain human medicines Item Column 1 Poison Column 2 Warning statement item number 1 ACITRETIN—for oral use 7, 62, 76 2 ACITRETIN—for topical use 62, 77 3 ADAPALENE—for oral use 7, 62, 76 4 ADAPALENE—for topical use 62, 77 5 AMBRISENTAN 7, 62, 76 6 BELUMOSUDIL 62, 77 7 BEXAROTENE—for oral use 7, 62, 76 8 BEXAROTENE—for topical use 62, 77 9 BOSENTAN 7, 62, 76 10 DIENESTROL 67 11 ETRETINATE—for oral use 7, 62, 76 12 ETRETINATE—for topical use 62, 77 13 ENZALUTAMIDE 7, 67, 87 14 FARICIMAB 76 15 FINERENONE 67, 111 16 FINGOLIMOD 76 17 ISAVUCONAZOLE 53 18 ISOTRETINOIN—for oral use 7, 62, 76 19 ISOTRETINOIN—for topical use 62, 77 20 LEFLUNOMIDE 7, 62, 87 21 LENALIDOMIDE—for oral use 7, 62, 76 22 LENALIDOMIDE—for topical use 62, 77 23 LEVOCABASTINE 62 24 MACITENTAN 7, 62, 76 25 MISOPROSTOL 53 26 PALOVAROTENE 7, 62, 76, 111 27 PLITIDEPSIN 7, 62, 63, 76, 87 28 POMALIDOMIDE 7, 62, 76 29 PONESIMOD 76 30 RIOCIGUAT 7, 62, 76 31 RUFINAMIDE 62, 76, 77 32 SAFINAMIDE 62, 76, 77 33 SELINEXOR 62 and 77 34 SELUMETINIB. 76 35 SITAXENTAN 7, 62, 76 36 TERIFLUOMIDE 7, 62, 87 37 THALIDOMIDE—for oral use 7, 62, 76 Authorised Version F2024L00589 registered 30/05/2024 Requirements for dispensing labels for medicines Appendix L Clause 2 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 361 Additional warning statements for certain human medicines Item Column 1 Poison Column 2 Warning statement item number 38 THALIDOMIDE—for topical use 62, 77 39 TIRZEPATIDE 67 40 TRASTUZUMAB DERUXTECAN 62, 77 41 TRETINOIN—for oral use 7, 62, 76 42 TRETINOIN—for topical use 62, 77 Authorised Version F2024L00589 registered 30/05/2024 Appendix M Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist 362 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist Note: Appendix M is intentionally blank. It is reserved for future use. Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 363 Index A ABACAVIR Schedule 4 ABAMECTIN Schedule 7 Schedule 6 Schedule 5 Appendix J, clause 1 ABATACEPT Schedule 4 ABCIXIMAB Schedule 4 ABEMACICLIB Schedule 4 ABIRATERONE ACETATE Schedule 4 ABROCITINIB Schedule 4 ABRUS PRECATORIUS cross reference: JEQUIRITY Schedule 10 ABSCISIC ACID Schedule 5 ACALABRUTINIB Schedule 4 ACAMPROSATE CALCIUM Schedule 4 ACARBOSE Schedule 4 ACEBUTOLOL Schedule 4 ACEPHATE Schedule 6 ACEPROMAZINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 364 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ACEQUINOCYL Schedule 5 ACETAMIPRID Schedule 6 ACETANILIDE cross reference: ALKYL ACETANILIDES Schedule 4 ACETARSOL Schedule 4 ACETAZOLAMIDE Schedule 4 ACETIC ACID Schedule 6 Schedule 5 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 ACETIC ANHYDRIDE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 ACETOHEXAMIDE Schedule 4 ACETONE cross reference: DESIGNATED SOLVENT Schedule 5 Appendix E, clause 3 Appendix F, clause 4 ACETORPHINE cross reference: CAS No. 25333-77-1 Schedule 9 ACETYL-ALPHA-METHYLFENTANYL cross reference: CAS No. 101860-00-8 Schedule 9 ACETYLCARBROMAL Schedule 4 ACETYLCHOLINE Schedule 4 Appendix G, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 365 ACETYLCYSTEINE Schedule 4 Schedule 2 ACETYLDIGITOXIN Schedule 4 ACETYLDIHYDROCODEINE Schedule 8 ACETYL ISOVALERYLTYLOSIN Schedule 4 ACETYLMETHADOL Schedule 8 ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE Schedule 4 ACETYLMORPHINES Schedule 8 4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE Appendix B, clause 3 ACETYLSTROPHANTHIDIN Schedule 4 ACIBENZOLAR-S-METHYL Schedule 7 Appendix J, clause 1 ACICLOVIR Schedule 4 ACIFLUORFEN Schedule 6 ACINITRAZOLE Schedule 6 ACIPIMOX Schedule 4 ACITRETIN Schedule 4 Appendix D, clause 2 Appendix F, clause 4 Appendix L, clause 2 ACLIDINIUM BROMIDE Schedule 4 ACLONIFEN Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index 366 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ACOKANTHERA OUABAIO Schedule 4 ACOKANTHERA SCHIMPERI Schedule 4 ACONITUM spp. Schedule 4 Schedule 2 ACORUS CALAMUS cross reference: CALAMUS Schedule 10 ACRIFLAVINE cross reference: ACRIFLAVINIUM CHLORIDE ACRIFLAVINUM CHLORIDE Schedule 7 Schedule 5 ACRIVASTINE Schedule 4 ACROLEIN Schedule 7 Appendix E, clause 3 Appendix F, clause 4 ACRYLONITRILE Schedule 7 Appendix J, clause 1 ADALIMUMAB Schedule 4 ADAPALENE Schedule 4 Schedule 3 Appendix F, clause 4 Appendix H, clause 1 Appendix L, clause 2 ADEFOVIR Schedule 4 ADENOSINE Schedule 4 ADIPHENINE Schedule 4 ADONIS VERNALIS Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 367 ADRAFINIL Schedule 4 ADRENALINE Schedule 4 Schedule 3 Appendix H, clause 1 ADRENOCORTICAL HORMONES Schedule 4 AFAMELANOTIDE cross reference: MELANOCYTE STIMULATING HORMONE, MELANOTAN I Schedule 4 AFATINIB DIMALEATE Schedule 4 AFIDOPYROPEN Appendix B, clause 3 AFLIBERCEPT Schedule 4 AFOXOLANER Schedule 5 AGALSIDASE Schedule 4 AGLEPRISTONE Schedule 4 AGOMELATINE Schedule 4 AKLOMIDE Schedule 5 ALACHLOR Schedule 7 Appendix J, clause 1 ALANYLGLUTAMINE Schedule 4 ALATROFLOXACIN MESILATE cross reference: ALATROFLOXACIN MESYLATE Schedule 4 ALBENDAZOLE Schedule 6 Schedule 5 Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 368 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ALCLOFENAC Schedule 4 ALCLOMETASONE Schedule 4 Schedule 3 Appendix F, clause 4 ALCOHOL, DEHYDRATED Appendix B, clause 3 ALCURONIUM Schedule 4 ALDESLEUKIN Schedule 4 ALDICARB Schedule 7 ALDOSTERONE Schedule 4 Appendix G, clause 1 ALDOXYCARB Schedule 7 ALDRIN Schedule 6 ALECTINIB Schedule 4 ALEFACEPT Schedule 4 Appendix D, clause 7 ALEMTUZUMAB Schedule 4 ALENDRONIC ACID Schedule 4 ALFACALCIDOL Schedule 4 ALFENTANIL Schedule 8 ALFUZOSIN Schedule 4 ALGICIDES Appendix A, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 369 ALGLUCERASE Schedule 4 ALGLUCOSIDASE Schedule 4 ALIMEMAZINE cross reference: TRIMEPRAZINE Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1 ALIROCUMAB Schedule 4 ALISKIREN Schedule 4 ALKALINE SALTS cross reference: LYE WATER, POTASSIUM CARBONATE. POTASSIUM PHOSPHATE, POTASSIUM SALTS, POTASSIUM SILICATE, SODIUM CARBONATE, SODIUM SALTS, SODIUM SILICATE(S) Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 ALKOXYAMFETAMINES cross reference: ALKOXYAMPHETAMINES Schedule 9 ALKOXYLATED FATTY ALKYLAMINE POLYMER Schedule 6 Schedule 5 ALKOXYPHENYLETHYLAMINES Schedule 9 ALKYLAMINES WITH STIMULANT PROPERTIES cross reference: 1,3-DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1-AMINOISOHEPTANE, DMHA, 1,5-DIMETHYLHEXYLAMINE, 4-METHYLHEXANE-2-AMINE, 1,3-DIMETHYLAMYLAMINE, DMAA, 4-AMINO-2-METHYLPENTANE CITRATE (AMP CITRATE), 1,4-DIMETHYLPENTYLAMINE, DMPA, 1,4-DIMETHYLAMYLAMINE, DMAA. Schedule 10 ALKYL NITRITES Schedule 4 Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 370 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ALKYLTHIOAMFETAMINES cross reference: ALKYLTHIOAMPHETAMINES Schedule 9 ALLERGENS Schedule 4 ALLETHRIN Schedule 6 Schedule 5 ALLOPURINOL Schedule 4 ALLOXYDIM Schedule 5 ALLYL ALCOHOL Schedule 7 Appendix J, clause 1 ALLYL CYCLOHEXANEACETATE (CAS No. 4728-82-9) Schedule 6 ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705-87-5) Schedule 6 ALLYL ESTERS (excluding derivatives) Schedule 6 ALLYLESTRENOL cross reference: ALLYLOESTRENOL Schedule 4 ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142-19-8) Schedule 6 ALLYL HEXANOATE (CAS No. 123-68-2) Schedule 6 ALLYL ISOVALERATE (CAS No. 2835-39-4) Schedule 6 ALLYL NONANOATE (CAS No. 7493-72-3) Schedule 6 ALLYL OCTANOATE (CAS No. 4230-97-1) Schedule 6 ALLYLOESTRENOL cross reference: ALLYLESTRENOL ALLYL PHENYLACETATE (CAS No. 1797-74-6) Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 371 ALLYLPRODINE cross reference: CAS No. 25384-17-2 Schedule 9 ALLYL TRIMETHYLHEXANOATE (CAS No. 68132-80-9) Schedule 6 ALOGLIPTIN Schedule 4 ALOSETRON Schedule 4 ALOXIPRIN Schedule 2 ALPELISIB Schedule 4 ALPHACETYLMETHADOL Schedule 8 ALPHA-CHLOROHYDRIN Schedule 6 Appendix F, clause 4 ALPHA-CYPERMETHRIN Schedule 7 Schedule 6 Schedule 5 ALPHADOLONE Schedule 4 ALPHAMEPRODINE cross reference: CAS No. 468-51-9 Schedule 9 ALPHAMETHADOL cross reference: CAS No. 17199-54-1 Schedule 9 ALPHA-METHYLFENTANYL cross reference: CAS No. 79704-88-4 Schedule 9 ALPHA-METHYLTHIOFENTANYL cross reference: CAS No. 103963-66-2 Schedule 9 ALPHAPRODINE Schedule 8 Authorised Version F2024L00589 registered 30/05/2024 Index 372 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP). cross reference: CAS No. 14530-33-7 Schedule 9 ALPHA1-PROTEINASE INHIBITOR (HUMAN) Schedule 4 ALPHAXALONE Schedule 4 ALPRAZOLAM Schedule 8 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 ALPRENOLOL Schedule 4 ALPROSTADIL Schedule 4 ALSEROXYLON Schedule 4 ALTEPLASE Schedule 4 ALTRENOGEST Schedule 4 ALTRETAMINE cross reference: HEXAMETHYLMELAMINE Schedule 4 ALUM Appendix B, clause 3 ALUMINIUM AMMONIUM SULFATE Appendix B, clause 3 ALUMINIUM POTASSIUM SULFATE Appendix B, clause 3 ALUMINIUM SILICATE Appendix B, clause 3 ALUMINIUM tris (ETHYLPHOSPHONATE) Appendix B, clause 3 AMANTADINE Schedule 4 AMBENONIUM CHLORIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 373 AMBRISENTAN Schedule 4 Appendix D, clause 6 Appendix F, clause 4 Appendix L, clause 2 AMBUCETAMIDE Schedule 4 AMBUTONIUM BROMIDE Schedule 4 AMCINONIDE Schedule 4 AMETOCTRADIN Appendix B, clause 3 AMETRYN Schedule 5 AMICARBAZONE Schedule 6 AMIDITHION Schedule 6 AMIDOPROPYL BETAINES Schedule 6 Appendix E, clause 3 AMIFAMPRIDINE Schedule 4 AMIFOSTINE Schedule 4 AMIKACIN Schedule 4 AMILORIDE Schedule 4 AMINACRINE cross reference: AMINOACRIDINE AMINES cross reference: CURING AGENTS FOR EPOXY RESINS Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 374 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 AMINOACRIDINE cross reference: AMINACRINE Schedule 7 Schedule 5 AMINOCAPROIC ACID Schedule 4 AMINOCARB Schedule 7 Schedule 6 2-AMINO-6-CHLORO-4-NITROPHENOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 4-AMINO-m-CRESOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 5-AMINO-o-CRESOL cross reference: 4-AMINO-2-HYDROXYTOLUENE AMINOCYCLOPYRACHLOR Schedule 5 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE cross reference: DOM, STP (CAS No. 15588-95-1), DOM HYDROCHLORIDE (CAS No. 15589-00-1) Schedule 9 AMINOETHOXYVINYLGLYCINE Schedule 6 2-AMINO-5-ETHYLPHENOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 AMINOGLUTETHIMIDE Schedule 4 4-AMINO-2-HYDROXYTOLUENE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 5-AMINOLEVULINIC ACID Schedule 4 1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 375 2-[(4-AMINO-2-METHYL-5-NITROPHENYL)AMINO]-ETHANOL cross reference: HC VIOLET 1 2-AMINO-5-METHYLPHENOL cross reference: CAS No. 2835-98-5 Schedule 10 Schedule 7 AMINOMETRADINE Schedule 4 4-AMINO-3-NITROPHENOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL cross reference: HC RED 13 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 AMINOPHENAZONE cross reference: AMIDOPYRINE (CAS No. 58-15-1), AMINOPHENAZONE HYDROCHLORIDE (CAS No. 6170-29-2) Schedule 10 Schedule 4 m-AMINOPHENOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 p-AMINOPHENOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 AMINOPHYLLINE Schedule 4 Schedule 3 4-AMINOPROPIOPHENONE cross reference: PARA-AMINOPROPIOPHENONE (PAPP) Schedule 7 Appendix J, clause 1 5-(2-AMINOPROPYL)INDAN cross reference: CAS No. 13396-94-6 Schedule 9 AMINOPTERIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 376 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 AMINOPYRALID Schedule 6 Schedule 5 4-AMINOPYRIDINE cross reference: FAMPRIDINE Schedule 7 Schedule 4 Appendix E, clause 3 Appendix J, clause 1 AMINOREX Schedule 4 AMINOSALICYLIC ACID Schedule 4 AMIODARONE Schedule 4 AMIPHENAZOLE Schedule 4 AMISOMETRADINE Schedule 4 AMISULBROM Schedule 5 AMISULPRIDE Schedule 4 Appendix K, clause 1 AMITON Schedule 7 AMITRAZ Schedule 6 AMITRIPTYLINE Schedule 4 Appendix K, clause 1 AMITROLE Schedule 5 AMLODIPINE Schedule 4 AMMI VISNAGA Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 377 AMMONIA cross reference: AMMONIUM HYDROXIDE, CHROMATES Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 AMMONIUM BROMIDE Schedule 4 AMMONIUM COCOYL ISETHIONATE Schedule 6 Appendix E, clause 3 AMMONIUM PERSULFATE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 AMMONIUM PHOSPHATE Appendix B, clause 3 AMMONIUM THIOCYANATE Schedule 5 Appendix E, clause 3 AMMONIUM THIOSULPHATE Appendix B, clause 3 AMOBARBITAL Schedule 8 Schedule 4 Appendix K, clause 1 AMODIAQUINE Schedule 4 AMOROLFINE Schedule 4 Schedule 2 AMOXAPINE Schedule 4 AMOXICILLIN Schedule 4 AMOXYCILLIN cross reference: AMOXICILLIN AMFETAMINE cross reference: AMPHETAMINE Schedule 8 Authorised Version F2024L00589 registered 30/05/2024 Index 378 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 AMPHOMYCIN Schedule 4 AMPHOTERICIN cross reference: AMPHOTERICIN B AMPHOTERICIN B Schedule 4 AMPICILLIN Schedule 4 AMPRENAVIR Schedule 4 AMPROLIUM Appendix B, clause 3 AMRINONE Schedule 4 AMSACRINE Schedule 4 AMYGDALIN cross reference: CAS No. 29883-15-6, APRICOT KERNELS Schedule 10 AMYL ACETATE Appendix B, clause 3 AMYL NITRITE Schedule 4 Schedule 3 Appendix E, clause 3 α-AMYLASE derived from Aspergillus niger Appendix B, clause 3 AMYL CINNAMALDEHYDE Appendix B, clause 3 AMYLOBARBITAL cross reference: AMOBARBITAL AMYLOBARBITONE cross reference: AMOBARBITAL AMYLOCAINE Schedule 4 ANABOLIC STEROIDAL AGENTS cross reference: ANDROSTERONE, STEROIDAL AGENTS Schedule 4 Appendix D, clause 5 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 379 ANAGRELIDE Schedule 4 ANAKINRA Schedule 4 ANASTROZOLE Schedule 4 ANCESTIM Schedule 4 ANCHUSA OFFICINALIS Schedule 10 ANCROD Schedule 4 ANDEXANET ALFA Schedule 4 ANDROGENIC STEROIDAL AGENTS cross reference: STEROIDAL AGENTS Schedule 4 Appendix D, clause 5 ANDROISOXAZOLE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) ANDROSTANOLONE Schedule 4 ANDROSTENEDIOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) ANDROSTENEDIONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) ANDROSTENEDIONE ALBUMEN Appendix B, clause 3 ANECORTAVE Schedule 4 ANGIOTENSIN AMIDE Schedule 4 ANHYDRIDES, ORGANIC ACID cross reference: CURING AGENTS FOR EPOXY RESINS Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 380 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ANIDULAFUNGIN Schedule 4 ANILERIDINE Schedule 8 ANILINE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 ANIRACETAM cross reference: RACETAMS Schedule 4 ANISE OIL Schedule 5 Appendix E, clause 3, Part 4 o-ANISIDINE cross reference: CAS No. 90-04-0, o-ANISIDINE HYDROCHLORIDE (CAS No. 134-29-2) Schedule 10 ANISTREPLASE Schedule 4 ANTAZOLINE Schedule 4 Schedule 2 ANTIBIOTIC SUBSTANCES cross reference: NISIN Schedule 4 ANTIGENS Schedule 4 ANTIHISTAMINES cross reference: ASTEMIZOLE, AZELASTINE, BILASTINE, CETIRIZINE, DESLORATADINE, FEXOFENADINE, LORATADINE, OLOPATADINE, TERFENADINE Schedule 4 Appendix F, clause 4 ANTIMONY cross reference: ANTIMONY COMPOUNDS, ANTIMONY CHLORIDE, ANTIMONY TITANATE Schedule 6 Schedule 4 Appendix E, clause 3 Appendix G, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 381 ANTISERA cross reference: IMMUNOSERA Schedule 4 AOD-9604 (CAS No. 221231-10-3) Schedule 4 Appendix D, clause 5 APALUTAMIDE Schedule 4 APIXABAN Schedule 4 APOCYNUM spp. Schedule 4 APOMORPHINE Schedule 4 Appendix G, clause 1 APRACLONIDINE Schedule 4 APRAMYCIN Schedule 4 APREMILAST Schedule 4 APREPITANT Schedule 4 APRICOT KERNELS cross reference: AMYGDALIN, HYDROCYANIC ACID APRONAL cross reference: ALLYLISOPROPYLACETYLUREA (CAS No. 528-92-7) Schedule 10 APROTININ Schedule 4 ARBUTIN (ALPHA) cross reference: ARBUTIN (BETA); ARBUTIN (DEOXY OR OTHER DERIVATIVES) Schedule 6 Appendix E, clause 3 Appendix F, clause 4 ARBUTIN (BETA) cross reference: ARBUTIN (ALPHA); ARBUTIN (DEOXY OR OTHER DERIVATIVES) Schedule 6 Schedule 4 Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 382 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix F, clause 4 ARBUTIN (DEOXY OR OTHER DERIVATIVES) cross reference: ARBUTIN (ALPHA); ARBUTIN (BETA) Schedule 6 Appendix E, clause 3 Appendix F, clause 4 ARECOLINE Schedule 4 ARIPIPRAZOLE Schedule 4 Appendix K, clause 1 ARISTOLOCHIA spp. Schedule 10 ARISTOLOCHIC ACID(S) cross reference: ASARUM spp, BRAGANTIA (CAS No. 313-67-7) Schedule 10 ARPRINOCID Schedule 7 Appendix J, clause 1 ARMODAFINIL Schedule 4 ARSENIC cross reference: ARSENIC TRIOXIDE, CACODYLIC ACID, TERMITE BARRIERS, COPPER-CHROME-ARSENIC, SELENIUM ARSENIDE, THIACETARSAMIDE Schedule 7 Schedule 6 Schedule 4 Appendix G, clause 1 Appendix J, clause 1 ARTEMETHER Schedule 4 ARTICAINE Schedule 4 ASARUM spp Schedule 10 ASCIMINIB Schedule 4 ASENAPINE Schedule 4 Appendix K, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 383 ASFOTASE ALFA Schedule 4 ASPARAGINASE cross reference: CRISANTASPASE Schedule 4 ASPARTIC ACID Appendix B, clause 3 ASPIRIN cross reference: CAFFEINE, PARACETAMOL, SALICYLAMIDE Schedule 6 Schedule 5 Schedule 4 Schedule 2 Appendix F, clause 4 ASTEMIZOLE Schedule 4 Appendix F, clause 4 ASTODRIMER SODIUM Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 ASULAM Appendix B, clause 3 ASUNAPREVIR Schedule 4 ATAMESTANE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) ATAZANAVIR Schedule 4 ATENOLOL Schedule 4 ATEZOLIZUMAB Schedule 4 ATIPAMEZOLE Schedule 4 ATOMOXETINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 384 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ATORVASTATIN Schedule 4 ATOSIBAN Schedule 4 ATOVAQUONE Schedule 4 ATRACURIUM BESILATE cross reference: ATRACURIUM BESYLATE Schedule 4 ATRAZINE Schedule 5 ATROPA BELLADONNA cross reference: BELLADONNA Schedule 4 Schedule 2 Appendix G, clause 1 ATROPINE Schedule 4 Schedule 2 Appendix G, clause 1 ATROPINE METHONITRATE Schedule 4 AURANOFIN Schedule 4 AUREOBASIDIUM PULLULANS (Strains DSM14940 and DSM14941) Appendix B AUROTHIOMALATE SODIUM Schedule 4 AVACOPAN Schedule 4 AVATROMBOPAG Schedule 4 AVELUMAB Schedule 4 AVILAMYCIN Schedule 4 AVIPTADIL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 385 AVOPARCIN Schedule 4 AXITINIB Schedule 4 AZACITIDINE Schedule 4 AZACONAZOLE Schedule 6 AZACYCLONOL Schedule 4 AZADIRACHTA INDICA cross reference: DEBITTERISED NEEM SEED OIL, NEEM Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 AZADIRACHTA INDICA EXTRACTS Schedule 5 AZAFENIDIN Schedule 7 AZAMETHIPHOS Schedule 6 AZAPERONE Schedule 4 AZAPROPAZONE Schedule 4 AZARIBINE Schedule 4 AZATADINE Appendix K, clause 1 AZATADINE Schedule 4 Schedule 3 AZATHIOPRINE Schedule 4 AZELAIC ACID Schedule 4 Schedule 2 Authorised Version F2024L00589 registered 30/05/2024 Index 386 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 AZELASTINE Schedule 4 Schedule 2 AZIMSULFURON Appendix B, clause 3 AZINPHOS-ETHYL Schedule 7 AZINPHOS-METHYL Schedule 7 AZITHROMYCIN Schedule 4 AZLOCILLIN Schedule 4 AZOBENZENE Schedule 6 AZOCYCLOTIN Schedule 7 Appendix F, clause 4 Appendix J, clause 1 AZO DYES (derivatives by diazotisation) Schedule 7 Appendix E, clause 3 Appendix F, clause 4 AZOXYSTROBIN Schedule 5 AZTREONAM Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 387 B BACAMPICILLIN Schedule 4 BACILLUS AMYLOLIQUEFACIENS cross reference: BACILLUS SUBTILIS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN MBI 600 Appendix B, clause 3 BACILLUS SPHAERICUS, STRAIN 2362 Appendix B, clause 3 BACILLUS SUBTILIS, STRAIN QST 713 cross reference: BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713 BACILLUS THURINGIENSIS cross reference: ENDOTOXIN Appendix B, clause 3 BACILLUS THURINGIENSIS DELTA ENDOTOXIN Schedule 5 BACILLUS TOYOI Appendix B, clause 3 BACITRACIN Schedule 4 BACLOFEN Schedule 4 Appendix K, clause 1 BACTERIAL CULTURE MEDIA cross reference: ANTIBIOTIC SUBSTANCES Appendix A, clause 1 BACTERICIDES Appendix A, clause 1 BACULOVIRUS CYDIA POMONELLA Appendix B, clause 3 BALOXAVIR MARBOXIL Schedule 4 BALSALAZIDE Schedule 4 BAMBERMYCIN cross reference: FLAVOPHOSPHOLIPOL Schedule 6 Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 388 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BAMBUTEROL Schedule 4 BAMETHAN Schedule 4 BAMIPINE Schedule 4 BARBITURATES Schedule 4 BARICITINIB Schedule 4 BARIUM SALTS cross reference: BARIUM METABORATE, BARIUM SULFATE Schedule 6 Appendix E, clause 3 BARIUM SILICOFLUORIDE Schedule 5 BASIC BLUE 26 Schedule 10 Schedule 6 BASIC ORANGE 31 cross reference: 2-[(4-AMINOPHENYL)AZO]-1,3-DIMETHYL-1H-IMIDAZOLIUM, CHLORIDE (CAS No. 97404-02-9) Schedule 10 Schedule 6 BASIC RED 76 (CAS No. 68391-30-0) cross reference: [7-HYDROXY-8-[(2 METHOXYPHENYL)AZO]-2-NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391-30-0) Schedule 7 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 BASIL OIL cross reference: METHYL CHAVICOL Schedule 5 Appendix E, clause 3 BASILIXIMAB Schedule 4 BATTERIES Appendix A, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 389 BAY OIL Schedule 6 Appendix E, clause 3 BAZEDOXIFENE Schedule 4 BEAUVERIA BASSIANA Schedule 6 Schedule 5 BECAPLERMIN Schedule 4 BECLAMIDE Schedule 4 BECLOMETASONE cross reference: BECLOMETHASONE Schedule 4 Schedule 2 BECLOMETHASONE cross reference: BECLOMETASONE BELATACEPT Schedule 4 BELIMUMAB Schedule 4 BELUMOSUDIL Schedule 4 Appendix L, clause 2 BELZUTIFAN Schedule 4 BEMEGRIDE Schedule 4 BENACTYZINE Schedule 4 BENALAXYL Schedule 5 BENAZEPRIL Schedule 4 BENDAMUSTINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 390 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BENDIOCARB cross reference: DENATONIUM BENZOATE Schedule 7 Schedule 6 Schedule 5 BENDROFLUAZIDE Schedule 4 BENETHAMINE PENICILLIN Schedule 4 BENFLURALIN Appendix B, clause 3 BENOMYL Schedule 7 Appendix F, clause 4 BENORYLATE Schedule 4 BENOXAPROFEN Schedule 4 BENPERIDOL Schedule 4 BENQUINOX Schedule 6 BENRALIZUMAB Schedule 4 BENSERAZIDE Schedule 4 BENSULFURON-METHYL Appendix B, clause 3 BENSULIDE Schedule 6 BENTAZONE Schedule 5 BENTONITE Appendix B, clause 3 BENZALKONIUM CHLORIDE Schedule 6 Schedule 5 Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 391 BENZATHINE PENICILLIN Schedule 4 BENZENE cross reference: LIQUID HYDROCARBONS Schedule 7 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1 1,2-BENZENEDIAMINE cross reference: CAS No. 95-54-5, 1,2-BENZENEDIAMINE DIHYDROCHLORIDE (CAS No. 615-28-1) Schedule 10 1,3-BENZENEDIAMINE cross reference: CAS No. 108-45-2 Schedule 10 1,2-BENZENEDIOL cross reference: CATECHOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 BENZETHIDINE cross reference: CAS No. 3691-78-9 Schedule 9 BENZHEXOL cross reference: TRIHEXYPHENIDYL BENZIDINE-CONGENER (3,3'-disubstituted) AZO DYES Schedule 7 BENZIDINE-BASED AZO DYES Schedule 7 BENZILONIUM Schedule 4 BENZOCAINE Schedule 4 Schedule 2 BENZODIAZEPINE DERIVATIVES Schedule 4 Appendix D, clause 5 BENZOFENAP Schedule 5 BENZOIC ACID Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index 392 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BENZOVINDIFLUPYR Schedule 6 BENZOYL PEROXIDE Schedule 5 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 BENZOYLINDOLES Schedule 9 BENZPHETAMINE Schedule 4 BENZTHIAZIDE Schedule 4 BENZATROPINE cross reference: BENZITROPINE Schedule 4 Appendix K, clause 1 BENZYDAMINE Schedule 4 Schedule 2 6-BENZYLADENINE Schedule 6 BENZYL BENZOATE Appendix B, clause 3 BENZYLMORPHINE Schedule 8 BENZYLPENICILLIN Schedule 4 BENZYLPIPERAZINE cross reference: BZP (CAS No. 2759-28-6), BENZYLPIPERAZINE TARTRATE (CAS No. 10510-56-2), BENZYLPIPERAZINE DIHYDROCHLORIDE (CAS No. 5321-63-1) Schedule 9 BEPHENIUM SALTS Schedule 2 BEPRIDIL Schedule 4 BERACTANT Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 393 BERGAMOT OIL Schedule 5 Appendix E, clause 3 Appendix F, clause 4 BERYLLIUM Schedule 6 Appendix F, clause 4 BESIFLOXACIN Schedule 4 BETACETYLMETHADOL cross reference: CAS No. 17199-59-6 Schedule 9 BETACYFLUTHRIN Schedule 7 Schedule 6 Schedule 5 BETA-CYPERMETHRIN Schedule 6 BETA-PHENYL-GAMMA-AMINOBUTYRIC ACID cross reference: PHENIBUT BETAHISTINE Schedule 4 BETA-HYDROXY-3-METHYLFENTANYL cross reference: CAS No. 78995-14-9 Schedule 9 BETA-HYDROXYFENTANYL cross reference: CAS No. 78995-10-5 Schedule 9 BETAINE HYDROCHLORIDE Appendix B, clause 3 BETAMEPRODINE cross reference: CAS No. 468-50-8 Schedule 9 BETAMETHADOL cross reference: CAS No. 17199-55-2 Schedule 9 BETAMETHASONE Schedule 4 1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 394 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BETAPRODINE cross reference: CAS No. 468-59-7 Schedule 9 BETAXOLOL Schedule 4 BETHANECHOL CHLORIDE Schedule 4 BETHANIDINE Schedule 4 BEVACIZUMAB Schedule 4 BEVANTOLOL Schedule 4 BEXAROTENE Schedule 4 Appendix D, clause 2 Appendix F, clause 4 Appendix L, clause 2 BEZAFIBRATE Schedule 4 BEZITRAMIDE Schedule 8 BEZLOTOXUMAB Schedule 4 BHC Schedule 6 BICALUTAMIDE Schedule 4 BICTEGRAVIR Schedule 4 BICYCLOPYRONE Schedule 6 Schedule 5 BIFENAZATE Appendix B, clause 3 BIFENTHRIN Schedule 7 Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 395 BIFLUORIDES cross reference: AMMONIUM BIFLUORIDE, AMMONIUM SALTS, POTASSIUM SALTS, SODIUM SALTS Schedule 7 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1 BIFONAZOLE Schedule 4 Schedule 2 BILASTINE Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 BIMATOPROST Schedule 4 BINIMETINIB Schedule 4 BIOALLETHRIN Schedule 6 Schedule 5 BIORESMETHRIN Schedule 5 BIPERIDEN Schedule 4 1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER Schedule 6 Appendix E, clause 3 Appendix F, clause 4 BISMUTH COMPOUNDS cross reference: BISMUTH CITRATE, BISMUTH FORMIC IODIDE, BISMUTH OXYCHLORIDE, BISMUTH SUBIODIDE Schedule 4 BISMUTH SUBNITRATE Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 396 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BISOPROLOL Schedule 4 N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMI NE cross reference: N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMI NE cross reference: N,N-bIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 BISPYRIBAC Schedule 5 BISTRIFLURON Appendix B, clause 3 BITHIONOL cross reference: CAS No. 97-18-7 Schedule 10 Schedule 6 Appendix F, clause 4 BIURET Appendix B, clause 3 BIVALIRUDIN Schedule 4 BIXAFEN Schedule 5 BIXLOZONE Appendix B, clause 3 BLAD (banda de Lupinus albus doce) Appendix B, clause 3 BLEOMYCIN Schedule 4 BLINATUMOMAB Schedule 4 BOCEPREVIR Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 397 BOLANDIOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) BOLASTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) BOLAZINE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) BOLDENONE cross reference: DEHYDROTESTOSTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) BOLENOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) BOLMANTALATE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) BORAGO OFFICINALIS cross reference: BORAGE Schedule 10 BORIC ACID cross reference: BORAX, SODIUM BORATE, POTASSIUM BORATE, MEA-BORATE, MIPA-BORATE Schedule 5 Schedule 4 Appendix E, clause 3 Appendix F, clause 4 BORON cross reference: BORATES, BORAX, BORIC ACID, BORON COMPOUNDS Schedule 4 BORON TRIFLUORIDE Schedule 7 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1 BORTEZOMIB Schedule 4 BOSCALID Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 398 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BOSENTAN Schedule 4 Appendix D, clause 6 Appendix F, clause 4 Appendix L, clause 2 BOSUTINIB Schedule 4 BOTULINUM TOXINS Schedule 4 BOVINE SOMATOTROPHIN Appendix B, clause 3 BPC-157 Schedule 4 Appendix D, clause 5 BRAGANTIA spp Schedule 10 BRENTUXIMAB VEDOTIN Schedule 4 BRETYLIUM TOSILATE Schedule 4 BRETYLIUM TOSYLATE cross reference: BRETYLIUM TOSILATE BREXPIPRAZOLE Schedule 4 Appendix K, clause 1 BRIGATINIB Schedule 4 BRIMONIDINE Schedule 4 Schedule 2 BRINZOLAMIDE Schedule 4 BRIVARACETAM cross reference: RACETAMS Schedule 4 Appendix K, clause 1 BRODIFACOUM Schedule 7 Schedule 6 Appendix J, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 399 BROFLANILIDE Schedule 6 Schedule 5 BROMACIL Appendix B, clause 3 BROMADIOLONE Schedule 7 Schedule 6 Appendix J, clause 1 BROMAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 BROMETHALIN Schedule 7 Schedule 6 BROMHEXINE Schedule 2 BROMIDES Schedule 4 BROMINE Schedule 7 Appendix J, clause 1 1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE cross reference: BROMO-DRAGONFLY (CAS No. 502759-67-3) Schedule 9 BROMOCRIPTINE Schedule 4 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE cross reference: BDMPEA (CAS No. 66142-81-2) Schedule 9 BROMOFORM Schedule 6 Schedule 4 Appendix E, clause 3 Appendix F, clause 4 BROMOPHOS Schedule 6 BROMOPHOS-ETHYL Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index 400 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 BROMOPROPYLATE Appendix B, clause 3 BROMOXYNIL Schedule 6 BROMPHENIRAMINE Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1 BROMUCONAZOLE Schedule 6 Schedule 5 BROMVALETONE Schedule 4 BROTIANIDE Schedule 6 BRUCINE Schedule 7 Appendix E, clause 3 Appendix J, clause 1 BRUGMANSIA spp. Schedule 4 BUCLIZINE Schedule 4 Schedule 3 Appendix K, clause 1 BUCLOSAMIDE cross reference: CAS No. 575-74-6 Schedule 10 BUDESONIDE Schedule 4 Schedule 2 BUFEXAMAC Schedule 4 BUFOTENINE cross reference: CAS No. 487-93-4 Schedule 9 BULEVIRTIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 401 BUMETANIDE Schedule 4 BUNAMIDINE Schedule 6 BUNIODYL SODIUM cross reference: CAS No. 1923-76-8, BUNIODYL BASE (CAS No. 1233-53-0) Schedule 10 BUPHENINE Schedule 4 BUPIRIMATE Appendix B, clause 3 BUPIVACAINE Schedule 5 Schedule 4 BUPRENORPHINE Schedule 8 Appendix K, clause 1 BUPROFEZIN Schedule 5 BUPROPION cross reference: AMFEBUTAMONE Schedule 4 BUSERELIN Schedule 4 BUSPIRONE Schedule 4 BUSULPHAN Schedule 4 BUTACAINE Schedule 4 BUTACARB Schedule 6 BUTAFENACIL Appendix B, clause 3 BUTAMBEN cross reference: BUTYL AMINOBENZOATE Schedule 4 1,4-BUTANEDIOL cross reference: CAS No. 110-63-4 Authorised Version F2024L00589 registered 30/05/2024 Index 402 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 10 BUTHIDAZOLE Schedule 5 BUTOBARBITAL Schedule 8 Appendix K, clause 1 BUTOBARBITONE cross reference: BUTOBARBITAL BUTOCONAZOLE Schedule 4 Schedule 3 Appendix H, clause 1 BUTONITAZENE cross reference: CAS No. 95810-54-1 Schedule 9 BUTORPHANOL Schedule 8 BUTOXYCARBOXIM Schedule 6 Schedule 5 2-BUTOXYETHANOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 BUTOXYPOLYPROPYLENE GLYCOL Appendix B, clause 3 2-BUTOXY-2'-THIOCYANODIETHYL ETHER Schedule 6 Appendix F, clause 4 BUTRACONAZOLE Schedule 4 BUTRALIN Schedule 5 BUTROXYDIM Schedule 5 n-BUTYL ALCOHOL Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 403 BUTYL AMINOBENZOATE cross reference BUTAMBEN BUTYL BENZYL PHTHALATE cross reference: CAS No. 85-68-7 Schedule 10 n-BUTYL BUTYRATE Appendix B, clause 3 n-BUTYL LACTATE Appendix B, clause 3 BUTYL NITRITE Schedule 4 Appendix E, clause 3 BUTYLCHLORAL HYDRATE Schedule 4 BUTYRIC ACID Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index 404 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 C CABAZITAXEL Schedule 4 CABERGOLINE Schedule 4 CABOTEGRAVIR Schedule 4 CABOZANTINIB Schedule 4 CACALIA spp. Schedule 10 CACODYLIC ACID Schedule 7 Schedule 6 CADMIUM COMPOUNDS cross reference: CADMIUM, CADMIUM ACETATE, CADMIUM CHLORIDE, CADMIUM NITRATE Schedule 6 Schedule 4 Appendix E, clause 3 CADUSAFOS Schedule 7 Schedule 6 CAFFEINE cross reference: PARACETAMOL, ASPIRIN, SALICYLAMIDE Schedule 6 Schedule 4 CAJUPUT OIL Schedule 6 Appendix E, clause 3 CALCIFEDIOL Schedule 4 CALCIFEROL Schedule 7 Schedule 6 Appendix J, clause 1 CALCIPOTRIOL Schedule 4 CALCITONIN SALMON Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 405 CALCITRIOL Schedule 4 CALCIUM CARBIMIDE Schedule 4 CALCIUM HYDROXYLAPATITE Schedule 4 CALCIUM POLYSTYRENE SULPHONATE Schedule 4 CALOTROPIS GIGANTEA Schedule 4 CALOTROPIS PROCERA Schedule 4 CALUSTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) CAMBENDAZOLE Schedule 6 CAMPHOR cross reference: ESSENTIAL OILS, LAVANDIN OIL, ROSEMARY OIL, SHUI OIL Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 CAMPHORATED OIL Schedule 4 CAMPHOTAMIDE Schedule 4 CANAGLIFLOZIN Schedule 4 CANAKINUMAB Schedule 4 CANDESARTAN CILEXETIL Schedule 4 CANDICIDIN Schedule 4 CANINE TICK ANTI-SERUM Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 406 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CANNABICHROMENE cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS CANNABIDIOL cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS Schedule 4 Schedule 3 Appendix F, clause 4 CANNABIDIOLIC ACID cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS CANNABIDIVAROL cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS CANNABIGEROL cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS CANNABINOIDS cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS CANNABINOL cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS CANNABIS cross reference: CANNABIS SATIVA, HEMP, HEMP SEED OIL, TETRAHYDROCANNABINOLS Schedule 9 Schedule 8 Appendix D, clause 1 Appendix K, clause 1 CANTHARIDIN Schedule 4 Appendix G, clause 1 CAPECITABINE Schedule 4 CAPREOMYCIN Schedule 4 CAPROMORELIN Schedule 4 Appendix D, clause 5 CAPTAFOL Schedule 7 Appendix J, clause 1 CAPTAN Schedule 6 CAPTODIAME Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 407 CAPTOPRIL Schedule 4 CAPURIDE Schedule 4 CARAMIPHEN Schedule 4 CARBACHOL Schedule 4 CARBADOX Schedule 7 Appendix J, clause 1 CARBAMAZEPINE Schedule 4 CARBAMIDE PEROXIDE cross reference: CAS No. 124-43-6 Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 CARBARYL Schedule 6 Schedule 5 Schedule 4 CARBAZOCHROME Schedule 4 CARBENDAZIM Schedule 7 CARBENICILLIN Schedule 4 CARBENOXOLONE Schedule 4 CARBETAMIDE Schedule 6 CARBETAPENTANE Schedule 2 CARBETOCIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 408 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CARBIDOPA Schedule 4 CARBIMAZOLE Schedule 4 CARBOCISTEINE Schedule 2 CARBOCROMEN Schedule 4 CARBOFURAN Schedule 7 CARBON DISULFIDE Schedule 6 Appendix E, clause 3 CARBON TETRACHLORIDE Schedule 7 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1 CARBONYL SULFIDE Schedule 7 Appendix J, clause 1 CARBOPHENOTHION Schedule 7 CARBOPLATIN Schedule 4 CARBOPROST Schedule 4 CARBOSULFAN Schedule 7 CARBOXIN Appendix B, clause 3 CARBROMAL Schedule 4 CARBUTAMIDE Schedule 4 CARBUTEROL Schedule 4 CARDARINE cross reference: CAS No. 317318-70-0 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 409 Schedule 10 CARFENTANYL Schedule 8 CARFENTRAZONE-ETHYL Appendix B, clause 3 CARFILZOMIB. Schedule 4 CARGLUMIC ACID Schedule 4 CARINDACILLIN Schedule 4 CARIPRAZINE Schedule 4 CARISOPRODOL Schedule 4 CARMUSTINE Schedule 4 CARNIDAZOLE Schedule 4 CARPROFEN Schedule 4 CARVEDILOL Schedule 4 CASIRIVIMAB Schedule 4 CASPOFUNGIN Schedule 4 CASSIA OIL Schedule 5 Appendix E, clause 3 Appendix F, clause 4 CASTOR OIL, MONOMALEATE Schedule 6 CATHINE Schedule 4 CATHINONES cross reference: SYNTHETIC CATHINONES Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index 410 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CATUMAXOMAB Schedule 4 CEDAZURIDINE Schedule 4 CEFACETRILE cross reference: CEPHACETRILE Schedule 4 CEFACLOR Schedule 4 CEFADROXIL Schedule 4 CEFALEXIN cross reference: CEPHALEXIN Schedule 4 CEFALORIDINE cross reference: CEPHALORIDINE Schedule 4 CEFALOTIN cross reference: CEPHALOTHIN, CEFALOTHIN Schedule 4 CEFAMANDOLE cross reference: CEPHAMANDOLE Schedule 4 CEFAPIRIN cross reference: CEPHAPIRIN Schedule 4 CEFAZOLIN cross reference: CEPHAZOLIN Schedule 4 CEFEPIME Schedule 4 CEFETAMET Schedule 4 CEFIXIME Schedule 4 CEFODIZIME Schedule 4 CEFONICID Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 411 CEFOPERAZONE Schedule 4 CEFOTAXIME Schedule 4 CEFOTETAN Schedule 4 CEFOTIAM Schedule 4 CEFOVECIN Schedule 4 CEFOXITIN Schedule 4 CEFPIROME Schedule 4 CEFPODOXIME Schedule 4 CEFQUINOME Schedule 4 CEFSULODIN Schedule 4 CEFTAROLINE FOSAMIL Schedule 4 CEFTAZIDIME Schedule 4 CEFTIBUTEN Schedule 4 CEFTIOFUR Schedule 4 CEFTRIAXONE Schedule 4 CEFUROXIME Schedule 4 CELECOXIB Schedule 4 Schedule 3 Appendix H, clause 1 CELIPROLOL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 412 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CELLULASE derived from Aspergillus niger Appendix B, clause 3 CENEGERMIN Schedule 4 CEPHAELIS ACUMINATA cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA Schedule 4 CEPHAELIS IPECACUANHA cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA Schedule 4 CEPHALEXIN cross reference: CEFALEXIN CEPHALONIUM Schedule 4 CEPHALOTHIN cross reference: CEFALOTIN CEPHRADINE Schedule 4 CERAMICS Appendix A, clause 1 CERITINIB Schedule 4 CERIVASTATIN Schedule 4 CERLIPONASE ALFA Schedule 4 CERTOLIZUMAB PEGOL Schedule 4 CERULETIDE Schedule 4 CETIRIZINE Schedule 4 Schedule 2 Appendix K, clause 1 CETRORELIX Schedule 4 CETUXIMAB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 413 CETYL ALCOHOL Appendix B, clause 3 CHAMOMILE OIL Appendix B, clause 3 CHEMISTRY SETS Appendix A, clause 1 CHENODEOXYCHOLIC ACID Schedule 4 CHINA CLAY Appendix B, clause 3 CHLOPHEDIANOL Schedule 2 CHLORAL FORMAMIDE Schedule 4 CHLORAL HYDRATE Schedule 4 Appendix K, clause 1 CHLORALOSE cross reference: ALPHA-CHLORALOSE Schedule 6 Schedule 4 CHLORAMBUCIL Schedule 4 CHLORAMPHENICOL Schedule 4 Schedule 3 CHLORANDROSTENOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) CHLORANTRANILIPROLE Appendix B, clause 3 CHLORAZANIL Schedule 4 CHLORBUTANOL Schedule 3 Schedule 2 Authorised Version F2024L00589 registered 30/05/2024 Index 414 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CHLORBUTOL cross reference: CHLOROBUTANOL CHLORCYCLIZINE Schedule 4 CHLORDANE Schedule 6 CHLORDECONE Schedule 7 Appendix J, clause 1 CHLORDIAZEPOXIDE Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 CHLORDIMEFORM Schedule 7 Appendix J, clause 1 CHLORFENAC Schedule 5 CHLORFENAPYR Schedule 7 Schedule 6 Schedule 5 CHLORFENETHOL Schedule 6 CHLORFENSON Schedule 5 CHLORFENVINPHOS Schedule 7 CHLORFLUAZURON Appendix B, clause 3 CHLORFLURENOL Appendix B, clause 3 CHLORHEXIDINE Schedule 7 Schedule 6 Schedule 5 CHLORIDAZON Appendix B, clause 3 CHLORIDE Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 415 CHLORINATING COMPOUNDS cross reference: BLEACHES, BROMOCHLORODIMETHYLHYDANTOIN, TRICHLOROISOCYANURIC ACID, CALCIUM HYPOCHLORITE, CHLORINE, DICHLOROETHYL ETHER, SODIUM HYPOCHLORITE Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1 CHLORINE cross reference: CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, DICHLOROISOCYANURIC ACID Schedule 7 Appendix G, clause 1 Appendix J, clause 1 CHLORMEQUAT Schedule 6 CHLORMERODRIN Schedule 4 CHLORMETHIAZOLE Schedule 4 Appendix K, clause 1 CHLORMEZANONE Schedule 4 CHLORNIDINE Schedule 5 CHLOROACETAMIDE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 CHLOROCRESOL Schedule 5 Appendix E, clause 3 2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 CHLOROFORM Schedule 6 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 416 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 4-CHLOROMETHANDIENONE Schedule 4 Appendix D, clause D (Anabolic and/or androgenic steroidal agents) CHLOROMETHIURON Schedule 7 Appendix J, clause 1 5-CHLORO-3-METHYL-4-NITROPYRAZOLE Schedule 7 2-CHLORO-5-NITRO-N-HYDROXYETHYL-p-PHENYLENEDIAMINE cross reference: PHENYLENEDIAMINES CHLOROPHACINONE Schedule 6 2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE Schedule 4 CHLOROPICRIN Schedule 7 Schedule 6 CHLOROPICRIN Appendix J, clause 1 CHLOROQUINE Schedule 4 CHLOROTHALONIL Schedule 6 CHLOROTHIAZIDE Schedule 4 4-CHLORO-o-TOLUIDINE Schedule 7 Appendix J, clause 1 CHLOROTRIANISENE Schedule 4 2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE Schedule 6 CHLOROXYDIENONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) CHLOROXYLENOLS Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 417 CHLORPHENAMINE cross reference: CHLORPHENIRAMINE Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1 CHLORPHENIRAMINE cross reference: CHLORPHENAMINE CHLORPHENTERMINE Schedule 4 CHLORPROMAZINE Schedule 4 Appendix K, clause 1 CHLORPROPAMIDE Schedule 4 CHLORPROPHAM Schedule 5 CHLORPROTHIXENE Schedule 4 CHLORPYRIFOS Schedule 6 Schedule 5 CHLORPYRIFOS-METHYL Schedule 6 CHLORQUINALDOL Schedule 4 CHLORSULFURON Schedule 5 CHLORTALIDONE Schedule 4 CHLORTETRACYCLINE Schedule 5 Schedule 4 CHLORTHAL-DIMETHYL Schedule 5 CHLORTHALIDONE cross reference: CHLORTALIDONE CHLORTHIAMID Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index 418 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CHLORTHIOPHOS Schedule 7 CHLORZOXAZONE Schedule 4 CHOLECALCIFEROL cross reference: COLECALCIFEROL Schedule 7 Appendix J, clause 1 CHOLERA VACCINE Schedule 4 CHOLESTYRAMINE cross reference: COLESTYRAMINE CHOLIC ACID Schedule 4 CHOLINE SALICYLATE Schedule 2 CHROMATES cross reference: AMMONIUM CHROMATE, BARIUM CHROMATE, CHROMIUM, COPPER-CHROME-ARSENIC, DICHROMATES, POTASSIUM CHROMATE, ZINC CHROMATE SODIUM CHROMATE, STRONTIUM CHROMATE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 CHROMIUM TRICHLORIDE HEXAHYDRATE Schedule 6 CHROMIUM TRIOXIDE cross reference: CHROMIC ACID Schedule 6 Appendix E, clause 3 Appendix F, clause 4 CHRYSOIDINE BASE cross reference: CAS No. 495-54-5 Schedule 10 Schedule 6 Appendix E, clause 3 CHYMOPAPAIN Schedule 4 CICLACILLIN Schedule 4 CICLESONIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 419 CICLOPIROX Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 CICLOSPORIN Schedule 4 CIDOFOVIR Schedule 4 CILASTATIN Schedule 4 CILAZAPRIL Schedule 4 CILGAVIMAB Schedule 4 CILOSTAZOL Schedule 4 CIMETIDINE Schedule 4 Schedule 3 Appendix F, clause 4 CIMICOXIB Schedule 4 CINACALCET Schedule 4 CINCHOCAINE Schedule 4 Schedule 2 CINCHOPHEN cross reference: CAS No. 132-60-5, CINCHOPHEN HYDROCHLORIDE (CAS No. 132-58 1), CINCHOPHEN SODIUM (CAS No. 5949-18-8) Schedule 10 CINEOLE cross reference: CAMPHOR OIL (white), ROSEMARY OIL Schedule 7 Appendix E, clause 3 CINMETHYLIN Schedule 5 CINNAMEDRINE Schedule 2 Authorised Version F2024L00589 registered 30/05/2024 Index 420 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CINNAMON BARK OIL Schedule 5 Appendix E, clause 3 Appendix F, clause 4 CINNAMON LEAF OIL Schedule 6 Appendix E, clause 3 CINNARIZINE Schedule 4 CINOXACIN Schedule 4 CIPROFLOXACIN Schedule 4 CISAPRIDE Schedule 4 CISATRACURIUM BESILATE cross reference: CISATRACURIUM BESYLATE Schedule 4 CIS-JASMONE cross reference: (Z)-JASMONE Schedule 5 CISPLATIN Schedule 4 CITALOPRAM Schedule 4 CITRONELLA OIL Appendix B, clause 3 CJC-1295 (CAS No. 863288-34-0) Schedule 4 Appendix D, clause 5 CLADRIBINE Schedule 4 CLANOBUTIN Schedule 4 CLARITHROMYCIN Schedule 4 CLARY SAGE OIL Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 421 CLASCOTERONE Schedule 4 CLAVULANIC ACID Schedule 4 CLEMASTINE Schedule 4 Schedule 3 Appendix K, clause 1 CLEMIZOLE Schedule 4 CLENBUTEROL Schedule 4 CLETHODIM Schedule 5 CLEVIDIPINE Schedule 4 CLIDINIUM BROMIDE Schedule 4 CLIMBAZOLE Schedule 6 Schedule 5 Appendix E, clause 3 CLINDAMYCIN Schedule 4 CLIOQUINOL cross reference: OXYQUINOLINE, CHLORQUINALDOL, HALQUINOL (CAS No. 130 26-7) Schedule 10 Schedule 4 CLITORIA TERNATEA EXTRACT Appendix B, clause 3 CLOBAZAM Schedule 4 CLOBETASOL Schedule 4 CLOBETASONE Schedule 4 Schedule 3 Appendix F, clause 4 Appendix H, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index 422 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CLOCORTOLONE Schedule 4 CLODINAFOP-PROPARGYL Schedule 6 CLODRONIC ACID cross reference: SODIUM CLODRONATE Schedule 4 CLOFARABINE Schedule 4 CLOFAZIMINE Schedule 4 CLOFENAMIDE Schedule 4 CLOFENTEZINE Schedule 5 CLOFIBRATE Schedule 4 CLOMAZONE Schedule 6 CLOMIFENE cross reference: CLOMIPHENE Schedule 4 Appendix D, clause 1 CLOMIPHENE cross reference: CLOMIFENE CLOMIPRAMINE Schedule 4 Appendix K, clause 1 CLOMOCYCLINE Schedule 4 CLONAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 CLONAZOLAM cross reference: CAS No. 33887-02-4 Schedule 9 CLONIDINE Schedule 4 Appendix K, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 423 CLONITAZENE cross reference: CAS No. 3861-76-5 Schedule 9 CLOPAMIDE Schedule 4 CLOPIDOGREL Schedule 4 CLOPIDOL Appendix B, clause 3 CLOPROSTENOL Schedule 4 CLOPYRALID Schedule 5 CLOQUINTOCET Schedule 5 CLORAZEPATE Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 CLOREXOLONE Schedule 4 CLORPRENALINE Schedule 4 CLORSULON Schedule 5 CLOSANTEL Schedule 6 CLOSTEBOL cross reference: 4-CHLOROTESTOSTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) CLOTHIANIDIN Schedule 6 Schedule 5 CLOTRIMAZOLE Schedule 6 Schedule 4 Schedule 3 Schedule 2 Authorised Version F2024L00589 registered 30/05/2024 Index 424 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix F, clause 4 Appendix H, clause 1 CLOVE OIL Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 CLOXACILLIN Schedule 4 CLOZAPINE Schedule 4 Appendix D, clause 1 Appendix K, clause 1 COAL TAR Schedule 10 COBALT cross reference: DICOBALT EDETATE Schedule 4 COBALT NAPHTHENATE Appendix B, clause 3 COBICISTAT Schedule 4 COBIMETINIB Schedule 4 COCA LEAF Schedule 9 COCAINE Schedule 8 N-COCO-1,3-DIAMINOPROPANE Schedule 6 COCOYL GLYCINATE Schedule 6 Appendix E, clause 3 COCOYL METHYL GLUCAMAIDE cross reference: 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL DERIVATIVES CODEINE Schedule 8 Schedule 4 Appendix K, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 425 CODEINE-N-OXIDE Schedule 8 CO-DERGOCRINE Schedule 4 CODOXIME cross reference: CAS No. 7125-76-0 Schedule 9 COLASPASE cross reference: ASPARAGINASE COLCHICINE Schedule 4 COLCHICUM AUTUMNALE Schedule 4 COLECALCIFEROL cross reference: CHOLECALCIFEROL Schedule 7 Appendix J, clause 1 COLESTIPOL Schedule 4 COLESTYRAMINE Schedule 4 COLFOSCERIL PALMITATE Schedule 4 COLISTIN Schedule 4 COLLAGEN Schedule 4 COLLAGENASE CLOSTRIDIUM HISTOLYTICUM Schedule 4 COLURACETAM cross reference: RACETAMS Schedule 4 CONCENTRATE OF POPPY STRAW Schedule 8 CONCIZUMAB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 426 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CONIUM MACULATUM cross reference: CONIINE (CAS No. 3238-60-6), CONIINE R-ISOMER (CAS No. 5985-99 9), CONIINE S-ISOMER (CAS No. 458-88-8) Schedule 10 CONVALLARIA KEISKI Schedule 4 CONVALLARIA MAJALIS Schedule 4 COPPER ACETATE Schedule 6 Schedule 5 COPPER COMPOUNDS cross reference: COPPER Schedule 6 Schedule 5 Schedule 4 Appendix A, clause 1 COPPER HYDROXIDE Schedule 6 Schedule 5 COPPER NITRATE cross reference: COPPER CHLORIDE Schedule 6 COPPER OXIDES Schedule 6 Schedule 5 COPPER OXYCHLORIDE Schedule 6 Schedule 5 COPPER SULFATE Schedule 6 Schedule 5 Appendix E, clause 3 CORIFOLLITROPIN ALFA cross reference: FOLLICLE STIMULANT, RECOMBINANT Schedule 4 Appendix D, clause 1 CORONILLA spp. Schedule 4 CORTICOSTERONE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 427 CORTICOTROPHIN Schedule 4 CORTISONE Schedule 4 COTARNINE cross reference: CAS No. 82-54-2, COTARNINE HYDROCHLORIDE (CAS No. 36647-02 6), COTARNINE CHLORIDE (CAS No. 10018-19-6) Schedule 10 CO-TRIMOXAZOLE Schedule 4 COUMAPHOS Schedule 7 Schedule 6 COUMARIN Schedule 4 COUMATETRALYL Schedule 7 Schedule 6 Schedule 5 Appendix J, clause 1 4-CPA Schedule 5 CREOSOTE cross reference: BEECHWOOD, PHENOL, WOOD Schedule 7 Schedule 6 Schedule 2 Appendix E, clause 3 CRESOLS Appendix E, clause 3 CRISABOROLE Schedule 4 CRIZOTINIB Schedule 4 CROFELEMER Schedule 4 CROSPOVIDONE Appendix B, clause 3 CROTALARIA spp. Schedule 10 Authorised Version F2024L00589 registered 30/05/2024 Index 428 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CROTON TIGLIUM cross reference: CROTON OIL Schedule 10 Appendix G, clause 1 CROTOXYPHOS Schedule 6 CRUFOMATE Schedule 6 CRYSTAL VIOLET cross reference: METHYLROSANILINIUM CHLORIDE, GENTIAN VIOLET CULICINOMYCES CLAVOSPORUS Appendix B, clause 3 CUPRIMYXIN Schedule 4 CURARE Schedule 4 13C-UREA Appendix B, clause 3 CYANAMIDE Schedule 6 CYANATRYN Schedule 5 CYANAZINE Schedule 6 CYANIDES cross reference: FERRICYANIDES, FERROCYANIDES Schedule 7 Appendix E, clause 3 Appendix F, clause 4 CYANOACRYLATE ESTERS Schedule 5 CYANOACRYLIC ACID ESTERS Appendix E, clause 3 4-CYANO-2-DIMETHYLAMINO-4,4'-DIPHENYLBUTANE cross reference: METHADONE INTERMEDIATE (CAS No. 125-79-1) Schedule 9 CYANOGEN cross reference: ETHANEDINITRILE, OXALONITRILE Schedule 7 Appendix J, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 429 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE cross reference: PETHIDINE INTERMEDIATE A Schedule 8 CYANTRANILIPROLE Schedule 5 CYANURIC ACID Schedule 5 Appendix E, clause 3 Appendix F, clause 4 CYAZOFAMID Schedule 5 CYCLAMIC ACID Appendix B, clause 3 CYCLANDELATE Schedule 4 CYCLANILIDE Schedule 6 CYCLANILIPROLE Appendix B CYCLIZINE Schedule 4 Schedule 3 Appendix K, clause 1 CYCLOBARBITAL Schedule 8 Appendix K, clause 1 CYCLOBARBITONE cross reference: CYCLOBARBITAL CYCLOBENZAPRINE Schedule 4 CYCLOBUTRIFLURAM Appendix B, clause 3 CYCLOFENIL Schedule 4 Appendix D, clause 1 CYCLOHEXANE Appendix B, clause 3 CYCLOHEXANOL ACETATE Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 430 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CYCLOHEXANONE PEROXIDE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 CYCLOHEXIMIDE Schedule 4 N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM cross reference: K-HDO Schedule 6 CYCLOHEXYLPHENOLS Schedule 9 CYCLOPENTHIAZIDE Schedule 4 CYCLOPENTOLATE Schedule 4 CYCLOPHOSPHAMIDE Schedule 4 CYCLOPROPANE Schedule 4 CYCLOPROTHRIN Schedule 5 CYCLOSERINE Schedule 4 Appendix J, clause 1 CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-84-2) Schedule 7 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 CYCLOSPORIN cross reference: CICLOSPORIN CYCLOTHIAZIDE Schedule 4 CYCLOXYDIM Schedule 5 CYCRIMINE Schedule 4 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 431 CYFLUFENAMID Schedule 5 CYFLUMETOFEN Schedule 5 CYFLUTHRIN Schedule 6 Schedule 5 CYHALOFOP-BUTYL Schedule 5 CYHALOTHRIN Schedule 7 CYHEXATIN Schedule 7 CYMARIN Schedule 4 CYMIAZOLE Schedule 5 CYNOGLOSSUM spp. Schedule 10 CYOMETRINIL Schedule 6 CYPERMETHRIN cross reference: ALPHA-CYPERMETHRIN AND BETA-CYPERMETHRIN, ZETA-CYPERMETHRIN Schedule 6 Schedule 5 CYPHENOTHRIN Schedule 6 Schedule 5 CYPRINID HERPESVIRUS-3 Appendix B, clause 3 CYPROCONAZOLE Schedule 5 CYPRODINIL Schedule 5 CYPROHEPTADINE Schedule 4 Schedule 3 Appendix K, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index 432 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 CYPROTERONE Schedule 4 CYROMAZINE Appendix B, clause 3 CYSTEAMINE cross reference: MERCAPTAMINE CYTARABINE Schedule 4 CYTHIOATE Schedule 6 Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 433 D 2,4-D Schedule 6 Schedule 5 DABIGATRAN Schedule 4 DABRAFENIB MESILATE Schedule 4 DACARBAZINE Schedule 4 DACLATASVIR Schedule 4 DACLIZUMAB Schedule 4 DACTINOMYCIN Schedule 4 DALFOPRISTIN Schedule 4 DALTEPARIN Schedule 4 DAMINOZIDE Schedule 5 DANAPAROID Schedule 4 DANAZOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) DANTHRON Schedule 4 DANTROLENE Schedule 4 Appendix K, clause 1 DAPAGLIFLOZIN Schedule 4 DAPOXETINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 434 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DAPSONE Schedule 4 DAPTOMYCIN Schedule 4 DARATUMUMAB Schedule 4 DARBEPOETIN Schedule 4 Appendix D, clause 5 DARIFENACIN Schedule 4 DAROLUTAMIDE Schedule 4 DARUNAVIR Schedule 4 DASABUVIR Schedule 4 DASATINIB Schedule 4 DATURA spp. Schedule 4 Schedule 2 DATURA STRAMONIUM cross reference: STRAMONIUM Schedule 4 Schedule 2 DATURA TATULA cross reference: STRAMONIUM Schedule 4 Schedule 2 DAUNORUBICIN Schedule 4 DAZOMET Schedule 6 2,4-DB Schedule 5 DEANOL cross reference: 2-(DIMETHYLAMINO)ETHANOL, DMEA, DIMETHYL MEA Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 435 DEBRISOQUINE Schedule 4 DECAMETHONIUM Schedule 4 DECITABINE Schedule 4 DECOQUINATE Schedule 5 DEFERASIROX Schedule 4 DEFERIPRONE Schedule 4 DEFIBROTIDE Schedule 4 DEFLAZACORT Schedule 4 DEGARELIX Schedule 4 DEHYDROCHLOROMETHYLTESTOSTERONE cross reference: CHLOROMESTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) DEHYDROCORTICOSTERONE Schedule 4 DELAVIRDINE cross reference: DELAVIRDINE MESILATE DELAVIRDINE MESILATE Schedule 4 DELPHINIUM STAPHISAGRIA cross reference: STAPHISAGRIA Schedule 2 DELTAMETHRIN Schedule 7 Schedule 6 Schedule 5 DEMBREXINE Schedule 5 Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 436 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DEMECARIUM Schedule 4 DEMECLOCYCLINE Schedule 4 DEMETON Schedule 7 DEMETON-O-METHYL Schedule 7 DEMETON-S-METHYL Schedule 7 DENGUE VACCINE cross reference: LIVE ATTENUATED CHIMERIC DENGUE VIRUS (SEROTYPES 1, 2, 3 and 4) Schedule 4 DENOSUMAB Schedule 4 DEOXYCHOLIC ACID Schedule 4 DEOXYCORTONE Schedule 4 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL DERIVATIVES cross reference: COCOYL METHYL GLUCAMAIDE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 DEOXYRIBONUCLEASE Schedule 4 DERACOXIB Schedule 4 DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT Schedule 4 DERQUANTEL Schedule 6 2,4-DES Schedule 5 DESCHLOROETIZOLAM cross reference: CAS No. 40054-73-7 Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 437 DESFERRIOXAMINE Schedule 4 DESFLURANE Schedule 4 DESIPRAMINE Schedule 4 Appendix K, clause 1 DESIRUDIN Schedule 4 DESLANOSIDE Schedule 4 DESLORATADINE Schedule 4 Schedule 2 DESLORELIN Schedule 4 DESMOPRESSIN cross reference: D.D.A.V.P. Schedule 4 DESOGESTREL Schedule 4 DESOMORPHINE cross reference: CAS No. 427-00-9 Schedule 9 DESONIDE Schedule 4 DESOXYMETHASONE Schedule 4 DESVENLAFAXINE Schedule 4 DETOMIDINE Schedule 4 DEUCRAVACITINIB Schedule 4 DEUTETRABENAZINE Schedule 4 Appendix K, clause 1 DEXAMETHASONE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 438 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DEXAMFETAMINE cross reference: DEXAMPHETAMINE Schedule 8 DEXCHLORPHENAMINE cross reference: DEXCHLORPHENIRAMINE Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1 DEXCHLORPHENIRAMINE cross reference: DEXCHLORPHENAMINE DEXFENFLURAMINE Schedule 4 DEXMEDETOMIDINE Schedule 4 DEXTRANS Appendix A DEXTROMETHORPHAN Schedule 4 Schedule 2 DEXTROMORAMIDE cross reference: MORAMIDE Schedule 8 Appendix K, clause 1 DEXTROPROPOXYPHENE Schedule 8 Schedule 4 Appendix D, clause 5 Appendix K, clause 1 DEXTRORPHAN Schedule 4 N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES cross reference: 3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-METHYLBENZ AMIDE *(U-47700) (CAS No. 82657-23-6) Schedule 9 N,N-DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES Cross reference: 3,4-DICHLORO-N-{[1-(DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH-7921) (CAS No. 55154-30-8) Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 439 4,4-DIAMINODIPHENYLMETHANE cross reference: METHYLENE DIANILINE Schedule 7 Appendix F, clause 4 Appendix J, clause 1 2,4-DIAMINO-5-METHYLPHENETOLE cross reference: PHENYLENEDIAMINES 2,4-DIAMINOPHENOXYETHANOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 DIAFENTHIURON Schedule 5 DIALIFOS Schedule 7 N,N-DIALLYLDICHLOROACETAMIDE Schedule 5 DIAMPROMIDE cross reference: CAS No. 552-25-0 Schedule 9 DIAMTHAZOLE Schedule 4 DIAVERIDINE Schedule 4 DIAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 DIAZINON Schedule 6 Schedule 5 DIAZOXIDE Schedule 4 DIBENZEPIN Schedule 4 DIBENZOPYRANS Schedule 9 DIBOTERMIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 440 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 1,2-DIBROMO-3-CHLOROPROPANE Schedule 7 Appendix J, clause 1 DIBROMOPROPAMIDINE Schedule 4 Schedule 2 DIBUTYL PHTHALATE cross reference: CAS No. 84-74-2 Schedule 10 DICAMBA Schedule 6 Schedule 5 DICLAZEPAM cross reference: CAS No. 2894-68-0 Schedule 9 DICHLOBENIL Schedule 6 o-DICHLOROBENZENE Appendix F, clause 4 DICHLOEOETHYL ETHER Appendix F, clause 4 DICHLOFENTHION Schedule 6 DICHLOFLUANID Schedule 6 DICHLONE Schedule 5 DICHLORALPHENAZONE Schedule 4 DICHLOROBENZENE Schedule 6 Schedule 5 Appendix E, clause 3 3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-METHYLBE NZAMIDE (U-47700) cross reference: N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES (CAS No. 82657-23-6) Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 441 DICHLOROETHYL ETHER Schedule 6 Appendix E, clause 3 DICHLOROETHYLENE Appendix F, clause 4 DICHLOROISOCYANURIC ACID cross reference: CHLORINE, CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, SODIUM DICHLOROISOCYANURATE Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 DICHLOROMETHANE cross reference: METHYLENE CHLORIDE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 3,4-DICHLORO-N-{[1-DIMETHYLAMINO)CYCLOHEXYL]METHYL} BENZAMIDE cross reference: AH-7921 (CAS No. 55154-30-8) Schedule 9 4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE Schedule 6 DICHLOROPHEN Schedule 6 Schedule 5 Schedule 4 2,4-DICHLORPROP Schedule 6 1,2-DICHLOROPROPANE Schedule 6 1,3-DICHLOROPROPENE Schedule 7 Appendix J, clause 1 DICHLORPHENAMIDE Schedule 4 DICHLORVOS Schedule 7 Schedule 6 Schedule 5 DICHROMATES Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 442 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DICLAZURIL Appendix B, clause 3 DICLOBUTRAZOL Schedule 5 DICLOFENAC Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 DICLOFOP-METHYL Schedule 6 DICLORAN Schedule 5 DICLOXACILLIN Schedule 4 DICOFOL Schedule 5 DICOPHANE cross reference: DDT (CAS No. 50-29-3) Schedule 10 DICROTOPHOS Schedule 7 DICYCLANIL Schedule 6 DICYCLOMINE Schedule 4 DIDANOSINE Schedule 4 DIDECYLDIMETHYLAMMONIUM SALTS Schedule 6 DIELDRIN Schedule 6 DIENESTROL Schedule 4 Appendix F, clause 4 Appendix L, clause 2 DIENOGEST Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 443 DIESEL Appendix E, clause 3 DIETHANOLAMINE Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 DIETHAZINE Schedule 4 DIETHYL CARBONATE Appendix B, clause 3 DIETHYLCARBAMAZINE Schedule 4 DIETHYLENE GLYCOL cross reference: DENATONIUM BENZOATE (CAS No. 111-46-6) Schedule 10 Schedule 6 Schedule 5 DIETHYLENE GLYCOL MONOBUTYL ETHER Schedule 5 Appendix E, clause 3 Appendix F, clause 4 DIETHYLENE GLYCOL MONOMETHYL ETHER cross reference: CAS No. 111-77-3 Schedule 10 Schedule 6 DIETHYLHEXYL PHTHALATE cross reference: DEHP (CAS No. 117-81-7) Schedule 10 DIETHYLPHTHALATE cross reference: CAS No. 84-66-2 Schedule 10 DIETHYLPROPION Schedule 4 DIETHYLTHIAMBUTENE cross reference: CAS No. 86-14-6, DIETHYLTHIAMBUTENE HYDROCHLORIDE (CAS No. 132-19-4) Schedule 9 DIETHYLTOLUAMIDE (DEET) Schedule 5 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 444 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 N,N-DIETHYLTRYPTAMINE cross reference: DET (CAS No. 61-51-8) Schedule 9 DIFELIKEFALIN Schedule 4 Appendix K, clause 1 DIFENACOUM Schedule 7 Schedule 6 Appendix J, clause 1 DIFENOCONAZOLE Schedule 5 DIFENOXIN Schedule 8 Schedule 4 Appendix K, clause 1 DIFENZOQUAT Schedule 6 DIFETHIALONE Schedule 7 Schedule 6 DIFLORASONE Schedule 4 DIFLOXACIN Schedule 4 DIFLUBENZURON Schedule 5 DIFLUCORTOLONE Schedule 4 DIFLUFENICAN Appendix B, clause 3 DIFLUNISAL Schedule 4 DIGITALIS LANATA Schedule 4 DIGITALIS PURPUREA Schedule 4 DIGITOXIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 445 DIGOXIN Schedule 4 DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab) Schedule 4 DIHYDRALAZINE Schedule 4 DIHYDROCODEINE Schedule 8 Schedule 4 Schedule 3 Appendix K, clause 1 DIHYDROERGOTOXINE Schedule 4 DIHYDROLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) 2,5-DIHYDRO-2-(1-METHYL-1-PHENYLETHYL)-5-PENTYL-1H-PYRIDO[4,3-B]IN DOL-1-ONE (SGT-151) cross reference: SGT-151, CUMYL-PEGACLONE (CAS No. 2160555-55-3) Schedule 9 DIHYDROMORPHINE Schedule 8 DIHYDROSTREPTOMYCIN Schedule 4 DIHYDROTACHYSTEROL Schedule 4 5,6-DIHYDROXYINDOLINE cross reference: CAS No. 29539-03-5, 5,6-DIHYDROXYINDOLINE HYDROBROMIDE (CAS No. 138937-28-7) Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 DIIODOHYDROXYQUINOLINE cross reference: IODOQUINOL (CAS No. 83-73-8) Schedule 10 Schedule 4 Schedule 3 Authorised Version F2024L00589 registered 30/05/2024 Index 446 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DI-IODOHYDROXYQUINOLINE cross reference: DIIODOHYDROXYQUINOLINE DIISOBUTYL PHTHALATE cross reference: CAS No. 84-69-5 Schedule 10 DIISOPROPYLAMINE DICHLOROACETATE Schedule 4 DIKEGULAC-SODIUM Appendix B, clause 3 DILTIAZEM Schedule 4 DIMEFOX Schedule 7 DIMENHYDRINATE Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 Appendix K, clause 1 DIMENOXADOL cross reference: CAS No. 509-78-4, DIMENOXADOL HYDROCHLORIDE (CAS No. 2424-75-1) Schedule 9 DIMEPHEPTANOL cross reference: CAS No. 545-90-4 Schedule 9 DIMERCAPROL Schedule 4 DIMETHANDROSTANOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) DIMETHAZINE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) DIMETHENAMID-P Schedule 6 DIMETHICODIETHYLBENZALMALONATE cross reference: POLYSILICONE-15 Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 447 DIMETHICONE cross reference: DIMETICONE DIMETHINDENE Schedule 4 Appendix K, clause 1 DIMETHIPIN Schedule 6 DIMETHIRIMOL Schedule 5 DIMETHOATE Schedule 6 DIMETHOMORPH Schedule 5 DIMETHOTHIAZINE Schedule 4 DIMETHOXANATE Schedule 4 2,5-DIMETHOXYAMFETAMINE cross reference: 2,5-DIMETHOXYAMPHETAMINE, DMA (CAS No. 2801-68-5), DMA HYDROCHLORIDE (CAS No. 24973-25-9) Schedule 9 2,5-DIMETHOXY-4-BROMOAMFETAMINE cross reference: 2,5-DIMETHOXY-4-BROMOAMPHETAMINE, DOB (CAS No. 64638-07 9) Schedule 9 2,5-DIMETHOXY-4-ETHYL-a-AMFETAMINE cross reference: 2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE, DOET (CAS No. 22004 32-6), DOET HYDROCHLORIDE (CAS No. 22139-65-7) Schedule 9 2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE cross reference: 2C-T-2 (CAS No. 207740-24-7) Schedule 9 2,5-DIMETHOXY-4-IODOPHENETHYLAMINE cross reference: 2C-I (CAS No. 69587-11-7) Schedule 9 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE cross reference: 2C-T-7 (CAS No. 207740-26-9) Schedule 9 2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE Schedule 6 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 448 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DIMETHYLACETAMIDE Schedule 6 Schedule 5 N,N-DIMETHYLAMFETAMINE cross reference: N,N-DIMETHYLAMPHETAMINE, DIMETAMFETAMINE (CAS No. 4075-96-1), DIMETAMFETAMINE S-ISOMER (CAS No. 17279-39-9) Schedule 9 4-DIMETHYLAMINOAZOBENZENE cross reference: MOCA, N,N-DIMETHYL-4-[PHENYLAZO]-BENZENAMINE Schedule 7 Appendix J, clause 1 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE cross reference: PSILOCINE, PSILOTSIN (CAS No. 520-53-6) Schedule 9 1,3-DIMETHYLAMYLAMINE cross reference: 4-METHYLHEXANE-2-AMINE, DMAA (CAS No. 105-41-9) Schedule 10 1,3-DIMETHYLBUTYLAMINE (DMBA) cross reference: OCTODRINE, 1-AMINOISOHEPTANE, DMHA, 1,5-DIMETHYLHEXYLAMINE, 4-METHYLHEXANE-2-AMINE, 1,3-DIMETHYLAMYLAMINE, DMAA, 4-AMINO-2-METHYLPENTANE CITRATE (AMP CITRATE), (CAS No. 108-09-8) Schedule 10 4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 N,N-DIMETHYLDECANAMIDE Schedule 6 DIMETHYL ETHER Appendix B, clause 3 1-(1,1-DIMETHYLETHYL)-2-METHOXY-4-METHYL-3,5-DINITROBENZENE (musk ambrette) cross reference: AMBER MUSK (CAS No. 83-66-9) Schedule 10 DI(METHYLOXYETHYL) PHTHALATE cross reference: CAS No. 117-82-8 Schedule 10 1,4-DIMETHYLPENTYLAMINE (DMPA) cross reference: 1,4-DIMETHYLAMYLAMINE (DMAA) (CAS No. 28292-43-5) Schedule 10 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 449 DIMETHYLFORMAMIDE cross reference: DESIGNATED SOLVENT Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 DIMETHYL FUMARATE Schedule 4 3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9 TRIMETHYL-6H-DIBENZO (b,d) PYRAN cross reference: DMHP (CAS No. 32904-22-6) Schedule 9 1,5-DIMETHYLHEXYLAMINE (DMHA) cross reference: 1,3-DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1-AMINOISOHEPTANE, DMHA, 4-METHYLHEXANE-2-AMINE, 1,3-DIMETHYLAMYLAMINE, DMAA, 4-AMINO-2-METHYLPENTANE CITRATE (AMP CITRATE), (CAS No. 543-82-8), 1,5-DIMETHYLHEXYLAMINE HYDROCHLORIDE (CAS No. 5984-59-8), 1,5-DIMETHYLHEXYLAMINE S-ISOMER (CAS No. 70419-10-2), 1,5-DIMETHYLHEXYLAMINE R-ISOMER (CAS No. 70419-11-3) Schedule 10 N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) cross reference: 3,4-METHYLENEDIOXY-N-α-DIMETHYLPHENYLETHYLAMINE, MDMA, MIDOMAFETAMINE (CAS No. 42542-10-9), MDMA HYDROCHLORIDE (CAS No. 64057-70-1) Schedule 9 Schedule 8 Appendix D, clause 5 Appendix D, clause 10 3,7-DIMETHYL-2,6-OCTADIENAL cross reference: CITRAL, NERAL, GERANIAL Schedule 5 3,7-DIMETHYL-2,6-OCTADIEN-1-OL cross reference: GERANIOL, NEROL, CITROL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 N,N-DIMETHYLOCTANAMIDE Schedule 6 DIMETHYLPHTHALATE cross reference: CAS No. 131-11-3 Schedule 10 DIMETHYL SULFATE Schedule 7 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 450 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DIMETHYL SULFOXIDE cross reference: COPPER SALICYLATE, METHYL SALICYLATE Schedule 6 Schedule 4 Appendix E, clause 3 Appendix F, clause 4 DIMETHYLTHIAMBUTENE cross reference: CAS No. 524-84-5 Schedule 9 N,N-DIMETHYLTRYPTAMINE cross reference: DMT (CAS No. 61-50-7) Schedule 9 DIMETICONE cross reference: DIMETHICONE Appendix B, clause 3 DIMETILAN Schedule 7 DIMETRIDAZOLE Schedule 4 DIMIRACETAM cross reference: RACETAMS Schedule 4 DIMPROPYRIDAZ Schedule 6 Schedule 5 DINICONAZOLE Schedule 5 2,4-DINITROCHLOROBENZENE Schedule 4 DINITROCRESOLS Schedule 7 Schedule 6 Schedule 4 Appendix E, clause 3 Appendix J, clause 1 DINITRONAPHTHOLS Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 451 2,4-DINITROPHENOL cross reference: CAS No. 51-28-5 Schedule 10 DINITROPHENOLS Schedule 10 Schedule 7 Schedule 6 Schedule 4 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1 DINITROTHYMOLS Schedule 4 DINOCAP Schedule 7 Appendix F, clause 4 DINOPROST Schedule 4 Appendix D, clause 1 DINOPROSTONE Schedule 4 Appendix D, clause 1 DINOSEB Schedule 7 Appendix J, clause 1 DINOTEFURAN Schedule 5 DI-n-PROPYL ISOCINCHOMERONATE (previously di-N propyl isocinchomeronate) Schedule 5 DIOXACARB Schedule 6 DIOXANE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 DIOXAPHETYL BUTYRATE cross reference: CAS No. 467-86-7 Schedule 9 DIPERODON Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 452 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DIPHACINONE Schedule 6 DIPHEMANIL Schedule 4 DIPHENAMID Schedule 5 DIPHENHYDRAMINE Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1 DIPHENIDOL Schedule 4 DIPHENOXYLATE Schedule 8 Schedule 4 Schedule 3 Appendix F, clause 4 Appendix H, clause 1 Appendix K, clause 1 DIPHENYLAMINE Appendix B, clause 3 DIPHENYLPYRALINE Schedule 4 Appendix K, clause 1 DIPHTHERIA TOXOID cross reference: TRIPLE ANTIGEN VACCINE Schedule 4 DIPIPANONE Schedule 8 DIPIVEFRIN Schedule 4 DIPROPYLENE GLYCOL Appendix B, clause 3 DIPYRIDAMOLE Schedule 4 DIQUAT Schedule 7 Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 453 DIRECT RED 254 cross reference: 2-NAPHTHALENESULFONIC ACID, 7-AMINO-4-HYDROXY-3-[[p-[(p-SULFOPHENYL)AZO]PHENYL]AZO]-, (3Z)-7-AMINO-4-OXO-3-[[4-[(4-SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLI DENE]NAPHTHALENE-2-SULFONIC ACID, (3Z)-7-AMINO-4-OXO-3-[[4-[(4-SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLI DENE]NAPHTHALENE-2-SULFONIC ACID BIS(TRIETHANOLAMINE) SALT, (3Z)-7-AMINO-4-OXO-3-[[4-[(4-SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLI DENE]NAPHTHALENE-2-SULFONIC ACID DISODIUM SALT Schedule 6 Schedule 5 DIRITHROMYCIN Schedule 4 DIRLOTAPIDE Schedule 4 DIROXIMEL FUMARATE Schedule 4 DISODIUM MANGANESE EDTA Appendix B, clause 3 DISOPHENOL Schedule 4 DISOPYRAMIDE Schedule 4 DISPERSE YELLOW 3 cross reference: CAS No. 2832-40-8 Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 DISTIGMINE Schedule 4 DISTILLATE Appendix E, clause 3 DISULFIRAM Schedule 6 Schedule 4 DISULFOTON Schedule 7 Schedule 6 DISULPHAMIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 454 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DITHIANON Schedule 6 DITHIAZANINE Schedule 6 Schedule 4 DITHIOPYR Schedule 5 DITHRANOL Schedule 3 DITIOCARB Schedule 4 DIUREDOSAN Schedule 6 DIURON Appendix B, clause 3 DOBUTAMINE Schedule 4 DOCETAXEL Schedule 4 DOCUSATE SODIUM cross reference: DIOCTYL SODIUM SULFOSUCCINATE Appendix B, clause 3 N-(N-DODECYL)-2-PYRROLIDONE cross reference: DESIGNATED SOLVENT, N-(N-OCTYL)-2-PYRROLIDONE, N-METHYL-2-PYRROLIDONE Schedule 6 Schedule 5 Appendix E, clause 3 DODINE Schedule 6 DOFETILIDE Schedule 4 DOLASETRON Schedule 4 DOLUTEGRAVIR Schedule 4 DOMPERIDONE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 455 DONEPEZIL Schedule 4 DOPAMINE Schedule 4 DOPEXAMINE Schedule 4 DORAMECTIN Schedule 7 Schedule 6 Schedule 5 DORAVIRINE Schedule 4 DORIPENEM Schedule 4 DORNASE Schedule 4 DORZOLAMIDE Schedule 4 DOSULEPIN cross reference: DOTHIEPIN. Schedule 4 Appendix K, clause 1 DOTHIEPIN cross reference: DOSULEPIN DOXANTRAZOLE Schedule 4 DOXAPRAM Schedule 4 DOXAZOSIN Schedule 4 DOXEPIN Schedule 4 Appendix K, clause 1 DOXORUBICIN Schedule 4 DOXYCYCLINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 456 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 DOXYLAMINE Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1 2,2-DPA cross reference: SODIUM 2,2-DICHLOROPROPIONATE Appendix B, clause 3 DROMETRIZOLE TRISILOXANE Appendix B, clause 3 DRONABINOL cross reference: DELTA-9-TETRAHYDROCANNABINOL, NABIXIMOLS Schedule 8 Appendix D, clause 3 Appendix K, clause 1 DRONEDARONE Schedule 4 DROPERIDOL Schedule 4 Appendix K, clause 1 DROSPIRENONE Schedule 4 DROSTANOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) DROTEBANOL Schedule 8 DROTRECOGIN Schedule 4 DSMA Schedule 7 Schedule 6 DUBOISIA LEICHHARDTII Schedule 4 Schedule 2 DUBOISIA MYOPOROIDES Schedule 4 Schedule 2 DUDDINGTONIA FLAGRANS, STRAIN IAH 1297 Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 457 DULAGLUTIDE Schedule 4 DULCIN cross reference: CAS No. 150-69-6 Schedule 10 DULOXETINE Schedule 4 Appendix K, clause 1 DUPILUMAB Schedule 4 DURVALUMAB Schedule 4 DUTASTERIDE Schedule 4 DYDROGESTERONE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 458 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 E (E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT 1-EN-3-OL cross reference: UNICONAZOLE-P Schedule 6 ECGONINE cross reference: CAS No. 481-37-8, ECGONINE HYDROCHLORIDE (CAS No. 5796-31 6), ECGONINE RACEMATE (CAS No. 876657-17-9) Schedule 9 ECONAZOLE Schedule 6 Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 ECOTHIOPATE cross reference: ECOTHIOPATE IODIDE Schedule 4 ECTYLUREA Schedule 4 ECULIZUMAB Schedule 4 EDARAVONE Schedule 4 EDETIC ACID cross reference: DICOBALT EDETATE Schedule 4 EDOXUDINE Schedule 4 EDROPHONIUM Schedule 4 EFALIZUMAB Schedule 4 EFAVIRENZ Schedule 4 EFLORNITHINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 459 EFORMOTEROL cross reference: FORMOTEROL ELBASVIR Schedule 4 ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS Appendix A, clause 1 ELECTRONIC COMPONENTS Appendix A, clause 1 ELETRIPTAN Schedule 4 Schedule 3 Appendix H, clause 1 ELEXACAFTOR Schedule 4 ELOSULFASE ALFA Schedule 4 ELOTUZUMAB Schedule 4 ELRANATAMAB Schedule 4 ELTENAC Schedule 4 ELTROMBOPAG Schedule 4 ELUXADOLINE Schedule 4 ELVITEGRAVIR Schedule 4 EMAMECTIN Schedule 7 Schedule 6 Schedule 5 EMEPRONIUM Schedule 4 EMETINE cross reference: CEPHAELIS ACUMINATA Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 460 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 EMODEPSIDE Schedule 6 Schedule 5 EMPAGLIFLOZIN Schedule 4 EMTRICITABINE Schedule 4 ENALAPRIL Schedule 4 ENASIDENIB Schedule 4 ENCORAFENIB Schedule 4 ENDOSULFAN Schedule 7 Schedule 6 ENDOTHAL Schedule 7 Schedule 6 ENDRIN Schedule 7 ENESTEBOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) ENFLURANE Schedule 4 ENFORTUMAB VEDOTIN Schedule 4 ENFUVIRTIDE Schedule 4 ENHANCING AGENTS cross reference: MAGNETIC RESONANCE IMAGING ENHANCING AGENTS, ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING Appendix A, clause 1 ENOBOSARM Schedule 4 Appendix D, clause 5 (SELECTIVE ANDROGEN RECEPTOR MODULATORS) ENOXACIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 461 ENOXAPARIN Schedule 4 ENOXIMONE Schedule 4 ENPROSTIL Schedule 4 ENROFLOXACIN Schedule 4 ENTACAPONE Schedule 4 ENTECAVIR Schedule 4 ENTRECTINIB Schedule 4 ENZALUTAMIDE Schedule 4 Appendix D, clause 6 Appendix F, clause 4 Appendix L, clause 2 EPHEDRA spp. Schedule 4 EPHEDRINE cross reference: EPHEDRA Schedule 4 Appendix D, clause 5 Appendix F, clause 4 EPICHLOROHYDRIN Schedule 7 Appendix F, clause 4 Appendix J, clause 1 EPICILLIN Schedule 4 EPIDERMAL GROWTH FACTOR cross reference: SH-OLIGOPEPTIDE-1, RH-OLIGOPEPTIDE-1 Schedule 7 Appendix G, clause 1 Appendix J, clause 1 EPINASTINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 462 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 EPINEPHRINE cross reference: ADRENALINE EPIRUBICIN Schedule 4 EPITIOSTANOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) EPLERENONE Schedule 4 EPOETINS cross reference: METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA Schedule 4 Appendix D, clause 5 EPOPROSTENOL Schedule 4 EPOXICONAZOLE Schedule 5 EPOXY RESINS, LIQUID cross reference: RESINS Schedule 5 Appendix E, clause 3 Appendix F, clause 4 EPRINOMECTIN Schedule 7 Schedule 6 Schedule 5 EPROSARTAN Schedule 4 EPSIPRANTEL Appendix B, clause 3 EPTC Schedule 6 EPTIFIBATIDE Schedule 4 EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN cross reference: IMMUNOGLOBULINSERGOMETRINE Schedule 4 ERENUMAB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 463 ERGOT Schedule 4 ERGOTAMINE Schedule 4 ERGOTOXINE Schedule 4 ERIBULIN MESILATE cross reference: ERIBULIN MESYLATE Schedule 4 ERLOTINIB Schedule 4 ERTAPENEM Schedule 4 ERTUGLIFLOZIN Schedule 4 ERYSIMUM spp. Schedule 4 Appendix G, clause 1 ERYTHRITYL TETRANITRATE Schedule 3 ERYTHROMYCIN Schedule 4 ERYTHROPOIETIN Schedule 4 Appendix D, clause 5 ERYTHROPOIETINS Schedule 4 Appendix D, clause 5 ESBIOTHRIN Schedule 6 Schedule 5 ESCITALOPRAM Schedule 4 ESFENVALERATE Schedule 6 Schedule 5 ESKETAMINE Schedule 8 Appendix K, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index 464 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ESLICARBAZEPINE ACETATE Schedule 4 ESMOLOL Schedule 4 ESOMEPRAZOLE Schedule 4 Schedule 2 Appendix H, clause 1 ESTETROL MONOHYDRATE Schedule 4 ESTRADIOL Schedule 5 Schedule 4 Appendix G, clause 1 ESTRAMUSTINE Schedule 4 ESTRIOL Schedule 4 ESTROGENS Schedule 4 ESTRONE Schedule 4 Appendix G, clause 1 ESTROPIPATE cross reference: PIPERAZINE ESTRONE SULFATE Schedule 4 ETACONAZOLE Schedule 7 Appendix J, clause 1 ETACRYNIC ACID Schedule 4 ETAFEDRINE Schedule 2 ETANERCEPT Schedule 4 ETHACRYNIC ACID cross reference: ETACRYNIC ACID ETHALFLURALIN Schedule 7 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 465 ETHAMBUTOL Schedule 4 ETHAMETSULFURON-METHYL Appendix B, clause 3 ETHAMIVAN Schedule 4 1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE cross reference: N-METHYLMETHANAMINE Schedule 5 ETHANOL cross reference: ETHYL ALCOHOL ETHANOLAMINE cross reference: MONOETHANOLAMINE ETHCHLORVYNOL Schedule 4 ETHEPHON Schedule 6 ETHER Schedule 6 Schedule 5 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 ETHERIFIED STARCHES Appendix A ETHINAMATE Schedule 4 ETHINYLESTRADIOL Schedule 4 ETHINYLOESTRADIOL cross reference: ETHINYLESTRADIOL ETHIOFENCARB Schedule 6 ETHION Schedule 7 ETHIONAMIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 466 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ETHISTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) ETHOATE-METHYL Schedule 6 ETHOFUMESATE Schedule 5 ETHOGLUCID Schedule 4 ETHOHEPTAZINE Schedule 4 ETHOPABATE Appendix B, clause 3 ETHOPROPAZINE Schedule 4 ETHOPROPHOS cross reference: LINSEED OIL Schedule 7 Schedule 6 ETHOSUXIMIDE Schedule 4 ETHOTOIN Schedule 4 2-ETHOXYETHANOL Schedule 7 Appendix F, clause 4 ETHOXYETHYLMERCURIC CHLORIDE Appendix F, clause 4 ETHOXYQUIN Schedule 5 ETHOXYSULFURON Schedule 5 ETHOXZOLAMIDE Schedule 4 ETHYL ACETATE Appendix B, clause 3 ETHYL ALCOHOL Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 467 ETHYL BROMIDE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 ETHYL BUTYRATE Appendix B, clause 3 ETHYL CHLORIDE Schedule 4 ETHYL FORMATE Schedule 6 ETHYL LACTATE Appendix B, clause 3 ETHYL METHACRYLATE Schedule 5 Appendix F, clause 4 ETHYLAMFETAMINE cross reference: ETHYLAMPHETAMINE Schedule 8 ETHYLBUTYLACETYL Appendix B, clause 3 ETHYLDIENOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) ETHYLENE CHLOROHYDRIN Schedule 6 Appendix F, clause 4 ETHYLENE DIBROMIDE Schedule 7 Appendix J, clause 1 ETHYLENE DICHLORIDE Schedule 6 ETHYLENE GLYCOL cross reference: DENATONIUM BENZOATE (CAS No. 107-21-1) Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 ETHYLENE GLYCOL MONOALKYL ETHERS Schedule 6 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 468 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ETHYLENE OXIDE Schedule 7 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1 ETHYLESTRENOL cross reference: ETHYLOESTRENOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) ETHYLHEXANEDIOL cross reference: ETHOHEXADIOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 2-ETHYLHEXANOIC ACID Schedule 6 Appendix E, clause 3 Appendix F, clause 4 ETHYLMERCURIC CHLORIDE Appendix F, clause 4 N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE cross reference: N-ETHYL MDA (CAS No. 82801-81-8), N-ETHYL MDA HYDROCHLORIDE (CAS No. 74341-78-9) Schedule 9 ETHYLMETHYLTHIAMBUTENE cross reference: CAS No: 441-61-2 Schedule 9 ETHYLMORPHINE Schedule 8 Schedule 4 Schedule 2 Appendix K, clause 1 ETHYLOESTRENOL cross reference: ETHYLESTRENOL ETHYNODIOL cross reference: ETYNODIOL ETICYCLIDINE cross reference: PCE (CAS No. 2201-15-2) Schedule 9 ETIDOCAINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 469 ETIDRONIC ACID cross reference: ETIDRONATE DISODIUM Schedule 4 ETILEFRIN Schedule 4 ETIPROSTON Schedule 4 ETODESNITAZENE cross reference: CAS No. 14030-76-3, ETAZENE Schedule 9 ETODOLAC Schedule 4 ETOFENAMATE Schedule 4 Schedule 2 ETOFENPROX Appendix B, clause 3 ETONITAZENE cross reference: CAS No. 911-65-9 Schedule 9 ETONITAZEPIPNE cross reference: CAS No. 734496-28-7, N-PIPERIDINO ETONITAZENE Schedule 9 ETONITAZEPYNE cross reference: CAS No. 2785346-75-8, N-PYRROLIDINO ETONITAZENE Schedule 9 ETONOGESTREL Schedule 4 ETOPOSIDE Schedule 4 ETORICOXIB Schedule 4 ETORPHINE cross reference: CAS No. 14521-96-1 Schedule 9 ETOXAZOLE Appendix B, clause 3 ETOXERIDINE cross reference: CAS No. 469-82-9 Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index 470 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ETRANACOGENE DEZAPARVOVEC Schedule 4 ETRASIMOD Schedule 4 ETRAVIRINE Schedule 4 ETRETINATE Schedule 4 Appendix D, clause 5 Appendix F, clause 4 Appendix L, clause 2 ETRIDIAZOLE Schedule 5 ETRIMFOS Schedule 6 ETYNODIOL cross reference: ETHYNODIOL Schedule 4 EUBACTERIUM sp. strain DSM11798 Appendix B, clause 3 EUCALYPTUS OIL Schedule 6 Appendix E, clause 3 EUGENOL Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 EUPATORIUM CANNABINUM cross reference: HEMP AGRIMONY Schedule 10 EVEROLIMUS Schedule 4 EXEMESTANE Schedule 4 EXENATIDE Schedule 4 EXPLOSIVES Appendix A, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 471 EXTRACT OF LEMON EUCALYPTUS cross reference: CORYMBIA CITRIODORA, OIL OF LEMON EUCALYPTUS Schedule 5 EZETIMIBE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 472 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 F FAMCICLOVIR Schedule 4 Schedule 3 Appendix H, clause 1 FAMOTIDINE Schedule 4 Schedule 2 Appendix F, clause 4 FAMOXADONE Schedule 6 FAMPHUR Schedule 7 Schedule 6 FARFUGIUM JAPONICUM Schedule 10 FARICIMAB Schedule 4 Appendix L, clause 2 FASORACETAM cross reference: RACETAMS Schedule 4 FEBANTEL Schedule 6 FEBUXOSTAT Schedule 4 FELBINAC Schedule 4 Schedule 2 FELODIPINE Schedule 4 FELYPRESSIN Schedule 4 FENAMIPHOS Schedule 7 Schedule 6 FENARIMOL Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 473 FENAZAFLOR Schedule 6 FENBENDAZOLE Schedule 5 FENBUCONAZOLE Schedule 5 FENBUFEN Schedule 4 FENBUTATIN OXIDE Schedule 6 FENCAMFAMIN Schedule 4 FENCHLORAZOLE-ETHYL Schedule 5 FENCHLORPHOS Schedule 6 FENCLOFENAC Schedule 4 FENETYLLINE cross reference: CAS No. 3736-08-1, FENETYLLINE HYDROCHLORIDE (CAS No. 1892 80-4) Schedule 9 FENFLURAMINE Schedule 4 Appendix K, clause 1 FENFURAM Appendix B, clause 3 FENHEXAMID Appendix B, clause 3 FENITROTHION Schedule 6 FENNEL OIL Schedule 5 Appendix E, clause 3 FENOFIBRATE Schedule 4 FENOLDOPAM Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 474 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FENOPROFEN Schedule 4 FENOPROP Schedule 5 FENOTEROL Schedule 4 FENOXACRIM Schedule 7 Schedule 6 FENOXAPROP-ETHYL Schedule 5 FENOXAPROP-p-ETHYL Schedule 5 FENOXYCARB Appendix B, clause 3 FENPIPRAMIDE Schedule 4 FENPIPRANE Schedule 4 FENPROPIDIN Schedule 6 FENPROPOREX Schedule 4 FENPROSTALENE Schedule 4 FENPYRAZAMINE Schedule 5 FENPYROXIMATE Schedule 6 FENSON Schedule 5 FENSULFOTHION Schedule 7 FENTANYL Schedule 8 Appendix K, clause 1 FENTEROL Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 475 FENTHION Schedule 7 Schedule 6 Schedule 5 FENTHION-ETHYL Schedule 7 FENVALERATE Schedule 6 FERRIC DERISOMALTOSE Schedule 4 FEXOFENADINE Schedule 4 Schedule 2 FEZOLINETANT Schedule 4 FIBRINOLYSIN Schedule 4 FIBROBLAST GROWTH FACTORS Schedule 4 Appendix D, clause 5 FIDAXOMICIN Schedule 4 FILGOTINIB Schedule 4 FILGRASTIM Schedule 4 FINASTERIDE Schedule 4 FINERENONE Schedule 4 Appendix L, clause 2 FINGOLIMOD Schedule 4 Appendix L, clause 2 FIPRONIL Schedule 6 Schedule 5 FIROCOXIB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 476 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FLAMPROP-METHYL Schedule 5 FLAMPROP-M-METHYL Schedule 5 FLAVOXATE Schedule 3 FLAZASULFURON Schedule 5 FLECAINIDE Schedule 4 FLEROXACIN Schedule 4 FLOCOUMAFEN Schedule 7 Schedule 6 FLOCTAFENINE Schedule 4 FLONICAMID Schedule 6 FLORASULAM Schedule 5 FLORFENICOL Schedule 4 FLORPYRAUXIFEN-BENZYL Appendix B, clause 3 FLORYLPICOXAMID Appendix B, clause 3 FLUANISONE Schedule 4 FLUAZAINDOLIZINE Schedule 6 Schedule 5 FLUAZIFOP-BUTYL Schedule 6 FLUAZIFOP-p-BUTYL Schedule 6 FLUAZINAM Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 477 FLUAZURON Schedule 5 FLUBENDAZOLE Schedule 5 FLUBENDIAMIDE Schedule 5 FLUBROMAZEPAM cross reference: CAS No. 2647-50-9 Schedule 9 FLUBROMAZOLAM cross reference: CAS No. 612526-40-6 Schedule 9 FLUCHLORALIN Schedule 5 FLUCLOROLONE Schedule 4 FLUCLOXACILLIN Schedule 4 FLUCOFURON Schedule 7 Schedule 6 FLUCONAZOLE Schedule 4 Schedule 3 Appendix F, clause 4 Appendix H, clause 1 FLUCYTHRINATE Schedule 7 FLUCYTOSINE Schedule 4 FLUDARABINE Schedule 4 FLUDIOXONIL Schedule 5 FLUDROCORTISONE Schedule 4 FLUENSULFONE Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index 478 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FLUFENAMIC ACID Schedule 4 FLUFENOXURON Appendix B, clause 3 FLUMAZENIL Schedule 4 FLUMETASONE cross reference: FLUMETHASONE Schedule 4 FLUMETHASONE cross reference: FLUMETASONE FLUMETHIAZIDE Schedule 4 FLUMETHRIN Schedule 6 Schedule 5 FLUMETSULAM Appendix B, clause 3 FLUMICLORAC PENTYL Schedule 5 FLUMIOXAZIN Schedule 7 Schedule 6 FLUNISOLIDE Schedule 4 FLUNITAZENE cross reference: CAS No. 2249-36-7, FLUNITAZENE HYDROCHLORIDE (CAS No. 2728 91-8) Schedule 9 FLUNITRAZEPAM Schedule 8 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 FLUNIXIN MEGLUMINE Schedule 4 FLUOCINOLONE Schedule 4 FLUOCINONIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 479 FLUOCORTIN Schedule 4 FLUOCORTOLONE Schedule 4 FLUOMETURON Appendix B, clause 3 FLUOPICOLIDE Appendix B, clause 3 FLUOPYRAM Schedule 5 FLUORESCEIN Schedule 4 FLUORIDES cross reference: SILICOFLUORIDES Schedule 6 Schedule 5 Schedule 4 Schedule 3 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 Appendix H, clause 1 FLUOROACETAMIDE Schedule 7 FLUOROACETIC ACID Schedule 7 Appendix J, clause 1 FLUOROMETHOLONE Schedule 4 4-FLUORO-N-METHYLAMFETAMINE cross reference: 4-FLUORO-N-METHYLAMPHETAMINE, 4-FLUORO-N-METHAMFETAMINE (CAS No. 351-03-1) Schedule 9 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE cross reference: AM-694 (CAS No. 335161-03-0) Schedule 9 FLUOROURACIL Schedule 4 FLUOXETINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 480 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FLUOXYMESTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) FLUPENTIXOL cross reference: FLUPENTHIXOL Schedule 4 Appendix K, clause 1 FLUPHENAZINE Schedule 4 Appendix K, clause 1 FLUPROPANATE cross reference: TETRAPION Schedule 6 FLUPROSTENOL Schedule 4 FLUPYRADIFURONE Schedule 6 FLUQUINCONAZOLE Schedule 6 FLURALANER cross-reference: CARBAMOYL BENZAMIDE, PHENYL ISOXAZOLINE Schedule 5 Schedule 4 FLURANDRENOLONE Schedule 4 FLURAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 FLURBIPROFEN Schedule 4 Schedule 2 FLUOROACETAMIDE Appendix J, clause 1 FLUOXAPIPROLIN Appendix B, clause 3 FLUROXENE Schedule 4 FLUROXYPYR Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 481 FLUSILAZOL Schedule 6 FLUSPIRILENE Schedule 4 FLUTAMIDE Schedule 4 FLUTICASONE cross reference: FLUTICASONE FUROATE, FLUTICASONE PROPIONATE Schedule 4 FLUTICASONE FUROATE cross reference FLUTICASONE FLUTICASONE PROPIONATE cross reference: FLUTICASONE Schedule 4 Schedule 2 FLUTOLANIL Appendix B, clause 3 FLUTRIAFOL Schedule 6 FLUVALINATE Schedule 6 Schedule 5 FLUVASTATIN Schedule 4 FLUVOXAMINE Schedule 4 FLUXAPYROXAD Schedule 5 FOLIC ACID Schedule 4 Schedule 2 FOLINIC ACID cross reference: CALCIUM FOLINATE Schedule 4 Schedule 2 FOLLICLE-STIMULATING HORMONE Schedule 4 Appendix D, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index 482 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FOLLISTATIN Schedule 4 Appendix D, clause 5 FOLLITROPIN ALFA cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN Schedule 4 Appendix D, clause 1 FOLLITROPIN BETA cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN Schedule 4 Appendix D, clause 1 FOLLITROPIN DELTA cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN Schedule 4 Appendix D, clause 1 FOLPET Schedule 7 Appendix J, clause 1 FOMEPIZOLE Schedule 4 FOMESAFEN SODIUM Schedule 6 FOMIVIRSEN Schedule 4 FONDAPARINUX Schedule 4 FOOD Appendix A, clause 1 FORAMSULFURON Schedule 5 FORCHLORFENURON Appendix B, clause 3 FORMALDEHYDE cross reference: FORMALDEHYDE CONDENSATION PRODUCT, FREE FORMALDEHYDE, METACRESOLSULPHONIC ACID, METHYLENE GLYCOL (CAS No. 50-00-0) Schedule 10 Schedule 6 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 483 FORMALDEHYDE CONDENSATION PRODUCT Schedule 6 FORMEBOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) FORMESTANE Schedule 4 FORMETANATE Schedule 7 FORMIC ACID Schedule 5 Appendix E, clause 3 Appendix F, clause 4 FORMOTEROL Schedule 4 FORMOTHION Schedule 6 FOSAMPRENAVIR Schedule 4 FOSAPREPITANT Schedule 4 FOSCARNET Schedule 4 FOSFESTROL cross reference: DIETHYLSTILBESTROL DIPHOSPHATE Schedule 4 FOSFOMYCIN Schedule 4 FOSINOPRIL Schedule 4 FOSNETUPITANT Schedule 4 FOSPHENYTOIN Schedule 4 FOSPIRATE Schedule 6 Schedule 5 FOSTEMSAVIR Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 484 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 FOSTHIAZATE Schedule 7 FOTEMUSTINE Schedule 4 FRAMYCETIN Schedule 4 FRITTED GLAZING OR ENAMELLING PREPARATIONS Appendix A, clause 1 FULLERS EARTH Appendix B, clause 3 FULVESTRANT Schedule 4 FUMAGILLIN Schedule 6 FUNGAL PROTEASE derived from Aspergillus niger Appendix B, clause 3 FURALAXYL Schedule 5 FURALTADONE Schedule 4 FURATHIOCARB Schedule 7 Schedule 5 FURAZABOL Schedule 4 FURAZOLIDONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) FURETHIDINE cross reference: CAS No. 2385-81-1 Schedule 9 FURFURAL cross reference: 2-FURANCARBOXALDEHYDE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 FUROSEMIDE cross reference: FRUSEMIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 485 FUSIDIC ACID Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 486 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 G GABAPENTIN Schedule 4 Appendix K, clause 1 GALANTAMINE Schedule 4 GALANTHUS spp. Schedule 4 GALCANEZUMAB Schedule 4 GALLAMINE Schedule 4 GALSULFASE Schedule 4 GAMMA BUTYROLACTONE cross reference: CAS No. 96-48-0 Schedule 10 GAMMA HYDROXYBUTYRATE cross reference: 4-HYDROXYBUTANOIC ACID, GHB, SODIUM OXYBATE Schedule 9 GAMMA-CYHALOTHRIN Schedule 7 Schedule 5 GANCICLOVIR Schedule 4 GANIRELIX Schedule 4 GATIFLOXACIN Schedule 4 GEFITINIB Schedule 4 GELATIN – SUCCINYLATED Appendix A GELSEMIUM SEMPERVIRENS Schedule 2 Appendix G, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 487 GEMCITABINE Schedule 4 Appendix K, clause 1 GEMEPROST Schedule 4 GEMFIBROZIL Schedule 4 GEMIFLOXACIN Schedule 4 GEMTUZUMAB OZOGAMICIN Schedule 4 GENTAMICIN Schedule 4 GENTIAN VIOLET cross reference: METHYLROSANILINIUM CHLORIDE, CRYSTAL VIOLET GERANIUM OIL Appendix B, clause 3 GESTODENE Schedule 4 GESTONORONE Schedule 4 GESTRINONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) GHRH INJECTABLE PLASMID Schedule 4 GIBBERELLIC ACID Appendix B, clause 3 GILTERITINIB Schedule 4 GITALIN Schedule 4 GIVOSIRAN Schedule 4 GLASS cross reference: CRYSTAL WARE Appendix A, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index 488 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 GLATIRAMER ACETATE Schedule 4 GLAZED POTTERY Appendix A, clause 1 GLECAPREVIR Schedule 4 GLIBENCLAMIDE Schedule 4 GLIBORNURIDE Schedule 4 GLICLAZIDE Schedule 4 GLIMEPIRIDE Schedule 4 GLIPIZIDE Schedule 4 GLIPTINS cross reference: DIPEPTIDYL PEPTIDASE-4 (DDP-4) INHIBITORS Schedule 4 GLISOXEPIDE Schedule 4 GLOFITAMAB Schedule 4 GLUCAGON Schedule 3 Appendix G, clause 1 Appendix H, clause 1 α-GLUCANASE derived from Aspergillus niger Appendix B, clause 3 GLUFOSINATE-AMMONIUM Schedule 5 GLUTARAL Schedule 6 Schedule 5 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 489 GLUTARALDEHYDE cross reference: GLUTARAL GLUTATHIONE Schedule 4 GLUTETHIMIDE Schedule 4 Appendix D, clause 5 Appendix K, clause 1 GLYCERYL THIOGLYCOLLATE Schedule 6 GLYCERYL TRINITRATE Schedule 4 Schedule 3 Appendix G, clause 1 Appendix H, clause 1 GLYCOLIC ACID Schedule 6 Appendix E, clause 3 Appendix F, clause 4 GLYCOPYRRONIUM Schedule 4 Schedule 3 GLYCOSYLATED HYDROQUINONE cross reference: HYDROQUINONE GLYMIDINE Schedule 4 GLYPHOSATE Schedule 5 GnRH VACCINE Schedule 4 GOLIMUMAB Schedule 4 GONADORELIN Schedule 4 GONADOTROPHIC HORMONES Schedule 4 GOSERELIN Schedule 4 GRAMICIDIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 490 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 GRANISETRON Schedule 4 GRAPIPRANT Schedule 4 GRAZOPREVIR Schedule 4 GREPAFLOXACIN Schedule 4 GRISEOFULVIN Schedule 4 GROWTH HORMONE RELEASING HORMONES *(GHRHs) Schedule 4 Appendix D, clause 5 GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6) Schedule 4 Appendix D, clause 5 GROWTH HORMONE RELEASING PEPTIDE *(GHRPs) Schedule 4 Appendix D, clause 5 GROWTH HORMONE SECRETAGOGUES *(GHSs) Schedule 4 Appendix D, clause 5 GUAIFENESIN cross reference: PARACETAMOL Schedule 4 Schedule 2 GUAIPHENESIN cross reference: GUAIFENESIN GUANABENZ Schedule 4 GUANACLINE Schedule 4 GUANETHIDINE Schedule 4 GUANFACINE Schedule 4 Appendix K, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 491 GUANIDINE Schedule 6 Schedule 4 Appendix E, clause 3 GUAZATINE Schedule 6 GUSELKUMAB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 492 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 H HACHIMYCIN Schedule 4 HAEMATIN Schedule 4 HAEMOPHILUS INFLUENZAE VACCINE Schedule 4 HALAUXIFEN METHYL Appendix B, clause 3 HALCINONIDE Schedule 4 HALOFANTRINE Schedule 4 HALOFENATE Schedule 4 HALOFUGINONE Schedule 7 Schedule 4 Appendix J, clause 1 HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS cross reference: DIBENZODIOXINS, HALOGENATED - DIBENZOFURANS, HALOGENATED, DIOXINS Schedule 7 Appendix J, clause 1 HALOPERIDOL cross reference: BUTYPHENONES Schedule 4 Appendix G, clause 1 Appendix K, clause 1 HALOSULFURON-METHYL Schedule 5 HALOTHANE Schedule 4 HALOXON Schedule 6 HALOXYFOP Schedule 6 HARMALA ALKALOIDS Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 493 HC RED 13 cross reference: 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL HC VIOLET 1 cross reference: 2-[(4-AMINO-2-METHYL-5-NITROPHENYL)AMINO]-ETHANOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 HCB Schedule 7 Appendix J, clause 1 HELIONAL Appendix B, Part 3 HELIOTROPIUM spp. Schedule 10 HEMEROCALLIS Schedule 4 HEMP SEED OIL cross reference: CANNABIDIOL, CANNABIS, TETRAHYDROCANNABINOLS HEPARINS Schedule 4 HEPATITIS A VACCINE Schedule 4 HEPATITIS B VACCINE Schedule 4 HEPTACHLOR Schedule 6 HEROIN cross reference: CAS No. 561-27-3, HEROIN HYDROCHLORIDE (CAS No. 1502-95-0) Schedule 9 HETACILLIN Schedule 4 HEXACHLOROPHANE cross reference: HEXACHLOROPHENE HEXACHLOROPHENE cross reference: HCB Schedule 6 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 494 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 HEXACONAZOLE Schedule 5 HEXAFLURON Appendix B, clause 3 HEXAMETHONIUM Schedule 4 HEXARELIN Schedule 4 Appendix D, clause 5 HEXAZINONE Schedule 6 Schedule 5 HEXETIDINE Schedule 4 HEXLOXYETHANOL Appendix F, clause 4 HEXOBENDINE Schedule 4 HEXOCYCLIUM Schedule 4 HEXOPRENALINE Schedule 4 HEXYL ACETATE Appendix B, clause 3 HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE) Schedule 4 HEXYL CINNAMALDEHYDE Appendix B, clause 3 3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN cross reference: PARAHEXYL (CAS No. 117-51-1) Schedule 9 HEXYLOXYETHANOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 HEXYTHIAZOX Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 495 HISTAMINE Schedule 4 HMG-CoA REDUCTASE INHIBITORS cross reference: STATINS Schedule 4 HOMATROPINE Schedule 4 HUMAN BLOOD PRODUCTS cross reference: ALBUMIN, ANTICOAGULATION COMPLEX, C1 ESTERASE INHIBITORS, CLOTTING FACTORS, CRYOPRECIPITATE, FIBRINOGEN, PLASMA, PLATELETS, PROTEIN C, PROTHROMBIN COMPLEX CONCENTRATE (PCC), RED CELLS, THROMBIN, WHOLE BLOOD, STEM CELLS Appendix A, clause 1 HUMAN CHORIONIC GONADOTROPHIN Schedule 4 HUMAN OSTEOGENIC PROTEIN-1 (OP-1) Appendix B, clause 3 HUMAN PAPILLOMAVIRUS VACCINE Schedule 4 HYALURONIC ACID Schedule 4 HYALURONIC ACID AND ITS POLYMERS Schedule 4 HYDRALAZINE Schedule 4 HYDRAMETHYLNON Schedule 6 Schedule 5 HYDRARGAPHEN Schedule 4 HYDRAZINE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 HYDROCARBONS LIQUID AROMATIC cross reference: AROMATIC EXTRACT OILS, Schedule 7 Appendix F, clause 4 HYDROCARBONS, LIQUID cross reference: BENZENE, DESIGNATED SOLVENT, DIESEL (DISTILLATE), DRY CLEANING FLUID, KEROSENE, LAMP OIL, LIGHT MINERAL OILS, LIQUID Authorised Version F2024L00589 registered 30/05/2024 Index 496 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 HYDROCARBONS, MINERAL OILS, MINERAL TURPENTINE, NAPHTHALENE, PARAFFIN OILS, PETROL, PETROLEUM OILS, REDUCERS, THINNERS, TOLUENE, WHITE SPIRIT, WHITE PETROLEUM SPIRIT, WHITE MINERAL OILS, XYLENE Schedule 5 Appendix E, clause 3 HYDROCHLORIC ACID Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 HYDROCHLOROTHIAZIDE Schedule 4 HYDROCODONE Schedule 8 Appendix K, clause 1 HYDROCORTISONE Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 HYDROCORTISONE ACETATE Schedule 3 Schedule 2 HYDROCYANIC ACID cross reference: CYANIDES, APRICOT KERNELS Schedule 7 Schedule 4 Appendix F, clause 4 Appendix G, clause 1 Appendix J, clause 1 HYDROFLUMETHIAZIDE Schedule 4 HYDROFLUORIC ACID cross reference: HYDROGEN FLUORIDE Schedule 7 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1 HYDROGEN PEROXIDE cross reference: CAS No. 7722-84-1 Schedule 10 Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 497 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 HYDROGEN SULFIDE Schedule 7 HYDROMORPHINOL Schedule 8 HYDROMORPHONE Schedule 8 Appendix K, clause 1 HYDROPRENE Appendix B, clause 3 HYDROQUINONE cross reference: ARBUTIN, GLYCOSYLATED HYDROQUINONE, MONOBENZONE Schedule 6 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 HYDROSILICOFLUORIC ACID cross reference: FLUOROSILICIC ACID, HEXAFLUOROSILIC ACID, HYDROFLUOSILICIC ACID, SILICOFLUORIC ACID Schedule 7 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 4-HYDROXYBUTANOIC ACID cross reference: CAS No. 591-81-1, SODIUM OXYBATE (CAS No. 502-85-2) Schedule 9 HYDROXYCARBAMIDE Schedule 4 HYDROXYCHLOROQUINE Schedule 4 Appendix D, clause 8 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL cross reference: CANNABICYCLOHEXANOL (CAS No. 70434-92-3), CP 47,497 C8 HOMOLOGUE, CP 47,497 (CAS No. 70434-82-1) Schedule 9 HYDROXYEPHEDRINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 498 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 4-[(2-HYDROXYETHYL)AMINO]-3-NITROPHENOL cross reference: 3-NITRO-p-HYDROXYETHYLAMINOPHENOL 2-HYDROXYETHYL METHACRYLATE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 [7-HYDROXY-8-[(2 METHOXYPHENYL)AZO]-2-NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391-30-0) cross reference: BASIC RED 76 (CAS No. 68391-30-0) HYDROXYPETHIDINE cross reference: CAS No. 468-56-4 Schedule 9 HYDROXYPHENAMATE Schedule 4 HYDROXYPROGESTERONE Schedule 4 HYDROXYPROPYL CELLULOSE Appendix B, clause 3 2-HYDROXYPROPYL METHACRYLATE Schedule 5 8-HYDROXYQUINOLINE cross reference: OXYQUINOLINE HYDROXYSTENOZOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) HYDROXYUREA cross reference: HYDROXYCARBAMIDE HYDROXYZINE Schedule 4 Appendix K, clause 1 HYGROMYCIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 499 HYOSCINE cross reference: HYOSCINE BUTYLBROMIDE Schedule 4 Schedule 2 Appendix G, clause 1 HYOSCINE BUTYLBROMIDE Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 HYOSCYAMINE Schedule 4 Schedule 2 Appendix G, clause 1 HYOSCYAMUS NIGER Schedule 4 Schedule 2 Appendix G, clause 1 HYPOTHALAMIC RELEASING FACTORS Schedule 4 Appendix G, clause 1 HYPROMELLOSE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 500 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 I IBAFLOXACIN Schedule 4 IBANDRONIC ACID Schedule 4 IBOGAINE Schedule 4 IBOTENIC ACID cross reference: MUSCIMOL Schedule 9 IBRITUMOMAB Schedule 4 IBRUTINIB Schedule 4 IBUFENAC Schedule 4 IBUPROFEN cross reference: PARACETAMOL Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 IBUTAMOREN cross reference: MK-677, NUTROBAL Schedule 4 Appendix D, clause 5 IBUTEROL Schedule 4 IBUTILIDE Schedule 4 ICATIBANT Schedule 4 ICODEXTRIN Appendix B, clause 3 IDARUBICIN Schedule 4 IDARUCIZUMAB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 501 IDEBENONE Schedule 4 IDOXURIDINE Schedule 4 IDURSULFASE Schedule 4 IFOSFAMIDE Schedule 4 ILOPROST Schedule 4 IMATINIB Schedule 4 IMAZALIL cross reference: ENILCONAZOLE Schedule 5 IMAZAMOX Schedule 5 IMAZAPIC Schedule 5 IMAZAPYR Schedule 5 IMAZETHAPYR Schedule 5 IMDEVIMAB Schedule 4 IMEPITOIN Schedule 4 IMIDACLOPRID Schedule 6 Schedule 5 IMIDAPRIL Schedule 4 IMIDOCARB Schedule 6 IMIGLUCERASE Schedule 4 IMINOCTADINE TRIALBESILATE Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index 502 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 IMIPENEM Schedule 4 IMIPRAMINE Schedule 4 Appendix K, clause 1 IMIPROTHRIN Schedule 6 Schedule 5 IMIQUIMOD Schedule 4 IMLIFIDASE Schedule 4 IMMUNOGLOBULINS cross reference: EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, POLYCLONAL ANTIBODIES Schedule 4 IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS Appendix A, clause 1 INCLISIRAN Schedule 4 INDACATEROL Schedule 4 INDANAZOLINE Schedule 2 INDAPAMIDE Schedule 4 INDAZIFLAM Schedule 6 INDINAVIR Schedule 4 INDOLE-3-ACETIC ACID Appendix B, clause 3 INDOMETACIN Schedule 4 Schedule 2 Appendix G, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 503 INDOMETHACIN cross reference: INDOMETACIN INDOPROFEN Schedule 4 INDORAMIN Schedule 4 INDOXACARB Schedule 6 Schedule 5 INFIGRATINIB Schedule 4 INFLIXIMAB Schedule 4 INFLUENZA AND CORYZA VACCINES cross reference: H5N1 INFLUENZA VIRUS HAEMAGGLUTININ Schedule 4 INGENOL MEBUTATE Schedule 4 INOTUZUMAB OZOGAMICIN Schedule 4 INOSITOL NICOTINATE Schedule 3 INPYRFLUXAM Schedule 6 INSULIN DEGLUDEC Schedule 4 INSULIN GLARGINE Schedule 4 INSULIN-LIKE GROWTH FACTOR I Schedule 4 INSULIN-LIKE GROWTH FACTORS Schedule 4 Appendix D, clause 5 INSULINS Schedule 4 INTERFERONS Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 504 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 INTERLEUKINS Schedule 4 INTRAOCULAR VISCOELASTIC PRODUCTS Appendix A, clause 1 IODINE cross reference: IODOPHORS Schedule 6 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 IODOMETHANE Schedule 7 Appendix J, clause 1 IODOPHORS cross reference: IODINE Schedule 6 Appendix E, clause 3 3-IODO-2-PROPYNYL BUTYL CARBAMATE cross reference: IODOCARB Schedule 6 Schedule 5 IODOSULFURON-METHYL-SODIUM Schedule 5 IODOTHIOURACIL Schedule 4 IOXYNIL Schedule 6 IPAMORELIN Schedule 4, Appendix D, clause 5 IPCONAZOLE Schedule 6 Schedule 5 IPFLUFENOQUIN Appendix B, Part 3 IPILIMUMAB Schedule 4 IPRATROPIUM Schedule 4 Schedule 2 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 505 IPRATROPIUM BROMIDE Appendix F, clause 4 IPRIFLAVONE Schedule 4 IPRINDOLE Schedule 4 IPRODIONE Appendix B, clause 3 IPRONIAZID Schedule 4 IRBESARTAN Schedule 4 IRINOTECAN Schedule 4 IRON COMPOUNDS cross reference: IRON OXIDES Schedule 6 Schedule 5 Schedule 4 Schedule 2 ISAVUCONAZOLE Schedule 4 Appendix L, clause 2 ISETHIONATE Appendix B, clause 3 ISOAMINILE Schedule 4 ISOAMYL NITRITE Schedule 4 Appendix E, clause 3 ISOBUTYL NITRITE Schedule 4 Appendix E, clause 3 ISOCARBOPHOS Schedule 7 ISOCARBOXAZID Schedule 4 ISOCONAZOLE Schedule 6 Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 506 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 3 Schedule 2 Appendix H, clause 1 ISOCYANATES Schedule 6 Appendix E, clause 3 Appendix F, clause 4 ISOCYCLOSERAM Schedule 6 ISOETARINE Schedule 4 ISOEUGENOL Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 ISOFENPHOS Schedule 7 ISOFETAMID Appendix B, clause 3 ISOFLURANE Schedule 4 ISOMETHADONE cross reference: CAS No. 466-40-0 Schedule 9 ISOMETHEPTENE Schedule 4 ISONIAZID Schedule 4 ISOPHORONE Schedule 5 Appendix E, clause 3 ISOPRENALINE Schedule 4 Appendix F, clause 4 ISOPRENE ALCOHOL Appendix B, clause 3 ISOPRINOSINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 507 ISOPROPAMIDE Schedule 4 Schedule 2 ISOPROPYL NITRITE cross reference: CAS No. 541-42-4 Schedule 10 ISOPROTURON Schedule 7 ISOPYRAZAM Schedule 6 ISOSORBIDE DINITRATE Schedule 4 Schedule 3 ISOSORBIDE MONONITRATE Schedule 4 ISOSTEARYL ALCOHOL ETHOXYLATE Appendix B, clause 3 ISOTIANIL Schedule 6 ISOTONITAZENE cross reference: CAS No. 14188-81-9 Schedule 9 ISOTRETINOIN Schedule 4 Appendix D, clause 5 Appendix F, clause 4 Appendix L, clause 2 ISOXABEN Schedule 5 ISOXAFLUTOLE Schedule 5 ISOXICAM Schedule 4 ISOXSUPRINE Schedule 4 ISRADIPINE Schedule 4 ITRACONAZOLE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 508 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 IVABRADINE Schedule 4 IVACAFTOR Schedule 4 IVERMECTIN Schedule 7 Schedule 5 Schedule 4 IVOSIDENIB Schedule 4 IXABEPILONE Schedule 4 IXAZOMIB Schedule 4 IXEKIZUMAB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 509 J JAPANESE ENCEPHALITIS VACCINE Schedule 4 JUNIPERUS SABINE cross reference: SAVIN(E) Schedule 10 Authorised Version F2024L00589 registered 30/05/2024 Index 510 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 K KAMBO cross reference: Secretion of the South American Giant Leaf Frog or Giant Monkey Frog (Phyllomedusa bicolor) Schedule 10 KANAMYCIN Schedule 4 KAOLIN Appendix B, clause 3 KEROSENE Appendix E, clause 3 KETAMINE Schedule 8 KETANSERIN Schedule 4 KETAZOLAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) KETOBEMIDONE cross reference: CAS No. 469-79-4, KETOBEMIDONE HYDROCHLORIDE (CAS No. 5965-49-1) Schedule 9 KETOCONAZOLE Schedule 4 Schedule 2 KETOPROFEN Schedule 4 Schedule 3 Appendix H, clause 1 KETOROLAC Schedule 4 KETOTIFEN Schedule 4 Schedule 2 KHELLIN Schedule 4 KINETIN Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 511 KITASAMYCIN Schedule 5 Schedule 4 KRATOM cross reference: MITRAGYNA SPECIOSA, MITRAGYNINE KRESOXIM-METHYL Appendix B, clause 3 KUNZEA OIL Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 512 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 L LABETALOL Schedule 4 LACIDIPINE Schedule 4 LACOSAMIDE Schedule 4 LAMBDA-CYHALOTHRIN Schedule 7 Schedule 6 Schedule 5 LAMIVUDINE Schedule 4 LAMOTRIGINE Schedule 4 Appendix K, clause 1 LANADELUMAB Schedule 4 LANATOSIDES Schedule 4 LANREOTIDE Schedule 4 LANSOPRAZOLE Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 LANTHANUM Schedule 4 LAPATINIB Schedule 4 LARONIDASE Schedule 4 LAROPIPRANT Schedule 4 LAROTRECTINIB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 513 LASALOCID Schedule 6 LASIODIPLODIA PSEUDOTHEOBROMAE Schedule 5 LATAMOXEF Schedule 4 LATANOPROST Schedule 4 LAUDEXIUM Schedule 4 LAURETH CARBOXYLIC ACIDS Schedule 6 Appendix E, clause 3 LAURIC ACID Appendix B, clause 3 LAUROMACROGOLS cross reference: LAURETH-9 Schedule 4 LAURYL ALCOHOL cross reference: 1-DODECANOL Appendix B, clause 3 LAURYL ISOQUINOLINIUM BROMIDE Schedule 6 Appendix E, clause 3 LAURYL SULFATE SALTS cross reference: SODIUM LAURYL SULPHATE, DODECYL SULFATES Schedule 6 Appendix E, clause 3 LAVANDIN OIL cross reference: CAMPHOR Appendix B, clause 3 LAVENDER OIL Appendix B, clause 3 LEAD COMPOUNDS cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES, SELENIUM Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 (in glazing preparations) Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 514 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 LEAD METALLIC Appendix B, clause 3 LEBRIKIZUMAB Schedule 4 LECANEMAB Schedule 4 LEDIPASVIR Schedule 4 LEFETAMINE Schedule 4 LEFLUNOMIDE Schedule 4 Appendix F, clause 4 Appendix L, clause 2 LEMBOREXANT Schedule 4 Appendix K, clause 1 LEMON OIL Schedule 5 Appendix E, clause 3 Appendix F, clause 4 LEMONGRASS OIL Schedule 5 LENACAPAVIR Schedule 4 LENALIDOMIDE Schedule 4 Appendix D, clause 4 Appendix F, clause 4 Appendix L, clause 2 LENOGRASTIM Schedule 4 LENVATINIB Schedule 4 LEPIDOPTEROUS SEX PHEROMONES Appendix B, clause 3 LEPIRUDIN Schedule 4 LEPTAZOL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 515 LEPTOPHOS Schedule 7 LEPTOSPERMUM SCOPARIUM OIL cross reference: MANUKA OIL Schedule 6 Appendix E, clause 3 LERCANIDIPINE Schedule 4 LESINURAD Schedule 4 LETERMOVIR Schedule 4 LETROZOLE Schedule 4 LEUPRORELIN Schedule 4 LEVALLORPHAN Schedule 4 LEVAMISOLE Schedule 6 Schedule 5 Schedule 4 LEVAMFETAMINE cross reference: LEVAMPHETAMINE Schedule 8 LEVETIRACETAM cross reference: RACETAMS Schedule 4 Appendix K, clause 1 LEVOBUNOLOL Schedule 4 LEVOBUPIVACAINE Schedule 4 LEVOCABASTINE Schedule 4 Schedule 2 Appendix F, clause 4 Appendix L, clause 2 Authorised Version F2024L00589 registered 30/05/2024 Index 516 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 LEVOCETIRIZINE Schedule 4 Schedule 2 Appendix K, clause 1 LEVODOPA Schedule 4 LEVOMEPROMAZINE cross reference: METHOTRIMEPRAZINE Schedule 4 LEVOMETHAMFETAMINE cross reference: LEVOMETHAMPHETAMINE Schedule 8 LEVOMETHORPHAN cross reference: CAS No. 125-70-2 Schedule 9 LEVOMILNACIPRAN Schedule 4 LEVOMORAMIDE Schedule 8 LEVONORGESTREL Schedule 4 Schedule 3 Appendix H, clause 1 LEVOPHENACYLMORPHAN cross reference: CAS No. 10061-32-2 Schedule 9 LEVORPHANOL Schedule 8 LEVOSIMENDAN Schedule 4 LIDOCAINE Schedule 5 Schedule 4 Schedule 2 LIDOFLAZINE Schedule 4 LIFITEGRAST Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 517 LIGNOCAINE cross reference: LIDOCAINE LIGULARIA DENTATA Schedule 10 LIME OIL Schedule 5 Appendix E, clause 3 Appendix F, clause 4 LIMONENE cross reference: DIPENTENE Appendix B, clause 3 LINACLOTIDE Schedule 4 LINAGLIPTIN Schedule 4 LINCOMYCIN Schedule 4 LINDANE cross reference: BHC Schedule 6 Schedule 5 Schedule 4 Schedule 2 LINEZOLID Schedule 4 LINOLEIC ACID Appendix B, clause 3 LINSEED FATTY ACIDS Appendix B, clause 3 LINURON Appendix B, clause 3 LIOTHYRONINE cross reference: TRIIODOTHYRONINE Schedule 4 LIPEGFILGRASTIM Schedule 4 LIQUORICE, DEGLYCYRRHISINISED Appendix B, clause 3 LIRAGLUTIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 518 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 LISDEXAMFETAMINE Schedule 8 LISINOPRIL Schedule 4 LISURIDE Schedule 4 LITHIUM Schedule 4 Schedule 2 LITHIUM PERFLUOROOCTANE SULFONATE Schedule 7 LIXISENATIDE Schedule 4 LOBELIA INFLATA Schedule 2 LOBELINE Schedule 2 LODOXAMIDE Schedule 4 Schedule 2 LOFEXIDINE Schedule 4 LOGIPARIN Schedule 4 LOMEFLOXACIN Schedule 4 LOMUSTINE Schedule 4 LOPERAMIDE Schedule 4 Schedule 2 Appendix F, clause 4 LOPINAVIR Schedule 4 LOPRAZOLAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) LORACARBEF Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 519 LORATADINE Schedule 4 Schedule 2 LORAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 LORLATINIB Schedule 4 LORMETAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) LOSARTAN Schedule 4 LOTEPREDNOL Schedule 4 LOTILANER Schedule 5 LOXAPINE Schedule 4 LUBRICANTS Appendix A, clause 1 LUFENURON Schedule 5 LUMACAFTOR Schedule 4 LUMEFANTRINE Schedule 4 LUMIRACOXIB Schedule 4 LURASIDONE Schedule 4 Appendix K, clause 1 LURBINECTEDIN Schedule 4 LUSPATERCEPT Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 520 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 LUTEINISING HORMONE Schedule 4 Appendix D, clause 1 LYMECYCLINE Schedule 4 LYSERGIC ACID cross reference: CAS No. 82-58-6 Schedule 9 LYSERGIDE cross reference: CAS No. 50-37-3 Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 521 M MACITENTAN Schedule 4 Appendix D, clause 6 Appendix L, clause 2 MACROGOLS Schedule 3 Schedule 2 MACROPHOMINA PHASEOLINA Schedule 5 MADURAMICIN Schedule 7 Schedule 5 Appendix J, clause 1 MAFENIDE Schedule 6 Schedule 4 MAGNESIUM CHLORATE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 MAGNESIUM HYDROXIDE Appendix B, clause 3 MAGNESIUM SULFATE Schedule 3 MALACHITE GREEN Schedule 7 Schedule 5 MALATHION cross reference: MALDISON, ORGANOPHOSPHORUS COMPOUNDS Schedule 6 Schedule 5 Schedule 3 Appendix E, clause 3 MALEIC HYDRAZIDE Appendix B, clause 3 MANCOZEB Schedule 5 MANDESTROBIN Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index 522 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MANDIPROPAMID Schedule 5 MANDRAGORA OFFICINARUM Schedule 4 MANGANESE DIOXIDE Appendix B, clause 3 MANNITYL HEXANITRATE Schedule 3 MANNOMUSTINE Schedule 4 MAPROTILINE Schedule 4 MARAVIROC Schedule 4 MARBOFLOXACIN Schedule 4 MARIBAVIR Schedule 4 MARJORAM OIL Schedule 5 Appendix E, clause 3 MAROPITANT Schedule 4 MATCHES Appendix A, clause 1 MAVACAMTEN Schedule 4 MAVACOXIB Schedule 4 MAZIDOX Schedule 7 MAZINDOL Schedule 4 Appendix K, clause 1 MCPA Schedule 6 Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 523 MCPB cross reference: (4-(4-CHLORO-2-METHYLPHENOXY)BUTANOIC ACID Schedule 6 MEASLES VACCINE Schedule 4 MEBANAZINE Schedule 4 MEBENDAZOLE Schedule 6 Schedule 5 Schedule 2 MEBEVERINE Schedule 4 MEBHYDROLIN Schedule 4 Appendix K, clause 1 MEBOLAZINE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) MEBUTAMATE Schedule 4 MECAMYLAMINE Schedule 4 MECARBAM Schedule 7 MECASERMIN Schedule 4 MECILLINAM Schedule 4 MECLOCYCLINE Schedule 4 MECLOFENAMATE Schedule 4 MECLOFENAMIC ACID Schedule 5 MECLOFENOXATE Schedule 4 MECLONAZEPAM cross reference: CAS No. 58662-84-3 Authorised Version F2024L00589 registered 30/05/2024 Index 524 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 9 MECLOQUALONE cross reference: CAS No. 340-57-8 Schedule 9 MECLOZINE cross reference: MECLIZINE Schedule 4 Schedule 2 Appendix K, clause 1 MECOPROP Schedule 6 Schedule 5 MECOPROP-P Schedule 6 MEDAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 MEDETOMIDINE Schedule 4 MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS Appendix A, clause 1 MEDICAL DEVICES cross reference: ANTICOAGULANT MEDICAL DEVICES, ARTIFICIAL TEARS, COLLAGEN, INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS, INTRA-ARTICULAR FLUIDS, URINARY CATHETERS Appendix A, clause 1 MEDIGOXIN cross reference: METHYLDIGOXIN Schedule 4 MEDROXYPROGESTERONE Schedule 4 MEDRYSONE Schedule 4 MEFENAMIC ACID Schedule 4 Schedule 2 Appendix F, clause 4 MEFENOREX Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 525 MEFENPYR-DIETHYL Schedule 5 MEFENTRIFLUCONAZOLE Schedule 5 MEFLOQUINE Schedule 4 MEFLUIDIDE Schedule 6 MEFRUSIDE Schedule 4 MEGASPHAERA ELSDENII strain 41125 Appendix B, clause 3 MEGESTROL Schedule 4 MELAGATRAN Schedule 4 MELALEUCA OIL cross reference: TEA TREE OIL Schedule 6 Appendix E, clause 3 MELANOTAN II cross reference: α–MELANOCYTE STIMULATING HORMONE Schedule 4 MELATONIN Schedule 4 Schedule 3 Appendix H, clause 1 MELENGESTROL Schedule 4 MELENGESTROL ACETATE Schedule 6 MELIA AZEDARACH Schedule 10 MELOXICAM Schedule 6 Schedule 4 MELPHALAN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 526 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MEMANTINE Schedule 4 MENAZON Schedule 6 MENINGOCOCCAL VACCINE Schedule 4 MENINGOCOCCAL GROUP B VACCINE cross reference: Neisseria Meningitidis Serogroup B Recombinant LP2086 (MnB rLP2086) Subfamily A Protein and Subfamily B Protein Schedule 4 MENOTROPHIN cross reference: HUMAN MENOPAUSAL GONADOTROPHIN Schedule 4 MEPACRINE Schedule 4 MEPENZOLATE Schedule 4 MEPHENESIN Schedule 4 MEPHENTERMINE Schedule 4 MEPINDOLOL Schedule 4 MEPIQUAT Schedule 5 MEPITIOSTANE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) MEPIVACAINE Schedule 4 MEPROBAMATE Schedule 4 Appendix K, clause 1 MEPTAZINOL Schedule 4 MEPYRAMINE Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 527 MEQUITAZINE Schedule 4 MERCAPTAMINE cross reference: CYSTEAMINE Schedule 6 Schedule 5 Schedule 4 Appendix K, clause 1 MERCAPTOACETIC ACID cross reference: THIOGLYCOLIC ACID Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 2-MERCAPTOETHANOL Schedule 6 MERCAPTOMERIN Schedule 4 MERCAPTOPURINE Schedule 4 MERCURIC CHLORIDE cross reference: CALOMEL Schedule 7 Appendix E, clause 3 MERCURIC IODIDE Appendix E, clause 3 MERCURIC NITRATE Appendix E, clause 3 MERCURIC OXIDE Schedule 6 Appendix E, clause 3 MERCURIC POTASSIUM IODIDE Appendix E, clause 3 MERCURIC THIOCYANATE Appendix E, clause 3 Appendix F, clause 4 MERCUROCHROME Schedule 6 Schedule 4 Schedule 2 Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 528 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MERCUROUS CHLORIDE cross reference: CORROSIVE SUBLIMATE Appendix E, clause 3 MERCURY cross reference: ETHOXYETHYLMERCURIC CHLORIDE, ETHOXYQUIN, PHENYL MERCURIC CHLORIDE Schedule 7 Schedule 4 Schedule 2 Appendix G, clause 1 Appendix J, clause 1 MERCURY metallic Appendix E, clause 3 MERCURY, organic compounds Appendix E, clause 3 MEROPENEM Schedule 4 MERSALYL Schedule 4 MESABOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) MESALAZINE Schedule 4 MESNA Schedule 4 MESOSULFURON-METHYL Appendix B, clause 3 MESOTRIONE Schedule 5 MESTANOLONE cross reference: ANDROSTALONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) MESTEROLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) MESTRANOL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 529 METACRESOLSULPHONIC ACID Schedule 6 Appendix F, clause 4 METAFLUMIZONE Schedule 5 METALAXYL Schedule 6 Schedule 5 METALDEHYDE Schedule 6 Schedule 5 Appendix E, clause 3 METAMFETAMINE cross reference: METHAMFETAMINE, METHAMPHETAMINE, METHYLAMFETAMINE, METHYLAMPHETAMINE Schedule 8 METAMITRON Schedule 6 METANDIENONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) METARAMINOL Schedule 4 METARHIZIUM ANISOPLIAE Appendix B, clause 3 METAZACHLOR Schedule 5 METAZOCINE cross reference: CAS No. 3734-52-9, METAZOCINE RACEMATE CIS-FORM (CAS No. 25144-79-0) Schedule 9 METCAMIFEN Appendix B, clause 3 METENOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) METERGOLINE Schedule 4 METFORMIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 530 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 METHABENZTHIAZURON Schedule 5 METHACHOLINE Schedule 4 METHACRIFOS Schedule 7 Schedule 6 Appendix J, clause 1 METHACYCLINE Schedule 4 METHADONE Schedule 8 Appendix K, clause 1 METHALLENESTRIL cross reference: METHALLENOESTRIL Schedule 4 METHAM cross reference: METHAM SODIUM Schedule 6 METHAMIDOPHOS Schedule 7 METHANDRIOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) METHANOL cross reference: CAS No. 67-56-1 Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 METHANTHELINIUM Schedule 4 METHAPYRILENE Schedule 7 METHAQUALONE cross reference: CAS No. 72-44-6, METHAQUALONE HYDROCHLORIDE (CAS No. 340 56-7) Schedule 9 METHAZOLAMIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 531 METHAZOLE Schedule 7 METHCATHINONE cross reference: CAS No. 5650-44-2, METHCATHINONE HYDROCHLORIDE (CAS No. 49656-78-2) Schedule 9 METHDILAZINE Schedule 4 Schedule 3 Appendix K, clause 1 METHENAMINE cross reference: 1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE, HEXAMINE, HEXAMETHYLENETETRAMINE Schedule 5 METHENOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) METHICILLIN Schedule 4 METHIDATHION Schedule 7 METHIMAZOLE cross reference: THIAMAZOLE Schedule 4 METHIOCARB Schedule 7 Schedule 6 Schedule 5 METHISAZONE Schedule 4 METHIOZOLIN Schedule 5 METHIXENE Schedule 4 METHOCARBAMOL Schedule 4 Appendix K, clause 1 METHOFLUTHRIN Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index 532 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 METHOHEXITONE Schedule 4 METHOIN Schedule 4 METHOMYL cross reference: DENATONIUM BENZOATE Schedule 7 Schedule 6 METHOPRENE Appendix B, clause 3 METHOTREXATE Schedule 4 METHOXAMINE Schedule 4 Schedule 2 Appendix F, clause 4 METHOXSALEN Schedule 4 METHOXYCHLOR Schedule 5 2-METHOXYETHANOL Schedule 7 Appendix F, clause 4 METHOXYETHYLMERCURIC ACETATE Schedule 7 Appendix J, clause 1 METHOXYETHYLMERCURIC CHLORIDE Schedule 7 Appendix J, clause 1 METHOXYFENOZIDE Appendix B, clause 3 METHOXYFLURANE Schedule 4 5-METHOXY-3,4-METHYLENEDIOXYAMFETAMINE cross reference: 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE, MMDA (CAS No. 13674-05-0), MMDA HYDROCHLORIDE (CAS No. 60676-84-8) Schedule 9 4-METHOXY- α –METHYLPHENYLETHYLAMINE cross reference: PMA (CAS No. 64-13-1), PMA HYDROCHLORIDE (CAS No. 3706-26-1) Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 533 5-METHOXY- α –METHYLTRYPTAMINE cross reference: 5-MeO-AMT (CAS No. 1137-04-8) Schedule 9 6-METHOXY-N2-METHYL-2,3-PYRIDINEDIAMINE Schedule 6 2-METHOXY-5-NITROPHENOL Schedule 6 METHOXYPHENAMINE Schedule 2 2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE cross reference: JWH-250 (CAS No. 864445-43-2) Schedule 9 METHSUXIMIDE Schedule 4 METHYCLOTHIAZIDE Schedule 4 METHYL ACETATE Appendix B, clause 3 METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL )-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE cross reference: SALVINORIN A (CAS No. 83729-01-5) Schedule 9 METHYL AMINOLEVULINATE Schedule 4 p-METHYLAMINOPHENOL Schedule 6 Appendix F, clause 4 4-METHYLAMINOREX cross reference: CAS No. 3568-94-3 Schedule 9 METHYLANDROSTANOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) METHYLATED SPIRIT(S) cross reference: DENATONIUM BENZOATE, ETHANOL, FLUORESCEIN Schedule 5 Appendix E, clause 3 Appendix F, clause 4 METHYL BENZOQUATE Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 534 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 METHYL BROMIDE Schedule 7 Appendix J, clause 1 METHYL CHLORIDE Appendix F, clause 4 METHYLCHLOROISOTHIAZOLINONE cross reference: METHYLISOTHIAZOLINONE Schedule 6 Appendix F, clause 4 METHYLCLOSTEBOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL Schedule 7 Schedule 6 1-METHYLCYCLOPROPENE Appendix B, clause 3 METHYLDESORPHINE cross reference: CAS No. 16008-36-9 Schedule 9 METHYLDIBROMO GLUTARONITRILE cross reference: CAS No. 35691-65-7 Schedule 10 Schedule 6 Appendix F, clause 4 METHYLDIHYDROMORPHINE Schedule 8 METHYLDOPA Schedule 4 4,4'-METHYLENEBIS[2-CHLOROANILINE] Schedule 7 Appendix J, clause 1 METHYLENE BISTHIOCYANATE Schedule 6 Appendix F, clause 4 METHYLENE BLUE Schedule 7 Schedule 5 Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 535 3,4-METHYLENEDIOXYAMFETAMINE cross reference: 3,4-METHYLENEDIOXYAMPHETAMINE, MDA, TENAMFETAMINE (CAS No. 4764-17-4) Schedule 9 3,4-METHYLENEDIOXYPYROVALERONE cross reference: MDPV (CAS No. 687603-66-3) Schedule 9 METHYLEPHEDRINE Schedule 2 METHYLERGOMETRINE Schedule 4 METHYL ETHYL KETONE cross reference: DESIGNATED SOLVENT Schedule 5 Appendix E, clause 3 Appendix F, clause 4 METHYL ETHYL KETONE OXIME Schedule 6 Appendix E, clause 3 Appendix F, clause 4 METHYL ETHYL KETONE PEROXIDE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 METHYLEUGENOL Schedule 6 Appendix E, clause 3, Appendix F, clause 4 3-METHYLFENTANYL cross reference: CAS No. 42045-86-3 Schedule 9 METHYLPHENYLPIRACETAM cross reference: RACETAMS Schedule 4 METHYL p-HYDROXYBENZOATE Appendix B, clause 3 METHYL ISOAMYL KETONE cross reference: DESIGNATED SOLVENT Schedule 5 Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 536 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 METHYL ISOBUTYL KETONE cross reference: DESIGNATED SOLVENT, METHYLATED SPIRIT(S) Schedule 5 Appendix E, clause 3 METHYL ISOTHIOCYANATE Schedule 6 METHYLISOTHIAZOLINONE cross reference: METHYLCHLOROISOTHIAZOLINONE Schedule 6 Appendix F, clause 4 METHYLMERCURY Schedule 4 Appendix G, clause 1 METHYL METHACRYLATE cross reference: CAS No. 80-62-6 Schedule 10 Schedule 6 Appendix F, clause 4 4-METHYLMETHCATHINONE cross reference: MEPHEDRONE (CAS No. 1189805-46-6) Schedule 9 N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE cross reference: MBDB (CAS No. 135795-90-3) Schedule 9 N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE cross reference: N-HYDROXY MDA (CAS No. 74698-47-8) Schedule 9 2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID cross reference: MORAMIDE INTERMEDIATE (CAS No. 3626-55-9) Schedule 9 METHYLNALTREXONE Schedule 4 METHYL NEODECANAMIDE Schedule 6 METHYLNORBORNYLPYRIDINE Schedule 6 METHYLONE *(MDMC) cross reference: CAS No. 186028-79-5, MDMC HYDROCHLORIDE (CAS No. 186028-80 8) Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 537 METHYLPENTYNOL Schedule 4 METHYLPHENIDATE Schedule 8 METHYLPHENOBARBITAL cross reference: BARBITURATE METHYLPREDNISOLONE Schedule 4 Appendix K, clause 1 METHYLPHENOBARBITONE cross reference: METHYLPHENOBARBITAL, BARBITURATE METHYLPREDNISOLONE 1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE cross reference: ACIDMPPP (CAS No. 13147-09-6), MPPP HYDROCHLORIDE (CAS No. 4968-48-3) Schedule 9 1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID cross reference: PETHIDINE INTERMEDIATE C Schedule 8 METHYLPREDNISOLONE Schedule 4 N-METHYL-2-PYRROLIDONE Schedule 6 Schedule 5 Appendix E, clause 3 2-METHYLRESORCINOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 METHYLROSANILINIUM CHLORIDE cross reference: CRYSTAL VIOLET (CAS No. 548-62-9), GENTIAN VIOLET, ACID VIOLET 49 (CAS No. 1694-09-3), ETHYL VIOLET (CAS No. 2390-59-2), BASIC BLUE 7 (CAS No. 2390-60-5), BASIC BLUE 26 (CAS No. 2580-56-5) Schedule 10 Schedule 6 Schedule 4 METHYL SALICYLATE Schedule 6 Schedule 5 Schedule 4 METHYL SALICYLATE LIQUID Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 538 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 METHYLTESTOSTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) 4-METHYLTHIOAMFETAMINE cross reference: 4-METHYLTHIOAMPHETAMINE (CAS No. 14116-06-4) Schedule 9 3-METHYLTHIOFENTANYL cross reference: CAS No. 86052-04-2 Schedule 9 2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5 TRIAZINE Schedule 5 METHYLTHIOURACIL Schedule 4 METHYLTRIENOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) METHYPRYLONE Schedule 4 METHYSERGIDE Schedule 4 METIRAM Schedule 5 METOBROMURON Schedule 5 METOCLOPRAMIDE Schedule 4 Schedule 3 METODESNITAZENE cross reference: CAS No. 14030-77-4, METAZENE Schedule 9 METOFLUTHRIN Schedule 6 Schedule 5 METOLACHLOR Schedule 5 METOLAZONE Schedule 4 METONITAZENE cross reference: CAS No. 14680-51-4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 539 Schedule 9 METOPON cross reference: CAS No. 143-52-2 Schedule 9 METOPROLOL Schedule 4 METOSULAM Schedule 6 METRAFENONE Schedule 6 Schedule 5 METRIBOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) METRIBUZIN Schedule 6 METRIFONATE cross reference: TRICHLORFON Schedule 4 METRONIDAZOLE cross reference: BENZOYL METRONIDAZOLE Schedule 4 METSULFURONMETHYL Appendix B, clause 3 METYRAPONE Schedule 4 MEVINPHOS Schedule 7 MEXILETINE Schedule 4 MEZLOCILLIN Schedule 4 MIANSERIN Schedule 4 Appendix K, clause 1 MIBEFRADIL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 540 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MIBOLERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) MICAFUNGIN Schedule 4 MICONAZOLE Schedule 6 Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 MIDAZOLAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 MIDODRINE Schedule 4 MIDOSTAURIN Schedule 4 MIFEPRISTONE Schedule 4 MIGALASTAT Schedule 4 MIGLITOL Schedule 4 MIGLUSTAT Schedule 4 MILBEMECTIN Schedule 6 Schedule 5 MILNACIPRAN Schedule 4 MILBEMYCIN OXIME Schedule 5 Schedule 4 MILRINONE Schedule 4 MINOCYCLINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 541 MINOXIDIL Schedule 4 Schedule 2 MIPAFOX Schedule 7 MIRABEGRON Schedule 4 MIREX Schedule 7 Appendix J, clause 1 MIRIKIZUMAB Schedule 4 MIRTAZAPINE Schedule 4 Appendix K, clause 1 MISOPROSTOL Schedule 4 Appendix F, clause 4 Appendix L, clause 2 MITOBRONITOL Schedule 4 MITOMYCIN Schedule 4 MITOTANE Schedule 4 MITOXANTRONE Schedule 4 MITRAGYNA SPECIOSA cross reference: KRATOM; MITRAGYNINE (CAS No. 4098-40-2) Schedule 9 MITRAGYNINE cross reference: (CAS No. 4098-40-2), KRATOM; MITRAGYNA SPECIOSA Schedule 9 MITRATAPIDE Schedule 4 MIVACURIUM CHLORIDE Schedule 4 MOBOCERTINIB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 542 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MOCLOBEMIDE Schedule 4 MODAFINIL Schedule 4 MOLGRAMOSTIM Schedule 4 MOLINATE Schedule 7 Appendix J, clause 1 MOLINDONE Schedule 4 MOLNUPIRAVIR Schedule 4 MOMETASONE Schedule 4 Schedule 3 Schedule 2 MOMFLUOROTHRIN Schedule 6 MONENSIN Schedule 6 Schedule 5 Schedule 4 MONEPANTEL Schedule 5 MONOBENZONE cross reference: HYDROQUINONE Schedule 4 MONOCLONAL ANTIBODIES Schedule 4 MONOCROTOPHOS Schedule 7 MONOETHANOLAMINE Schedule 6 Schedule 5 Schedule 4 Appendix E, clause 3 Appendix F, clause 4 MONTELUKAST Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 543 MOPERONE Schedule 4 MORANTEL Schedule 6 Schedule 5 MORAZONE Schedule 4 MORICIZINE Schedule 4 MORPHERIDINE cross reference: CAS No. 469-81-8 Schedule 9 MORPHINE Schedule 8 Appendix K, clause 1 MORPHINE METHOBROMIDE Schedule 8 MORPHINE-N-OXIDE Schedule 8 (1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1- YLMETHANONE cross reference: JWH-200 (CAS No. 103610-04-4) Schedule 9 MOTOR, HEATING or FURNACE FUELS cross reference: FUELS, FUELS, HOBBY - FUELS, TOY, KEROSENE, METHANOL, PETROL Appendix A, clause 1 MOTRAZEPAM Schedule 4 MOTRETINIDE Schedule 4 MOXIDECTIN Schedule 7 Schedule 6 Schedule 5 Schedule 4 MOXIFLOXACIN Schedule 4 MOXONIDINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 544 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 MSMA Schedule 7 Schedule 6 MUMPS VACCINE Schedule 4 MUPIROCIN Schedule 4 MURAGLITAZAR Schedule 4 MUROMONAB Schedule 4 MUSCIMOL cross reference: CAS No. 2763-96-4, MUSCIMOL HYDROBROMIDE (CAS No. 18174-72 6) Schedule 9 MUSTINE cross reference: NITROGEN MUSTARD Schedule 4 MYCLOBUTANIL Schedule 5 MYCOPHENOLIC ACID cross reference: MYCOPHENOLATE MOFETIL Schedule 4 MYRISTIC ACID Appendix B, clause 3 MYROPHINE cross reference: CAS No. 467-18-5 Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 545 N NAA cross reference: NAPTHALENEACETIC ACID Schedule 5 NABILONE Schedule 8 NABIXIMOLS cross reference: CANNABICHROMENE, CANNABIDIOL, CANNABIDIOLIC ACID, CANNABIDIVAROL, CANNABIGEROL, CANNABINOIDS, CANNABINOL, CANNABIS SATIVA, TETRAHYDROCANNABINOLIC ACID, TETRAHYDROCANNABINOLS, TETRAHYDROCANNABIVAROL Schedule 8 Appendix D, clause 1 Appendix K, clause 1 NABUMETONE Schedule 4 NADOLOL Schedule 4 NADROPARIN Schedule 4 NAFARELIN Schedule 4 NAFTIDROFURYL Schedule 4 NALBUPHINE Schedule 4 Appendix K, clause 1 NALED Schedule 6 Schedule 5 NALIDIXIC ACID Schedule 4 NALMEFENE Schedule 4 NALORPHINE Schedule 4 NALOXEGOL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 546 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 NALOXONE Schedule 4 Schedule 3 Appendix H, clause 1 NALTREXONE Schedule 4 NANDROLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) NAPHAZOLINE Schedule 2 Appendix F, clause 4 NAPHTHALENE cross reference: CAS No. 91-20-3 Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 Appendix G, clause 1 1,5-NAPHTHALENEDIOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 2,7-NAPTHALENEDIOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 NAPHTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE cross reference: JWH-073 (CAS No. 208987-48-8) Schedule 9 NAPHTHALOPHOS Schedule 7 Schedule 6 1-NAPHTHOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 NAPHTHOYLINDOLES Schedule 9 NAPHTHOYLPYRROLES Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 547 NAPHTHYLMETHYLINDENES Schedule 9 NAPHTHYLMETHYLINDOLES Schedule 9 NAPROPAMIDE Appendix B, clause 3 NAPROXEN Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 NAPTALAM Schedule 5 NAPTHYL ACETAMIDE Appendix B, clause 3 NARASIN Schedule 6 Schedule 4 NARATRIPTAN Schedule 4 Schedule 3 Appendix H, clause 1 NATALIZUMAB Schedule 4 NATAMYCIN cross reference: PIMARCIN Schedule 4 NATEGLINIDE Schedule 4 NEBACUMAB Schedule 4 NEBIVOLOL Schedule 4 NEBRACETAM cross reference: RACETAMS Schedule 4 NEDOCROMIL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 548 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 NEFAZODONE Schedule 4 NEFIRACETAM cross reference: RACETAMS Schedule 4 NEFOPAM Schedule 4 NELARABINE Schedule 4 NELFINAVIR Schedule 4 NEOMYCIN Schedule 4 NEOSCYTALIDIUM NOVAEHOLLANDIAE Schedule 5 NEOSTIGMIN Schedule 4 NEPAFENAC Schedule 4 NERATINIB Schedule 4 NERIUM OLEANDER Schedule 4 Appendix G, clause 1 NEROLI OIL Appendix B, clause 3 NESIRITIDE Schedule 4 NETILMICIN Schedule 4 NETOBIMIN Schedule 6 Schedule 5 NETUPITANT Schedule 4 NEVIRAPINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 549 NIALAMIDE Schedule 4 NICARBAZIN Appendix B, clause 3 NICARDIPINE Schedule 4 NICERGOLINE Schedule 4 NICKEL SULFATE Schedule 6 NICLOSAMIDE Schedule 2 NICOCODINE cross reference: CAS No. 3688-66-2, NICOCODINE HYDROCHLORIDE (CAS No. 58263 01-7) Schedule 9 NICODICODINE cross reference: CAS No. 808-24-2 Schedule 9 NICOFURANOSE Schedule 4 NICOMORPHINE cross reference: CAS No. 639-48-5, NICOMORPHINE HYDROCHLORIDE (CAS No. 12040-41-4) Schedule 9 NICORANDIL Schedule 4 NICOTINE Schedule 7 Schedule 4 Appendix D, clause 5 Appendix F, clause 4 Appendix J, clause 1 NICOTINIC ACID cross reference: NICOTINAMIDE Schedule 4 Schedule 3 NICOTINYL ALCOHOL Schedule 3 Authorised Version F2024L00589 registered 30/05/2024 Index 550 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 NICOUMALONE Schedule 4 NIFEDIPINE Schedule 4 NIFENAZONE Schedule 4 NIFOXIPAM cross reference: CAS No. 74723-10-7 Schedule 9 NIKETHAMIDE Schedule 4 NILOTINIB Schedule 4 NILUTAMIDE Schedule 4 NIMESULIDE Schedule 4 NIMIDANE Schedule 7 Schedule 6 NIMODIPINE Schedule 4 NIMORAZOLE Schedule 4 NINTEDANIB Schedule 4 NIRAPARIB Schedule 4 NIRIDAZOLE Schedule 4 NIRMATRELVIR Schedule 4 NIRSEVIMAB Schedule 4 NISIN Appendix B, clause 3 NISOLDIPINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 551 NITENPYRAM Schedule 6 NITISINONE Schedule 4 NITRAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 NITRENDIPINE Schedule 4 NITRIC ACID Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 NITRIC OXIDE Schedule 4 NITROBENZENE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 NITROFEN Schedule 7 Appendix J, clause 1 NITROFURANTOIN Schedule 4 NITROFURAZONE Schedule 4 3-NITRO-p-HYDROXYETHYLAMINOPHENOL cross reference: 4-[(2-HYDROXYETHYL)AMINO]-3-NITROPHENOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 NITROPHENOLS Schedule 6 Appendix E, clause 3 Appendix F, clause 4 NITROPRUSSIDES Schedule 7 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 552 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 NITROSCANATE Schedule 5 2-NITROTOLUENE Schedule 7 NITROUS OXIDE Schedule 4 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 NITROXOLINE Schedule 4 NITROXYNIL Schedule 6 NIVOLUMAB Schedule 4 NIZATIDINE Schedule 4 Schedule 2 Appendix F, clause 4 NOMEGESTROL Schedule 4 NOMIFENSINE Schedule 4 NONANOIC ACID Schedule 5 NONOXINOL 9 Schedule 6 Schedule 5 Appendix E, clause 3 NORACYMETHADOL cross reference: CAS No. 1477-39-0, NORACYMETHADOL HYDROCHLORIDE (CAS No. 5633-25-0) Schedule 9 NORADRENALINE Schedule 4 Appendix F, clause 4 19-NORANDROSTENEDIOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 553 19-NORANDROSTENEDIONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) NORANDROSTENOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) NORBOLETHONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) NORBORMIDE Schedule 5 NORCLOSTEBOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) NORCODEINE Schedule 8 NORELGESTROMIN Schedule 4 NOREPINEPHRINE cross reference: NORADRENALINE NORETHANDROLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) NORETHISTERONE Schedule 4 NORFLOXACIN Schedule 4 NORFLURAZON Appendix B, clause 3 NORGESTREL Schedule 4 NORIBOGAINE Schedule 4 NORLEVORPHANOL cross reference: CAS No. 1531-12-0, NORLEVORPHANOL HYDROBROMIDE (CAS No. 63732-85-4), NORLEVORPHANOL RACEMATE (CAS No. 39131-41-4) Schedule 9 NORMAL HUMAN IMMUNOGLOBULIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 554 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 NORMETHADONE Schedule 8 Appendix K, clause 1 NORMETHANDRONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) NORMORPHINE cross reference: CAS No. 466-97-7, NORMORPHINE HYDROCHLORIDE (CAS No. 3372 02-9) Schedule 9 NORPIPANONE cross reference: CAS No. 561-48-8, NORPIPANONE HYDROCHLORIDE (CAS No. 6033 41-6), NORPIPANONE HYDROBROMIDE (CAS No. 6033-42-7) Schedule 9 NORTRIPTYLINE Schedule 4 Appendix K, clause 1 NOSCAPINE Schedule 2 NOVALURON Appendix B, clause 3 NOVOBIOCIN Schedule 4 NOXIPTYLINE Schedule 4 NUCLEAR POLYHEDROSIS VIRUS OF Helicoverpa armigera occlusion bodies Appendix B, clause 3 NUSINERSEN Schedule 4 NUTMEG OIL Schedule 5 NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION Appendix A, clause 1 NYSTATIN Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 555 O OBETICHOLIC ACID Schedule 4 OCLACITINIB Schedule 4 OCRELIZUMAB Schedule 4 OCRIPLASMIN Schedule 4 OCTAMYLAMINE Schedule 4 OCTATROPINE Schedule 4 1-OCTEN-3-OL Schedule 6 OCTHILINONE Schedule 6 OCTREOTIDE Schedule 4 OCTYL ALCOHOLS Appendix B, clause 3 N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE cross reference: OCTYLBICYCLOHEPTENEDICARBOXIMIDE Schedule 5 OCTYL NITRITE Schedule 4 Appendix E, clause 3 N-(N-OCTYL)-2-PYRROLIDONE cross reference: DESIGNATED SOLVENT, N-(N-DODECYL)-2-PYRROLIDONE, N-METHYL-2-PYRROLIDONE Schedule 6 Schedule 5 Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 556 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 OESTRADIOL cross reference: ESTRADIOL OESTRIOL cross reference: ESTRIOL OESTROGENS cross reference: ESTROGENS OESTRONE cross reference: ESTRONE OFATUMUMAB Schedule 4 OFLOXACIN Schedule 4 OLANZAPINE Schedule 4 Appendix K, clause 1 OLAPARIB Schedule 4 OLAQUINDOX Schedule 6 OLARATUMAB Schedule 4 OLEANDOMYCIN Schedule 5 Schedule 4 OLEANDRIN Schedule 4 OLEIC ACID Appendix B, clause 3 N-OLEYL-1,3-DIAMINOPROPANE Schedule 6 OLIPUDASE ALFA Schedule 4 OLMESARTAN Schedule 4 OLODATEROL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 557 OLOPATADINE Schedule 4 Schedule 2 OLSALAZINE Schedule 4 OMBERACETAM cross reference: RACETAMS, NOOPEPT, N-PHENYLACETYL-L-PROLYLGLYCINE ETHYL ESTER Schedule 4 OMBITASVIR Schedule 4 OMALIZUMAB Schedule 4 OMEGA-3-ACID ETHYL ESTERS Schedule 4 OMEPRAZOLE Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 OMETHOATE Schedule 7 Schedule 6 Schedule 5 ONASEMNOGENE ABEPARVOVEC Schedule 4 ONDANSETRON Schedule 4 OPICAPONE Schedule 4 OPIPRAMOL Schedule 4 OPIUM cross reference: NOSCAPINE, PAPAVERINE Schedule 8 Appendix K, clause 1 ORANGE OIL (BITTER) Schedule 5 Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 558 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ORANGE OIL, SWEET Appendix B, clause 3 ORBIFLOXACIN Schedule 4 ORCIPRENALINE Schedule 4 Appendix F, clause 4 ORGANOPHOSPHORUS COMPOUNDS cross reference: MALATHION Schedule 4 ORLISTAT Schedule 4 Schedule 3 ORNIDAZOLE Schedule 4 ORNIPRESSIN Schedule 4 ORPHENADRINE Schedule 4 ORTHOPTERIN Schedule 4 OSELTAMIVIR Schedule 4 OSILODROSTAT Schedule 4 OSIMERTINIB Schedule 4 OUABAIN Schedule 4 OVANDROTONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) OXABETRINIL Appendix B, clause 3 OXABOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) OXACILLIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 559 OXADIARGYL Schedule 5 OXADIAZON Schedule 6 OXADIXYL Schedule 5 OXALATES Appendix F, clause 4 OXALIC ACID Schedule 6 Appendix E, clause 3 Appendix F, clause 4 OXALIPLATIN Schedule 4 OXAMYL Schedule 7 OXANDROLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) OXANTEL EMBONATE Schedule 5 OXAPROZIN Schedule 4 OXAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 OXCARBAZEPINE Schedule 4 OXATHIAPIPROLIN Appendix B, clause 3 OXEDRINE cross reference: SYNEPHRINE Schedule 4 OXETACAINE cross reference: OXETHAZAINE Schedule 4 Schedule 2 OXFENDAZOLE Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index 560 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 OXIBENDAZOLE Schedule 5 OXICONAZOLE Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 OXIRACETAM cross reference: RACETAMS Schedule 4 OXITROPIUM Schedule 4 OXOLAMINE Schedule 4 OXOLINIC ACID Schedule 4 OXPENTIFYLLINE cross reference: PENTOXIFYLLINE OXPRENOLOL Schedule 4 OXYBUPROCAINE Schedule 4 OXYBUTYNIN Schedule 4 OXYCARBOXIN Schedule 5 OXYCLOZANIDE Schedule 6 OXYCODONE Schedule 8 Appendix K, clause 1 OXYDEMETON METHYL Schedule 7 OXYFLUORFEN Appendix B, clause 3 OXYMESTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 561 OXYMETAZOLINE Schedule 2 Appendix F, clause 4 OXYMETHOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) OXYMORPHONE Schedule 8 OXYPHENBUTAZONE Schedule 4 OXYPHENCYCLIMINE Schedule 4 OXYPHENISATIN cross reference: CAS No. 125-13-3 Schedule 10 OXYPHENONIUM Schedule 4 OXYQUINOLINE Schedule 2 Appendix F, clause 4 OXYTETRACYCLINE Schedule 5 Schedule 4 OXYTHIOQUINOX Schedule 5 OXYTOCIN Schedule 4 Appendix G, clause 1 OZANIMOD Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 562 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 P PACLITAXEL Schedule 4 PACLOBUTRAZOL Schedule 5 PAECILOMYCES LILACINUS STRAIN 251 Schedule 6 PAINT Appendix F, clause 4 PALBOCICLIB Schedule 4 PALIFERMIN Schedule 4 PALIPERIDONE Schedule 4 Appendix K, clause 1 PALIVIZUMAB Schedule 4 PALMAROSA OIL Appendix B, clause 3 PALMITIC ACID Appendix B, clause 3 PALONOSETRON Schedule 4 PALOVAROTENE Schedule 4 Appendix F, clause 4 Appendix L, clause 2 PAMAQUIN Schedule 4 PAMIDRONIC ACID cross reference: PAMIDRONATE DISODIUM Schedule 4 PANCREATIC ENZYMES cross reference: LIPASE Schedule 4 PANCURONIUM Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 563 PANITUMUMAB Schedule 4 PANOBINOSTAT Schedule 4 PANTOPRAZOLE Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 PAPAVERETUM Appendix K, clause 1 PAPAVERINE cross reference: OPIUM Schedule 4 Schedule 2 PAPER Appendix A, clause 1 PARA-AMINOPROPIOPHENONE (PAPP) cross reference: 4-AMINOPROPIOPHENONE PARACETAMOL cross reference: ASPIRIN, IBUPROFEN, METOCLOPRAMIDE, SALICYLAMIDE, CAFFEINE Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 para-DICHLOROBENZENE cross reference: PDB Appendix F, clause 4 PARA-FLUOROFENTANYL cross reference: CAS No. 90736-23-5 Schedule 9 PARAFORMALDEHYDE cross reference: FREE FORMALDEHYDE (CAS No. 30525-89-4) Schedule 10 Schedule 6 Schedule 2 Appendix E, clause 3 PARALDEHYDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 564 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PARAMETHADIONE Schedule 4 PARAMETHASONE Schedule 4 PARAQUAT Schedule 7 PARATHION Schedule 7 PARATHION-METHYL Schedule 7 Schedule 6 PARBENDAZOLE Schedule 6 PARECOXIB Schedule 4 PARICALCITOL Schedule 4 PARITAPREVIR Schedule 4 PAROMOMYCIN Schedule 4 PAROXETINE Schedule 4 PASIREOTIDE Schedule 4 PATCHOULI OIL Appendix B, clause 3 PATIROMER SORBITEX CALCIUM Schedule 4 PATISIRAN Schedule 4 PAZOPANIB Schedule 4 PEBULATE Schedule 6 PECAZINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 565 PECTINASE derived from Aspergillus niger Appendix B, clause 3 PEFLOXACIN Schedule 4 PEGAPTANIB Schedule 4 PEGASPARGASE Schedule 4 PEGBOVIGRASTIM Appendix B, clause 3 PEGCETACOPLAN Schedule 4 PEGFILGRASTIM Schedule 4 PEGINTERFERON Schedule 4 PEGVALIASE Schedule 4 PEGVISOMANT Schedule 4 PEMIGATINIB Schedule 4 PERAMIVIR Schedule 4 PHENOLS Appendix E, clause 3 PEMBROLIZUMAB Schedule 4 PEMETREXED Schedule 4 PEMOLINE Schedule 4 PEMPIDINE Schedule 4 PENBUTOLOL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 566 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PENCICLOVIR Schedule 4 PENCONAZOLE Schedule 5 PENCYCURON Appendix B, clause 3 PENDIMETHALIN Schedule 5 PENETHAMATE Schedule 4 PENFLUFEN Schedule 5 PENICILLAMINE Schedule 4 PENNYROYAL OIL Schedule 6 Appendix E, clause 3 PENTACHLOROPHENOL Schedule 7 Schedule 6 Appendix F, clause 4 PENTADECANOIC ACID Appendix B, clause 3 PENTAERYTHRITYL TETRANITRATE Schedule 4 PENTAGASTRIN Schedule 4 PENTAMETHONIUM Schedule 4 PENTAMIDINE Schedule 4 PENTAZOCINE Schedule 8 Appendix K, clause 1 PENTHIENATE Schedule 4 PENTHIOPYRAD Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 567 PENTOBARBITONE cross reference: PENTOBARBITAL PENTOBARBITAL Schedule 8 Schedule 4 Appendix D, clause 9 Appendix K, clause 1 PENTOLINIUM Schedule 4 PENTOSAN POLYSULFATE SODIUM Schedule 4 PENTOXIFYLLINE Schedule 4 1-PENTYL-3-(1-NAPHTHOYL)INDOLE cross reference: JWH-018 (CAS No. 209414-07-3) Schedule 9 1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE cross reference: JWH-122 (CAS No. 619294-47-2) Schedule 9 PEPPERMINT OIL Appendix B, clause 3 PERACETIC ACID Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 PERAMPANEL Schedule 4 Appendix D, clause 5 Appendix K, clause 1 PERFLUIDONE Schedule 6 PERGOLIDE Schedule 4 PERHEXILINE Schedule 4 PERICIAZINE Schedule 4 Appendix K, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index 568 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PERICYAZINE cross reference: PERICIAZINE PERINDOPRIL Schedule 4 PERMANGANATES cross reference: POTASSIUM PERMANGANATE Schedule 6 Appendix F, clause 4 PERMETHRIN Schedule 6 Schedule 5 Schedule 4 PERPHENAZINE Schedule 4 Appendix K, clause 1 PERTUSSIS ANTIGEN cross reference: TRIPLE ANTIGEN VACCINE Schedule 4 PERTUZUMAB Schedule 4 PETASITES spp. Schedule 10 PETHIDINE Schedule 8 Appendix K, clause 1 PETROL Schedule 5 Appendix E, clause 3 PHEDRAZINE Schedule 2 PHENACEMIDE Schedule 4 PHENACETIN Schedule 4 PHENADOXONE cross reference: CAS No. 467-84-5, PHENADOXONE HYDROCHLORIDE (CAS No. 545 91-5) Schedule 9 PHENAGLYCODOL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 569 PHENAMPROMIDE cross reference: CAS No. 129-83-9 Schedule 9 PHENAZOCINE cross reference: CAS No. 127-35-5, PHENAZOCINE RACEMATE (CAS No. 58073-76-0), PHENOAZOCINE HYDROBROMIDE (CAS No. 1239-04-9) Schedule 9 PHENAZONE Schedule 5 Schedule 4 Schedule 2 PHENAZOPYRIDINE Schedule 4 PHENCYCLIDINE cross reference: PCP (CAS No. 77-10-1), PHENCYCLIDINE HYDROCHLORIDE (CAS No. 956-90-1) Schedule 9 PHENDIMETRAZINE Schedule 8 PHENELZINE Schedule 4 Appendix K, clause 1 N-PHENETHYL-4-PIPERIDONE cross reference: CAS No. 39742-60-4 Schedule 9 PHENETICILLIN Schedule 4 PHENFORMIN Schedule 4 PHENGLUTARIMIDE Schedule 4 PHENIBUT cross reference: BETA-PHENYL-GAMMA-AMINOBUTYRIC ACID (CAS No. 1078-21-3), PHENIBUT HYDROCHLORIDE (CAS No. 3060-41-1), PHENIBUT HYDROBROMIDE (CAS No. 103095-38-1) Schedule 9 PHENINDIONE Schedule 4 PHENIRAMINE Schedule 4 Schedule 3 Authorised Version F2024L00589 registered 30/05/2024 Index 570 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Schedule 2 Appendix K, clause 1 PHENISATIN Schedule 4 PHENISOPHAM Schedule 5 PHENMEDIPHAM Appendix B, clause 3 PHENMETRAZINE Schedule 8 PHENOBARBITAL Schedule 4 Appendix K, clause 1 PHENOBARBITONE cross reference: PHENOBARBITAL PHENOL cross reference: CREOSOTE, PHENOLS, TAR, XYLENOLS Schedule 6 Schedule 5 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 PHENOLPHTHALEIN Schedule 4 PHENOMORPHAN cross reference: CAS No. 468-07-5 Schedule 9 PHENOPERIDINE Schedule 8 Appendix K, clause 1 PHENOTHIAZINE Schedule 6 D-PHENOTHRIN Appendix B, clause 3 PHENOXYBENZAMINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 571 2-PHENOXYETHANOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 PHENOXYMETHYL OXIRANE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 PHENOXYMETHYLPENICILLIN Schedule 4 PHENPROMETHAMINE cross reference: CAS No. 93-88-9 Schedule 10 PHENSUXIMIDE Schedule 4 PHENTERMINE Schedule 4 Appendix D, clause 5 PHENTHIMENTONIUM Schedule 4 PHENTOLAMINE Schedule 4 PHENYLACETYLINDOLES Schedule 9 PHENYLBUTAZONE Schedule 4 PHENYLENEDIAMINES cross reference: ALKYLATED, ARYLATED, HALOGENATED and NITRO-PHENYLENEDIAMINES, DIETHYL-PARA-PHENYLENEDIAMINE, DIMETHYL-PARA-PHENYLENEDIAMINE Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 PHENYLEPHRINE cross reference: CODEINE, IBUPROFEN, PARACETAMOL Schedule 4 Schedule 2 Appendix F, clause 4 1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE cross reference: PEPAP (CAS No. 64-52-8) Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index 572 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PHENYLMERCURIC ACETATE cross reference: MERCURY Schedule 7 Appendix J, clause 1 PHENYL METHYL KETONE cross reference: DESIGNATED SOLVENT Schedule 5 Appendix E, clause 3 o-PHENYLPHENOL Schedule 5 Appendix E, clause 3 Appendix F, clause 4 4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER cross reference: PETHIDINE INTERMEDIATE B Schedule 8 PHENYL METHYL PYRAZOLONE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 PHENYLPIRACETAM cross reference: RACETAMS Schedule 4 PHENYLPROPANOLAMINE Schedule 4 PHENYLTOLOXAMINE Schedule 4 Appendix K, clause 1 PHENYTOIN Schedule 4 Appendix F, clause 4 PHLEUM PRATENSE POLLEN EXTRACT (Timothy-grass pollen extract) Schedule 4 PHOLCODINE Schedule 8 Schedule 4 Schedule 2 Appendix K, clause 1 PHORATE Schedule 7 PHOSALONE Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 573 PHOSFOLAN Schedule 7 PHOSMET Schedule 6 PHOSPHIDES, METALLIC cross reference: ALUMINIUM PHOSPHIDE, MAGNESIUM PHOSPHIDE, ZINC PHOSPHIDE Schedule 7 Appendix J, clause 1 PHOSPHINE Schedule 7 Appendix J, clause 1 PHOSPHODIESTERASE TYPE 5 INHIBITORS Schedule 4 PHOSPHONIC ACID cross reference: PHOSPHOROUS ACID Schedule 5 Appendix E, clause 3 Appendix F, clause 4 PHOSPHORIC ACID Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 PHOSPHORUS Appendix G, clause 1 PHOSPHORUS, YELLOW Schedule 7 Appendix E, clause 3 Appendix F, clause 4 PHOTOGRAPHIC PAPER or FILM Appendix A, clause 1 PHOXIM Schedule 6 o-PHTHALADEHYDE Appendix F, clause 4 o-PHTHALALDEHYDE Appendix E, clause 3 PHTHALALDEHYDE Schedule 6 Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index 574 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PHTHALYLSULFATHIAZOLE Schedule 4 PHYSOSTIGMINE Schedule 4 PHYTASE Appendix B, clause 3 PIBRENTASVIR Schedule 4 PICARIDIN Schedule 5 PICLORAM Appendix B, clause 3 PICOLINAFEN Appendix B, clause 3 PICRAMIC ACID (including its salts) cross reference: 2-AMINO-4,6-DINITROPHENOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 PICRIC ACID Appendix E, clause 3 Appendix F, clause 4 PICROTOXIN Schedule 4 PIGMENTS Appendix A, clause 1 PILOCARPINE Schedule 4 PIMECROLIMUS Schedule 4 PIMELIC ACID Appendix B, clause 3 PIMINODINE cross reference: CAS No. 13495-09-5, PIMINODINE DIHYDROCHLORIDE (CAS No. 113862-30-9). PIMINODINE ESILATE (CAS No. 7081-52-9) Schedule 9 PIMOBENDAN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 575 PIMOZIDE Schedule 4 Appendix K, clause 1 PINACIDIL Schedule 4 PINDOLOL Schedule 4 PINDONE Schedule 6 PINE OILS Schedule 6 Schedule 5 PINOXADEN Schedule 6 Schedule 5 PIOGLITAZONE Schedule 4 PIPECURONIUM Schedule 4 PIPEMIDIC ACID Schedule 4 PIPENZOLATE Schedule 4 PIPER METHYSTICUM cross reference: KAVA, KAVALACTONES Schedule 4 PIPERACILLIN Schedule 4 PIPERAZNE Schedule 5 Schedule 2 PIPERIDINE Schedule 4 PIPERIDOLATE Schedule 4 PIPERONYL BUTOXIDE Appendix B, clause 3 PIPEROPHOS Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index 576 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PIPOBROMAN Schedule 4 PIPOTHIAZINE Schedule 4 PIPRADROL Schedule 4 PIRACETAM cross reference: RACETAMS Schedule 4 PIRBUTEROL Schedule 4 PIRENOXINE cross reference: CATALIN Schedule 4 PIRENZEPINE Schedule 4 PIRETANIDE Schedule 4 PIRFENIDONE Schedule 4 PIRIMICARB Schedule 6 Schedule 5 PIRIMIPHOS-ETHYL Schedule 6 PIRIMIPHOS-METHYL Schedule 6 PIRITRAMIDE Schedule 8 PIROXICAM Schedule 4 PIRPROFEN Schedule 4 PITAVASTATIN Schedule 4 PITUITARY HORMONES Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 577 PIVAMPICILLIN Schedule 4 PIZOTIFEN Schedule 4 Appendix K, clause 1 PLASMID DNA (rE. coli DH5α pINGhT) cross reference: VACCINES – PLASMID DNA PLERIXAFOR Schedule 4 PLICAMYCIN Schedule 4 PLITIDEPSIN Schedule 4 Appendix L, clause 2 PNEUMOCOCCAL VACCINE Schedule 4 PODOPHYLLOTOXIN cross reference: PODOPHYLLIN Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 PODOPHYLLUM EMODI cross reference: PODOPHYLLIN Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 PODOPHYLLUM PELTATUM cross reference: PODOPHYLLIN Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4 Appendix H, clause 1 PODOPHYLLUM RESIN cross reference: PODOPHYLLIN Appendix G, clause 1 POLIHEXANIDE cross reference: 1-(DIAMINOMETHYLIDENE)-2-HEXYLGUANIDINE, POLY (IMINOCARBONIMIDOYLIMINOCARBONIMIDOYL IMINO-1,6-HEXANEDIYL), Authorised Version F2024L00589 registered 30/05/2024 Index 578 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 POLYHEXAMETHYLENE BIGUANIDE (PHMB) Schedule 6 Appendix E, clause 3 Appendix F, clause 4 POLIOMYELITIS VACCINE Schedule 4 POLIXETONIUM SALTS Schedule 6 Schedule 5 POLOXALENE Appendix B, clause 3 POLY (GNRF) OVALBUMIN Appendix B, clause 3 POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE cross reference: POLYDADMAC Appendix B, clause 3 POLY(OXY-1,2-ETHANEDIYL), α [2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α HYDROXY-,MONO-C13-15-ALKYL ETHERS Schedule 5 Appendix E, clause 3 POLYACRYLAMIDE Schedule 4 POLYCAPROLACTONE Schedule 4 POLYESTRADIOL Schedule 4 POLYETHANOXY (15) TALLOW AMINE Schedule 5 Appendix E, clause 3 POLYHEDROSIS VIRUS of Helico zea occlusion bodies Appendix B, clause 3 POLYLACTIC ACID Schedule 4 POLYMYXIN Schedule 4 POLYOXIN D ZINC SALT Schedule 5 POLYSORBATE 20 Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 579 POLYSULFATED GLYCOSAMINOGLYCANS Schedule 4 POLYTHIAZIDE Schedule 4 POMALIDOMIDE Schedule 4 Appendix D, clause 4 Appendix F, clause 4 Appendix L, clause 2 PONATINIB Schedule 4 PONESIMOD Schedule 4 Appendix L, clause 2 PORACTANT Schedule 4 PORCELAIN Appendix A, clause 1 PORCINE SOMATOTROPHIN Appendix B, clause 3 POSACONAZOLE Schedule 4 POTASSIUM AZELOYL DIGLYCINATE Schedule 6 POTASSIUM BICARBONATE Appendix B, clause 3 POTASSIUM BROMATE Schedule 6 Appendix E, clause 3 POTASSIUM BROMIDE Schedule 4 POTASSIUM CHLORATE Schedule 5 Schedule 2 Appendix E, clause 3 POTASSIUM CHLORIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 580 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 POTASSIUM CYANATE Schedule 6 Appendix E, clause 3 POTASSIUM HYDROXIDE cross reference: CAS No. 1310-58-3 Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 POTASSIUM METABISULPHITE Schedule 5 Appendix F, clause 4 POTASSIUM NITRITE Schedule 7 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 POTASSIUM PERCHLORATE Schedule 4 POTASSIUM PEROXOMONOSULFATE TRIPLE SALT Schedule 6 Schedule 5 POTASSIUM PERSULFATE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 POTASSIUM SORBATE Appendix B, clause 3 POTASSIUM SULFIDE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 PRACTOLOL Schedule 4 PRADOFLOXACIN Schedule 4 PRALATREXATE Schedule 4 PRALIDOXIME Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 581 PRALLETHRIN Schedule 6 Schedule 5 PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2) (GHRP-2) Schedule 4 Appendix D, clause 5 PRALSETINIB Schedule 4 PRAMIPEXOLE Schedule 4 PRAMIRACETAM cross reference: RACETAMS Schedule 4 PRAMOCAINE Schedule 4 PRAMPINE Schedule 4 PRASTERONE cross reference: DEHYDROEPIANDROSTERONE, DEHYDROISOANDROSTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) PRASUGREL Schedule 4 PRAVASTATIN Schedule 4 PRAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 PRAZIQUANTEL Schedule 4 PRAZOSIN Schedule 4 PREDNISOLONE Schedule 4 PREDNISONE Schedule 4 PREGABALIN Schedule 4 Appendix K, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index 582 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PREGNENOLONE Schedule 4 PRENALTEROL Schedule 4 PRENYLAMINE Schedule 4 PRILOCAINE Schedule 4 Schedule 2 PRIMAQUINE Schedule 4 PRIMIDONE Schedule 4 PRINTING INKS or INK ADDITIVES Appendix A, clause 1 PROBENECID Schedule 4 PROBUCOL Schedule 4 PROCAINAMIDE Schedule 4 PROCAINE Schedule 4 PROCAINE BENZYLPENICILLIN Schedule 4 PROCAINE PENICILLIN cross reference: PROCAINE BENZYLPENICILLIN PROCARBAZINE Schedule 4 PROCHLORAZ Schedule 6 PROCHLORPERAZINE Schedule 4 Schedule 3 Appendix K, clause 1 PROCYCLIDINE Schedule 4 Schedule 2 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 583 PROCYMIDONE Schedule 7 PROFENOFOS Schedule 6 PROFOXYDIM Schedule 5 PROGESTERONE Schedule 5 Schedule 4 Appendix G, clause 1 PROGESTOGENS Schedule 4 PROGLUMIDE Schedule 4 PROGUANIL Schedule 4 PROHEPTAZINE cross reference: CAS No. 77-14-5 Schedule 9 PROHEXADIONE CALCIUM Schedule 5 PROLINTANE Schedule 4 PROMACYL Schedule 6 PROMAZINE Schedule 4 Appendix K, clause 1 PROMETHAZINE Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1 PROMETRYN Schedule 5 PROMOXOLANE Schedule 4 PROPACHLOR Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index 584 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PROPAFENONE Schedule 4 PROPAMIDINE Schedule 4 Schedule 2 PROPAMOCARB Schedule 5 PROPANIDID Schedule 4 PROPANIL Schedule 5 PROPANTHELINE Schedule 4 PROPAQUIZAFOP Schedule 5 PROPARGITE Schedule 6 PROPENTOFYLLINE Schedule 4 PROPERIDINE cross reference: CAS No. 561-76-2 Schedule 9 PROPETAMPHOS Schedule 6 PROPETANDROL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) PROPICONAZOLE Schedule 6 Schedule 5 PROPINEB Schedule 6 PROPIONIBACTERIUM ACNES Schedule 4 PROPIONIC ACID Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 585 PROPIRAM Schedule 8 PROPOFOL Schedule 4 PROPOXUR Schedule 6 Schedule 5 PROPRANOLOL Schedule 4 Appendix G, clause 1 PROPYL ACETATES Appendix B, clause 3 n-PROPYL ALCOHOL Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 n-PROPYL NITRITE cross reference: CAS No. 543-67-9 Schedule 10 PROPYLENE GLYCOL Appendix B, clause 3 2-PROPYLENE GLYCOL 1-MONOMETHYL Appendix B, clause 3 PROPYLENE OXIDE Schedule 7 Appendix J, clause 1 PROPYLHEXEDRINE Schedule 4 PROPYLTHIOURACIL Schedule 4 PROPYPHENAZONE Schedule 4 PROPYZAMIDE Schedule 5 PROQUAZONE Schedule 4 PROQUINAZID Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index 586 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PROSCILLARIDIN Schedule 4 PROSTAGLANDINS Schedule 4 PROSTIANOL Schedule 4 PROSULFOCARB Schedule 6 PROSULFURON Schedule 6 PROTAMINE Schedule 4 PROTHIOCONAZOLE Appendix B, clause 3 PROTHIOCONAZOLE-DESCHLORO Schedule 5 PROTHIOCONAZOLE-TRIAZOLIDINETHIONE Schedule 5 PROTHIOFOS Schedule 6 PROTHIONAMIDE Schedule 4 PROTHIPENDYL Schedule 4 PROTIRELIN Schedule 4 PROTONITAZENE cross reference: CAS No. 95958-84-2 Schedule 9 PROTOVERATRINES Schedule 4 PROTRIPTYLINE Appendix K, clause 1 PROTRIPTYLINE Schedule 4 PROXYMETACAINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 587 PRUCALOPRIDE Schedule 4 PSEUDOEPHEDRINE Schedule 4 Schedule 3 PSEUDOMONAS FLUORESCENS Appendix B, clause 3 PSILOCYBINE cross reference: PSILOCYBIN, CAS No. 520-52-5 Schedule 9 Schedule 8 Appendix D, clause 5 Appendix D, clause 10 PTERIDIUM spp. Schedule 10 D-PULEGONE Schedule 6 Appendix E, clause 3 PULMONARIA spp. Schedule 10 PYDIFLUMETOFEN Appendix B, clause 3 PYMETROZINE Schedule 5 PYRACLOFOS Schedule 6 PYRACLOSTROBIN Schedule 5 PYRAFLUFEN-ETHYL Schedule 5 PYRANTEL Schedule 2 PYRASULFOTOLE Schedule 5 PYRAZINAMIDE Schedule 4 PYRAZOLAM cross reference: CAS No. 39243-02-2 Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index 588 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 PYRAZOPHOS Schedule 6 PYRETHRINS cross reference: CHRYSANTHEMIC ACID ESTERS, CINEROLONE, JASMOLONE, PYRETHRIC ACIDS, PYRETHROLONE Schedule 5 Schedule 2 PYRIDABEN Schedule 6 Schedule 5 PYRIDALYL Schedule 6 PYRIDATE Schedule 6 PYRIDINOLCARBAMATE Schedule 4 PYRIDOSTIGMINE Schedule 4 PYRIDOXAL Schedule 4 PYRIDOXAMINE Schedule 4 PYRIDOXINE Schedule 4 PYRIFENOX Schedule 5 PYRIMETHAMINE Schedule 4 PYRIMETHANIL Appendix B, clause 3 PYRINURON Schedule 7 Appendix J, clause 1 PYRIOFENONE Schedule 6 Schedule 5 PYRIPROLE Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 589 PYRIPROXYFEN Appendix B, clause 3 PYRITHIOBAC SODIUM Schedule 5 PYRITHIONE COPPER Schedule 6 PYRITHIONE ZINC Schedule 6 Schedule 5 Schedule 2 Appendix E, clause 3 PYROVALERONE Schedule 4 PYROXASULFONE Schedule 6 PYROXSULAM Schedule 6 PYRVINIUM cross reference: VIPRYNIUMA Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 590 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Q QUASSIA Appendix B, clause 3 QUATERNARY AMMONIUM COMPOUNDS cross reference: BENZALKONIUM CHLORIDE, DIALKYL and DIALKOYL QUATERNARY AMMONIUM COMPOUNDS Schedule 6 Schedule 5 Appendix E, clause 3 QUAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) QUETIAPINE Schedule 4 Appendix K, clause 1 QUINAGOLIDE Schedule 4 QUINALBARBITONE cross reference: SECOBARBITAL QUINAPRIL Schedule 4 QUINBOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) QUINCLORAC Schedule 5 QUINETHAZONE Schedule 4 QUINIDINE Schedule 4 QUININE cross reference: QUININE (CAS No. 130-95-0), QUININE SULFATE (1:1) (CAS No. 549-56-4), QUININE SULFATE (2:1) (CAS No. 804-63-7), QUININE SULFATE (2:1) DIHYDRATE (CAS No. 6119-70-6), QUININE SULFATE (1:1) HEPTAHYDRATE (CAS No. 6183-68-2), QUININE DIHYDROCHLORIDE (CAS No. 60-93-5), QUININE MONOHYDROCHLORIDE (CAS No. 130-89-2), QUININE HYDROCHLORIDE DIHYDRATE (CAS No. 6119-47-7), QUININE HYDROCHLORIDE (UNSPECIFIED) (CAS No. 7549-43-1) Schedule 7 Schedule 6 Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 591 Schedule 4 Appendix F, clause 4 QUINISOCAINE cross reference: DIMETHISOQUINE Schedule 4 QUINOLINE cross reference: 2,3-BENZAPYRIDINE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 QUINOXYFEN Appendix B, clause 3 QUINTOZENE cross reference: PENTACHLORONITROBENZENE Schedule 5 QUINUPRISTIN Schedule 4 QUIZALOFOP ETHYL cross reference: QUIZALOFOP ETHYL (D + ISOMER) Schedule 6 QUIZALOFOP-p-ETHYL Schedule 6 Schedule 5 QUIZALOFOP-p-TEFURYL Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index 592 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 R RABEPRAZOLE Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 RABIES VACCINE Schedule 4 RACEMETHORPHAN cross reference: CAS No. 510-53-2 Schedule 9 RACEMORAMIDE Schedule 8 RACEMORPHAN cross reference: CAS No. 297-90-5 Schedule 9 RACETAMS Schedule 4 RACTOPAMINE Schedule 5 Schedule 4 RADIOGRAPHIC CONTRAST MEDIA cross reference: RADIOPAQUES Appendix A, clause 1 RADIOISOTOPES Appendix A, clause 1 RALOXIFENE Schedule 4 RALTEGRAVIR Schedule 4 RALTITREXED Schedule 4 RAMIPRIL Schedule 4 RAMUCIRUMAB Schedule 4 RANIBIZUMAB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 593 RANITIDINE Schedule 4 Schedule 2 Appendix F, clause 4 RANOLAZINE Schedule 4 RAPACURONIUM Schedule 4 RASAGILINE Schedule 4 RASBURICASE Schedule 4 RAUWOLFIA SERPENTINA Schedule 4 RAUWOLFIA VOMITORIA Schedule 4 RAZOXANE Schedule 4 REBOXETINE Schedule 4 RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN Schedule 4 RED YEAST RICE Schedule 4 REGDANVIMAB Schedule 4 REGORAFENIB Schedule 4 RELUGOLIX Schedule 4 REMIFENTANIL Schedule 8 REMDESIVIR Schedule 4 REMOXIPRIDE Schedule 4 REPAGLINIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 594 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 RESCALURE cross reference: (3S,6R)-(3S,6S)-6-isopropenyl-3-methyldec-9-en-1-yl acetate Schedule 6 RESERPINE Schedule 4 RESLIZUMAB Schedule 4 RESMETHRIN Schedule 6 Schedule 5 RESORCINOL cross reference: 1,3-BENZENEDIOL Schedule 6 Appendix E, clause 3 Appendix F, clause 4 RETAPAMULIN Schedule 4 RETEPLASE Schedule 4 RETIGABINE Schedule 4 Appendix K, clause 1 RHIZOBIUM RHIZOGENES Appendix B, clause 3 RIBAVIRIN Schedule 4 RIBOCICLIB Schedule 4 RIDAFOROLIMUS Schedule 4 RIFABUTIN Schedule 4 RIFAMPICIN Schedule 4 RIFAMYCIN Schedule 4 RIFAPENTINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 595 RIFAXIMIN Schedule 4 RILPIVIRINE Schedule 4 RILUZOLE Schedule 4 RIMEGEPANT Schedule 4 RIMEXOLONE Schedule 4 RIMITEROL Schedule 4 RIMONABANT Schedule 4 RIMSULFURON Schedule 5 RIOCIGUAT Schedule 4 Appendix D, clause 4 Appendix L, clause 2 RIPRETINIB Schedule 4 RISANKIZUMAB Schedule 4 RISDIPLAM Schedule 4 RISEDRONIC ACID Schedule 4 RISPERIDONE Schedule 4 Appendix K, clause 1 RITODRINE Schedule 4 RITONAVIR Schedule 4 RITUXIMAB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 596 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 RIVAROXABAN Schedule 4 RIVASTIGMINE Schedule 4 RIZATRIPTAN Schedule 4 Schedule 3 Appendix H, clause 1 ROBENACOXIB Schedule 4 ROBENIDINE Schedule 5 ROFECOXIB Schedule 4 ROFLUMILAST Schedule 4 ROLICYCLIDINE cross reference: PCPY, PHP (CAS No. 2201-39-0) Schedule 9 ROLITETRACYCLINE Schedule 4 ROLZIRACETAM cross reference: RACETAMS Schedule 4 ROMIDEPSIN Schedule 4 ROMIFIDINE Schedule 4 ROMIPLOSTIM Schedule 4 ROMOSOZUMAB Schedule 4 RONIDAZOLE Schedule 4 ROPINIROLE Schedule 4 ROPIVACAINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 597 ROSEMARY OIL Appendix B, clause 3 ROSIGLITAZONE Schedule 4 ROSIN cross reference: COLOPHONY Schedule 5 ROSOXACIN Schedule 4 ROSUVASTATIN Schedule 4 ROTENONE cross reference: CUBE Schedule 6 ROTIGOTINE Schedule 4 Appendix K, clause 1 ROXIBOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) ROXITHROMYCIN Schedule 4 RUBELLA VACCINE Schedule 4 RUBOXISTAURIN Schedule 4 RUFINAMIDE Schedule 4 Appendix K, clause 1 Appendix L, clause 2 RUPATADINE Schedule 4 Appendix K, clause 1 RUXOLITINIB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 598 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 S SACITUZUMAB GOVITECAN Schedule 4 SACUBITRIL Schedule 4 SAFINAMIDE Schedule 4 SAFLUFENACIL Schedule 7 Schedule 5 SAFROLE cross reference: CAS No. 94-59-7, SASSAFRAS OIL Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 SAGE OIL cross reference: DALMATIAN, THUJONE Schedule 6 Appendix E, clause 3 SAGE OIL (Spanish) cross reference: CAMPHOR Appendix B, clause 3 SALBUTAMOL Schedule 4 Schedule 3 Appendix F, clause 4 SALCATONIN cross reference: CALCITONIN SALMON SALICYLAMIDE cross reference: ASPIRIN, CAFFEINE, PARACETAMOL Schedule 4 Schedule 2 Appendix F, clause 4 SALICYLANILIDE Schedule 5 SALICYLIC ACID cross reference: CHOLINE SALICYLATE Schedule 3 Appendix H, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 599 SALINOMYCIN Schedule 6 Schedule 4 SALMETEROL Schedule 4 SALVIA DIVINORUM Schedule 9 SANDALWOOD OIL Appendix B, clause 3 SANGUINARIA CANADENSIS (bloodroot) Schedule 10 SANGUINARINE cross reference: CAS No. 2447-54-3, SANGUINARIA CANADENSIS (bloodroot) SANTONIN Schedule 3 SAPROPTERIN Schedule 4 SAQUINAVIR Schedule 4 SARILUMAB Schedule 4 SAROLANER Schedule 6 Schedule 5 SARS-COV-2 (COVID-19) VACCINE Schedule 4 SASSAFRAS OIL cross reference: SAFROLE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 SAXAGLIPTIN Schedule 4 SCHOENOCAULON OFFICINALE cross reference: SABADILLA Schedule 4 SCHRADAN Schedule 7 Authorised Version F2024L00589 registered 30/05/2024 Index 600 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 SCOPOLIA CARNIOLICA Schedule 4 SEAWEED Appendix B, clause 3 SEBELIPASE ALFA Schedule 4 SECBUTOBARBITAL Schedule 8 Appendix K, clause 1 SECBUTOBARBITONE cross reference: SECBUTOBARBITAL SECOBARBITAL Schedule 8 Appendix K, clause 1 SECUKINUMAB Schedule 4 SEDAXANE Schedule 5 SEEDS Appendix A, clause 1 SELAMECTIN Schedule 5 SELECTIVE ANDROGEN RECEPTOR MODULATORS cross reference: SARM Schedule 4 Appendix D, clause 5 SELEGILINE Schedule 4 SELENIUM cross reference: BARIUM SELENATE, SELENIUM COMPOUNDS, SELENIUM ARSENIDE, SELENIUM SULFIDE Schedule 7 Schedule 6 Schedule 4 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 Appendix G, clause 1 SELETRACETAM Cross reference RACETAMS Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 601 Schedule 4 Appendix K, clause 1 SELEXIPAG Schedule 4 SELINEXOR Schedule 4 Appendix L, clause 2 SELPERCATINIB Schedule 4 SELUMETINIB Schedule 4 Appendix L, clause 2 SEMAGLUTIDE Schedule 4 SEMDURAMICIN Schedule 7 Schedule 6 SENECIO spp. Schedule 10 SERELAXIN Schedule 4 SERMORELIN Schedule 4 SERTINDOLE Schedule 4 SERTRALINE Schedule 4 SETHOXYDIM Schedule 5 SEVELAMER Schedule 4 SEVOFLURANE Schedule 4 SEX HORMONES Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 602 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 SH-OLIGOPEPTIDE-1, RH-OLIGOPEPTIDE-1 cross reference: EPIDERMAL GROWTH FACTOR SIBUTRAMINE Schedule 4 SIDURON Schedule 5 SILANDRONE Schedule 4 Appendix D, clause 5 (Anabolic steroidal agent) SILDENAFIL Schedule 4 SILICOFLUORIDES cross reference: BARIUM SILICOFLUORIDE, FLUORIDES, FLUOROSILICATES, HEXAFLUOROSILICATES MAGNESIUM FLUOSILICATE, Schedule 6 Schedule 5 SILICONES Schedule 10 Schedule 4 Appendix F, clause 4 SILODOSIN Schedule 4 SILTUXIMAB Schedule 4 SILVER Schedule 2 SILVER NITRATE cross reference: SILVER SALTS Schedule 6 Appendix E, clause 3 SILVER OXIDE Appendix B, clause 3 SILVER SULFADIAZINE Schedule 4 SIMAZINE Appendix B, clause 3 SIMEPREVIR Schedule 4 SIMVASTATIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 603 SINBIOALLETHRIN Schedule 6 Schedule 5 SINGLE-USE TUBES Appendix A, clause 1 SIPONIMOD Schedule 4 SIROLIMUS Schedule 4 SISOMICIN Schedule 4 SITAGLIPTIN Schedule 4 SITAXENTAN Schedule 4 Appendix D, clause 6 Appendix F, clause 4 Appendix L, clause 2 SLIMICIDES Appendix A, clause 1 SODIUM ALUMINATE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 SODIUM BICARBONATE Appendix B, clause 3 SODIUM BROMATE Schedule 6 Appendix E, clause 3 SODIUM BROMIDE Schedule 5 Schedule 4 SODIUM CELLULOSE PHOSPHATE Schedule 4 SODIUM CHLORATE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 604 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 SODIUM CROMOGLYCATE Schedule 4 Schedule 2 SODIUM DIACETATE Schedule 5 Appendix E, clause 3 SODIUM DICHLOROISOCYANURATE Appendix E, clause 3 SODIUM DODECYLBENZENE SULFONATE Schedule 5 Appendix E, clause 3, Part Appendix F, clause 4 SODIUM FLUORIDE Appendix F, clause 4 SODIUM GLYCEROPHOSPHATE HYDRATE Schedule 4 SODIUM HYDROGEN SULFATE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 SODIUM HYDROSULFITE Schedule 5 Appendix F, clause 4 SODIUM HYDROXIDE cross reference: CAS No. 1310-73-2, LYE WATER Schedule 10 Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 SODIUM LAURETH-6 CARBOXYLATE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 SODIUM METABISULPHITE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 SODIUM MORRHUATE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 605 SODIUM NITRITE Schedule 7 Schedule 6 Schedule 5 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 SODIUM NITROPRUSSIDE Schedule 4 SODIUM OXYBATE Schedule 8 Appendix D, clause 1 Appendix K, clause 1 SODIUM PERCARBONATE Schedule 6 Schedule 5 Appendix E, clause 3 SODIUM PERSULFATE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 SODIUM PHENYLBUTYRATE Schedule 4 SODIUM PHOSPHATE Schedule 4 Schedule 3 SODIUM PICOSULFATE Schedule 3 SODIUM POLYSTYRENE SULPHONATE Schedule 5 Schedule 4 SODIUM PROPIONATE Appendix B, clause 3 SODIUM SALICYLATE Schedule 4 SODIUM STANNATE Schedule 5, Appendix E, clause 3 SODIUM SULFIDE Schedule 6 Schedule 5 Appendix E, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 606 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Appendix F, clause 4 SODIUM TETRADECYLSULFATE Schedule 4 SODIUM TRICHLOROACETATE Appendix E, clause 3 SODIUM ZIRCONIUM CYCLOSILICATE. Schedule 4 SODIUMHYDROSULFITE Appendix E, clause 3 SOFOSBUVIR Schedule 4 SOLASODINE Schedule 4 SOLIFENACIN Schedule 4 SOMAPACITAN Schedule 4 SOMATOSTATIN Schedule 4 SOMATOTROPIN EQUINE Schedule 4 SOMATROPIN cross reference: HUMAN GROWTH HORMONE Schedule 4 Appendix D, clause 5 SONIDEGIB Schedule 4 SONTOQUINE Schedule 4 SORAFENIB Schedule 4 SOTALOL Schedule 4 SOTORASIB Schedule 4 SOTROVIMAB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 607 SPARFLOXACIN Schedule 4 SPARTEINE Schedule 4 SPECTINOMYCIN Schedule 4 SPESOLIMAB Schedule 4 SPINETORAM Schedule 5 SPINOSAD Schedule 5 SPIRAMYCIN Schedule 4 SPIRAPRIL Schedule 4 SPIROMESIFEN Schedule 5 SPIRONOLACTONE Schedule 4 SPIROPIDION Schedule 6 SPIROTETRAMAT Schedule 6 SPIROXAMINE Schedule 6 SQUILL Schedule 2 STANOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) STANOZOLOL Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) STAR ANISE OIL Schedule 5 STAVUDINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 608 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 STENABOLIC (SR9009) and other synthetic REV-ERB agonists cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667 Schedule 4 Appendix D, clause 5 STENBOLONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) STERIC ACID Appendix B, clause 3 STEROID HORMONES Schedule 4 STILBESTROL cross reference: STILBOESTROL, DIETHYLSTILBESTROL Schedule 4 STIRIPENTOL Schedule 4 Appendix K, clause 1 STREPTODORNASE Schedule 4 STREPTOKINASE Schedule 4 STREPTOMYCES LYDICUS WYEC 108 Appendix B, clause 3 STREPTOMYCIN Schedule 4 STRONTIUM RANELATE Schedule 4 STROPHANTHINS Schedule 4 STROPHANTHUS spp. Schedule 4 Appendix G, clause 1 STRYCHNINE cross reference: NUX VOMICA Schedule 7 Schedule 4 Appendix E, clause 3 Appendix G, clause 1 Appendix J, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 609 STRYCHNOS spp. Schedule 4 STYRAMATE Schedule 4 STYRENE cross reference: DESIGNATED SOLVENT Schedule 5 Appendix E, clause 3 Appendix F, clause 4 SUCCIMER Schedule 4 SUCRALFATE Appendix B, clause 3 SUCROFERRIC OXYHYDROXIDE Schedule 4 SUFENTANIL Schedule 8 SUGAMMADEX Schedule 4 SULBACTAM Schedule 4 SULCOFURON Schedule 7 Schedule 6 Appendix E, clause 3 Appendix J, clause 1 SULCONAZOLE Schedule 4 Schedule 2 SULESOMAB Appendix B, clause 3 SULFACETAMIDE Schedule 5 Schedule 4 Schedule 3 SULFADIAZINE Schedule 5 Schedule 4 SULFADIMETHOXINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 610 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 SULFADIMIDINE Schedule 5 Schedule 4 SULFADOXINE Schedule 4 SULFAFURAZOLE Schedule 4 SULFAGUANIDINE Schedule 4 SULFAMERAZINE Schedule 5 Schedule 4 SULFAMETHIZOLE Schedule 4 SULFAMETHOXAZOLE Schedule 4 SULFAMETHOXYDIAZINE Schedule 4 SULFAMETHOXYPYRIDAZINE Schedule 4 SULFAMETROLE Schedule 4 SULFAMIC ACID Schedule 6 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 SULFAMONOMETHOXINE Schedule 4 SULFAMOXOLE Schedule 4 SULFAPHENAZOLE Schedule 4 SULFAPYRIDINE Schedule 4 SULFAQUINOXALINE Schedule 4 SULFASALAZINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 611 SULFATHIAZOLE Schedule 5 Schedule 4 SULFATROXAZOLE Schedule 4 SULFENTRAZONE Schedule 7 SULFINPYRAZONE Schedule 4 SULFLURAMID Schedule 6 SULFOMETURON-METHYL Schedule 5 SULFOMYXIN Schedule 4 SULFONAMIDES cross reference: SULFACETAMIDE, SULPHANILAMIDE Schedule 4 SULFONMETHANE cross reference: ALKYL SULFONALS, SULFONAL Schedule 4 SULFOSULFURON Appendix B, clause 3 SULFOTEP Schedule 7 SULFOXAFLOR Schedule 6 Schedule 5 SULFURIC ACID Schedule 6 Appendix E, clause 3 Appendix F, clause 4 SULFURYL FLUORIDE Schedule 6 SULINDAC Schedule 4 SULPHATED POLYSACCHARIDES Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 612 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 SULPROFOS Schedule 6 SULTAMICILLIN Schedule 4 SULTHIAME Schedule 4 SUMATRIPTAN Schedule 4 Schedule 3 Appendix H, clause 1 SUNIFIRAM cross reference: RACETAMS Schedule 4 SUNITINIB Schedule 4 SUPROFEN Schedule 4 SUTILAINS Schedule 4 SUVOREXANT Schedule 4 Appendix K, clause 1 SUXAMETHONIUM Schedule 4 SUXETHONIUM Schedule 4 SYMPHYTUM spp. cross reference: COMFREY Schedule 10 Schedule 5 Appendix F, clause 4 SYNTHETIC CANNABINOMIMETICS Schedule 9 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 613 T 2,4,5-T Schedule 6 TACRINE Schedule 4 TACROLIMUS Schedule 4 TADALAFIL Schedule 4 TAFAMIDIS Schedule 4 TAFASITAMAB Schedule 4 TAFENOQUINE SUCCINATE Schedule 4 TAFLUPROST Schedule 4 TAGRAXOFUSP Schedule 4 TALAZOPARIB Schedule 4 TALIGLUCERASE ALFA Schedule 4 TALIMOGENE LAHERPAREPVEC Schedule 4 TALLOW ALKYLAMINE ACETATES Schedule 6 N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE Schedule 6 TAMOXIFEN Schedule 4 TAMSULOSIN Schedule 4 TANACETUM VULGARE cross reference: OIL OF TANSY, TANSY OIL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 614 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TANNIC ACID Appendix B, clause 3 TANNIC ACID/BENZYL ALCOHOL PRODUCT Appendix B, clause 3 TAPENTADOL Schedule 8 Appendix K, clause 1 TAR ACIDS Schedule 6 TASONERMIN Schedule 4 TAZAROTENE Schedule 4 Appendix F, clause 4 TAZOBACTAM Schedule 4 TB-500 Schedule 4 Appendix D, clause 5 2,3,6-TBA Schedule 5 T-CELL RECEPTOR ANTIBODY Schedule 4 TCMTB cross reference: 2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE Schedule 6 TDE cross reference: 1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE Schedule 6 Schedule 5 TEBENTAFUSP Schedule 4 TEBUCONAZOLE cross reference: TERBUCONAZOLE Schedule 5 TEBUFENOZIDE Schedule 5 TEBUFENPYRAD Schedule 6 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 615 TEBUTHIURON Schedule 6 TECLISTAMAB Schedule 4 TEDUGLUTIDE Schedule 4 TEFLUTHRIN Schedule 7 Schedule 5 TEGAFUR Schedule 4 TEGASEROD Schedule 4 TEICOPLANIN Schedule 4 TELAPREVIR Schedule 4 TELBIVUDINE Schedule 4 TELITHROMYCIN Schedule 4 TELMISARTAN Schedule 4 TELOTRISTAT ETHYL Schedule 4 TEMAZEPAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) Appendix K, clause 1 TEMEPHOS Schedule 6 Schedule 5 TEMOZOLOMIDE Schedule 4 TEMSIROLIMUS Schedule 4 TENECTEPLASE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 616 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TENIPOSIDE Schedule 4 TENOCYCLIDINE cross reference: TCP (CAS No. 21500-98-1) Schedule 9 TENOFOVIR Schedule 4 TENOXICAM Schedule 4 TEPOTINIB Schedule 4 TEPOXALIN Schedule 4 TEPP Schedule 8 TEPRALOXYDIM Schedule 5 TERAZOSIN Schedule 4 TERBACIL Appendix B, clause 3,Part 3 TERBINAFINE Schedule 4 Schedule 2 TERBUFOS Schedule 7 TERBUTALINE Schedule 4 Schedule 3 Appendix F, clause 4 TERBUTHYLAZINE Schedule 6 TERBUTRYN Schedule 5 TERFENADINE Schedule 4 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 617 TERIFLUNOMIDE Schedule 4 Appendix F, clause 4 Appendix L, clause 2 TERIPARATIDE Schedule 4 Appendix D, clause 1 TERLIPRESSIN Schedule 4 TERMITE BARRIERS Appendix A, clause 1 TERODILINE Schedule 4 TEROPTERIN Schedule 4 TERPENES, CHLORINATED cross reference: CHLORINATED TERPENES Schedule 6 Appendix E, clause 3 Appendix F, clause 4 TESTOLACTONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) TESTOSTERONE Schedule 6 Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) Appendix G, clause 1 TETANUS ANTITOXIN Schedule 4 TETANUS TOXOID cross reference: TRIPLE ANTIGEN VACCINE Schedule 4 1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE cross reference: HEXAMINE, HEXAMETHYLENETETRAMINE, METHENAMINE Schedule 5 TETRABENAZINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 618 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TETRACAINE cross reference: AMETHOCAINE Schedule 4 Schedule 2 TETRACHLOROETHANE Schedule 7 Appendix E, clause 3 Appendix F, clause 4 Appendix J, clause 1 TETRACHLOROETHYLENE cross reference: DESIGNATED SOLVENT Schedule 6 Schedule 5 Schedule 2 Appendix E, clause 3 Appendix F, clause 4 TETRACHLORVINPHOS Schedule 5 TETRACONAZOLE Schedule 6 Schedule 5 TETRACOSACTIDE Schedule 4 TETRACOSACTRIN cross reference: TETRACOSACTIDE TETRACYCLINE Schedule 5 Schedule 4 TETRADIFON Schedule 6 TETRAETHYLAMMONIUM Schedule 4 TETRAHYDROCANNABINOLIC ACID cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS TETRAHYDROCANNABINOLS cross reference: CANNABIS, HEMP SEED OIL, NABIXIMOLS Schedule 9 Schedule 8 Appendix D, clause 1 Appendix K, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 619 TETRAHYDROCANNABIDIVAROL cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS TETRAHYDROFURFURYL ALCOHOL Schedule 6 TETRAHYDROZOLINE cross reference: TETRYZOLINE 2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE cross reference: STABAXOL Schedule 7 Schedule 6 Appendix J, clause 1 TETRAMETHRIN Schedule 5 TETRAMISOLE Schedule 6 TETRANILIPROLE Schedule 5 TETROXOPRIM Schedule 4 TETRYZOLINE cross reference: TETRAHYDROZOLINE Schedule 2 Appendix F, clause 4 TEZACAFTOR Schedule 4 THALIDOMIDE Schedule 4 Appendix D, clause 2 Appendix F, clause 4 Appendix L, clause 2 THALLIUM cross reference: THALLIUM SULFATE Schedule 7 Appendix J, clause 1 THAUMATIN Appendix B, clause 3 THEBACON Schedule 8 THEBAINE Schedule 8 Authorised Version F2024L00589 registered 30/05/2024 Index 620 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 THENYLDIAMINE Schedule 4 Appendix K, clause 1 THEOPHYLLINE Schedule 4 Schedule 3 THEVETIA PERUVIANA Schedule 4 THEVETIN Schedule 4 THIABENDAZOLE Schedule 5 Schedule 2 THIACETARSAMIDE Schedule 4 THIACLOPRID Schedule 6 THIAMBUTOSINE Schedule 4 THIAMETHOXAM Schedule 6 Schedule 5 THIAZAFLURON Schedule 6 THIAZOPYR Schedule 5 THIAZOSULFONE Schedule 4 THIDIAZURON Appendix B, clause 3 THIETHYLPERAZINE Schedule 4 Appendix K, clause 1 THIFENSULFURON Schedule 5 THIOACETAZONE Schedule 4 THIOBENCARB Schedule 5 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 621 THIOCARLIDE Schedule 4 THIODICARB Schedule 6 Schedule 5 THIOFANOX Schedule 7 THIOFENTANYL cross reference: CAS No. 1165-22-6 Schedule 9 THIOGUANINE cross reference: TIOGUANINE THIOMESTERONE cross reference: TIOMESTERONE Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) THIOMETON Schedule 6 THIOPENTAL Schedule 4 THIOPENTONE cross reference: THIOPENTAL THIOPHANATE-METHYL Schedule 6 Schedule 5 THIOPROPAZATE Schedule 4 Appendix K, clause 1 THIOPROPERAZINE Schedule 4 THIORIDAZINE Schedule 4 Appendix K, clause 1 THIOSTREPTON Schedule 4 THIOTEPA cross reference: TRIETHYLENE THIOPHOSPHORAMIDE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 622 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 THIOTHIXENE Schedule 4 Appendix K, clause 1 THIOURACIL Schedule 4 THIOUREA cross reference: ALKYL THIOUREAS Schedule 6 Schedule 4 Appendix E, clause 3 Appendix F, clause 4 THIRAM Schedule 6 THUJONE Schedule 6 Appendix E, clause 3 THYME OIL Schedule 5 Appendix E, clause 3 THYMOL Schedule 6 THYMOSIN BETA 4 (THYMOSIN β4) Schedule 4 Appendix D, clause 5 THYMOXAMINE Schedule 4 THYROID Schedule 4 THYROTROPHIN cross reference: TSH Schedule 4 THYROXINE Schedule 4 Appendix G, clause 1 TIAFENACIL Appendix B, clause 3 TIAGABINE Schedule 4 TIAMULIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 623 TIANEPTINE Schedule 4 Appendix D, clause 5 TIAPROFENIC ACID Schedule 4 TIARAMIDE Schedule 4 TIBOLONE Schedule 4 TICAGRELOR Schedule 4 TICARCILLIN Schedule 4 TICLOPIDINE Schedule 4 TIEMONIUM Schedule 4 TIENILIC ACID Schedule 4 TIGECYCLINE Schedule 4 TIGILANOL TIGLATE Schedule 4 TIGLOIDINE Schedule 4 TIGOLANER Schedule 6 Schedule 5 TILDIPIROSIN Schedule 4 TILETAMINE Schedule 4 TILIDINE Schedule 8 TILMANOCEPT Schedule 4 TILMICOSIN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 624 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TILUDRONIC ACID cross reference: DISODIUM TILUDRONATE Schedule 4 TIMBER cross reference: WALLBOARD Appendix A, clause 1 TIMOLOL Schedule 4 TIMOTHY-GRASS POLLEN EXTRACT cross reference: PHLEUM PRATENSE POLLEN EXTRACT Schedule 4 TIN ORGANIC COMPOUNDS cross reference: DIALKYL TIN COMPOUNDS, DIBUTYL TIN COMPOUNDS, DIETHYL TIN COMPOUNDS, DIMETHYL TIN DICHLORIDE, DIMETHYL TIN COMPOUNDS, DIPROPYL TIN COMPOUNDS, FENBUTATIN OXIDE, ORGANO TIN-COMPOUNDS, TBTO, TRIALKYL TIN COMPOUNDS, TRIBUTYL TIN COMPOUNDS, TRIETHYL TIN COMPOUNDS, TRIMETHYL TIN COMPOUNDS, TRIPHENYL TIN COMPOUNDS, TRIPROPYL TIN COMPOUNDS Schedule 7 TINIDAZOLE Schedule 4 TINZAPARIN Schedule 4 TIOCARBAZIL Schedule 5 TIOCONAZOLE Schedule 4 Schedule 3 Schedule 2 Appendix H, clause 1 TIOGUANINE cross reference: THIOGUANINE Schedule 4 TIOTROPIUM Schedule 4 TIPEPIDINE Schedule 4 TIPIRACIL Schedule 4 TIPRANAVIR Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 625 TIRBANIBULIN Schedule 4 TIRILAZAD Schedule 4 TIROFIBAN Schedule 4 TIRZEPATIDE Schedule 4 Appendix L, clause 2 TISLELIZUMAB Schedule 4 TIXAGEVIMAB Schedule 4 TOBRAMYCIN Schedule 4 TOCAINIDE Schedule 4 TOCERANIB Schedule 4 TOCILIZUMAB Schedule 4 TOFACITINIB Schedule 4 TOLAZAMIDE Schedule 4 TOLAZOLINE Schedule 4 TOLBUTAMIDE Schedule 4 TOLCAPONE Schedule 4 TOLCLOFOS-METHYL Schedule 5 TOLFENAMIC ACID Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 626 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 o-TOLIDINE Schedule 7 Appendix E, clause 3 Appendix J, clause 1 TOLMETIN Schedule 4 TOLONIUM Schedule 4 TOLPROPAMINE Schedule 4 TOLRESTAT Schedule 4 TOLTERODINE Schedule 4 TOLTRAZURIL Schedule 5 TOLUENE cross reference: XYLENE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 2,4-TOLUENEDIAMINE cross reference: CAS No. 95-80-7 Schedule 10 TOLUENEDIAMINES Schedule 10 Schedule 6 Appendix E, clause 3 Appendix F, clause 4 o-TOLUIDINE cross reference: CAS No. 95-53-4 Schedule 10 TOLVAPTAN Schedule 4 TOLYLFLUANID Schedule 6 TOPIRAMATE Schedule 4 TOPOTECAN Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 627 TOPRAMEZONE Schedule 5 TORASEMIDE Schedule 4 TOREMIFENE Schedule 4 TOXOIDS Schedule 4 TRABECTEDIN Schedule 4 Appendix K, clause 1 TRALKOXYDIM Schedule 5 TRAMADOL Schedule 4 Appendix K, clause 1 TRAMAZOLINE Schedule 2 Appendix F, clause 4 TRAMETINIB DIMETHYL SULFOXIDE Schedule 4 TRANDOLAPRIL Schedule 4 TRANEXAMIC ACID cross reference: CETYL TRANEXAMATE Schedule 4 TRANSFLUTHRIN Schedule 6 TRANYLCYPROMINE Schedule 4 Appendix K, clause 1 TRASTUZUMAB Schedule 4 TRASTUZUMAB DERUXTECAN Schedule 4 Appendix L, clause 2 TRASTUZUMAB EMTANSINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 628 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TRAVOPROST Schedule 4 TRAZODONE Schedule 4 TRENBOLONE cross reference: TRIENBOLONE, TRIENOLONE Schedule 5 Schedule 4 Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents) TREOSULPHAN Schedule 4 TREPROSTINIL Schedule 4 TRESTOLONE Schedule 4 Appendix D, clause 5 (androgenic steroidal agents) TRETAMINE Schedule 4 TRETINOIN Schedule 4 Appendix D, clause 4 Appendix F, clause 4 Appendix L, clause 2 TRIACETYLOLEANDOMYCIN Schedule 4 TRIADIMEFON Schedule 6 Schedule 5 TRIADIMENOL Schedule 5 TRI-ALLATE Schedule 5 TRIAMCINOLONE Schedule 4 Schedule 3 Schedule 2 Appendix F, clause 4, Part 2 Appendix H, clause 1 TRIAMIPHOS Schedule 7 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 629 TRIAMTERENE Schedule 4 TRIASULFURON Appendix B, clause 3 TRIAZBUTIL Schedule 7 TRIAZIQUONE Schedule 4 TRIAZOLAM Schedule 4 Appendix D, clause 5 (Benzodiazepine derivatives) TRIBENURON-METHYL Schedule 5 TRIBUFOS cross reference: s,s,s-TRIBUTYLPHOSPHOROTRITHIOATE Schedule 7 TRICHLORFON cross reference: METRIFONATE Schedule 6 TRICHLORMETHIAZIDE Schedule 4 TRICHLOROACETIC ACID Schedule 6 Schedule 5 Schedule 4 Appendix E, clause 3 Appendix F, clause 4 TRICHLOROACETIC ACID ALKALI SALTS Schedule 5 Appendix E, clause 3 1,1,1-TRICHLOROETHANE cross reference: CAS No. 71-55-6, DESIGNATED SOLVENT Schedule 10 Schedule 5 Appendix E, clause 3 Appendix F, clause 4 TRICHLOROETHYLENE cross reference: TRICHLOROETHENE Schedule 6 Schedule 4 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 630 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TRICHLOROISOCYANURIC ACID cross reference: CHLORINATING COMPOUNDS Appendix E, clause 3 TRICHLOROPHENOL Schedule 6 Appendix F, clause 4 TRICHODERMA HARZIANUM Appendix B, clause 3 TRICHODESMA AFRICANA Schedule 10 TRICLABENDAZOLE Schedule 6 TRICLOFOS Schedule 4 TRICLOPYR Schedule 6 TRICLOSAN Schedule 6 TRICYCLAMOL Schedule 4 TRIDEMORPH Schedule 6 TRIDIHEXETHYL Schedule 4 TRIDIPHANE Schedule 5 TRIENTINE Schedule 4 TRIETAZINE Schedule 5 TRIETHANOLAMINE cross reference: TROLAMINE TRIETHYL PHOSPHATE Schedule 6 Appendix E, clause 3 TRIETHYLENE GLYCOL Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 631 TRIFAROTENE Schedule 4 TRIFLOXYSTROBIN Schedule 5 TRIFLOXYSULFURON Appendix B, clause 3 TRIFLUDIMOXAZIN Schedule 5 TRIFLUMIZOLE Schedule 5 TRIFLUMURON Schedule 5 TRIFLUOPERAZINE Schedule 4 Appendix K, clause 1 TRIFLUOROMETHANESULFONIC ACID Schedule 6 Appendix E, clause 3 Appendix F, clause 4 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE cross reference: TFMPP (CAS No. 15532-75-9), TFMPP HYDROCHLORIDE (CAS No. 16015-69-3) Schedule 9 TRIFLUPERIDOL Schedule 4 TRIFLUPROMAZINE Schedule 4 TRIFLURALIN Appendix B, clause 3 TRIFLURIDINE Schedule 4 TRIFORINE Appendix B, clause 3 TRIHEXYPHENIDYL cross reference: BENZHEXOL Schedule 4 TRIISOPROPANOLAMINE LAURYL ETHER SULFATE Schedule 5 Appendix E, clause 3 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 632 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TRILOSTANE Schedule 4 TRIMEPERIDINE cross reference: CAS No. 29606-10-8 Schedule 9 TRIMEPRAZINE cross reference: ALIMEMAZINE TRIMETAPHAN Schedule 4 TRIMETHOPRIM Schedule 4 3,4,5-TRIMETHOXY- α –METHYLPHENYLETHYLAMINE cross reference: TMA (CAS No. 1082-88-8), TMA HYDROCHLORIDE (CAS No. 5688-80 2) Schedule 9 3,4,5-TRIMETHOXYPHENETHYLAMINE cross reference: MESCALINE, METHOXYPHENAMINE, METHOXY-PHENYLETHYLAMINE (CAS No. 54-04-6), MESCALINE HYDROCHLORIDE (CAS No. 832-92-8), MESCALINE HYDROGEN SULFATE (CAS No. 5967-42-0), MESCALINE HEMISULFATE (CAS No. 642-73-9) Schedule 9 1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE cross reference: CAS No. 17097-73-3 Schedule 9 TRIMIPRAMINE Schedule 4 Appendix K, clause 1 TRIMUSTINE Schedule 4 TRINEXAPAC-ETHYL Schedule 5 TRINITROPHENOL Schedule 6 Schedule 4 3,6,9-TRIOXAUNDECANEDIOIC ACID Schedule 5 Appendix F, clause 4 TRIOXYSALEN Schedule 4 TRIPARANOL cross reference: CAS No. 78-41-1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 633 Schedule 10 TRIPELENNAMINE Schedule 4 TRIPLE ANTIGEN VACCINE cross reference: DIPHTHERIA TOXOID, PERTUSSIS ANTIGEN, TETANUS TOXOID TRIPROLIDINE Schedule 4 Schedule 3 Schedule 2 Appendix K, clause 1 TRIPTORELIN Schedule 4 TRISODIUM NITRILOTRIACETATE Schedule 6 TRITICONAZOLE Schedule 5 TROGLITAZONE Schedule 4 TROLAMINE Schedule 5 Schedule 4 Appendix E, clause 3 Appendix F, clause 4 TROMETAMOL Schedule 4 TROPICAMIDE Schedule 4 TROPISETRON Schedule 4 TROVAFLOXACIN Schedule 4 TROXIDONE Schedule 4 TRYPTOPHAN Schedule 4 TUAMINOHEPTANE Schedule 2 TUCATINIB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 634 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 TUBERCULIN Schedule 4 TUBOCURARINE Schedule 4 TULATHROMYCIN Schedule 4 TULOBUTEROL Schedule 4 TURPENTINE OIL cross reference: OIL OF TURPENTINE Schedule 5 Appendix E, clause 3 TUSSILAGO FARFARA cross reference: COLTSFOOT Schedule 10 TYLOSIN Schedule 4 TYMAZOLINE Schedule 4 Appendix F, clause 4 TYPHOID VACCINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 635 U ULIPRISTAL Schedule 4 Schedule 3 Appendix H, clause 1 ULOCLADIUM OUDEMANSII Appendix B, clause 3 UMECLIDINIUM Schedule 4 UNIFIRAM cross reference: RACETAMS Schedule 4 UNOPROSTONE Schedule 4 UPADACITINIB Schedule 4 URACIL Schedule 4 URAPIDIL Schedule 4 UREA Appendix B, clause 3 URETHANE Schedule 4 UROFOLLITROPIN cross reference: FOLLICLE-STIMULATING HORMONE, HUMAN Schedule 4 Appendix D, clause 1 UROKINASE Schedule 4 URSODEOXYCHOLIC ACID Schedule 4 USTEKINUMAB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 636 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 V VACCINES Schedule 4 VACCINES – PLASMID DNA cross reference: PLASMID DNA (rE. coli DH5α pINGhT) Schedule 4 VACCINIA VIRUS VACCINE Schedule 4 VADADUSTAT Schedule 4 Appendix D, clause 5 VALACICLOVIR Schedule 4 VALDECOXIB Schedule 4 VALGANCICLOVIR Schedule 4 VALNOCTAMIDE Schedule 4 VALPROIC ACID Schedule 4 VALSARTAN Schedule 4 VAMIDOTHION Schedule 6 VANCOMYCIN Schedule 4 VANDETANIB Schedule 4 VARDENAFIL Schedule 4 VARENICLINE Schedule 4 VARICELLA VACCINE Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 637 VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN (RECOMBINANT) cross reference: RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN VASOPRESSIN Schedule 4 VECURONIUM Schedule 4 VEDAPROFEN Schedule 4 VEDOLIZUMAB Schedule 4 VELAGLIFLOZIN Schedule 4 VELAGLUCERASE ALFA Schedule 4 VELPATASVIR Schedule 4 VEMURAFENIB Schedule 4 VENETOCLAX Schedule 4 VENLAFAXINE Schedule 4 VERAPAMIL Schedule 4 VERATRUM Schedule 4 VERICIGUAT Schedule 4 VERNAKALANT Schedule 4 VERNOLATE Schedule 5 VERTEPORFIN Schedule 4 VETIVER OIL Appendix B, clause 3 Authorised Version F2024L00589 registered 30/05/2024 Index 638 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 VIDARABINE Schedule 4 VIGABATRIN Schedule 4 VILANTEROL Schedule 4 VILDAGLIPTIN Schedule 4 VILOXAZINE Schedule 4 VINBLASTINE Schedule 4 VINCAMINE Schedule 4 VINCLOZOLIN Schedule 6 Appendix F, clause 4 VINCRISTINE Schedule 4 VINDESINE Schedule 4 VINFLUNINE Schedule 4 VINORELBINE Schedule 4 VINYL ACETATE MONOMER Schedule 6 Appendix E, clause 3 Appendix F, clause 4 VINYL CHLORIDE Schedule 7 Appendix J, clause 1 VINYL ETHER Schedule 4 VIRGINIAMYCIN Schedule 5 Schedule 4 VISMODEGIB Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 639 VISNADINE Schedule 4 VITAMIN A Schedule 4 VITAMIN D cross reference: COLECALCIFEROL, ERGOCALCIFEROL Schedule 4 Schedule 3 Appendix H, clause 1 VITAMIN K cross reference: PHYTOMENADIONE Appendix B, clause 3 VITREOUS ENAMELS Appendix A, clause 1 VORAPAXAR Schedule 4 VORETIGENE NEPARVOVEC Schedule 4 VORICONAZOLE Schedule 4 VORINOSTAT Schedule 4 VORTIOXETINE Schedule 4 VOSORITIDE Schedule 4 VOXILAPREVIR Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 640 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 W WALLBOARD cross reference: TIMBER Appendix A, clause 1 WARFARIN Schedule 6 Schedule 5 Schedule 4 WRITING CORRECTION PENS Appendix A, clause 1 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 641 X XAMOTEROL Schedule 4 XANTHINOL NICOTINATE Schedule 4 XANTHOPHYLL cross reference: LUTEIN Appendix B, clause 3 XIMELAGATRAN Schedule 4 XIPAMIDE Schedule 4 XYLANASE derived from Aspergillus niger Appendix B, clause 3 XYLAZINE Schedule 4 XYLENE cross reference: TOLUENE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 XYLOMETAZOLINE Schedule 2 Appendix F, clause 4 Authorised Version F2024L00589 registered 30/05/2024 Index 642 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 Y YLANG YLANG OIL Appendix B, clause 3 YOHIMBINE cross reference: ASPIDOSPERMA QUEBRACHO Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 643 Z (Z)-9-TRICOSENE cross reference: TRICOSENE Appendix B, clause 3 ZAFIRLUKAST Schedule 4 ZALCITABINE Schedule 4 ZALEPLON Schedule 4 ZANAMIVIR Schedule 4 ZANUBRUTINIB Schedule 4 ZERANOL Schedule 6 Schedule 4 ZETA-CYPERMETHRIN Schedule 7 Schedule 6 ZIDOVUDINE Schedule 4 ZILPATEROL Schedule 4 ZILUCOPLAN Schedule 4 ZIMELDINE Schedule 4 ZINC BORATE Schedule 6 ZINC CHLORIDE Schedule 4 Schedule 2 Appendix E, clause 3 ZINC COMPOUNDS Schedule 4 Authorised Version F2024L00589 registered 30/05/2024 Index 644 Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 ZINC LACTATE Schedule 6 Appendix F, clause 4 ZINC NAPHTHENATE Appendix B, clause 3 ZINC para-PHENOLSULFONATE Schedule 6 ZINC SULFATE Schedule 6 Appendix E, clause 3 Appendix F, clause 4 ZINEB cross reference: DITHIOCARBAMATES, MANCOZEB, PROPINEB, THIRAM Schedule 5 ZIPRASIDONE Schedule 4 Appendix K, clause 1 ZIRAM Schedule 7 Schedule 6 ZOLAZEPAM Schedule 4 ZOLEDRONIC ACID Schedule 4 ZOLMITRIPTAN Schedule 4 Schedule 3 Appendix H, clause 1 ZOLPIDEM Schedule 4 Appendix K, clause 1 ZONISAMIDE Schedule 4 Appendix K, clause 1 ZOPICLONE Schedule 4 Appendix K, clause 1 ZOXAZOLAMINE Schedule 4 ZUCLOPENTHIXOL Schedule 4 Authorised Version F2024L00589 registered 30/05/2024